








































































The	 GBS|CIDP	 Foundation	 International	 is	 the	 preeminent	 global	 non-profit	 organization	 supporting
individuals	 and	 their	 families	 affected	 by	 Guillain-Barré	 syndrome	 (GBS),	 chronic	 inflammatory













































































































































































































































































































































































































































of	 the	 1900s,	 pathological	 studies	 showed	 inflammation	 and	 tissue	 damage	 throughout	 the	 nerves	 and
spinal	roots.	The	clinical	picture	appeared	rather	uniform.	In	the	mid-1950s,	C.	Miller	Fisher	described
his	 eponymous	 syndrome	 of	 eye	 movement	 paralysis,	 loss	 of	 tendon	 reflexes	 and	 ataxia	 which	 may
overlap	with	GBS	[6].	In	the	last	quarter	of	the	1900s,	American	and	Chinese	investigators	identified	a
paralytic	syndrome	due	to	predominantly	motor	neuropathy	[7].	Others	have	described	formes	frustes	and
more	 chronic	 clinical	 courses.	 Increasingly	 sophisticated	 electrophysiology	 has	 distinguished
predominantly	demyelinating	disease	 from	 forms	due	 to	primary	 axonal	degeneration	or,	most	 recently,
forms	 due	 to	 nodal	 conduction	 block	 without	 either	 demyelination	 or	 axonal	 degeneration.	 With
increasingly	refined	diagnostic	criteria	[8],	epidemiological	studies	have	shown	that	GBS	is	a	worldwide
problem	 but	 with	 a	 preponderance	 of	 different	 clinical	 forms	 in	 different	 geographical	 regions.	 The
ongoing	massive	international	GBS	outcome	study	(IGOS),	with	more	than	1,000	records,	will	give	new
insights	into	these	variations.
The	 first	 pathological	 studies	 emphasized	 cellular	 infiltration	 by	 macrophages	 as	 responsible	 for
damaging	the	myelin	sheaths	with	T	cells	directed	against	myelin	proteins	as	instigating	the	process.	This
mechanism	 is	 certainly	 the	 cause	 of	 experimental	 autoimmune	 neuritis.	 It	 arises	 spontaneously	 in	mice
lacking	specific	genes	which	control	T	cell	regulation.	However,	some	human	pathological	studies	have
shown	 deposition	 of	 immunoglobulin	 and	 complement	 on	 the	 surface	 of	 myelin	 sheaths,	 suggesting
antibody	rather	 than	T-cell	mechanisms	 in	GBS.	In	mouse	and	rabbit	models,	antibodies	 to	glycolipids,




mechanism	 causing	 GBS.	 With	 the	 latest	 microarray	 technology,	 antibodies	 to	 complex	 arrays	 of
glycolipids	are	detectable	in	the	more	common	demyelinating	form	of	GBS	as	well	as	in	the	axonal	forms
of	the	disease	and	Fisher	syndrome.













many	 claims	 of	 successful	 treatment	 reflect	 anything	 other	 than	 the	 natural	 history	 of	 the	 disease.
However,	 recovery	 is	 often	 slow	 and	 incomplete,	 which	 has	 stimulated	 the	 launch	 of	 randomised
controlled	 trials.	 Cochrane	 systematic	 reviews	 contain	 convenient	 meta-analyses	 of	 their	 results.
Surprisingly,	 corticosteroids,	 the	panacea	 for	many	 inflammatory	diseases,	 turned	out	 to	be	 ineffective.
The	 first	 treatment	 shown	 to	be	able	 to	hasten	 recovery	and	 shorten	 the	disease	was	plasma	exchange.
Intravenous	immunoglobulin	is	as	effective	and	more	convenient	and	so	more	commonly	used	where	it	is
available.	The	 success	of	 these	 two	 treatments	has	made	 further	progress	more	difficult	because	 it	 has
become	unacceptable	to	omit	treatment	with	one	of	them.	It	is	encouraging	that	there	is	an	ongoing	trial	of
the	complement	inhibitor	eculizumab	founded	on	observations	in	a	relevant	animal	model.	We	hope	that
this	 book	will	 stimulate	 others	 to	 test	 some	 of	 the	many	 available	 newer	 immunomodulatory	 agents	 to






















It	 has	 been	 a	 century	 since	 the	 famous	 description	was	 first	 published	 in	 1916	by	Guillain,	Barré	 and
Strohl	of	an	acute	onset	polyneuropathy	with	albumino-cytologic	dissociation	 in	 the	cerebrospinal	 fluid
(CSF)	and	clinical	 recovery.	This	new	disorder	was	distinguished	from	acute	poliomyelitis	which	also
caused	acute	onset	weakness	but	exhibited	asymmetry,	variable	recovery,	and	an	inflammatory	CSF.	As
time	passed,	 the	disease	became	best	known	by	 the	names	of	 its	 first	2	authors.	Strohl’s	name	receded
from	 the	 roll-call,	 and	 Landry’s	 prior	 description	 also	 became	 increasingly	 overlooked	 as	 the	 current
eponym	 took	 its	 place	 in	 the	 medical	 hall	 of	 fame.	 Thus	 the	 Landry-Guillain-Barré-Strohl	 syndrome
became	 the	 Guillain-Barré	 syndrome,	 more	 commonly	 referred	 to	 just	 as	 GBS.	 GBS	 today	 is	 known
worldwide	where	the	incidence	is	a	steady	2	cases	per	100,000	of	population	per	year.	On	this	basis,	we
estimate	 there	 are	 over	 100,000	 cases	 per	 annum	worldwide.	GBS	 is	 now	 the	most	 common	 cause	 of
onset	flaccid	paralysis,	as	polio	has	receded	due	to	vaccination.





work.	 Authors	 were	 thus	 assigned	 the	 brief	 of	 choosing	 roughly	 10	 publications,	 their	 ‘Top	 10’,	 that
influenced	their	thinking	around	the	subject	of	GBS.	A	wide	range	of	authors	from	emeritus	professors	to
junior	medical	 students	 from	 around	 the	 world	 were	 invited	 to	 contribute	 their	 thoughts	 on	 particular
topics,	each	in	their	writing	style.	The	result	is	a	collection	of	63	essays	from	110	authors	presented	in	a
highly	 eclectic	 format.	 Some	 contributors	 have	 stuck	 firmly	 to	 the	 Top	 10	 format,	 while	 others	 have
written	 conventional	 accounts	 of	 their	 topic.	 Some	 are	 poetic,	 yet	 others	 prosaic.	Contents	 range	 from






The	 book’s	 foreword	was	written	 by	 2	 of	 the	most	 important	GBS	 researchers,	 Professors	 R.A.C.
Hughes	 and	 A.K.	 Asbury,	 who	 have	 made	 seminal	 contributions	 to	 the	 field	 over	 a	 lifetime	 of





GBS	 Outcome	 Study	 (IGOS)—a	 multinational	 collaborative	 effort	 led	 by	 the	 Rotterdam	 GBS	 group
involving	 over	 1,000	 GBS	 patients,	 all	 contributing	 to	 a	 massive	 collection	 of	 clinical,
electrophysiological,	biospecimens,	and	outcomes	data.	This	will	be	a	rich	source	of	study	for	years	to
come.	 Important	 advances	 in	GBS	have	 come	 from	studies	 in	 the	 Indian	 subcontinent,	China,	Asia	 and
Japan,	and	these	are	well	covered.
The	Clinical	section	highlights	those	disorders	that	originally	were	not	thought	to	be	classic	GBS,	an
acute	 ascending	 sensory-motor	 polyneuropathy,	 but	 that	 were	 eventually	 realized	 to	 be	 part	 of	 the
spectrum	 of	 GBS.	 These	 disorders,	 ranging	 from	 Miller	 Fisher	 syndrome	 to	 acute	 motor	 axonal
neuropathy,	 and	 lesser-known	 syndromes	 have	 indeed	 taught	 us	 much	 about	 the	 classic	 syndrome.




to	 the	 first	 inkling	 that	 this	was	 an	 autoimmune	 disorder	 and	 supported	 both	 the	 humoral	 and	 cellular
hypotheses	 of	 the	 disease.	 Physiology	 has	 helped	 refine	 the	 pathophysiological	 understanding	 of	GBS,
leading	to	the	more	recent	concepts	of	the	node	of	Ranvier	as	a	major	site	of	action	in	the	evolution	of	the
disease.	 Imaging	 promises	 to	 provide	 new	 insights,	 as	 it	 can	 look	 at	 the	 whole	 nervous	 system	 or






diarrhoea,	 Campylobacter	 jejuni	 and	 GBS,	 gangliosides	 and	 GBS,	 auto-antibodies	 and	 GBS,	 and
genetics	 and	GBS.	 These	 and	 others	 have	 led	 to	 the	 current	 understanding	 of	 GBS	 as	 an	 autoimmune
disorder	 in	which	a	genetically	susceptible	 individual	comes	 into	contact	with	a	specific	 inciting	agent
and	then	develops	antibodies	against	that	agent	which	mistakenly	identify	the	nerve	as	similar	and	attack
it.
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We	draw	 attention,	 in	 this	 note,	 to	 a	 clinical	 syndrome	which	we	have	 observed	 in	 two	patients.	This
syndrome	is	characterized	by	motor	disturbance,	abolition	of	the	tendon	reflexes	with	preservation	of	the
cutaneous	 reflexes,	paraesthesia	with	mild	disorders	of	objective	sensation,	pain	at	pressure	of	muscle
masses,	 slightly	 accentuated	 changes	 of	 the	 electric	 reactions	 of	 nerves	 and	muscles	 and	 very	 notable
hyperalbuminosis	of	 the	cerebrospinal	 fluid	with	absence	of	cytological	 reaction	 (albumino-cytological
dissociation).	This	syndrome	appeared	 to	depend	on	a	concomitant	 involvement	of	spinal	 roots,	nerves
and	muscles,	most	probably	of	infectious	or	toxic	nature.	It	must	be	differentiated	from	simple	radiculitis,
pure	polyneuritis	and	polymyalgia.	Experimental	research	using	a	graphic	method	on	the	speed	of	reflexes
and	 their	 delayed	 time,	 on	 the	 modalities,	 the	 muscular	 contractility,	 show	 that,	 in	 reality,	 the	 whole
peripheral	 neuro-muscular	 system	 is	 involved	 in	 the	 syndrome.	 We	 also	 particularly	 insist	 on	 the










These	 various	 disorders	 evolved	 without	 obvious	 cause:	 the	 patient	 didn’t	 have	 a	 recent	 infectious




The	 muscular	 strength	 was	 globally	 decreased	 in	 the	 upper	 and	 lower	 limbs	 but	 without	 a	 total
paralysis;	 this	decrease	of	 the	muscular	 strength	was	especially	prominent	 in	 the	extremities	where	we
noticed	an	extreme	weakness	of	the	flexion	and	the	extension	of	toes,	foot,	fingers	and	hands.

































tingling	 in	 the	 feet,	 but	 it	 persisted	 in	 the	 hands.	 Tendon	 reflexes	 were	 still	 absent.	 A	 repeat	 lumbar




hands	 although	 this	was	 attenuated.	 Tendon	 reflexes	were	 clinically	 absent,	 there	were	 no	withdrawal














had	 no	 symptoms	 of	 food	 poisoning	 or	 other;	 moreover,	 he	 was	 very	 convinced	 that	 he	 had	 never
contracted	syphilis.
On	the	5th	of	September,	we	noted	the	following	findings.




The	examination	of	 electrical	 reactions	 showed	a	 slight	hyper-excitability	of	nerves	and	muscles	 to
faradic	 current.	With	 galvanic	 current,	 excitability	 increased	 slightly,	 especially	 for	 the	 nerves	 of	 the
upper	limb;	there	was	no	reaction	of	degeneration.
The	patellar	reflexes	were	very	difficult	to	elicit	due	to	muscle	hypertonia;	they	seemed	to	be	present.
The	Achilles	 and	medio-plantar	 reflexes	were	 absent.	 The	 upper	 limb	 reflexes	 could	 not	 be	 assessed
because	 of	 the	 hypertonia	 and	 the	 impossibility	 of	 a	 complete	 muscular	 relaxation.	 Plantar	 cutaneous
reflexes	 brought	 a	 frank	 flexion	 of	 toes;	 cremasteric	 and	 abdominal	 cutaneous	 reflexes	 were	 normal.
There	was	no	withdrawal	reflex	either	when	the	back	of	the	foot	was	pinched	or	by	hyperflexion	of	the
toes,	but	the	patient	perceived	the	sensations	caused	by	these	excitations.








and	 Chemistry	 Laboratory	 of	 the	 army	 contained	 neither	 sugar	 nor	 albumin	 or	 indoxyl;	 the	 chemical
elements	were	in	their	normal	proportion.
It	is	necessary	to	note	that	a	skin	rash	appeared	3	or	4	days	previously,	mainly	localized	in	the	upper
thorax	 and	 in	 the	 lower	 abdominal	 region.	 The	 eruption	was	 characterized	 by	 erythema	 and	 papulous
spots.	Except	for	these	regions	the	eruptive	elements	were	disseminated	on	the	rest	of	the	thorax	and	the





tendon	reflexes	apart	 from	the	 left	biceps	reflex,	 the	maintenance	of	cutaneous	reflexes,	muscle	pain	on






Both	 observations	 which	 we	 have	 just	 recounted	 are	 completely	 similar.	 These	 two	 patients,	 without
detectable	visible	cause,	developed	a	clinical	syndrome,	characterized	by	disorders	of	all	the	muscles	of
the	 upper	 and	 lower	 limbs,	 worse	 distally,	 the	 loss	 of	 tendon	 reflexes	 with	 preservation	 of	 all	 the
cutaneous	 reflexes,	 paresthesia	 with	 mild	 disorders	 of	 objective	 sensation,	 pain	 when	 pressure	 was
applied	 to	muscle	masses,	 small	modifications	 of	 the	 electric	 reactions	 of	 nerves	 and	muscles	 and	 the
distinct	finding	in	the	cerebrospinal	fluid	of	a	marked	hyperalbuminosis	without	cytological	reaction.
The	 hyperalbuminosis	 of	 the	 cerebrospinal	 fluid	without	 cellular	 reaction	 is	 a	 peculiarity	which	 is
important	to	emphasize.	This	albumino-cytological	dissociation	(Sicard	and	Foix)	is	observed	most	of	the
time	 in	 certain	medullary	 compression,	 in	Pott’s	 disease	 and	 in	 certain	 cases	of	 syphilis	 of	 the	 central




healthy	 individual	 in	 the	 same	 situation.	 Passive	movements	 remained	 normal.	 The	 limited	 number	 of
voluntary	movements,	as	described	above,	were	rigid	and	marked	with	a	certain	lethargy.	Examination	of
the	tendinous	reflexes	proved	difficult	since	the	required	stretching	of	the	relevant	muscles	was	prevented
by	 the	 ongoing	 contraction	 taking	 place	 in	 the	 antagonists.	Despite	 these	 findings,	which	we	 encounter
frequently	enough	in	meningitis	cases,	the	patient	was	able	to	assume	a	seated	position	by	stretching	the
arms	 out	 almost	 completely,	 whilst	 simultaneously	 applying	 light	 support	 to	 the	 knees	 to	 prevent	 any
bending.	The	lower	limbs	could	rise	almost	to	a	right	angle	with	the	trunk,	and	bend	like	those	of	a	normal





certain	 facial	 palsies	 are	 not	 an	 exception	 to	 the	 peripheral	wounds	 of	 the	 nerves,	 as	 it	 is	 classically
believed.
All	 the	disorders	observed	in	these	two	patients	belong	to	a	simultaneous	pathology	of	spinal	roots,
peripheral	 nerves	 and	 muscles.	 The	 major	 hyperalbuminosis	 in	 the	 cerebrospinal	 fluid	 testifies	 to

















In	 this	patient,	while	 the	 tendon	 reflexes	appeared	absent	during	clinical	examination	 throughout	 the
course	 of	 the	 disease,	 the	 graphic	 inscription	 showed	 some	 contraction	 of	 quadriceps,	 femoral	 and
gastrocnemius	muscles	under	the	influence	of	direct	muscle	percussion;	the	tendons	of	these	muscles	and
their	muscle	masses	 showed	 interesting	peculiarities.	 From	 the	 onset	 of	 the	 disease,	 the	 search	 for	 the
patellar	 reflex	 brought	 a	 contraction	 after	 mechanical	 shock	 which	 we	 see	 clearly	 in	 Figure	 1.	 This
contraction,	 strikingly	 weaker	 than	 that	 obtained	 in	 a	 healthy	 subject,	 occurs	 after	 a	 delay	 of
approximately	0.056s,	and	 is	not	 followed	by	 the	 second,	more	ample	and	 longer	contraction	normally
seen	 as	 part	 of	 a	 delayed	 reflex.	We	 noticed	 0.152s	 after	 the	 beginning	 of	 the	 excitement	 a	 very	 light
uprising	of	 the	curve,	 indicating	 the	vestige	of	 the	 reflex	contraction.	The	patellar	 reflex	 is	also	almost
completely	 reduced	 to	 an	 idiomuscular	 reflex	 until	 the	 cure	 of	 the	 disease.	 During	 this	 period	 the
percussion	of	the	mass	of	quadriceps	provoked	a	beautiful	muscular	contraction	occurring	with	a	delay	of








is	approximately	0.110s—and	is	not	 followed	by	 the	normal	delayed	reflex	contraction.	But,	 instead	of
what	occurred	for	the	patellar	reflex,	these	changes	partially	reversed,	and,	already	on	September	5th	(see
Figure	3),	repeat	testing	revealed	a	more	ample,	brisker,	faster	muscular	shock	(0.055s),	followed	by	a





It	 is	worth	 noting	 that,	 at	 the	 beginning	 of	 the	 disease,	 although	 the	 percussion	 of	 the	Achilles	 and
gastrocnemius	 tendons	 didn’t	 provoke	 any	muscular	 contraction,	 the	 investigation	 of	 the	medio-plantar
reflex	 brought	 the	 second	 contraction,	with	 a	 0.144s	 delay	 constituting	what	we	 have	 to	 consider	 as	 a
reflex	contraction	of	low	intensity	(see	Figure	2).
Furthermore,	 whereas	 a	 simple	 clinical	 examination	 revealed	 only	 the	 abolition	 of	 the	 tendinous
reflexes,	 a	 detailed	 analysis	 of	 the	myographic	 curves,	 by	 revealing	which	 elements	 of	 the	 reflex	 are
abnormal,	 leads	us	to	a	series	of	worthwhile	remarks.	Firstly,	 the	complete	disappearance	of	 the	reflex
part	of	 the	myographic	curve	or,	when	 it	 remains,	 its	 extreme	delay	and	 reduced	amplitude	and	 speed,
shows	 us	 the	 deep	 and	 dominant	 change	 of	 the	 nervous	 drivers	 or	 of	 the	 central	 part	 of	 the	 reflex.	 In
addition,	the	muscular	shock	is	also	modified,	decreased	in	height,	slowed,	and	delayed	in	its	appearance;
this	causes	us	to	think	that	the	muscular	element	was	also	touched	by	the	process	of	poisoning.	Finally,	the
comparison	 of	 curves	 obtained	 after	 percussion	 of	 the	 patellar	 tendon	 and	 from	 the	 Achilles’	 tendon
allows	us	to	notice	a	different	evolution	for	these	reflexes.	Whereas	the	first	one	was	quickly	abolished
and	 didn’t	 return	 until	 the	 the	 patient	 had	 left	 the	 hospital,	 the	 second,	 although	 seeming	 abolished
clinically,	was	 detectable	 using	 the	 graphic	method	 and	 had	 characteristics	 getting	 gradually	 closer	 to
normal	 earlier.	We	 insist	 on	 this	 important	 fact	 that	 the	 graphic	 method	 allows	much	more	 precise
assessment	of	the	state	of	tendon	reflex	than	an	examination	with	the	hammer.












Jean	 Baptiste	 Octave	 Landry,	 born	 in	 1826	 (a	 year	 before	 J.M.	 Charcot),	 as	 a	 young	medical	 student
voluntarily	 treated	patients	 during	 the	 cholera	 epidemic	of	 1850,	 and	 then	 trained	during	his	 residency
alternatively	in	medicine	and	surgery.	However,	his	medical	thesis	in	1854,	General	considerations	on
pathogenesis	and	therapeutic	indications	of	nervous	diseases,	showed	a	decided	interest	in	neurology
[1].	 In	 1859	 he	 published	 a	 paper	 entitled	Acute	ascending	paralysis	 in	which	 he	 gave	 the	 following
description.











puncture	 having	 been	 introduced	 in	 1891	 by	 Quincke	 in	 his	 search	 for	 a	 method	 of	 draining
hydrocephalus.	If	the	hallmark	is	indeed	albumino-cytological	dissociation,	it	is	evident	that	the	syndrome







Confirmation	 of	 the	 importance	 of	 the	 work	 of	 Landry	 was	 given	 by	 Jules	 Dejerine	 (1849–1917),
future	professor	of	neurology	at	the	Salpêtrière	Hospital,	who	wrote	in	his	medical	thesis	(1879),	Studies
on	nervous	system	lesions	in	the	acute	ascending	paralysis,	“Landry	was	the	first	to	draw	attention	to	a













an	atrophy	of	 the	peripheral	nerves.	He	said,	“Not	 least	 important	nor	 least	 interesting	in	 the	history	of
these	peripheral	paralyses	 is	 their	extension	 to	a	 large	part	of	 the	nervous	system—one	could	speak	of
generalisation—to	the	point	of	compromising	life	through	the	invasion	of	the	most	essential	nerves	such	as
the	vagus	nerve”	[7].	He	was	the	first	to	carry	out	an	electric	exploration,	using	Duchenne	de	Boulogne’s





clinical	 or	 pathological	 aspects	was	worthy	of	 note	 until	 the	 description	of	Guillain,	Barré	 and	Strohl
[8,9].
Neurology	in	Paris	at	the	Turn	of	the	Century
After	 the	 death	 of	Charcot	 in	 1893,	 the	main	 subject	 of	 discussion	 among	 neurologists	 remained	what
constituted	 the	 true	 nature	 of	 hysteria.	Within	 this	 debate	 a	 turning	 point	 appeared	with	 the	 studies	 of











Pierre	Marie	 (1853–1940)	 succeeded	Dejerine	 in	 1917	 until	 his	 retirement	 in	 1923.	He	 described








Besides	 a	 heavy	 traumatic	 pathology	 affecting	 the	 central	 nervous	 system	 and	 peripheral	 nerves,
combat	 conditions	 and	 social	 attitudes	 during	 the	 war	 resulted	 in	 a	 considerable	 number	 of	 mental
disorders.	The	distinction	between	emotional	 stress	 and	psychic	 trauma	directly	 related	 to	 fighting	and
simulation	was	a	major	concern	for	army	physicians.	The	Société	de	Neurologie	and	representatives	of
allied	medical	centres	held	a	joint	meeting	in	1916.	Many	of	the	works	from	this	meeting	were	published
after	 the	war,	 such	as	 the	book	by	Babinski	 and	Froment,	Hysteria	 and	pithiatism	and	 reflex	 nervous




Georges	Guillain	 classed	 first	 at	 the	 resident	 exam	 in	 1898	 and	 had	 the	 possibility	 of	working	 among
prestigious	mentors	in	neurology,	completing	his	residency	with	P.	Marie.	It	was	under	Marie’s	direction
that	Guillain	carried	out	his	anatomical	works	(on	the	pyramidal	tracts	and	internal	capsule),	emphasising
in	 a	 special	 lecture	 the	 importance	 for	 a	 neurologist	 to	 think	 as	 an	 anatomist,	 a	 physiologist	 and	 a
biologist.	In	this	way	he	started	with	the	study	of	cerebrospinal	fluid	(focusing	on	the	benzoin	colloidal
reaction	in	nervous	syphilis).
Jean	 Alexandre	 Barré,	 a	 resident	 under	 Babinski	 in	 1909–1910,	 defended	 his	 thesis	 on	 tabes
arthropathies.	He	started	a	long	collaboration	with	Guillain	during	the	war	and	became	his	friend.	While











the	 nervous	 system.	 This	 characteristic	 was	 for	 them	 absolutely	 different	 from	 infectious	 polyneuritis.
They	rejected	the	hypothesis	of	any	similarity	with	the	acute	febrile	neuritis	recognised	by	Osler	in	1892










shaving’s	 a	 danger	 and	 buttoning	 laborious”.	 At	 the	 end	 of	 the	 war,	 Cushing	 showed	 some	 signs	 of
improvement.	 Back	 in	 Boston	 in	 February	 1919,	 he	 resumed	 his	 operative	 schedule,	 but	 remained
exhausted	after	operations.	He	attributed	this	fatigue	to	his	previous	‘polyneuritis’.
The	 exact	 diagnosis	 of	 his	 illness	 was	 unknown	 and	 particularly	 difficult	 to	 establish	 due	 to	 an
association	 with	 peripheral	 vascular	 disorder.	 For	 S.C.	 Reich	 [11],	 the	 combination	 of	 progressive
weakness	of	the	limbs,	together	with	areflexia	and	bilateral	facial	paralysis	substantiates	the	diagnosis	of






















When,	 in	 1916,	Georges	Guillain	 (1876–1961),	 Jean-Alexandre	Barré	 (1880–1967)	 and	André	 Strohl
(1887–1977)	 described	 2	 soldiers	 admitted	 to	 the	 ‘Centre	 neurologique’	 of	 the	 6th	 Army	 based	 near
Amiens	with	tingling	and	progressive	weakness	in	the	limbs,	electrical	inexcitability	of	the	reflexes	and
‘hyperalbuminose	 …	 sans	 reaction	 cellulaire’	 in	 the	 cerebrospinal	 fluid,	 the	 condition	 was	 initially
known	as	‘acute	febrile	or	ascending	polyneuritis’	 [1].	Abe	(AB)	Baker	(1908–1988)	responded	to	 the
hint	 dropped	 by	 Guillain,	 who	 soon	 started	 referring	 to	 ‘our	 syndrome’,	 and	 described	 cases	 of
encephalomyeloradiculitis	 as	 the	 ‘Guillain-Barré	disease’.	Generally	 left	 out	 in	 the	 cold	 thereafter,	 the
1977	obituary	notice	of	Strohl	refers	to	the	syndrome	of	‘Guillain,	Strohl	and	Barré’.	Also	jostling	for	a
place	 on	 the	 podium	when	 speaking	 of	 ‘acute	 ascending	 paralysis’	 is	 the	 description	 in	 1859	 by	 Jean




is	 primarily	 a	 disease	 of	 the	 spinal	 cord	 or	 peripheral	 nerve	 [5].	 But,	 in	 recent	 years,	 neurology	 has
settled	 for	 the	 abbreviated	 GBS	 (Guillain-Barré	 syndrome)	 when	 referring	 to	 acute	 post-infectious
polyneuritis.
Thomas	Willis	entitled	the	last	of	his	12	treatises	Pharmacutice	rationalis	(1674–1675),	emphasising
that	 treatment	 in	 medicine	 should	 be	 mechanism-based	 [6].	 But	 that	 ideal	 presupposed	 a	 concept	 of
disease	 and	 a	 system	 for	 nomenclature	 [7].	By	 the	 late	 17th	 century,	 as	 far	 as	 the	nervous	 system	was
concerned,	not	much	had	changed	for	over	2	millennia	since	the	Greeks	and	Romans	rationalized	existing
concepts.	Magic	medicine	 ignored	 the	 sick	 individual	 as	 a	 source	 of	 information.	 Plato	 (427–327	BC)
believed	in	health	as	a	state	of	harmony;	disease	was	an	excess,	alteration	or	relocation	of	body	(earth,
fire,	 air	 and	water)	 and	 soul.	Hippocrates	 (460–377	BC)	 internalized	medicine,	 relating	 disease	 to	 the
individual	 and	 illustrated	 his	 ideas	 with	 case	 histories	 describing	 the	 onset,	 duration	 and	 outcome	 of
symptoms.	 For	 Galen	 (AD	 130–200),	 disease	 had	 a	 locus	 and	 a	 pathological	 process;	 function	 was
affected	 first	 and	 alterations	 in	 structure	 then	 followed.	 It	 was	 a	 short	 step	 to	 extend	 the	 concept	 of






from	 the	 spinal	 cord	 that	 is	 contained	 in	 the	 bones	 of	 the	 back”.	 Thomas	 Sydenham	 (1624–1689)
advanced	 the	 concept	of	natural	history,	detected	by	observation	of	untreated	disease	over	 time.	There
followed	 studies	 on	 the	 anatomical	 seat	 of	 disease	 (Giovanni	 Morgagni,	 1682–1771);	 and	 the	 final







Famous	 doctors	 were	 remembered	 through	 diseases	 named	 after	 them.	 Later,	 a	 mechanism-based
taxonomy	 seemed	 preferable,	 and	 pathology	 started	 contributing	 to	 the	 classification	 of	 disease.	Now,
acronym	 competed	with	 eponym	 inmedical	 nosology.	 In	 the	 present	 context,	 a	 variety	 of	 abbreviations
emerged	for	the	Guillain-Barré	syndrome	based	on	different	patterns	of	the	natural	history	and	variations
in	 the	 pathology	 responsible	 for	 acute,	 recurrent	 and	 chronic	 inflammatory	 demyelinating	 and	 axonal
polyneuropathies—the	family	of	AIDP,	CIDP,	AMAN,	AMSAN	and	their	many	first-,	second-	and	third-
degree	 relatives.	 Nonetheless,	 custodians	 of	 the	 eponym	 fought	 back,	 as	 the	 celebration	 of	 this	 book
concedes.	In	the	preface	to	Neurological	Eponyms,	Peter	Koehler,	George	Bruyn	(1928–2002)	and	John





many	 eponymous	 attributions	 attract	 rival	 claims	 for	 priority	 on	behalf	 of	 others	who	provided	 earlier
accounts	 of	 that	 particular	 disorder.	 Indeed,	 a	 brief	 wander	 through	 any	 reasonable	 library	 easily
identifies	examples	appearing	before	the	eponym-defining	publication(s).	In	writing	A	Practical	Treatise
of	Painful	Distempers	with	Some	Effectual	Methods	of	Curing	Them,	Exemplified	in	a	Great	Variety	of





to	 walk.	 A	 complete	 cure	 of	 the	 complaint,	 caused	 ‘by	 acrid	 particles	 brought	 into	 contact	 with	 the
extremities	of	 the	nerves	of	her	feet’,	was	soon	effected	through	the	judicious	administration	of	various










the	 whole	 of	 both	 extremities	 …	 and	 finally	 …	 to	 become	 altogether	 paralytic”	 [12].	 This	 and	 the
subsequent	work	 of	 Louis	Duménil	 (1823–1890)	 of	Rouen	 [13]	went	 largely	 unnoticed.	 (Sir)	William
Gowers	 (1845–1915)	 considered	 that	 only	when	 “fresh	 facts	were	 brought	 forward	 by	 [Alex]	 Joffroy
[1844–1908],	 (Ernst	 von)	 Leyden	 [1832–1910]	 and	 [Sir]	 Thomas	Grainger	 Stewart	 [1837–1900]	was
attention	 generally	 directed	 to	 the	 subject	 of	 peripheral	 neuritis”	 [14].	 Grainger	 Stewart	 reported	 3
examples	of	 the	 illness	already	described	by	Graves	[15].	He	noted	 loss	of	 the	 tendon	reflexes	 (which
Grainger	 Stewart	 had	 introduced	 into	 routine	medical	 practice	 in	 the	United	Kingdom),	 and	 electrical
inexcitability	of	the	limbs.	One	patient	died.	Whereas	the	brachial	plexus	was	normal,	the	axis	cylinders











changes.	 2.	 There	 is	 a	 change	 in	 the	 n[erve]	 medullary	 sheath	 centre	 of	 n[erve]	 and	 sens[ory]	 struct[ure].	 Often	 the
changes	proper	 to	 the	n[erve]	begin	at	periphery	and	spread	up	 towards	centre.	Occasionally	 there	are	patches	on	 the







Pasted	 alongside	 is	 the	 printed	 galley	 summarising	 the	 lecture	 with	 the	 annotation:	 “Some	 get	 a






Ropper	 credit	 James	Wardrop	 (1782–1869)	 and	Charles-Prosper	Ollivier	 d’Angers	 (1796–1845)	with
original	 contributions	 to	 the	 subject	 [17].	Readers	 of	 this	 book	will	 have	 little	 difficulty	 in	 identifying
additional,	equally	deserving	celebrants.	But	if	we	are	to	stick	with	eponym	for	describing	patients	with
































The	 importance	of	hearing	patient	narratives	of	disease—‘hearing	 the	patient’s	voice’—is	 increasingly








The	American	author	Joseph	Heller	 (1923–1999),	most	noted	 for	his	1961	novel	Catch-22,	 developed
GBS	in	late	1981	and	subsequently	wrote	an	account	of	his	illness,	No	Laughing	Matter	(1986)	[1].	The
book	 consists	 of	 alternating	 chapters	 by	 Heller	 and	 his	 friend	 Speed	 Vogel,	 so	 that	 both	 patient	 and
collateral	 narratives	 are	 provided,	 although	 it	might	 be	 argued	 that	Vogel	 is	 simply	Heller’s	 alter	 ego
(page	 220),	 since	 during	 the	 author’s	 illness	 Vogel	 lived	 in	 his	 house,	 wore	 his	 clothes,	 forged	 his
signature	on	cheques,	dealt	with	his	fan	mail,	and	‘more	or	less	assumed	his	identity’	(page	72).










He	 spoke	 to	 his	 physician	 to	 report	 his	 symptoms,	 who	 diagnosed	 GBS	 over	 the	 telephone	 and
arranged	to	see	him,	followed	shortly	 thereafter	by	a	neurological	consult	 (with	Dr	Walter	Sencer)	and
admission	to	the	medical	intensive	care	unit	of	the	Mount	Sinai	Hospital	in	New	York	(Sencer	published	a















such	 that	 after	3	months	and	3	days	he	 left	Mount	Sinai	Hospital	 for	 a	 rehabilitation	 facility	 (the	Rusk
Institute	at	the	New	York	University	Medical	Center)	until	mid-May	1982.
In	 passing,	 Vogel	 gives	 an	 answer	 to	 the	 perennial	 question	 of	 why	 we	 refer	 to	 ‘Guillain-Barré
syndrome’	and	not	‘Guillain-Barré-Strohl	syndrome’,	despite	the	tripartite	authorship	of	the	original	1916
paper.	 One	 of	 Heller’s	 friends	 was	 the	 novelist	 Mario	 Puzo	 (1920–1999),	 author	 of	 The	 Godfather








It	was	 also	 in	 1981	 that	Tony	Benn	 (1925–2014),	 an	English	Labour	Party	 politician	 and	 socialist,
developed	 GBS	 just	 at	 the	 time	 that	 he	 was	 campaigning	 (ultimately	 unsuccessfully)	 for	 the	 deputy











He	 told	me,	 “I	 think	 I	know	what	 this	 is.	 If	 this	was	only	a	medical	consideration,	 I	would	 recommend	you	came	 into
hospital	at	once.”
I	said,	“Well,	I’m	perfectly	happy	to	do	that	because	I	am	simply	incapacitated.”
Benn	 was	 then	 in	 hospital	 from	 6th	 to	 17th	 June,	 when	 there	 are	 no	 diary	 entries	 [2].	 Following
discharge	from	hospital,	he	noted	on	24th	June	that	“I	have	to	rest	in	the	afternoon,	and	it’s	still	painful	to
walk”,	but	there	do	not	seem	to	be	any	other	comments	on	possible	sequelae	in	the	abridged	diary	entries,
























(1909)	by	Frances	Hodgson	Burnett;	 and	Pollyanna	Whittier	 in	Pollyanna	 (1913)	by	Eleanor	H	Porter
[5,6].	 All	 these	 novels	 predate	 the	 original	 description	 of	 GBS,	 but	 the	 fictional	 possibilities	 of	 this
paralysing	disorder	have	subsequently	been	exploited	on	occasion.
Likewise,	 playwrights	 have	 sometimes	 featured	 characters	with	 paralysis,	 for	 example	The	 Sacred





the	 description	 of	 the	 disease	 within	 the	 novel	 which	 jar	 the	 clinical	 reader.	 The	 patient	 suffers
progressive	weakness	over	a	few	weeks	(contrary	to	the	blurb,	“…	gone	to	a	party	…	when	he	left,	he
was	crippled”),	but	despite	his	seeing	numbers	of	clinicians	and	undergoing	a	lumbar	puncture,	no	clear
diagnosis	 emerges,	 other	 than	 polyneuropathy,	 possibly	 related	 to	 his	 underlying	 diabetes.	Despite	 this
lack	of	diagnostic	clarity,	a	referral	to	rehabilitation	services	is	made,	before	transfer	to	another	medical
centre	 where	 the	 diagnosis	 is	 immediately	 made	 by	 a	 physician	 and	 confirmed	 by	 a	 neurologist	 who
labels	 some	 of	 the	 previously	 consulted	 professionals	 ‘irresponsible’.	 However,	 the	 timeframe	 of	 the
novel	is	a	little	difficult	to	follow	and	it	may	be	that	neurological	decline	has	been	going	on	for	more	than
8	 weeks;	 indeed	 the	 neurologist	 considers	 that	 this	 is	 the	 ‘slow	 kind’	 of	 GBS,	 and	 “considers	 yours
chronic	inflammatory	demyelinating	polyneuropathy”	(pages	67–68);	so,	not	GBS	at	all!	This	may	explain











that	 the	 “leading	 cause	 of	 death	 related	 to	GBS	 is	 suicide”	 (page	69),	 though	how	a	 paralysed	patient
might	achieve	this	is	not	made	clear.
Although	 accuracy	 or	 consistency	 is	 not	 necessarily	 to	 be	 anticipated	 in	 a	 work	 of	 fiction,	 one
seriously	worries	for	any	GBS	patient	or	family	who	might	use	this	book	as	a	source	of	information	about
the	 disease;	 the	 frontispiece	 disclaimer,	 with	 direction	 to	 Guillain-Barré	 Foundation	 International	 for
information	regarding	the	disease,	is	a	welcome	inclusion.
In	 Thaw	 by	 Monica	 Roe	 [8],	 the	 narrating	 voice	 is	 that	 of	 Dane	 Rafferty,	 an	 18-year-old	 skier
recovering	 from	 GBS	 in	 a	 rehabilitation	 centre	 in	 Florida,	 far	 distant	 from	 his	 family	 and	 friends	 in
upstate	New	York.	The	action	takes	place	over	a	2-month	period,	with	flashbacks	to	premorbid	days	and
disease	 onset.	 Hence	 the	 focus	 is	 more	 on	 the	 recovery	 phase,	 particularly	 the	 input	 from	 a
physiotherapist,	 Anya,	 and	 an	 occupational	 therapist	 (no	 doctor	 ever	 darkens	 these	 pages!);	 this	 is







This	 table	 contraption	 that	 can	 be	 cranked	 from	 horizontal	 to	 completely	 vertical,	 bringing	 the	 person	 on	 it	 along	 like












This	 lament	 sounds	 like	 the	 voice	 of	 experience,	 but,	 like	 the	 other	 passages	 quoted,	 is	 seamlessly
assumed	 within	 the	 narrative.	 Most	 readers	 will	 probably	 be	 more	 concerned	 with	 whether	 Dane
recovers	 fully,	gets	back	 to	 skiing,	 and	makes	 it	 up	with	his	girlfriend	 (who	ditched	him	when	he	was
paralysed,	 intubated	 and	 ventilated—some	 girls	 surely	 know	 how	 to	 pick	 their	moment!).	 But	 there	 is
much	to	enjoy	in	this	book	if	reading	with	neurological	spectacles	on.
Historical	Diagnoses	of	GBS
Appeal	 to	 the	historical	 record	may	help	 to	answer	 the	question	as	 to	whether	 cases	of	GBS	occurred
before	1916.	However,	since	CSF	findings	were	part	of	the	diagnostic	characterisation	by	Guillain	and
his	 colleagues,	 and	 lumbar	 puncture	was	 only	 performed	 after	 1897,	 cases	 conforming	 to	 the	 original
clinical	and	 investigational	description	(dissociation	albumino-cytologique)	occurring	before	 the	1916
publication	would	 seem	unlikely.	Hence	 inferences	 based	 on	 clinical	 features	 are	 the	 only	 recourse	 to
answer	the	question	of	historical	cases.
For	 example,	 Reich	 suggested	 that	 the	 renowned	 American	 neurosurgeon	 Harvey	 Cushing	 (1869–
1939)	suffered	 from	GBS	in	1918	when	an	undiagnosed	 illness	characterised	 (in	Cushing’s	diaries)	by
symmetrical	 weakness,	 numbness	 and	 paresthesias	 of	 the	 hands	 and	 feet,	 areflexia,	 bilateral	 facial
paresis,	diplopia,	and	fever	prevented	him	from	operating	[9].
Another,	more	formalised,	example	of	this	diagnostic	revisionism	relates	to	the	diagnosis	of	Franklin
Delano	 Roosevelt	 (1882–1945),	 32nd	 president	 of	 the	 United	 States	 of	 America	 (1933–1945),	 who
suffered	a	paralytic	illness	in	1921	which	is	widely	believed	to	have	been	due	to	poliomyelitis.	Goldman
and	colleagues	re-examined	the	clinical	features	as	recorded	in	biographies	of	FDR	(he	never	underwent
lumbar	 puncture	 or	 neurophysiological	 testing	 as	 far	 as	 is	 known)	 and	 undertook	 a	 Bayesian	 (i.e.,
probabilistic)	 analysis	 of	 8	 key	 symptoms	 [10].	 By	 multiplying	 prior	 probabilities	 by	 symptom
probabilities,	Goldman	and	colleagues	calculated	that	6	out	of	the	8	symptoms	had	posterior	probabilities










It	 seems	 implausible	 that	 GBS	 did	 not	 exist	 before	 Guillain,	 Barré,	 and	 Strohl	 took	 to	 print,	 thus
characterising	GBS	as	a	disease	entity.	This	same	condition	seems	to	be	described,	for	example,	 in	 the
reports	 by	 Landry	 [11]	 (1859),	Wardrop	 [12,13]	 (1834),	 and	Warrington	 (1903)	 [14].	 Thus	 a	 ‘100th
anniversary’	of	GBS	is	in	some	ways	a	cultural	construct.	Clinical	knowledge	of	GBS	which	has	accrued
over	the	century	has	sometimes	transferred	into	the	literary	domain,	spawning	both	personal	and	fictional
(or	possibly	 ‘factional’)	 accounts	of	 the	disease,	 as	well	 as	 attempts	 at	 retrospective	diagnosis,	which


















































greater	 science	 was	 to	 come	 from	 his	 serendipitous,	 prior	 trip	 on	 the	 Beagle.	 Landry’s	 eloquent



























the	 reflex	 arc.	 They	 also	 emphasised	 the	 albuminocytological	 dissociation	 in	 the	 cerebrospinal	 fluid
(CSF)	 of	 the	 2	 soldiers,	 both	 of	whom	 had	 raised	 CSF	 protein.	 The	 authors	 of	 this	 paper,	mentioned
innumerable	times	in	this	book,	had	no	idea	of	the	causation	of	their	illness.	They	were	very	insistent	that
the	soldiers	did	not	have	venereal	disease,	despite	syphilis	being	rife	in	the	trenches,	and	they	remained
unsure	whether	 the	cause	was	intoxication	or	 infection.	What	we	remain	sure	about	 is	 that	syphilis	still





early	 part	 of	 the	 20th	 century.	 Leyden	 [7]	 had	 described	 an	 intense	 cellular	 nerve	 infiltration,	 but
Haymaker	and	Kernohan,	 in	a	highly	influential	paper	[8],	commenced	thoughts	on	processes	other	than
infectious	inflammation.	They	described	the	‘limited	pathological	material’	of	50	fatal	cases.	Oedema	and
nerve	 root	 swelling,	 possibly	 secondary	 to	 infection,	were	 blamed	 for	 the	 pathology	 seen	 and	 a	 cell-
mediated	 pathogenesis	 fell	 out	 of	 favour.	 Perhaps	 this	 was	 the	 beginning	 of	 thoughts	 of	 a	 humoral
pathogenesis,	 before	 any	 knowledge	 of	 antibodies.	 They	 also	 heralded	 the	 future	 heterogeneity	 of	 the
Guillain-Barré	 syndromes	 with	 the	 statement	 that	 ‘from	 the	 clinical	 standpoint	 all	 forms	 are	 initially





external	 ophthalmoplegia,	 without	 long	 tract	 signs	 or	 central	 nervous	 system	 involvement	 and	 with
albumin-cytological	 dissociation	 in	 one	 case	 [9].	 Guillain	 himself	 probably	 described	 a	 similar	 case
much	earlier	 [10].	Miller	Fisher	 syndrome	 is	now	recognised	as	a	distinct	clinical	entity,	with	varying
amounts	of	overlap	to	GBS,	part	of	 the	heterogeneity	recognised	by	others.	Perhaps	 the	other	 important
milestone	 associated	 with	 Miller	 Fisher	 syndrome	 is	 its	 association	 with	 antibodies	 to	 gangliosides,
thought	to	be	key	to	the	pathogenesis.	We	now	recognise	that	IgG1	antibodies	to	GQ1b	are	found	in	almost







the	 management	 of	 acute	 inflammatory	 neuropathy	 since	 the	 prognosis	 is	 not	 improved,	 the	 rate	 of
recovery	is	slowed	and	the	chance	of	relapse	may	be	increased”.	Looked	at	simply,	this	paper	sets	out	a
negative	 trial	 suggesting	 that	 prednisolone	 is	 ineffective	 and	 possibly	 harmful.	 Looking	 back	 now,	 the
paper	 has	 had	 a	much	 further	 range	 of	 influence,	 still	 reaching	 into	 the	 21st	 century.	 Firstly,	 it	 sets	 a








Study	 Group,	 under	 Dr	 McKhann’s	 guidance,	 published	 the	 first	 really	 significant	 trial	 of	 effective
treatment	for	GBS	[13].	This	trial	was	massive	for	its	time,	including	245	adults	and	children	with	GBS
within	 30	 days	 of	 diagnosis.	 This	 sort	 of	 study	 size	 in	 GBS	 has	 only	 recently	 been	 exceeded	 with
IGOS1000,	 which	 has	 already	 included	 more	 than	 1,000	 participants	 in	 2016.	 The	 paper	 is	 widely
misquoted	and	misunderstood,	especially	when	it	comes	to	the	use	of	IVIg,	shown	later	to	be	of	equivalent
efficacy	 to	plasma	exchange.	What	 is	 seldom	recognised	 is	 that	neither	plasma	exchange	nor	 IVIg	have
been	shown	to	terminate	the	progress	of	GBS,	reduce	disability	or	abort	the	nadir	of	disease.	The	GBS
Study	 Group	 trial	 clearly	 demonstrated	 a	 more	 rapid	 recovery,	 approximately	 halving	 the	 time	 to	 1
Hughes	 grade	 improvement	 or	 to	 be	 extubated	 if	 ventilated.	 This	 translates	 of	 course	 into	 a	 massive
reduction	in	complications	of	GBS.
1990–1994:	Andrew	Wiles	Proves	Fermat’s	Last	Theorem
Guy	 McKhann	 and	 colleagues	 from	 Johns	 Hopkins	 and	 China	 described	 a	 fascinating	 epidemic
neuromuscular	paralysis	in	their	Lancet	paper	of	1991	[14].	So	frequently	in	science	it	is	the	things	that
are	not	 expected	 that	 are	 the	most	 interesting.	They	observed,	 “On	 the	basis	of	 clinical	 features	 alone,
many	 of	 the	 children	 and	 young	 adults	 in	 China	 would	 be	 considered	 to	 have	 GBS.”	 but	 the
electrophysiological	and	epidemic	features	were	not	those	seen	in	Western	GBS—this	was	a	new,	GBS-
like	 disease.	 From	 this	 paper	 acute	 motor	 axonal	 neuropathy	 (AMAN)	 and	 acute	 motor	 and	 sensory
axonal	neuropathy	(AMSAN)	were	conceived.	A	common	infectious	initiation	with	Campylobacter	jejuni






For	 the	 last	40	years	 the	study	of	GBS	has	been	 littered	with	attempts	 to	produce	a	disease	model	 that
reproduced	 an	 acute	 inflammatory	 peripheral	 nerve	 disease	 in	 animals.	 Kadlubowski	 and	 Hughes’
description	of	EAN	 in	1979	by	 immunisation	with	bovine	myelin	protein	 antigens	 (mainly	P2)	was	 an
early	successful	attempt.	Adoptive	transfer	EAN	produced	a	T-cell	model	of	the	disease.	More	latterly	the
beautiful	 demonstration	 of	 the	 development	 of	 a	 spontaneous	 neuropathy	 by	 subverting	 immunological
tolerance	with	a	transgenic	mouse	producing	P0-specific	T	cells	in	2009	added	a	key	piece	to	the	jigsaw
to	 join	 up	 the	 immunological	 ‘dot	 to	 dot’	 puzzle	 from	 instigation	 to	 completion	 of	 disease	 in	 GBS.
Arguably	 the	most	striking	model	description,	however,	was	by	Nobuhiro	Yuki	and	colleagues	 in	2001
[15],	with	a	rabbit	animal	model	caused	by	sensitisation	with	GM1	ganglioside.	This	paper	re-ignited	the




So	 the	world	 of	worm	 science	 turned	 full	 circle,	 and	 in	 2009	Mitra	 and	 colleagues	 demonstrated	 that
exposing	 earthworms	 to	 vibratory	 frequencies	 of	 less	 than	 500Hz	 caused	 them	 to	 emerge	 from	 their




derives	 from	 the	 work	 of	 Hugh	 Willison	 with	 complement	 inhibition.	 Halstead	 and	 colleagues
demonstrated	 the	 complete	 abrogation	 of	 an	 antibody-mediated	 acute	 inflammatory	 neuropathy	 in	mice
[16].	Although	 the	 human	 pilot	 study	 in	multifocal	motor	 neuropathy	was	 negative	 [17],	 at	 the	 time	 of














































The	centenary	of	Guillain,	Barré	and	Strohl’s	 landmark	description	of	Guillain-Barré	 syndrome	 (GBS)











The	 literature	 on	 GBS	 reports	 several	 cases	 of	 patients	 with	 concomitant	 papilloedema,	 but	 the
association	 is	 not	 widely	 known.	 In	 1954,	 Gardner	 and	 colleagues	 hypothesized	 that	 papilloedema	 in
GBS	 and	 in	 other	 conditions,	 such	 as	 ependymoma	 of	 the	 cauda	 equina,	 acoustic	 tumour	 and
poliomyelitis,	 arises	as	a	 result	of	 elevated	CSF	protein.	 In	elegant	 experiments	 in	anaesthetized	dogs,
they	 demonstrated	 that	 elevated	 CSF	 protein	 can	 slow	 absorption	 of	 CSF,	 presumably	 by	 partially
obstructing	the	arachnoid	villi,	leading	to	increased	intracranial	pressure	(ICP)	and	papilloedema	[1].
This	finding	accorded	with	an	earlier	postmortem	observation	in	a	GBS	patient	who	had	elevated	ICP,
papilloedema,	 a	 normal	 ventriculogram	 and	 a	 tendency	 for	CSF	 fluid	 to	 clot	 after	 lumbar	 puncture,	 of
deposition	 of	 ‘amorphous	 material’	 at	 the	 Pacchionian	 granulation	 of	 the	 arachnoid	 villi	 [2].	 Further
support	 for	 impaired	CSF	absorption	 leading	 to	raised	ICP	and	papilloedema	comes	from	a	 later	study
showing	deranged	CSF	flow	in	a	patient	with	GBS	who	also	had	elevated	CSF	protein	and	hydrocephalus
[3].
Other	 reports	 have	 disputed	 the	 hypothesis	 of	 impaired	 CSF	 absorption	 for	 various	 reasons,	 chief
among	 them	 being	 that,	 in	 individual	 patients,	 the	 level	 of	 elevated	 protein	 does	 not	 necessarily






Historically,	 numerous	 cases	 have	 been	 described	 recognizing	 central	 nervous	 system	 (CNS)
demyelination	 in	 patients	 with	 GBS	 [6,7],	 but	 the	 association	 is	 rare.	 GBS	 and	 acute	 disseminated
encephalomyelitis	 (ADEM)	 are	 distinct,	 monophasic,	 acquired,	 multifocal,	 demyelinating	 diseases	 of
subacute	onset	which	 follow	 in	 the	days	 to	weeks	after	 infection	or	vaccination.	Both	are	presumed	 to
have	 an	 autoimmune	 basis	 and	 seemingly	 respond	 to	 immunotherapies	 such	 as	 plasma	 exchange	 or





of	 both	 the	 peripheral	 nervous	 system	 (PNS)	 and	 CNS.	 Presently,	 the	 identity	 of	 this	 common	myelin
epitope	is	unknown,	but	myelin	protein	P1	in	the	PNS	is	identical	to	myelin	basic	protein	in	the	CNS,	so
an	epitope	shared	between	the	PNS	and	CNS	is	conceivable	[9].






Bickerstaff’s	 original	 description	 of	what	 came	 to	 be	 known	 as	 ‘Bickerstaff’s	 brainstem	 encephalitis’





The	 reason	why	BBE	patients	 should	 complain	 of	 nausea	 is	 not	 clear.	One	 explanation	 is	 that	 it	 is




well	 [13].	Observations	 in	support	of	CNS	involvement,	at	 least	 in	a	proportion	of	patients	with	BBE,
include	abnormal	EEG	findings	with	encephalopathy,	increased	infratentorial	T2	signal	changes	on	MRI,




Numerous	 publications	 on	 GBS	 refer	 to	 the	 concept	 of	 molecular	 mimicry	 converting	 an	 allo-antigen
response	 to	 an	 auto-antigen	 response,	 suggesting	 an	 infection	 triggering	 an	 initial	 adaptive	 immune
response,	followed	by	a	cross	reactivity	to	a	neural	antigen	in	the	context	of	an	interaction	between	the
infection	and	the	individual’s	HLA	characteristics.
Confounding	 this	 hypothesis	 is	 the	 lack	 of	 a	 general	 association	 of	 HLA	 with	 GBS,	 unlike	 most
autoimmune	 diseases.	 This	 lack	 of	 association	 in	 GBS	 is	 unlike	 the	 situation	 in	 chronic	 relapsing





any	general	 study.	This	 is	 intellectually	 the	easiest	 consideration	because	 it	 accepts	 the	hypothesis.
There	 is	 some	 limited	 support	 for	 this	 idea	 of	 subgroup	 analysis	 in	 the	 context	 of	 the	 1976–1977
influenza	vaccine,	or	for	certain	infections	[18,19,20].
2.	 Major	 HLA	 are	 not	 the	 determinants	 of	 this	 molecular	 mimicry	 and	 other	 adaptive	 systems
determining	 nonpeptide	 antibodies	 or	 NK	 pathways	 transduce	 this	 response.	 This	 is	 discussed	 in
Yoshi	(see	below).









GBS	differs	 in	a	number	of	aspects	 from	most	classic	autoimmune	diseases,	with	 lack	of	a	clear	HLA






patients	 compared	 with	 healthy	 controls	 [23].	 After	 plasmapheresis,	 they	 found,	 NK	 cell	 function
recovered	to	normal	range.	In	contrast,	NK	cell	numbers	did	not	change.










A	 role	 for	 cytokines	 in	 the	 pathogenesis	 of	 GBS	 has	 been	 proposed	 ever	 since	 the	 detection	 of	 the
therapeutic	effect	of	plasma	exchange,	which	suggested	soluble	factors	are	involved.	The	role	of	TNF-α






More	 recently	 TNF-α	 polymorphisms	 showed	 genetic	 differences	 in	 GBS	 patients	 versus	 healthy
controls.	A	meta-analysis	examining	12	 studies	 from	diverse	geographical	 areas	confirmed	 that	TNF-α
polymorphism	308	A/G	was	significantly	associated	with	 the	 risk	of	developing	GBS	[30].	Parallel	 to




This	points	 towards	a	 complex	 role	of	TNF-α	 in	 the	pathogenesis	of	GBS;	 indeed,	 such	a	 role	has








We	 include	 2	 papers,	 but	 commend	 the	whole	 edition	 on	GBS,	 the	 very	 first	 supplement	 of	Annals	 of
Neurology.	It	reported	on	a	GBS	conference	sponsored	by	the	Kroc	Foundation,	endowed	by	the	founder
of	the	McDonald’s	hamburger	chain.
Prineas’	 paper	 provides	 a	 fascinating	 review	 of	 the	 early	 pathological	 studies	 of	GBS	 and	 related
diseases	 [35].	 Initially	 such	 cases	were	 not	 accepted	 as	 being	 a	 disorder	 of	 the	 peripheral	 nerves,	 as
anterior	 horn	 cell	 changes	were	 present,	 suggesting	 this	was	 spinal	 in	 aetiology.	 Charcot’s	 strength	 of
opinion	contributed.	Slowly	this	evolved	into	acceptance	that	 the	peripheral	nerves	were	involved,	and
the	anterior	horn	cell	changes	were	a	postmortem	artefact.
Later	 studies	 reviewed	 indicated	 that	 pathological	 changes	 were	 patchy	 and	 particularly	 where
anterior	 and	 posterior	 roots	 join	 to	 form	 the	 spinal	 nerves.	 These	 dissections	 of	 large	 numbers	 of
necropsy	GBS	cases	early	in	the	disease	course	are	unlikely	to	be	repeated.	These	demonstrated	that	the







and	 1977.	 This	 resulted	 in	 the	 American	 Academy	 of	 Neurology	 collaborating	 with	 a	 national	 GBS
surveillance	system	initiated	by	the	Centers	for	Disease	Control.	Their	paper	confirms	that	the	additional
GBS	cases	 after	 the	 1976–1977	vaccination	 program	occurred	 in	 the	 first	 5	weeks	 and	peaked	 at	 2–3

















northern	 France.	 In	 addition	 to	 the	 war	 wounds	 there	 were	 numerous	 infections,	 arising	 from	 poor
hygiene,	as	well	as	zoonoses,	with	endemic	rats	and	 lice	 in	 the	fields	and	forests	behind	 the	front,	and
Ixodes	ricinus	 ticks,	 the	European	vector	for	Lyme	neuroborreliosis,	even	now	prevalent	in	this	part	of
France	[39].
Febrile	 polyneuritis	 was	 discussed	 contemporaneously,	 by	 Lieutenant-Colonel	 Gordon	 Holmes,
Consultant	Neurologist,	British	Armies	 in	France	 [40].	Richard	Hughes	writes,	 “It	 is	puzzling	 to	know
what	modern	disease	Osler	and	Holmes	were	describing	since	absence	of	fever	is	 the	rule	in	Guillain-
Barré	 Syndrome”	 [41].	 Polio	 and	 diphtheria	 are	 discussed	 therein;	 syphilis	 and	 spinal	 compressions
and/or	 Pott’s	 disease	 (tuberculosis)	 were	 discussed	 by	 Guillain	 and	 his	 colleagues.	 However,	 Lyme
disease	and	trench	fever	may	be	forgotten	differentials	for	the	historical	context.	Holmes’	paper	noted	an
association	with	trench	fever.





may	 cause	meningoencephalitis	with	 cellular	 pleocytosis.	 Trench	 fever	 caused	marked	 loss	 of	 fighting
man	power	and	consequent	investigation	[44]:	“It	 is	curious	that	 the	sniffing	up	the	nose	of	the	infected
excreta	of	lice	did	not	give	rise	to	infection,	whereas	the	placing	of	the	same	material	in	the	conjunctival





Neurologists	will	 recall	 such	 histories,	 and	while	many	 cases	will	 be	 parainfectious	myalgia	 or	 some





















































































Although	 relatively	 uncommon	 compared	 to	many	 other	 neurologic	 illnesses,	Guillain-Barré	 syndrome
(GBS)	has	been	 the	 focus	of	 some	of	 the	most	 intense	and	extensive	epidemiologic	assessments	of	any
illness.	This	has	primarily	been	driven	by	an	apparent	causal	association	between	GBS	and	a	particular
formulation	of	the	influenza	vaccine.	As	such,	our	understanding	of	the	epidemiology	of	GBS	is	intimately







newly	 recognized	 syndrome.	 However,	 the	 epidemiology	 of	 the	 syndrome	 was	 poorly	 understood;
epidemiology	as	a	distinct	medical	discipline	was	 still	 in	 its	 early	 stages	at	 this	 time,	 and	 the	 relative
rarity	 of	 the	 condition	made	 epidemiologic	 studies	 challenging.	 Nevertheless,	 over	 time,	 case	 reports
began	 to	 trickle	 into	 small	 case	 series,	 and	 from	 this	 trickle,	 several	 epidemiologic	 factors	 of	 GBS
seemed	to	emerge:	it	was	relatively	uncommon;	it	seemed	to	affect	males	more	commonly	than	females;	it
could	 occur	 at	 any	 age;	 and	 it	 was	 often	 associated	 with	 some	 antecedent	 prodrome	 suggestive	 of
infection,	 particularly	 upper	 respiratory	 tract	 infections.	 Information	 on	 incidence,	 demographics,	 and
other	basic	epidemiologic	data	were	gleaned	from	larger	studies	on	the	occurrence	of	neurologic	disease
in	general.
Early	 assessments	 of	 the	 epidemiology	 of	 GBS	were	 hampered	 primarily	 by	 one	 thing—lack	 of	 a




The	 first	 true	 descriptive	 epidemiologic	 study	 of	 GBS	 was	 published	 in	 1973	 by	 Lesser	 and






requisite.	This	was	 the	 first	comprehensive	study	 to	validate,	 in	a	 systematic	and	standardized	 fashion,
many	of	the	epidemiologic	features	of	GBS	that	we	now	take	for	granted.	During	that	34-year	period,	29
patients	 meeting	 the	 case	 criteria	 were	 identified,	 resulting	 in	 a	 mean	 annual	 incidence	 of	 1.6
cases/100,000	population/year;	males	were	slightly	more	likely	to	be	affected	than	females.	Rates	were
highest	in	the	40–59	age	group	(though,	notably,	due	to	small	sample	size	the	standard	errors	in	each	age
group	 were	 large).	 Cases	 were	 not	 clustered	 in	 any	 season,	 or	 in	 any	 given	 year.	 An	 antecedent
respiratory	 or	 infectious	 illness	 closely	 preceding	 neurologic	 illness	 onset	 was	 reported	 in	 16	 (55%)
cases.
The	Lesser	 study	was	 followed	up	by	a	subsequent	assessment	using	 the	same	methodology	and	 the
same	database,	extending	the	investigation	period	through	1976,	and	included	a	case-control	component







infectious	 illness	 in	 the	 4	weeks	 preceding	GBS	 onset	 than	 the	 age-	 and	 sex-matched	 controls,	 but	 no
differences	in	terms	of	exposure	to	prior	immunizations,	allergic	or	metabolic	disorders,	or	exposure	to
toxins,	suggesting	an	important	relationship	between	prior	infections	and	GBS.
Together,	 these	 papers	 solidified	 many	 of	 the	 basic	 epidemiologic	 tenets	 of	 GBS	 that	 had	 been




the	Olmsted	County	papers	 [4];	 the	 findings	 in	 this	 study	were	commensurate	with	 the	Olmsted	County
data	with	the	exception	that	the	San	Joaquin	evaluation	failed	to	demonstrate	a	male	predominance,	most
likely	due	to	small	sample	size	(n	=	18).
Aside	 from	 these	 assessments,	 surprisingly	 little	 work	 on	 the	 basic	 epidemiology	 of	 GBS	 was
conducted	 from	 identification	of	 the	 syndrome	until	 the	 swine	 flu	 (H1N1)	campaign	of	1976.	Globally,
what	work	was	being	 conducted	 consisted	of	 case	 reports	 and	 case	 series	 using	varying	 classification
schemes,	case	ascertainment	methodologies,	and	denominators	resulting	in	a	vertigo-inducing	variety	of
estimates	of	incidence,	seasonality	versus	no	seasonality,	age	distributions	and	other	basic	epidemiologic





to	 one	 of	 the	 relatively	 widely	 accepted	 case	 definitions/case	 criteria	 for	 GBS.	 After	 this	 laborious
process,	a	resultant	63	papers	survived	to	the	point	of	full	review.
To	review	the	results	of	McGrogan’s	assessment	is	to	appreciate	the	immense	diversity	of	fundamental






the	vast	majority	 (89%	of	 the	63	 studies)	of	 studies	were	conducted;	 for	 the	 rest	of	 the	world,	 so	 few
assessments	 had	 been	 conducted	 as	 to	 preclude	 comment	 on	 geographical	 trends.	 An	 important





further	 refine	 these	 incidence	 estimates	 in	North	America	 and	 Europe	 [6].	 Beginning	with	 the	 articles
cited	by	McGrogan,	and	inclusive	of	several	other	studies	published	subsequent	to	McGrogan’s	article,
we	conducted	a	meta-analysis	of	the	most	thorough	epidemiologic	papers	published	up	to	2009.	To	obtain
the	 most	 accurate	 incidence	 estimates,	 we	 applied	 specific	 and	 tight	 criteria.	 Because	 so	 little	 was
understood	 about	 the	 epidemiology	 of	 GBS	 elsewhere,	 we	 included	 only	 articles	 estimating	 GBS
incidence	in	North	American	and	European	countries;	studies	had	to	include	at	least	20	cases;	data	had	to
be	 population-based;	 and	 a	 diagnosis	 of	GBS	 had	 to	 be	 confirmed	 by	 a	 subject	matter	 expert	 using	 a
widely	 accepted	 case	 definition	 for	 GBS.	 This	 study	 identified	 1,683	 nonduplicative	 publications,	 of





















years	was	 in	 the	30–39	age	group,	while	 the	highest	was	 in	 the	youngest	age	group	(<10	years	of	 age;
1.15/100,000/year).	The	2	notable	findings	from	this	study	were	the	relatively	low	crude	incidence	when
compared	 to	 other	 studies	 using	 such	 robust	 case-finding	 methodologies,	 and	 the	 finding	 of	 a	 high
incidence	among	children	and	lower	incidence	in	adults.
The	 findings	 of	 this	 study	 continue	 to	 perplex	 me;	 their	 study	 design	 was	 sound,	 they	 were	 well-
powered	 to	 detect	 their	 cases,	 but	 the	 age-specific	 data	 differs	 from	 nearly	 every	 other	 GBS
epidemiologic	 study.	 The	 authors	make	 several	 suggestions	 as	 to	why	 this	 finding	might	 be,	 including
more	 complete	 case	 ascertainment	 among	 children,	misdiagnosis	 of	GBS	 in	 this	 age	 group	 and	 a	 true





years	 (2006	 and	 2007),	 they	 calculated	 a	 crude	 incidence	 rate	 fell	 between	 1.5	 and	 2.5	 per	 100,000













a	 syndrome	 that	 has	 undergone	 some	 of	 the	 most	 extensive	 epidemiologic	 scrutiny	 of	 human	 medical







literature.	However,	 substantiation	of	an	etiologic	or	causal	nature	of	 such	associations	with	data	 from
clinical	trials	or	large	epidemiologic	studies	is	generally	lacking.	Thus,	the	occurrence	of	many	clinical
events	 that	 are	 associated	 with	 a	 particular	 vaccine	 by	 virtue	 of	 temporal	 proximity	 is	 substantially
different	than	demonstrating	a	causal	relationship.
GBS	and	Vaccines:	The	Early	Years















GBS	began	 to	be	viewed	specifically	 through	a	vaccine-filtered	 lens	 in	1976.	This	was	 the	year	of	 the
U.S.	 bicentennial—1976	marked	 the	 200th	 birthday	 of	 the	 nation.	Against	 this	 backdrop	 of	 patriotism,
fireworks	and	celebration,	the	understanding	of	GBS	was	about	to	be	changed	forever.
In	early	February	of	1976,	the	New	Jersey	Department	of	Health	obtained	isolates	of	influenza	viruses




the	catastrophic	1918	‘swine	flu’	pandemic	 that	 resulted	 in	millions	of	deaths	worldwide.	Surveillance






to	 produce	 enough	 H1N1	 vaccine	 to	 immunize	 the	 entire	 U.S.	 population;	 the	 manufacturers	 balked,






Before	 the	 campaign	 was	 launched,	 a	 nationwide	 passive	 surveillance	 system	 was	 established	 to
evaluate	 any	 possible	 adverse	 events	 following	 this	 immunization.	 A	 young	 CDC	 epidemiologist,	 Dr
Larry	 Schonberger,	 was	 put	 in	 charge	 of	 overseeing	 and	monitoring	 this	 program.	 Trained	 in	 internal
medicine	and	just	arriving	as	a	CDC	staff	member	after	his	studies	in	epidemiology	at	Johns	Hopkins	and
anxious	 to	 begin	 applying	 his	 epidemiologic	 knowledge,	 Dr	 Schonberger	 took	 on	 the	 project,	 never
anticipating	the	storm	that	was	to	come.	By	2	December,	2	clusters	of	GBS	were	reported	to	CDC	from	2
different	 U.S.	 states.	 Out	 of	 an	 abundance	 of	 caution,	 these	 clusters	 led	 to	 the	 initiation	 of	 active
surveillance	for	GBS	cases	 in	 these	2	states	and	2	additional	states,	and	shortly	 thereafter	7	additional
states,	to	evaluate	the	possibility	of	a	causal	relationship	between	GBS	and	the	influenza	vaccinations.	As
Dr	Schonberger	crunched	the	numbers,	he	became	intrigued;	as	more	GBS	cases	came	in,	intrigue	turned
into	 concern.	 In	 this	 pre-desktop	 computer	 era,	 Dr	 Schonberger	 spent	 hours	 comparing	 rates	 of	 GBS
among	vaccinees	and	nonvaccinees,	and	became	convinced	that	something	was	out	of	the	ordinary—there
appeared	 to	 be	 a	 plausible	 association	 between	 the	 vaccine	 and	GBS.	Using	person-time	 analysis,	 the
data	suggested	that	recent	vaccinees	had	a	7-fold	greater	incidence	of	GBS	compared	with	those	who	had
not	received	the	vaccine.	On	the	basis	of	these	preliminary	findings,	and	the	weakening	evidence	that	a
swine	 flu	 pandemic	 was	 actually	 going	 to	 emerge,	 the	 vaccination	 campaign	 was	 suspended	 on	 16
December	 1976	 (Dr	 Schonberger	 recalls	 the	 secretary	 of	Health	 and	Human	Services	 telling	 him	 in	 a
stern	and	somewhat	irritated	voice,	“You	better	be	right	about	this.”)






immunization	 program)	 and	 31	 January	 1977.	 This	 focused	 surveillance	 on	 GBS	 identified	 a	 total	 of
1,098	 cases;	 532	 (48.5%)	 occurred	 sometime	 after	 receipt	 of	 a	 swine	 flu	 vaccine.	 Many	 notable




2.	 The	 distribution	 of	 cases	 occurring	 by	 week	 after	 vaccination	 clustered	 in	 the	 first	 5	 weeks,
particularly	in	weeks	2	and	3	after	vaccination.	Compared	to	the	expected	rates,	the	relative	risks	for






4.	 The	 reported	 relative	 risk	 (RR)	of	GBS	 for	 the	6-week	period	 after	 vaccination	 in	 adults	was	7.6
(95%	 CI	 6.7–8.6),	 resulting	 in	 an	 attributable	 risk	 (AR)	 during	 this	 period	 of	 0.88	 GBS
cases/100,000	vaccinees.




with	 those	 recently	vaccinated	having	a	significantly	elevated	attack	 rate	 in	every	adult	age	group.	The






of	GBS;	 full	 evaluation	 of	 cases	 by	 a	 trained	 neurologist	was	 not	 required,	 and	many	 non-neurologist
practitioners	may	not	have	had	enough	familiarity	with	the	syndrome	to	arrive	at	a	correct	diagnosis;	and
the	 intense	 publicity	 surrounding	 the	 swine	 flu	 immunization	 effort	may	have	 led	many	practitioners	 to
over-diagnose	any	peripheral	neuropathy	among	vaccinees	as	GBS.	Similarly,	 the	CDC	did	not	conduct
an	 independent	 medical	 record	 review	 of	 the	 1,098	 cases	 submitted	 as	 GBS.	 It	 was	 noted	 that	 the
characteristics	of	a	number	of	cases	accepted	by	the	CDC	did	not	conform	to	accepted	diagnostic	criteria
for	GBS.	Finally,	 the	 publicity	 surrounding	 the	 campaign	may	have	biased	practitioners	 towards	 over-
reporting	 GBS	 among	 vaccinees,	 or	 alternatively	 under-reporting	 GBS	 among	 unvaccinated	 patients.
These	points	were	summarized	in	a	scathing	editorial	published	in	the	Archives	of	Neurology	by	Kurland
and	colleagues	[11].
As	 legal	 claims	 against	 the	U.S.	 government	 for	 damage	 caused	by	 the	H1N1	vaccine	mounted,	 the
pressure	on	Dr	Schonberger	similarly	increased.	Schonberger	and	others	at	the	CDC	were	deposed,	and
Schonberger	 found	 himself	 trying	 to	 explain	 the	 epidemiologic	 principles	 behind	 the	 association	 to
litigious	lawyers	and	patients.	“It	was	the	most	stressful	time	of	my	life”,	he	recalls.	Ultimately,	the	U.S.





its	 risk	 assessment	 on	 the	 most	 definite	 and	 severely	 affected	 cases	 (those	 with	 ‘extensive	 motor
involvement’).	 It	 also	 decided	 to	 use	 2	 different	 estimates	 of	 the	 expected	 background	 rates	 of	 GBS.
Based	 on	 the	 ‘extensive	 motor	 involvement’	 cases,	 the	 panel	 confirmed	 the	 original	 findings	 of	 a
significantly	elevated	risk	of	GBS	among	vaccinees	that	peaked	at	weeks	2–3	following	vaccination	and
lasted	for	at	least	6	weeks.	The	panel	reported	that	this	vaccine	effect	possibly	lasted	for	8–10	weeks,	but











specific	 HLA	 haplotypes	 amongst	 92	 GBS	 cases	 and	 100	 controls	 that	 were	 clearly	 associated	 with
development	of	GBS	following	the	1976	influenza	vaccine.
Perhaps	 the	 most	 creative	 attempt	 to	 establish	 a	 biological	 underpinning	 to	 this	 association	 was
performed	by	Nachamkin	and	colleagues	[14].	This	study	assessed	the	potential	association	of	influenza
vaccines	with	anti-ganglioside	antibodies.	Particular	Campylobacter	jejuni	serotypes	have	been	found	to
have	a	 strong	association	with	 the	development	of	GBS,	which	 is	hypothesized	 to	be	due	 to	molecular
mimicry	between	bacterial	surface	lipooligosaccharides	which	express	peripheral	nerve	ganglioside-like
epitopes,	resulting	in	the	production	of	cross-reactive	antibodies.	It	has	been	hypothesized	that,	since	C.




several	 other	 influenza	 vaccine	 formulations	 that	 had	 not	 been	 associated	with	 increased	 risk	 of	GBS.
Mice	were	inoculated	with	vaccine;	additional	mice	were	inoculated	with	C.	 jejuni—one	serotype	 that
displays	GM1	ganglioside	mimicry	as	a	positive	control,	and	one	with	no	GM1	ganglioside	mimicry	as	a
negative	 control.	 The	 immunized	mice	 were	 found	 to	 have	 no	 antibodies	 to	C.	 jejuni,	 suggesting	 that
Campylobacter	 antigens	 were	 not	 present	 in	 the	 vaccine	 formulations.	 However,	 all	 immunized	 mice
developed	anti-GM1	IgM	and	IgG	antibodies,	with	significant	increases	in	such	antibodies	observed	over








The	 association	 of	 the	 1976	 influenza	 vaccine	 with	 GBS	 obviously	 led	 to	 great	 concern	 about	 the
potential	of	subsequent	seasonal	 influenza	vaccines	 to	 lead	 to	a	similar	association.	Between	1977	and
2009,	at	least	9	published	assessments	of	the	risk	of	GBS	following	influenza	vaccines	were	conducted
(Table	7.1)	[15–24].	Of	these	9	studies,	2	involved	active,	population-based	surveillance,	medical	record
reviews	 and	 patient	 interviews	 [19,24].	 Three	 used	 searches	 of	 large	 datasets	 that	 enabled	 linking	 of
disease	 codes	 and	 vaccination	 information	 and	 the	 comparison	 of	 GBS	 attack	 rates	 in	 different	 time
windows	 after	 vaccination	 [20,22,23].	Two	 involved	 active	 sentinel	 neurologist	 surveillance	 [17,	 25].
One	used	hospital	discharge	data	without	a	link	to	vaccination	information	[18]	and	one	assessed	reports
to	a	national	passive	vaccine-adverse	event	surveillance	system	[21].	Two	of	 these	studies	suggested	a
small	 but	 statistically	 significant	 increase	 in	 risk	 of	 GBS	 following	 various	 formulations	 of	 influenza




formulations	 since	 1976	 would	 suggest	 that	 this	 risk,	 if	 any,	 is	 much	 smaller	 than	 that	 observed	 in














During	 the	 spring	of	 2009,	 the	world	witnessed	 the	 emergence	of	 yet	 another	H1N1	 influenza	virus	 of
swine	origin.	Unfortunately,	unlike	the	1976	H1N1	influenza	virus,	the	2009	virus	was	definitely	a	serious
public	 health	 threat;	 in	 April	 2009,	 the	 virus	 was	 identified	 in	 specimens	 obtained	 from	 2
epidemiologically	 unlinked	 patients	 in	 the	 United	 States.	 Similar	 viruses	 were	 rapidly	 identified	 in
Mexico,	 Canada,	 and	 subsequently	 other	 countries	 throughout	 the	 world;	 by	 the	 summer	 of	 that	 year,
94,512	confirmed	cases	with	429	deaths	were	reported	to	the	World	Health	Organization	(WHO),	leading
to	the	declaration	of	a	pandemic.
The	 global	 emergence	 of	 the	 pandemic	 (H1N1)	 2009	 virus	 (pH1N1),	 and	 its	 rapid	 global	 spread
associated	with	community-wide	outbreaks,	hospitalizations	and	deaths	prompted	rapid	development	of
new	influenza	A	(H1N1)	2009	monovalent	vaccine	that	could	be	produced	in	sufficient	quantities	 to	be
used	globally.	The	association	of	GBS	with	 the	1976	swine	 flu	vaccine	had	 left	public	health	officials
shell-shocked,	and	 immediately	 led	 to	questions	about	a	similar	association	of	neurologic	disease	with
vaccines	against	the	p(H1N1)	2009	virus,	also	partially	of	swine	origin.
Although	 the	 safety	 and	 efficacy	 of	 the	 influenza	 A	 (H1N1)	 2009	 monovalent	 vaccine	 was	 to	 be
assessed	 through	 a	 small	 number	 of	 limited	 clinical	 trials,	 the	 interval	 between	 vaccine
development/manufacturing	and	widespread	use	of	the	vaccine	was	extremely	short,	pre-licensure	safety
data	was	quite	limited,	and	post-licensure	safety	surveillance	was	going	to	take	many	months	to	collect
and	assess.	Such	was	 the	angst	about	a	 repeat	of	 the	1976	situation	 that	a	group	of	us	at	CDC	huddled
together	 on	 a	 Saturday	 afternoon	 shortly	 after	 recognition	 of	 the	 pandemic,	 deliberating	 the	 need	 to
conduct	 surveillance	 for	GBS	 in	 the	 face	 of	 the	 vaccination	 campaign,	 and	 if	 so,	 how.	Ultimately,	we
decided	to	implement	real-time,	active,	population-based	surveillance	for	GBS	following	p(H1N1)	2009
monovalent	vaccine	in	order	to	inform	public	health	recommendations	regarding	the	relative	benefit	and





estimated	 baseline	 rates	 of	 GBS.	 Surveillance	 commenced	 on	 1	 October	 2009	 (coincident	 with	 the
introduction	of	the	U.S.	vaccine),	and	continued	through	31	May	2010.	The	assessment	was	overseen	by
the	 CDC,	 and	 conducted	 amongst	 CDC’s	 10	 Emerging	 Infections	 Program	 (EIP)	 sites;	 the	 EIP	 sites
constitute	 a	 platform	 to	 perform	 population-based	 real-time	 surveillance	 for	 a	 number	 of	 different
conditions	in	10	U.S.	states,	encompassing	a	population	of	approximately	49	million	residents.	Learning
from	the	criticisms	of	the	1976	evaluation,	each	EIP	site	established	a	surveillance	network	comprised	of
neurologists	 and	 other	 healthcare	 providers	 that	 was	 queried	weekly	 to	 stimulate	 reporting	 of	 suspect
GBS	cases;	hospital	discharge	data	were	also	reviewed	(ICD-9	code	357.0)	to	capture	additional	cases
not	reported	through	the	provider	network.	Cases	were	stratified	into	2	broad	age	groups	(0–24	years;	≥
25	 years)	 to	 ensure	 ascertainment	 of	 sufficient	 person-time.	 Trained	 surveillance	 officers	 reviewed
medical	records	and	conducted	telephone	interviews	with	suspected	cases	to	obtain	basic	demographics,
risk	 factors	 and	 vaccination	 status,	 and	 determined	 date	 of	 receipt	 of	 p(H1N1)	 and	 seasonal	 influenza
vaccines.	Cases	were	then	classified	according	to	Brighton	criteria	case	definitions	for	GBS	(Appendix)
[27];	patients	meeting	Brighton	Levels	1–3	(akin	 to	suspect,	probable	and	confirmed)	were	 included	 in
analysis.	The	observed	number	of	GBS	cases	was	compared	with	the	number	of	expected	cases,	which
we	 estimated	 by	 applying	 age-specific	GBS	 background	 rates	 to	 the	 EIP	 population.	GBS	 background
rates	were	estimated	by	modelling	published	population-based	GBS	rates.





The	 411	GBS	 cases	 in	 the	 EIP	 catchment	was	 similar	 to	 the	 expected	 number	 for	 the	 surveillance
population	(age-adjusted	observed/expected	ratio:	1.21,	95%	CI	0.91–1.74),	as	well	as	among	persons
0–24	and	≥	25	years	old.	Data	suggested	11	total	excess	GBS	cases	during	the	surveillance	period	and	an







per	million	 p(H1N1)	 doses	 administered,	was	 similar	 to	 that	 associated	with	 some	 previous	 seasonal
influenza	 vaccine	 formulations	 and	 was	 10-fold	 lower	 than	 the	 excess	 risk	 associated	 with	 the	 1976
vaccine.
In	 contrast	 to	 the	 finding	 of	 less	 than	 one	 excess	GBS	 case	 per	million	 doses	 of	 p(H1N)1	 vaccine
administered,	 numerous	 studies	 have	 demonstrated	 the	 effectiveness	 of	 p(H1N1)	 vaccine	 in	 preventing
pandemic	 influenza	 A	 (H1N1)	 2009	 infections;	 the	 CDC	 estimated	 that	 the	 use	 of	 p(H1N1)	 vaccine
prevented	713,000	 to	1.5	million	cases,	3,900	 to	10,400	hospitalizations,	and	200	 to	520	deaths	 in	 the
United	States	during	the	same	time	period	[28].	Thus,	the	small	but	real	increased	risk	of	developing	GBS
following	the	p(H1N1)	vaccine	was	dwarfed	by	the	benefits	of	receiving	the	vaccine	[29–31].





was	 associated	 with	 a	 small	 but	 real	 increased	 risk	 of	 developing	 GBS	 in	 the	 6–8	 weeks	 following
receipt	of	vaccine.	Subsequent	seasonal	influenza	vaccines,	including	the	2009	p(H1N1)	swine	influenza














Earlier	 formulations	 of	 rabies	 vaccine,	which	 entailed	 inoculation	 of	 live	 rabies	 virus	 into	mature
sheep	 or	 goat	 brain	 and	 inactivated	 with	 phenol,	 appeared	 to	 be	 associated	 with	 a	 higher-than-
expected	incidence	of	‘neuroparalytic	adverse	events’	thought	to	be	GBS	[36,37].	This	was	presumed
to	be	due	to	the	presence	of	brain	protein	in	the	formulated	vaccine,	with	the	possible	generation	of






During	 and	 shortly	 after	 the	 immunization	 campaign,	 several	 hospitals	 reported	 admitting	 unusually
large	numbers	of	suspected	GBS	patients,	with	10	cases	admitted	during	the	first	quarter	and	6	cases
during	 the	second	quarter	of	1985,	corresponding	 to	 the	 immunization	campaign	[38–40].	However,
later	 studies	 assessing	monthly	 reports	 of	GBS	between	 1981	 and	 1986	 suggest	 that	 the	 number	 of
GBS	 cases	 started	 to	 rise	 prior	 to	 the	OPV	 campaign;	 since	 there	 had	 been	 an	 influenza	 epidemic
between	December	and	April	of	 that	year,	 the	authors	concluded	that	 the	small	apparent	 increase	 in
GBS	 observed	 during	 that	 time	 could	 have	 been	 associated	 with	 the	 circulation	 of	 wild-type




toxoid	 conjugate	vaccine	 (Menactra;	MCV4)	 appears	 to	have	been	 a	 false	 alarm.	The	vaccine	was
licenced	in	January	2005	for	use	in	the	United	States	for	persons	aged	11–55;	in	February	2005	a	U.S.
immunization	advisory	committee	recommended	MCV4	vaccination	for	11-	12-year-old	children	and
before	 high	 school	 entry	 for	 individuals	 not	 previously	 vaccinated,	 in	 addition	 to	 the	 ongoing
recommendations	 for	 routine	 vaccination	 for	 persons	 living	 in	 college	 dormitories,	 army	 bases,
prisons	 or	 other	 crowded	 living	 conditions.	 By	 October	 2005,	 5	 cases	 of	 GBS	 following	MCV4
vaccination	had	been	reported	to	the	Vaccine	Adverse	Events	Reporting	System	(VAERS),	a	national





the	 passive	 nature	 of	 VAERS	 reporting	 and	 the	 imprecise	 estimated	 background	 rate	 of	 GBS	 in
adolescents	 at	 that	 time.	 Subsequent	 evaluations	 of	 GBS	 risk	 following	 MCV4	 using	 controlled
studies	 and	 other	 systematic	 methodologies	 have	 failed	 to	 substantiate	 any	 increased	 risk	 of	 GBS
following	MCV4	[43].
Tetanus	toxoid	vaccine,	in	the	form	of	tetanus-diphtheria	(Td)	vaccine,	has	been	associated	with	one
apparent	 case	 of	 challenge/rechallenge	 in	which	 a	 42-year-old	male	 developed	GBS	 following	Td
vaccine	 on	 3	 separate	 occasions	 over	 a	 13-year	 period,	 raising	 the	 possibility	 of	 causality	 in	 this
individual	 [44].	However,	 larger	 assessments	 of	GBS	 following	 tetanus	 toxoid-containing	vaccines
have	failed	to	substantiate	an	increased	risk	[45].
The	 fundamental	 fact,	 as	 stated	 earlier,	 that	 one	 can	 find	 a	 case	 report	 of	 nearly	 any	 vaccine	 being
followed	temporally	by	onset	of	GBS	does	not	equate	to	‘causality’.	Vaccines	have	truly	been	one	of	the




of	 GBS,	 or	 any	 other	 neurologic	 illness,	 for	 that	 matter,	 following	 vaccines	 is	 far	 outweighed	 by	 the
benefits	of	receipt	of	the	vaccine.
During	 the	 next	 100	 years,	 hopefully,	 we	 will	 gain	 a	 better	 understanding	 of	 the	 incidence,
epidemiology	 and	 risk	 factors	 for	GBS	 in	Africa,	Asia,	 the	Middle	East	 and	 other	 areas	 of	 the	 globe.





















































































































4.	 CSF	with	 a	 total	 white	 cell	 count	<	 50	 cells/mm3	 (with	 or	 without	 CSF	 protein	 elevation	 above
















Guillain-Barré	 syndrome	 (GBS)	 is	 a	 disorder	with	 no	 boundaries.	Reports	 have	 been	 published	 about
patients	 from	 all	 geographical	 areas,	 including	 males	 and	 females	 of	 all	 ages.	 With	 a	 current	 world
population	 of	 7.4	 billion	 people	 and	 an	 incidence	 rate	 of	 1	 to	 2	 per	 100,000	 per	 year,	 the	 estimated
number	of	persons	 that	yearly	develop	GBS	 is	about	100,000.	However,	GBS	 is	also	a	 relatively	 rare
disease	for	clinicians	and	researchers	and	it	may	be	difficult	to	develop	sufficient	clinical	expertise	or	to
collect	sufficient	data	for	research.
The	 current	 chapter	 is	 a	 plea	 that	 patients,	 clinicians	 and	 researchers	 would	 all	 benefit	 from
international	collaboration	in	their	general	aim	to	reduce	the	worldwide	burden	of	disease.	We	would	like
to	 illustrate	 this	 by	 indicating	 several	 topics	 in	 research	 which	 strongly	 benefit	 from	 international
collaboration.
Compare	Incidence	Rates	to	Identify	Risk	Factors	for	Developing	GBS
GBS	 is	 probably	 caused	 by	 a	 combination	 of	 host	 and	 environmental	 susceptibility	 factors	which	may
differ	 per	 geographical	 area.	To	be	 able	 to	 identify	 these	 factors	 it	will	 be	 important	 to	 conduct	 large
incidence	studies	that	use	the	same	case	definitions	and	study	design.	The	incidence	of	GBS	worldwide
has	 been	 reported	 between	 0.4	 and	 3.25	 per	 100,000	 person-years.	 In	 one	 meta-analysis	 in	 North
American	and	European	countries,	the	incidence	was	0.81–1.89	(median	1.11)	per	100,000	person-years
[1,2].	Although	this	range	could	be	considered	to	be	wide,	it	is	even	more	variable	when	incidence	rates
of	 non-Western	 countries	 are	 considered.	 For	 example,	 the	 lowest	 incidence	 rate	 of	 0.4	 per	 100,000
persons	has	been	 reported	 in	one	hospital-based	 study	 in	Brazil,	whereas	 the	highest	 incidence	 rate	of
3.25	has	 been	 reported	 in	 children	 from	Bangladesh	 (<15	years	 if	 age)	 (see	Table	8.1)	 [3,4,5].	 These
results	are	based	on	a	relatively	small	number	of	patients	and	have	not	been	confirmed	in	larger	studies
but	 theymay	 indicate	 that	 the	 exposure	 to	 infections	 as	 well	 as	 host	 factors	 may	 influence	 the	 risk	 of
developing	GBS.
Another	variability	 regarding	 the	epidemiology	of	GBS	worldwide	 is	whether	 seasonal	 fluctuations
are	observed.	Some	studies	report	a	peak	in	the	winter,	others	in	the	summer	and	the	remaining	report	no
seasonal	fluctuations	whatsoever.	One	meta-analysis	concluded	that	in	Western	countries,	the	Middle	East










About	 two-third	of	patients	 report	symptoms	of	a	 respiratory	or	gastrointestinal	 tract	 infection	within	3
weeks	beforeonset	of	GBS.	A	specific	infectious	cause	has	been	identified	in	about	half	of	patients,	with
Campylobacter	jejuni	being	the	predominant	cause.	Other	infectious	agents	which	have	been	identified	in
relation	 to	 GBS	 are	 cytomegalovirus,	 Epstein-Barr	 virus,	 Mycoplasma	 pneumonia,	 Haemophilus
influenzae,	 influenza	 A	 virus	 and	 recently	 hepatitis	 E	 virus	 [7].	 The	 frequencies	 of	 these	 preceding
infections,	 however,	 highly	 differ	 between	 various	 geographical	 areas.	 Without	 international
collaboration	it	will	be	difficult	 to	define	 if	 these	differences	are	real	or	represent	differences	 in	study
design	 and	 techniques	 used	 to	 demonstrate	 such	 infections.	 There	 are	 various	 examples	 of	 such
comparative	 and	 international	 studies.	 One	 example	 is	 the	 collaborative	 study	 between	 Japan	 and	 the
Netherlands	 investigating	 the	 frequency	 of	 preceding	 infections	 with	 C.	 jejuni	 and	 2	 serological







amyotrophy	 [10,11].	 The	 combination	 of	 patient	 cohorts	 and	 techniques	 was	 crucial	 to	 making	 these
discoveries.
Various	 types	 of	 infection	 are	 known	 to	 precipitate	 GBS	 but	 the	 type	 of	 infections	 may	 differ	 per
geographical	 area.	 By	 collecting	 data	 and	 biosamples	 from	 patients	 in	 various	 areas	 using	 the	 same




some	 patients	 may	 develop	 secondary	 axonal	 degeneration.	 Tom	 Feasby	 challenged	 this	 concept	 by







that	 these	 patients	 did	 have	 a	 different	 form	 of	 GBS	 with	 predominantly	 motor	 signs	 and	 an	 axonal
polyneuropathy,	the	so-called	acute	motor	axonal	neuropathy	(AMAN).
Later	 studies	 have	 shown	 that	 there	 is	 a	 distinct	 geographical	 variation	 in	 frequency	 of	AMAN.	 In
Europe	and	North	America,	AMAN	accounts	for	only	3–17%	of	GBS	cases,	whereas	this	proportion	is
much	 higher	 in	 Asia	 and	 South	 America	 (30%	 to	 65%).	 The	 opposite	 applies	 to	 the	 demyelinating
subtype,	 acute	 inflammatory	 demyelinating	 polyneuropathy	 (AIDP),	 which	 is	 present	 in	 69–90%	 of
Western	GBS	patients	and	in	only	20–40%	of	Asian	and	South	American	patients	[15].	One	international
collaborative	study	between	Japan	and	Italy	confirmed	these	findings	[16].	The	cause	of	the	geographical








AMAN	 patients	 without	 excessive	 temporal	 dispersion	 (reversible	 conduction	 failure	 or	 conduction
blocks).	This	may	result	in	fallaciously	diagnosing	AMAN	patients	with	reversible	conduction	failure	as
AIDP	 patients.	 Despite	 attempts	 to	 include	 diagnostic	 criteria	 to	 identify	 this	 reversible	 conduction
failure,	 there	 still	 was	 a	 shift	 from	AIDP	 to	AMAN	with	 serial	 nerve	 conduction	 studies.	 Uncini	 and
Kuwabara	also	show	that	on	top	of	this	difficulty,	there	are	numerous	terms	to	describe	this	phenomenon,
making	 the	 confusion	 complete.	 Moreover,	 electrophysiological	 departments	 frequently	 use	 their	 own
standards	 and	 protocols.	 For	 these	 reasons,	 comparing	 study	 results	 from	 different	 countries	 about




Too	 many	 patients	 with	 GBS	 are	 living	 in	 low-income	 countries	 where	 the	 majority	 only	 receive
supportive	 care	 at	 the	most.	But	 patients	 from	high-income	 countries	who	 are	 treated	with	 intravenous
immunoglobulins	(IVIg)	or	plasma-exchange	(PE)	also	show	a	considerable	mortality	of	about	3%	to	7%,
and	about	10–20%	of	the	patients	remain	permanently	severely	disabled	[7].
We	would	 like	 to	 illustrate	 the	difference	 in	 outcome	of	GBS	 in	 low-	versus	 high-income	areas	 by
comparing	2	 studies.	The	 first	 study	was	carried	out	 in	 the	Netherlands	 in	 a	 cohort	of	527	patients,	of
which	 the	majority	weretreated	with	either	 IVIg	or	PE,	with	mortality	 rate	of	2.8%	[18].	Most	patients
died	 from	 cardiovascular	 or	 autonomic	 complications	 and	 death	 occurred	 most	 frequently	 during	 the
recovery	phase.
A	second	study	from	Bangladesh,	with	a	prospective	study	design	similar	 to	 that	of	 the	Dutch	study,
showed	that	only	one-quarter	of	the	patients	were	treated	with	IVIg	and	that	the	mortality	rate	was	14%.
Several	patients	died	because	of	 respiratory	 failure	and	 lack	of	 facilities	 to	offer	ventilation	at	an	 ICU
[19].
These	results	show	the	alarming	difference	in	health	care	and	outcome	of	GBS	between	Western	and
developing	 countries.	 Hopefully,	 international	 collaboration,	 not	 only	 of	 researchers	 but	 also	 from
governments	and	medical	services,	can	eliminate	the	global	differences	in	outcome	after	GBS.
International	Collaboration	on	Treatment	Trials





In	 earlier	 decades,	 there	 were	 only	 2	 studies	 on	 PE	 or	 IVIg	 with	 international	 collaboration:	 the









that	 every	 nation	 has	 its	 own	 regulations.	 This	 makes	 it	 difficult	 to	 set	 up	 international	 RCTs.	 An
infrastructure	and	network	of	dedicated	centres	 for	conducting	 therapeutic	 studies	may	strongly	support
the	conduct	of	therapeutic	studies.	Less	strict	rules	apply	for	observational	studies	and	the	International
GBS	Outcome	Study	(IGOS)	is	currently	running	in	18	countries.	The	main	aim	of	IGOS	is	to	be	better
able	 to	 predict	 disease	 course	 and	 outcome	 in	 individual	 patients,	 but	 it	 also	 provides	 a	 platform	 for
evaluating	different	 therapeutic	 strategies	 internationally.	Hopefully,	 these	 results	 could	be	a	 stepup	 for
further	(international)	RCTs	to	confirm	the	observational	findings.
InternationalOrganizations
The	 GBS-CIDP	 Foundation	 International	 (http://www.gbs-cidp.org/)	 is	 an	 international	 patient
organization,	currently	represented	in	43	countries.	Their	aim	is	to	provide	“access	to	early	and	accurate
diagnosis,	appropriate	and	affordable	treatment,	and	knowledgeable	support	devices”.	The	organization
consists	of	 a	global	network	of	volunteers,	healthcare	professionals,	 researchers	 and	 industry	partners.
This	organization	already	plays	an	 important	 role	 in	 international	collaboration	between	clinicians	and
researchers.
In	 2007	 the	 Inflammatory	Neuropathy	Consortium	 (INC)	was	 raised	 by	Richard	Hughes	 to	 support
international	 research	 in	GBS	 and	 other	 neuropathies.	 This	 consortium	made	 it	 possible	 to	 initiate	 the
International	GBS	Outcome	Study	(IGOS)	(www.gbsstudies.org).	The	aim	of	the	prospective	longitudinal
cohort	study	is	to	define	all	biological	and	clinical	determinants	and	predictors	of	the	clinical	course	and
outcome	of	 individual	patients	with	GBS.	The	strength	of	 IGOS	is	 the	highly	detailed	and	standardized
collections	 of	 clinical	 data	 and	 biomaterials	 in	 18	 different	 countries	 from	 6	 continents.	 This	 way	 of
collection	 will	 ensure	 that	 the	 results	 from	 different	 countries	 are	 highly	 comparable.	 Moreover,	 by
combining	 forces	 the	 IGOS	consortium	has	been	able	 to	 include	currently	1,146	patients	with	GBS,	an
unprecedentedly	 large	 number	 of	 well-defined	 patients.	 The	 consortium	 of	 about	 100	 clinicians	 and




Islam,	Badrul	 Islam	and	Professor	Deen	Mohammed,	providing	 the	opportunity	 to	compare	for	 the	first




























































year	 collaboration	 between	 a	 team	 of	 colleagues	 from	 Johns	 Hopkins	 University,	 the	 University	 of
Pennsylvania,	and	colleagues	in	Beijing	and	Shijiazhuang.
I	made	a	 longer	visit	 to	Beijing	 in	October	1988.	At	 that	 time	 I	 saw	about	30	children	and	had	 the
opportunity	 to	 examine	 10	 thoroughly.	 I	 also	 had	 the	 opportunity	 to	 discuss	 this	 form	 of	 GBS	 with
Professor	Zhu	Fu-Tang,	a	90-year-old	paediatrician	and	founder	of	 the	Beijing	Children’s	Hospital.	Dr








services	 were	 overwhelmed.	 The	 cases	 were	 almost	 exclusively	 in	 the	 summer,	 starting	 in	May,	 and
dropping	off	by	October.	There	were	more	boys	than	girls	(60/40).	The	cases	came	from	rural	areas,	not
from	the	cities.	There	was	no	clustering	of	cases;	no	multiple	cases	from	a	single	village;	only	1	instance
of	2	cases	 in	 the	 same	 family;	 and	no	 involvement	of	exposed	medical	personnel.	The	age	distribution
was	 strikingly	 different	 from	 ‘western	 GBS’,	 being	 predominantly	 children.	 A	 prodromal	 illness	 was





to	 get	 some	 funding	 from	 the	 Rockefeller	 Foundation	 and	 were	 prepared	 to	 go	 when	 things	 were
disrupted,	in	June	1989,	by	the	events	at	Tiananmen	Square	and	other	areas.	In	the	meantime,	Dr	Chun-Yun






patients	had	been	previously	healthy.	The	 first	 symptom,	particularly	 in	children,	was	unsteadiness	and
falling,	 followed	 quickly	 by	 bilateral,	 symmetrical	 leg	 weakness.	 The	 disease	 then	 might	 skip	 to	 the
cranial	nerves,	with	facial	weakness	and	swallowing	difficulties	and	then	breathing	difficulties.	The	last
phase	would	be	bilateral	weakness	of	the	arms.	The	duration	of	onset	could	be	as	short	as	2	to	3	days,	or,







the	 patient	 upstairs	 and	 put	 him	 back	 on	 his	 respirator.	 (I	 was	 afraid	 he	 might	 die	 while	 we	 were
examining	him.)	Tony	came	back	a	few	minutes	later	and	said	‘Don’t	embarrass	them—they	have	run	out







action	 potentials.	 This	 finding	 was	 very	 different	 from	 the	 typical	 understanding	 of	 Guillain-Barré




























as	 Dr	 Asbury	 and	 colleagues	 had	 described	 in	 1969	 [3].	 Rather,	 in	 fatal	 cases,	 there	 was	 extensive
Wallerian–like	degeneration	of	motor	axons	(thus	called	acute	motor	axonal	neuropathy	[AMAN]),	and,	in
some	 cases,	 involvement	 of	 both	 sensory	 and	 motor	 axons	 (thus	 called	 acute	 sensory-motor	 axonal
neuropathy	[AMSAN]).	In	both	instances	a	prominent	feature	was	the	presence	of	macrophages	within	the
periaxonal	 space,	 displacing	 the	 axon	 (Figure	 9.3).	 The	 movement	 of	 macrophages	 to	 the	 axon	 was
defined	[4–6].	These	clues	suggested	that	the	macrophages	were	attracted	to	something	in	the	paranodal
or	nodal	regions.	Under	Jack’s	leadership,	Charlene	Macko,	Kazim	Sheikh	and	Tony	Ho	later	carried	out








lengthening	and	 two	overlying	macrophages	 in	a	case	of	AMAN.	(G)	A	macrophage	 in	 the	 internodal	axon	beginning	 to	extend







met	Dr	Zhu	Fu-tang	(Figure	9.4).	Guy	was	very	 interested	 in	his	observation	 that	 this	disease	suddenly
increased	in	prevalence	in	the	1970s.	We	did	not	get	any	real	clues	on	the	first	day	we	visited	him.	During
the	next	day,	Guy	asked	him	the	same	question,	‘What	happened	twenty	years	ago?’	again	to	no	avail.	On














my	 internship	 at	Massachusetts	General	Hospital	 in	 the	 basement	 bacteriological	 lab,	 learning	 how	 to
grow	Campylobacter	under	microaerophilic	conditions.	This	turned	out	to	be	a	good	investment.	After	my
internship,	 I	 spent	 the	 summer	 of	 1992	 at	 Shijiazhuang	 seeing	 these	 patients,	 doing	 nerve	 conduction
studies,	and	teaching	our	Chinese	colleagues	how	to	culture	Campylobacter.	This	is	when	we	found	the
striking	association	with	chickens.	A	14-year-old	girl	came	 in	with	advancing	disease.	She	 told	us	 that
she	was	studying	in	the	city.	Her	mother	had	called	her	and	asked	her	to	come	back	to	the	village	to	take
care	of	a	‘sick’	chicken.	After	feeding	the	chicken	with	some	form	of	medicine	(presumably	vitamins),	she
fell	 ill	 and	became	paralyzed.	We	 sent	 a	 team	 to	her	 village	 to	 examine	 these	 chickens	 and	 took	 stool
cultures.	The	pictures	were	striking:	several	chickens	had	their	heads	drooped	to	one	side	(Figure	9.5).
The	 nerve	 pathology	 in	 the	 chickens	 showed	 the	 typical	 axonal	 damage	we	 had	 seen	 in	 humans.	 In
addition,	we	were	able	 to	 isolate	Campylobacter	 jejuni	 from	 the	girl	 and	 these	 chickens.	We	 took	 the
natural	next	step.	Dr	Li	bought	some	live	chickens	from	the	market	and	fed	them	Campylobacter.	To	our
surprise,	in	the	first	batch	of	33,	all	got	diarrhoea	and	half	became	weak.	In	the	second	batch,	a	quarter
developed	 paralysis.	 These	 weak	 chickens	 had	 pathology	 in	 their	 sciatic	 nerves	 similar	 to	 AMAN








axonal	damage	consistent	with	AMAN.	Examining	 these	monkeys’	nerves	showed	 that	 they	 indeed	also
had	motor	axonal	damage.
Figure	9.4		Top	from	right	to	left:	Dr	Zhu	Fu-Tang	(centre),	Dr	Hu-sheng	Wu	(left),	Dr	Arthur	Asbury,	Dr	Guy	McKhann,	Dr	Tony






Kentucky	 roots,	 adeptly	 showing	Nachamkin	and	 I	how	 to	handle	 these	chickens	and	how	 to	 feed	 them





between	 the	 Fisher	 syndrome	 and	 IgG	 anti-GQ1b.	 Our	 initial	 investigation	 had	 focused	 on	 anti-GM1
antibody	 because	 there	 were	 reports	 of	 its	 association	 with	 GBS.	 Later,	 collaborating	 with	 Professor
Hugh	Willison,	we	were	able	to	investigate	the	anti-glycoconjugate	profile	and	to	correlate	with	different
subtypes	 of	 GBS.	 What	 we	 found	 was	 that	 both	 AMAN	 and	 AIDP	 patients	 had	 elevated	 anti-
glycoconjugate	antibody	to	GM1,	GD1b	and	GA1.	However,	only	the	AMAN	patients	had	elevated	GD1a
[12],	suggesting	that	this	may	be	the	pathogenic	epitopes	for	AMAN.	Because	C.	jejuni’s	liposaccharides
shared	sugar	structures	similar	 to	 those	of	gangliosides,	 the	question	arose	as	 to	whether	 the	antibodies
were	generated	against	these	epitopes.	The	investigation	turned	out	to	be	very	fruitful.	Irving	was	able	to
show	 that	 the	pathogenic	strain	of	C.	 jejuni	 (mostly	Penner	19)	did	contain	GM1,	GD1a-like	epitopes,
suggesting	that	‘molecular	mimicry’	may	be	the	underlying	pathogenesis.	Further	evidence	suggested	that
motor	axons	were	particularly	enriched	with	GD1a	epitopes,	which	may	explain	the	predominant	motor





amplitude	distal	motor-evoked	potentials	 return	a	year	 later	walking	with	only	 limited	 residual	muscle




United	 States,	 not	 China.	We	 saw	 a	 woman	 with	Campylobacter-associated	 AMAN	 at	 Hopkins.	 She
improved	 quickly	 following	 plasmapheresis.	 Motor-point	 biopsy	 showed	 denervated	 neuromuscular









they	 saw	 [16].	 At	 that	 time	 they	 were	 testing	 a	 live	 polio	 vaccine	 in	 Mexico	 when	 these	 children
developed	acute	flaccid	paralysis.	Even	though	the	children	had	non-inflammatory	CSF,	both	Manuel	and
Albert	were	 blamed	 for	 the	 outbreak.	Albert	was	 forced	 to	 leave	Mexico	 and	Manuel	was	 ostracized
from	the	Mexico	medical	community.
We	followed	up	this	lead	and	tracked	down	Manuel	in	a	little	alley	in	Mexico	City.	To	our	surprise,	he
had	 kept	 all	 the	 original	 pathology	 from	 these	 children.	 We	 brought	 these	 pathology	 blocks	 back	 to




We	 then	made	 several	 trips	 to	Mexico	 and	 discovered	 that	 there	were	 still	 children	 suffering	 from
acute	 motor	 axonal	 neuropathy,	 and	 that	 AMAN	was	 occurring	 in	 the	 summer,	 as	 in	 China.	We	 were
successful	 in	 culturing	 Campylobacter	 jejuni	 from	 these	 children.	 When	 these	 Campylobacter	 were


































































polio	 still	 continues,	 focus	has	now	shifted	 to	other,	non-polio	virus-related	causes	of	AFP	 (NP-AFP).
There	are	number	of	conditions	that	may	lead	to	NP-AFP,	which	include	toxic,	metabolic,	infective	and




between	GBS	 and	 other	NP-AFP	 can	 be	 difficult.	 Correct	 identification	 of	GBS	 cases	 help	 guide	 the
appropriate	management	of	patients,	especially	when	resources	are	limited	and	the	cost	of	immunotherapy
is	a	major	factor.	There	is	extensive	literature	available	describing	GBS	incidence	rates	in	the	Western
world,	 but	 similar	 data	 from	 developing	 countries	 are	 lacking.	 Availability	 of	 these	 data	 is	 hugely
important,	not	only	for	the	better	understanding	of	the	disease	pattern	in	this	region	but	also	for	resource
allocation	 and	 formulation	of	 national	 health	 policies.	 Similarly,	 from	Western	 literature	we	know	 that
most	patients	with	GBS	make	a	good	recovery	but	about	20%	remain	disabled	after	a	year;	however,	the
overall	 burden	 of	 GBS	 in	 developing	 countries	 is	 not	 known,	 especially	 when	 there	 is	 no	 universal
availability	of	immunotherapy	and	rehabilitation	facilities	in	these	countries.	Conducting	comprehensive





100,000	 inhabitants.	 When	 it	 comes	 to	 specialist	 neurology	 care,	 as	 of	 2013	 there	 were	 only	 1,100
practising	 neurologists,	 of	 which	 half	 were	 based	 in	 big	 cities,	 which	 effectively	 equates	 to	 one
neurologist	per	1	million	inhabitants.	In	comparison,	the	United	Kingdom	has	10	neurologists	per	million.
Thus,	availability	of	specialist	neurology	care	is	grossly	inadequate	and	the	vast	majority	of	GBS	cases
are	managed	 by	 general	 physicians	 in	 peripheral	 hospitals	 [1].	 Grossly	 inadequate	 public	 health	 care
resources	force	patients	to	use	private	health	care	facilities,	which	provide	up	to	80%	of	patient	care	in
these	countries	 [2].	 In	most	GBS	cases,	diagnosis	 is	made	clinically	and	additional	 tests	such	as	nerve




treatment	 facilities	 such	 as	 plasma	 exchange	 (PE)	 and	 mechanical	 ventilators	 are	 available.	 On	 an
average,	PE	costs	 around	1,200	USD,	while	 indigenous	 IVIg	costs	 around	2,400	USD;	 therefore	PE	 is
frequently	 preferred	 over	 IVIg	 treatment.	Often	 poorer	 patients	 are	 treated	with	mechanical	 ventilation
without	 IVIg	 or	 plasmapheresis,	 especially	 in	 government	 hospitals	 where	 plasma	 exchange	 is	 not
available.	 Rehabilitation	 of	 GBS	 patients	 poses	 a	 further	 challenge	 due	 to	 the	 inadequate	 numbers	 of
specialist	centres,	which	in	turn	contributes	to	poor	outcome.
Due	 to	 huge	 socioeconomic	 and	 cultural	 constraints	 and	 various	 other	 health	 care	 priorities,
subcontinent	countries	are	far	behind	in	GBS	care	and	research.
While	literature	from	some	countries	is	limited	to	case	reports	and	retrospective	studies,	countries	like








describes	 8	 paediatric	 GBS	 cases.	 What	 is	 striking	 in	 this	 case	 series	 is	 that	 one	 GBS	 patient	 was
wrongly	 diagnosed	 and	 treated	 as	 having	 ‘post	 diphtheritic	 polyneuropathy’	 and	 3	 patients	 died	 of
respiratory	failure	due	to	the	unavailability	of	mechanical	ventilators.	Interestingly,	6	out	of	the	8	cases	in









Western	 world,	 Tharakan	 and	 colleagues	 published	 their	 experience	 of	 25	 GBS	 patients	 treated	 with
small-volume	plasma	exchange	(SVPE),	with	promising	results	[6].	However,	what	is	surprising	is	 that
despite	being	a	cheap	alternative	 to	conventional	PE,	very	 little	effort	has	been	made	 to	validate	 these






1990s.	 GBS	 was	 traditionally	 considered	 to	 be	 a	 demyelinating	 disease	 until	 Feasby	 and	 colleagues
challenged	 this	 view	 and	 published	 the	 first	 report	 of	 ‘acute	 axonal	GBS’	 in	 1986	 [7].	McKhann	 and
colleagues	 later	 substantiated	 this	 view	 and	 described	 a	 case	 series	 of	 Chinese	 GBS	 patients	 with
predominant	axonal	degeneration	as	an	underlying	pathology	[8].	Not	far	behind,	within	a	year,	Gupta	and
colleagues	published	 the	 first	AMAN	case	series	 in	 India,	describing	clinical	and	electrophysiological






initial	 criteria	was	 designed	 according	 to	 the	 traditional	 thinking	 that	GBS	 represents	 a	 demyelinating
disorder	of	peripheral	nerves;	however,	when	this	view	was	challenged,	new	criteria	were	designed	to
accommodate	 ‘axonal	 GBS’.	 One	 of	 the	 issues	 regarding	 these	 criteria	 is	 the	 ‘EP	 definition	 of
demyelination’,	 which	 is	 completely	 arbitrary	 without	 any	 laboratory	 evidence.	 Kalita	 and	 colleagues
conducted	 a	 study	 comparing	 the	 diagnostic	 sensitivity	 of	 6	 different	 criteria	 and	 found	 significant






luxury	 in	 the	developing	world.	 In	 the	 context	 of	GBS,	 this	 interesting	 report	 by	Gupta	 and	 colleagues
describes	the	overall	rehabilitation	outcomes	of	35	GBS	patients	[11].	The	study	showed	that	only	14%	of
patients	diagnosed	with	GBS	were	admitted	 to	a	 rehabilitation	unit,	which	 is	well	below	 the	 figure	of
40%	 in	 some	 earlier	 studies.	 It	 also	 showed	 that	 while	 most	 patients	 make	 a	 very	 good	 functional







world.	 Integrated	 yoga	 programmes,	 in	 addition	 to	 traditional	 physiotherapy,	 have	 been	 shown	 to	 be
effective	in	long-term	rehabilitation	of	various	rheumatologic	disorders.	In	this	fascinating	pilot	study,	the
authors	conducted	a	single	blind	randomised	control	trial	of	22	GBS	patients,	comparing	the	efficacy	of
yoga	 with	 conservative	 treatment,	 and	 although	 the	 study	 failed	 to	 show	 any	 beneficial	 effect	 of
pranayama	 and	 meditation	 on	 patients’	 pain,	 anxiety	 and	 depression	 level,	 it	 showed	 significant







also	highlights	an	 interesting	 fact	 that	 in	countries	 like	Bangladesh,	GBS	rates	are	at	 least	2	 to	3	 times
higher	than	what	has	been	reported	in	the	Americas	and	Europe,	and	the	burden	of	this	disabling	disease
could	be	much	higher	 than	we	 all	 think.	 In	 this	 study	 Islam	and	 colleagues	 systematically	 analysed	 the
surveillance	 data	 on	 reported	AFP	 cases	 from	Bangladesh	 and	 have	 shown	 that	while	Bangladesh	 has
been	successful	in	eradicating	poliomyelitis	since	2000,	non-polio	AFP	cases	are	continue	to	occur,	with





This	 fascinating	 article	 by	 Islam	 and	 colleagues	 portrays	 a	 real-time	 picture	 of	 GBS	 in	 developing












in	 these	 patients	 by	 molecular	 mimicry	 and	 induction	 of	 a	 cross-reactive	 immune	 response	 to	 nerve








Access	 to	costly	 immune	 therapy	such	as	 IVIG	and	PE	for	GBS	patients	 remains	a	major	challenge	for
most	low-income	developing	countries.	A	full	course	of	intravenous	immunoglobulin,	for	an	adult	of	60





GBS	continues	 to	remain	a	 leading	cause	of	AFP	in	subcontinent	countries.	While	 the	 true	 incidence	of
GBS	in	these	countries	is	not	known,	there	are	very	good	reasons	to	believe	that	the	incidence	is	higher





Concerted	 efforts	 by	 the	 international	 GBS	 community	 are	 needed	 to	 bridge	 this	 gap	 between	 the
developing	 and	 developed	 world.	With	 recent	 globalisation,	 the	 socio-economic	 landscape	 is	 rapidly












































folktales.	 Could	 he	 find	 the	 legendary	 sword	 here?	He	 is	 trying	 to	 get	 answers	 to	 questions	 that	 have
troubled	him	for	many	years.
My	quest	began	when	I	was	a	young	resident	 in	neurology	training.	I	met	a	college	student	suffering
from	 acute	 onset	 dysarthria	 and	 dysphagia.	 There	was	 no	 evidence	 of	 other	 neurological	 symptoms	 or
signs,	but	he	had	had	an	upper	respiratory	tract	infection	(URI)	in	the	preceding	days.	All	investigations,
including	 a	 brain	 MRI,	 electrophysiology	 and	 blood	 work,	 including	 for	 acetylcholine	 receptor
antibodies,	 did	 not	 reveal	 the	 answer.	 I	 could	 do	 nothing	 for	 that	 young	 patient.	Although	 the	 patient’s
symptoms	improved	spontaneously	over	time,	a	question	still	remained.	What	was	the	true	cause	of	acute
dysphagia?
Time	 passed	 and	 I	 entered	 a	 fellowship	 training	 course	 in	 the	 neuromuscular	 division.	 I	 met	 3
consecutive	 cases	 with	 diplopia	 within	 2	 months.	 Two	 of	 them	 had	 preceding	 URIs.	 The	 interesting
features	 were	 that	 they	 all	 had	 asymmetric	 and	 incomplete	 bilateral	 oculomotor	 palsy	 with	 internal
ophthalmoplegia,	 without	 apparent	 gait	 disorders,	 falling	 or	 ataxia.	 “How	 should	 I	 conceive	 of	 and
differentiate	 this	kind	of	case	when	I	meet	 it?	What	can	I	do	for	 them?”	I	 thought.	A	test	for	anti-GQ1b
antibodies	was	strongly	positive	in	the	acute	phase	serum	in	all	these	patients	[1].	If	this	antibody	was	not
positive	 or	 even	 if	 we	 could	 not	 perform	 a	 study	 for	 this	 antibody,	 should	 we	 interpret	 this	 kind	 of
problem	as	a	variant	form	of	autoimmune	neuropathy?	What	if	we	did	not	know	whether	this	antibody	had
a	very	close	relationship	with	Miller	Fisher	syndrome	(MFS)	[2]?	If	so,	MFS	could	appear	with	various
features	other	 than	 the	 classical	 triad.	 In	 addition,	 the	 anti-GQ1b	antibody	 syndrome	can	manifest	with
various	features	overlapping	those	of	Guillain-Barré	syndrome	(GBS)	and	MFS	[3].
After	 several	 months,	 I	 met	 another	 interesting	 case,	 a	 22-year-old	 man	 suffering	 from	 acute
quadriparesis	after	several	days	of	diarrhoea.	There	was	apparent	evidence	of	peripheral	neuropathy	in
his	 nerve	 conduction	 study.	But	 in	 neurological	 examination	 his	muscle	 stretch	 reflex	was	 exacerbated












Subsequently,	 I	 learned	 that	 interpreting	electrophysiological	 findings	 in	GBS	 is	complicated	by	 the
dynamic	 changes	 in	 these	 patients.	 Many	 neurologists	 in	 my	 home	 country	 thought	 that	 GBS	 mainly
damaged	 the	 peripheral	 nerve	 myelin.	 Finally	 I	 found	 that	 not	 all	 electrophysiological	 studies	 will
necessarily	reveal	the	correct	underlying	pathophysiological	mechanism.	Evidence	was	accumulating	that
some	of	the	patients’	real	problems	lay	in	the	peripheral	nerve	axon,	even	though	in	electrophysiological
studies	 they	 displayed	 the	 traditional	 features	 of	 demyelination	 [7].	 In	 addition,	 anti-ganglioside




was	 a	 very	 confusing	 situation	 with	 2	 studies	 producing	 completely	 contradictory	 results	 [9,10].	 If
electrophysiological	classifications	cannot	determine	this,	it	would	be	better	to	find	the	presence	of	auto-
antibodies.	So	I	decided	to	get	some	additional	help	from	the	expert	of	a	neighbouring	country	and	visited
Professor	 Kusunoki’s	 laboratory,	 which	 had	 sera	 from	 many	 Korean	 GBS	 patients.	 We	 found	 very
interesting	results	from	the	analysis	of	anti-ganglioside	antibodies	and	clinical	information.	Various	kinds
of	anti-ganglioside	antibodies	were	positive	in	more	than	50%	of	Korean	GBS	patients,	and	the	patients
with	 positive	 antibodies	 associated	 with	 the	 axonal	 subtype	 were	 classified	 as	 having	 demyelinating
neuropathy	 according	 to	 electrophysiological	 criteria.	But	most	 of	 those	 exhibiting	 demyelinating	GBS
with	positive	antibodies	showed	pure	motor	presentation	with	conduction	block	and	normal	conduction
velocity.	This	meant	 that	 the	antibodies	could	determine	 the	underlying	pathophysiology	[11].	We	found
that	studying	the	anti-ganglioside	antibodies	was	essential	to	understanding	the	disease.
I	wondered	 how	many	 variant	 types	 of	GBS	 existed	 in	my	 home	 country.	What	 could	we	 learn	 by
finding	anti-ganglioside	antibodies	 from	 these	various	 types	of	GBS?	 In	MFS,	we	 identified	a	delayed
facial	 palsy	 [12].	 Even	 though	 it	 was	 rare,	 there	 was	 another	 variant	 of	 GBS	 presenting	 with	 facial
diplegia	without	 prominent	 limb	weakness.	These	 patients	 showed	minor	 changes	 in	 electrophysiology
with	 tingling	hands	and	negative	anti-ganglioside	antibodies	 [13].	 In	addition,	ophthalmoplegia	 in	GBS
was	more	closely	associated	with	anti-GT1a	antibodies	than	was	MFS	[11].	Finally,	there	was	a	group	of
patients	who	could	not	be	classified	as	a	representing	subtype	according	to	criteria.	They	apparently	had
a	 type	 of	GBS	with	 acute	 bulbar	 palsy	 accompanied	 by	 various	 degrees	 of	 ophthalmoplegia	 or	 ataxia




information	during	 assessment?	Recently,	 there	was	 an	 interesting	 article	 about	whether	U.S.	President
Roosevelt	suffered	from	poliomyelitis	or	GBS.	According	to	this	story,	he	was	frequently	misdiagnosed






















































The	Guillain-Barré	 syndrome	 (GBS)	 consists	 of	 a	 heterogeneous	 group	 or	 spectrum	 of	 acute	 immune-
mediated	 polyradiculoneuropathies.	 In	 classical	 textbook	 cases,	 a	 patient	 will	 present	 with	 ascending
bilateral	weakness	and	sensory	disturbances	of	 the	 legs	and	arms,	 in	a	proportion	combined	with	pain,
cranial	 and	 autonomic	 nerve	 involvement,	 or	 respiratory	 weakness.	 The	 rapid	 development	 of	 these
symptoms	combined	with	 a	 flaccid	paresis	 and	 reduced	 tendon	 reflexes	 at	 neurological	 examination	 in
absence	of	other	causes	will	usually	lead	to	the	early	diagnosis	of	GBS.	In	other	cases,	the	diagnosis	may
be	 less	 straightforward.	 Diagnosis	 in	 patients	 at	 the	 boarders	 of	 the	 GBS	 spectrum	 or	 with	 ‘overlap
syndromes’	may	 be	more	 challenging.	A	 continuous	 spectrum	 from	paraparetic	 to	 pharyngeal-cervical-
brachial	variant	is	recognized,	although	international	discussion	remains	whether	purely	sensory	deficits,
hyperreflexia	 or	 spinal	 cord	 involvement	 should	 be	 considered	 as	 a	 part	 of	 the	GBS	 spectrum.	 These
diagnostic	 dilemmas	 also	 apply	 to	 clinical	 overlap	 syndromes	 with	 Miller	 Fisher	 and	 Bickerstaff
encephalitis.	Another	 diagnostic	 dilemma	may	occur	 in	 the	 acute	 phase	when	 a	 specific	 symptom,	 like
pain,	 predominates	 or	 when	 it	 is	 less	 evident	 that	 causes	 other	 than	 GBS	 should	 be	 considered	 and
excluded.	Accurate	and	early	diagnosis,	however,	is	essential,	considering	that	patients	require	treatment









of	 limb	 paralysis	 including	 syphilis,	 tuberculosis	 and	 poliomyelitis.	 Around	 40	 years	 later	 an	 unusual





campaign	 of	 1976–1977	 when	 there	 was	 a	 suspected	 increase	 in	 the	 incidence	 of	 GBS	 after	 this
vaccination.	This	diagnostic	problem	led	 to	 the	 introduction	of	more	strictly	defined	diagnostic	criteria
for	 GBS	 in	 1978	 by	 the	 US	 National	 Institute	 Neurological	 Disorders	 and	 Stroke	 (NINDS)	 [5].	 The
criteria	 were	 reaffirmed	 in	 1990	 and	 are	 still	 the	 most	 widely	 used	 for	 GBS	 to	 date,	 especially	 in
scientific	 research	(Table	12.1)	 [6].	The	key	 features	 in	 these	 criteria	 are	 the	presence	of	 symmetrical
flaccid	weakness	and	decreased	reflexes	and	the	absence	of	alternative	causes.
Additional	attempt	has	been	made	 to	classify	GBS	patients	 into	different	subgroups,	 for	example	by
incorporating	 nerve	 conduction	 studies	 (NCS)	 and	 anti-ganglioside	 results	 [7].	 The	 Brighton
collaboration	developed	different	 levels	of	diagnostic	certainty	 in	order	 to	standardize	case	definitions
with	the	aim	of	improving	vaccine	safety	(Table	12.2)	[8].	Development	of	new	criteria	continued,	with
detailed	descriptions	of	the	different	subgroups	[9].	An	important	limitation	of	most	of	these	criteria	for
current	 clinical	 practice	 is	 that	 the	 monophasic	 course	 becomes	 evident	 after	 a	 follow-up	 of	 days	 to





GBS	 is	 still	 considered	 to	 be	 a	 syndrome,	 because	 there	 are	 at	 present	 no	 diagnostic	 and	 pathogenic
markers	available	with	 sufficient	 sensitivity	and	specificity.	There	are,	however,	 several	 investigations
that	can	be	helpful	to	support	the	clinical	diagnosis.
Cerebrospinal	Fluid	Examination









Many	different	antibodies	 to	single,	or	combinations	of,	gangliosides	have	been	 identified	 in	 the	serum
from	 patients	 in	 the	 acute	 phase	 of	 GBS.	 In	 specific	 clinical	 situations,	 testing	 for	 some	 of	 these
antibodies	 may	 be	 helpful	 to	 finding	 support	 for	 a	 diagnosis	 of	 GBS.	 Up	 to	 now,	 the	 most	 clinically
relevant	 anti-ganglioside	 tests	 are	 for	 patients	 suspected	 of	 having	 MFS	 (anti-GQ1b)	 or	 acute	 motor
axonal	neuropathy	(AMAN)	(anti-GM1	and	anti-GD1a	IgG).	The	general	low	frequency	of	each	specific
antibody	in	other	patients	with	GBS	results	in	a	low	negative	predictive	value.	Moreover,	the	presence	of
anti-gangliosides	 could	 also	 occur	 in	 other	 diseases.	 Another	 disadvantage	 of	 using	 anti-ganglioside
serology	 for	 the	diagnosis	of	GBS	 is	 that	 a	 test	 result	may	only	occur	 at	 a	 later	 stage,	when	 important
clinical	decisions	about	monitoring	and	 treatment	have	already	been	 taken.	Research	 into	antibodies	 to
gangliosides	 and	other	 peripheral	 nerve	 targets,	 however,	 is	 rapidly	progressing,	 and	 faster	 techniques
supporting	more	sensitive	and	more	specific	tests	may	emerge	in	the	near	future.
Nerve	Conduction	Studies
NCS	 can	 help	 to	 support	 the	 clinical	 diagnosis	 of	 GBS	 and	 to	 discriminate	 between	 axonal	 and
demyelinating	 subtypes	 of	 GBS.	Unfortunately,	 there	 are	 2	 important	 diagnostic	 limitations	 of	 NCS	 in










This	 underappreciated	 diagnostic	 test	 in	 GBS	 is	 pointed	 out	 by	 the	 fact	 that	 the	 only	 prospective





enhancement	 is	an	additional	and	 independent	 factor	 is	not	clear	at	 this	point.	The	 importance	of	nerve
root	 enhancement	 is	 supported	 by	 the	 correlation	 with	 pain,	 GBS	 disability	 grade	 and	 duration	 of
recovery.	For	patients	with	a	variant	GBS	it	might	be	more	useful	to	image	the	clinically	relevant	area,








sets	 of	 diagnostic	 criteria	 for	 an	 acute	 monophasic	 immune-mediated	 disease.	 Regarding	 the	 future
diagnostic	criteria	for	this	spectrum	of	immune-mediated	neuropathies,	2	aspects	are	very	relevant.
First,	 the	 diagnostic	 criteria	 should	 be	 pragmatic	 and	 support	 the	 clinician	 at	 the	 emergency
department	confronted	with	a	patient	with	rapidly	progressive	symmetrical	limb	weakness.	These	criteria
should	be	a	combination	of	neurological	and	additional	investigations	of	which	results	are	available	on
the	 same	 day	 to	 prevent	 delay	 of	 treatment.	 If	 no	 ideal	 diagnostic	 biomarker	 becomes	 available,	 a
combination	of	major	and	minor	criteria	would	be	able	to	cover	the	extensive	variety	of	symptoms	within
this	clinical	spectrum.	Importantly,	diagnostic	criteria	also	provide	the	diagnostic	boundary	of	GBS	when
a	patient	doesn’t	 fulfil	 these	criteria	and	 the	clinician	 is	encouraged	 to	continue	 the	search	for	 the	right
diagnosis.
Improvement	 of	 these	 criteria	 could	 be	 achieved	 by	 incorporating	 additional	 investigations	 in	 the
future,	 for	example,	development	of	a	diagnostic	 test	which	screens	patient	 sera	 for	a	whole	battery	of
different	antibodies.	Also,	prospective	clinical	trials	should	include	MRI	data	of	clinical	relevant	areas
of	 patients	 and	 investigate	 the	 relation	 between	 nerve	 root	 enhancement	 and	 onset	 of	 symptoms.	 It	 is
possible	that	nerve	root	enhancement	on	MRI	with	normal	cell	count	in	CSF	might	be	very	specific	for	an
‘acute	 immune	mediated	neuropathy’.	Future	 investigation	 should	also	point	out	 the	diagnostic	value	of
biomarkers	and	ultrasound.
The	 second	 should	 be	 classification	 criteria,	 to	 divide	 the	 broad	 spectrum	 of	 GBS	 patients	 into
homogenous	groups.	Where	the	diagnostic	criteria	should	look	for	the	common	pathway	of	acute	immune
neuropathies,	the	classification	criteria	should	point	out	the	differences	in	this	clinical	spectrum.	These
different	 subgroups	 are	 not	 only	 formed	 by	 similarities	 regarding	 signs	 and	 symptoms	 but	 also	 by
retrospective	clinical	data,	like	disease	course.	Also,	different	additional	tests	could	be	incorporated	into
these	 classification	 criteria,	 for	 example	 NCS	 results	 or	 future	 biomarkers	 which	 may	 take	 days	 to
process.	 Currently,	 the	 aim	 of	 this	 classification	would	 be	mainly	 for	 research	 purposes,	 as	 treatment




One	 hundred	 years	 since	 Guillain,	 Barré	 and	 Strohl’s	 publication,	 the	 diagnosis	 of	 the	 GBS	 is	 still
challenging	 due	 to	 a	 broad	 clinical	 spectrum	 without	 specified	 boarders	 and	 the	 lack	 of	 specific
diagnostic	tests.	Future	investigations	should	provide	the	diagnostic	value	of	biomarkers,	ultrasound	and
especially	MRI	with	gadolinium.	One	option	 is	 to	develop	diagnostic	and	classification	criteria	for	 the








































IgG	antibody	against	ganglioside	GQ1b	was	discovered	 in	MFS.	 In	 this	 top-10	 story,	many	papers	are
from	Japan,	perhaps	because	Japanese	research	groups	have	some	advantages	in	this	field:	a	fairly	high
incidence	of	MFS	in	Japan	compared	with	other	countries	(27%	of	all	GBS	cases	 including	MFS	[1]),








each	 other	 in	 the	 early	 1950s,	 and	might	 have	 been	waiting	 for	 the	 third	 one,	 the	Case	 1	 in	 the	 ‘Case
Reports’,	who	was	fully	studied	in	Massachusetts	General	Hospital	(MGH)	and	must	have	prompted	him
to	 this	paper	finally.	Fisher	seemed	to	already	have	some	idea	even	 in	 the	first	patient	 (the	Case	3),	 in
whom	 “although	 no	 diagnosis	 was	 made,	 a	 rise	 in	 the	 cerebrospinal-fluid	 protein	 was	 looked	 for”
because	 of	 polyneuropathic	 symptoms,	 the	 numbness	 of	 the	 fingers	 and	 areflexia.	 Albuminocytologic
dissociation,	 however,	 was	 not	 detected	 in	 a	 lumber	 tap	 at	 the	 end	 of	 6	weeks.	 The	 detailed	 clinical
information	on	the	second	patient	(the	Case	2)	came	from	a	hospital	file.	He	saw	this	patient	because	of
an	 unrelated	matter,	 and	 the	 patient	 recounted	 a	 past	 history	 of	 total	 ophthalmoplegia.	One	of	 the	most
important	 points	 that	 made	 him	 conclude	 that	 this	 syndrome	 was	 a	 variant	 of	 GBS,	 would	 be	 the
albuminocytological	dissociation	 in	 the	 cerebrospinal	 fluid,	 and	 this	was	 eventually	 detected	 from	 the
serial	spinal	tap	in	the	third	patient	at	MGH.	The	biochemical	feature	common	to	GBS	might	be	needed
for	 the	conclusion.	 Interestingly,	 episodes	of	 an	antecedent	 infection,	which	 is	now	 in	 the	centre	of	 the
pathogenesis	of	GBS	and	MFS,	were	not	so	emphasized.
This	 paper	 established	 the	 concept	 of	 the	 syndrome	 almost	 by	 itself.	 Atypical	 features	 obviously
attributed	to	the	central	nervous	system	(CNS)	were	also	described,	such	as	changes	in	arousal	level	and
a	preserved	Bell’s	phenomenon	in	a	state	of	total	external	ophthalmoplegia,	implying	the	true	extent	of	the
disorder.	Despite	 these	 and	 other	 features	 that	 could	 not	 be	 easily	 attributed	 to	 peripheral	 lesions,	 his
reluctant	conclusion	with	respect	to	the	core	manifestations	was	a	variant	of	GBS	with	“an	unusual	and
unique	 disturbance	 of	 peripheral	 neurons”.	 This	 conclusion	 might	 be	 owed	 to	 Fisher’s	 career	 in







IgG	 anti-GQ1b	 antibody	 in	 MFS	 was	 first	 reported	 in	 1992	 [3].	 This	 antibody	 was	 identified	 in	 a
deductive	 screening	 approach.	 In	 the	 context	 of	 this	 research	 field,	 where	 Ilyas	 and	 colleagues	 first
reported	 anti-ganglioside	 antibodies	 in	 GBS	 in	 1988	 [4],	 it	 would	 be	 a	 matter	 of	 time	 before	 this
discovery,	and	the	antibody	was	soon	reported	independently	[5,6].	This	paper	in	Neurology	in	1993	[7]





was	 demonstrated	 by	 the	 combination	 of	Campylobacter	 jejuni,	 anti-GM1	 antibody	 and	 acute	 motor
axonal	 neuropathy.	The	 story	of	MFS	and	GQ1b—a	high	positive	 rate	 of	 the	 antibody	 and	 consistency
between	 clinical	 findings	 and	 specific	 antigen	 distribution—is	 a	 good	 example	 of	 the	 second	 part.
Clinically,	IgG	anti-GQ1b	antibody	is	tightly	associated	with	acute	ophthalmoplegia	following	infectious
episodes:	MFS,	GBS	with	ophthalmoplegia,	and	acute	ophthalmoplegia	without	ataxia,	which	could	be	a
mild	 or	 incomplete	 form	 of	 MFS.	 Histochemically,	 GQ1b	 antigen	 accumulates	 specifically	 in	 the
paranodal	region	of	the	3	cranial	nerves	(oculomotor,	trochlear	and	abducens).	Biochemically,	the	amount
of	ganglioside	GQ1b	in	these	3	nerves	is	significantly	higher	than	in	the	other	cranial	nerves	or	peripheral





















in	 human	 tissue.	 Considering	 the	 consistent	 combination	 of	 the	 triad	 in	 typical	MFS,	 it	 is	 simple	 and







individual	 intrafusal	 fibres	 of	 limb-muscle	 spindles	 at	 the	 equatorial	 region,	where	 abundant	 group	 1a
sensory	terminals	wrap	around	the	fibres.	This	observation	supports	the	involvement	of	group	1a	afferents
from	 the	 muscle	 spindles	 in	 ataxia	 and	 areflexia.	 This	 immunohistochemical	 study	 also	 revealed	 that
GD1b	 and	GQ1b/GT1a	were	 localized	 similarly,	 but	 that	 anti-GD1b	 antibody	 is	 not	 usually	 linked	 to











animals,	 including	 up	 to	 crab-eating	 macaque,	 has	 failed	 to	 find	 an	 animal	 that	 expresses	 the	 GQ1b
epitope	in	the	ocular	motor	nerves	as	it	is	in	humans.	Willison’s	research	group	has	extensively	studied
the	 pathological	 effects	 of	 patient	 sera,	 their	 IgG	 fractions	 and	monoclonal	 antibodies	 (mAbs)	 against
GQ1b	using	an	ex-vivo	mouse	hemidiaphragm	preparation	[14].	Their	series	of	works	has	demonstrated:
(A)	patients’	 sera,	patients’	 IgG	and	 the	mAbs	cause	neuromuscular	block;	 (B)	 the	blocking	effect	was




expanded	 to	 the	 human	 disease,	 but	 the	 GQ1b-antigen	 was	 also	 detected	 in	 the	 NMJ	 of	 the	 human
extraocular	muscles	[12].	Neuromuscular	transmission	has	been	studied	in	MFS	patients	using	single	fibre






MFS	 in	Japan	 [16].	This	 remains	 the	 largest	case	series	 from	a	single	centre	so	 far	and	has	drawn	 the





An	 ongoing	 debate	 is	 the	 nosological	 position	 of	MFS:	 is	 it	 a	 variant	 of	GBS	 or	 a	 kind	 of	 brainstem




antibody	was	 discovered,	 it	 appeared	 to	 be	 an	 attractive	 biomarker	 that	 could	 be	 used	 to	 answer	 the
debate.	 Yuki	 detected	 the	 antibody	 in	 all	 3	 patients	 diagnosed	 as	 BBE	 and	 revealed	 the	 common
immunological	features	in	MFS	and	BBE	[18].	His	research	group	then	increased	the	number	of	patients
to	53	BBE	and	466	MFS	patients,	and,	several	years	later,	compared	clinical,	serological,	radiological
and	 physiological	 features	 [19].	 Interesting	 observations	 in	 this	 study	 regarded	 the	 loss	 of	 soleus	 H-
reflexes	and	the	detection	of	1-Hz	power-spectrum	peak	on	the	postural	body-sway	analysis,	which	both
suggest	 dysfunction	 in	1a	 fibres.	These	were	 found	 in	 about	 70%	of	both	BBE	and	MFS	cases.	While






To	 have	 an	 effective	 discussion	 about	 the	 relationship	 between	MFS	 and	 BBE,	we	 have	 to	 know	 the
makeup	of	the	groups	in	question.	A	Japanese	nationwide	survey	on	BBE	has	given	a	suggestion	regarding
this	 point	 [20].	 It	 revealed	 that	 BBE	 patients	with	 atypical	 neurological	 findings	 or	without	 IgG	 anti-
GQ1b	antibodies	had	features	different	from	those	with	typical	neurological	findings	with	the	antibodies.
Atypical	symptoms	were	linked	to	longer	duration	from	onset	to	nadir,	slower	recovery,	higher	frequency
of	 brain	 MRI	 abnormality,	 and	 increased	 protein	 concentration	 and	 marked	 pleocytosis	 in	 CSF.	 This






treatment	 other	 than	 those	 related	 to	 antibodies,	 especially	 in	 severe	 cases	 with	 profound	 CNS
manifestations.
Table	13.2	is	my	personal	arrangement	of	MFS-related	conditions.	They	are	divided	into	3	categories:
typical	 MFS	 (the	 prototype	 of	 these	 conditions);	 MFS-minus,	 in	 which	 ataxia	 or	 ophthalmoplegia	 is













One	 patient	 in	 Fisher’s	 original	 paper	 developed	 the	 syndrome	 following	 pneumonia,	which	 probably
resulted	 from	 Haemophilus	 influenzae.	 This	 short	 but	 faithful	 description	 attracted	 the	 attention	 of
researchers	to	this	gram-negative	organism	in	the	respiratory	tract,	especially	after	the	historical	success
of	 molecular	 mimicry	 theory	 in	 the	 case	 of	 Campylobacter	 jejuni.	 Koga	 and	 colleagues	 performed
comprehensive	 studies	on	 antecedent	 infection	 in	MFS	and	 found	 serologically	 significant	 associations
between	the	disease	and	both	H.	influenzae	and	C.	jejuni	[22].	C.	jejuni	strains	isolated	from	MFS	were
significantly	associated	with	the	GQ1b	epitope	when	detected	using	antibodies,	and	biochemical	analyses
identified	a	possible	GT1a-mimicking	 tri-sialosyl	oligosaccharide	 structure	 in	 the	 lipooligosaccharides
(LOSs).	As	 for	H.	 influenzae,	 epitopes	 recognized	with	 anti-GQ1b	antibody	were	 also	detected	 in	 the
LOSs	extracted	from	clinical	isolates	of	MFS	patients.	Finally,	in	an	H.	influenzae	strain	isolated	from	an
MFS	patient,	Houliston	 and	 co-workers	biochemically	 identified	 a	novel	 disialosyl	 galactose	 structure






Although	 tetra-sialosyl	 oligosaccharide	 structures	 in	 LOS	 that	 exactly	 mimic	 GQ1b	 have	 not	 been
identified,	 immunization	 of	 animals	with	 the	GT1a-mimicking	 LOS	 from	C.	 jejuni	 has	 been	 shown	 to
induce	 antibodies	 that	 react	 with	 both	 GQ1b	 and	 GT1a	 [24].	 In	 the	 human	 disease,	 those	 mimicking
molecules	 could	 induce	 anti-GQ1b/GT1a	 antibodies.	A	 group	 of	 I-type	 lectins	 primarily	 expressed	 on















3.	 What	 are	 the	 immunological	 pathogenic	 factors	 in	 sero-negative	 cases,	 in	 whom	 anti-GQ1b/GT1a
antibodies	are	not	detected?

































































Guillain-Barré	 syndrome	 (GBS)	was	 thought	 of	 as	 the	 classic	 demyelinating	 disease	 of	 the	 peripheral
nervous	system	(PNS).	I	was	drawn	to	it	by	my	interest	in	demyelination	and	in	particular	by	my	interest
in	the	physiology	of	demyelination.	I	had	investigated	the	nature	of	nerve	conduction	in	regenerating	nerve
fibres	 in	 the	 laboratory	of	Professor	Tom	Sears	at	Queen	Square,	UK	and	observed	 the	 transition	 from
continuous	 to	 saltatory	 conduction	 in	 these	 fibres	 as	 they	 became	 myelinated.	 I	 published	 work	 on
conduction	 block	 in	 demyelinating	 GBS	 with	 my	 colleague	 Bill	 Brown.	 With	 my	 colleagues,	 I	 had
investigated	 passive	 transfer	 models	 of	 demyelination	 using	 both	 rabbit	 anti-galactocerebroside
antibodies	and	rat	T	cells.	 I	was	 thus	startled	when	I	came	upon	a	patient	with	GBS	who	didn’t	 fit	 the
model	of	demyelination	but	rather	turned	out	to	have	an	axonal	form	of	GBS.	Publication	of	this	work	was





observation	but	 the	 limitation	of	being	a	snapshot	 in	 time.	The	 latter	allows	 repeated	observations	but,
limited	by	its	indirect	nature,	requires	inferences.
The	 first	 major	 pathological	 study	 of	 GBS,	 by	 Haymaker	 and	 Kernohan	 [1],	 examined	 the	 central
nervous	system	and	the	nerve	roots,	but	not	the	peripheral	nerves,	in	50	autopsied	cases.	They	described
oedema	 in	 the	 nerve	 roots	 and	 adjacent	 spinal	 nerves	 and	 infiltration	 of	 lymphocytes	 and	 phagocytes,
which	 they	 thought	might	 be	 secondary.	They	 saw	demyelination	 and	what	 they	 thought	was	 secondary
axonal	degeneration.	In	their	last	case,	of	a	patient	who	died	after	46	days,	the	axonal	degeneration	was




including	 those	 at	 early	 stages	 of	 their	 illness.	 They	 observed	 demyelination	 of	 varying	 degrees	 in	 all
cases	as	well	as	axonal	injury/degeneration	in	most.	They	noted	that	“axonal	interruption	and	consequent
Wallerian	degeneration	was	observed	frequently,	most	commonly	and	to	a	more	marked	degree	in	cases
with	 the	 more	 intense	 inflammatory	 changes”.	 Like	 Haymaker	 and	 Kernohan,	 they	 considered	 axonal
degeneration	to	be	secondary,	but	in	their	case,	secondary	to	the	inflammation.
Waksman	and	Adams	[3]	described	experimental	allergic	neuritis	(EAN),	the	first	experimental	model
for	GBS	which	 they	 induced	 by	 immunization	 of	 rabbits	with	 sciatic	 nerve	 tissue	 plus	 adjuvants.	This
model	mimicked	human	GBS	and	was	analogous	to	experimental	allergic	encephalomyelitis	(EAE),	 the
experimental	 model	 of	 multiple	 sclerosis.	 They	 observed	 intense	 lymphocyte	 and	 mononuclear	 cell
inflammation,	 widespread	 demyelination	 and	 lesser	 degrees	 of	 axonal	 degeneration,	 again	 presumably
secondary.
Many	electrophysiological	studies	of	GBS,	by	McLeod	[4]	and	others,	have	detected	typical	signs	of
demyelination,	 including	 slowed	 conduction	 velocities,	 temporal	 dispersion	 of	 the	 compound	 muscle
action	potential	evoked	by	nerve	stimulation	and	delayed	‘F’	 responses.	 In	1984,	Bill	Brown	and	I	 [5]
described	the	significance	of	widespread	conduction	block	secondary	to	demyelination	as	the	major	cause
of	 acute	 weakness	 in	 most	 GBS	 patients.	 We	 also	 pointed	 out	 the	 common	 occurrence	 of	 axonal
degeneration	and	noted	 its	 role	 in	 the	residual	weakness	and	 limited	recovery	 in	some	patients.	At	 that




of	 severe	GBS	 so	 that	 she	was	 quadriplegic	with	marked	 cranial	 nerve	 abnormalities	 and	 respiratory
failure	within	36	hours.	She	had	minor	sensory	findings.	Electrophysiological	studies	done	by	Bill	Brown
showed	 inexcitable	 motor	 nerves,	 a	 very	 unusual	 finding.	 She	 showed	 no	 improvement,	 developed
autonomic	instability	and	died	at	day	28	after	a	cardiac	arrest.
Joe	 Gilbert	 and	 I	 carried	 out	 an	 autopsy	 within	 hours	 of	 her	 death,	 on	 a	 Sunday,	 sampling	 the
peripheral	 nervous	 system	very	 extensively.	We	 found	widespread	 severe	 axonal	 degeneration	on	 light
microscopy	 from	 the	 nerve	 roots	 to	 the	 periphery,	 unaccompanied	 by	 evidence	 of	 demyelination	 or
lymphocytic	 inflammation.	This	was	confirmed	by	 teased	 fibre	 studies	and	electron	microscopy,	where
we	also	found	evidence	of	unmyelinated	fibre	loss.	My	colleagues	and	I	cared	for	4	more	very	acute	GBS





We	were	 convinced	 that	we	 had	 seen	 something	 new,	 and	we	 submitted	 an	 abstract	 describing	 our
findings	 for	 presentation	 at	 the	American	Academy	of	Neurology	meeting	 in	 1986	 entitled	 ‘Inexcitable
Motor	Nerves	in	GBS’.	Apparently,	the	selection	committee	was	not	excitable	either	and	they	rejected	our








me	 in	 debate.	 But	 before	 they	 had	 their	 chance,	 the	 2	 chairmen	 challenged	 me	 on	 our	 findings	 and
interpretations.	The	main	points	of	criticism	were	 that	such	severe	axonal	degeneration	must	have	been
secondary	 to	 demyelination	 and	 inflammation,	 and	 that	 since	 our	 autopsied	 patient	 died	 after	 28	 days,
those	findings	could	have	subsided	and	hence	we	missed	them.	I	defended	our	position,	saying	that	if	the
axonal	 degeneration	 we	 observed	 had	 been	 secondary,	 the	 inflammation	 and	 demyelination	must	 have
been	extreme	and	widespread	and	we	couldn’t	possibly	have	missed	it.	We	were	quite	confident	that	we




antigen	 was	 increased	 and	 that	 the	 amount	 of	 axonal	 degeneration	 correlated	 with	 the	 amount	 of
inflammation	and	demyelination	[8].	This	supported	our	contention	that,	if	the	severe	axonal	degeneration








anti-GM1	 antibodies	 attached	 to	 the	 nodal	 axolemma	 and	 triggered	 complement-mediated	 destruction
facilitated	by	macrophages.
Nevertheless,	 the	controversy	continued,	with	major	 figures	 in	peripheral	nerve	 research	expressing
scepticism	 of	 our	 work.	 Two	 books	 on	 GBS	 failed	 to	 endorse	 us,	 although	 Richard	 Hughes	 was
supportive	in	his	1990	book	Guillain-Barré	Syndrome	[10].	Two	years	later,	P.K.	Thomas	said	that	GBS
was	“no	longer	a	simple	concept”	and	did	support	the	notion	of	an	axonal	form	of	the	disease	[11].	Cros
and	 Triggs	 in	 1993	 then	 argued	 that	 we	 failed	 to	 find	 evidence	 of	 demyelination	 and	 lymphocytic
inflammation	in	our	autopsied	case	because	the	lesions	might	have	been	focal	and	because	of	“incomplete











that	 axonal	 degeneration	 in	GBS	 can	 occur	 by	 2	 different	mechanisms.	 It	 also	 showed	 that	 inexcitable
motor	nerves	may	be	caused	by	severe	acute	demyelination.
Meanwhile,	Guy	McKhann,	Jack	Griffin,	David	Cornblath	and	colleagues	in	1993	described	a	series
of	cases	of	apparent	GBS	occurring	 in	northern	China	 in	children	which	were	predominantly	axonal	 in
nature	 but	 seemed	 to	 have	 a	 good	prognosis	 [15].	 I	 visited	Shijiazhuang	 in	China	 in	 1995	with	David
Cornblath	and	saw	a	ward	filled	with	these	young	patients,	many	of	them	being	ventilated	by	their	parents
by	hand.	Remarkably,	 the	outcome	was	very	good	 for	most.	This	new	form	of	GBS	was	different	 from
what	we	described	but	offered	strong	support	that	GBS	was	not	a	uniform	entity.
The	 most	 important	 support	 for	 our	 thesis	 came	 from	 the	 same	 Johns	 Hopkins	 group,	 led	 by	 Jack
Griffin	[16,17].	In	a	series	of	14	patients	who	died	with	GBS	in	Hebei	province	China,	4	had	pathology













this	 information	 is	 that,	 ultimately,	we	 should	 be	 able	 to	 identify	 patients	 by	 their	 subtype	 early	 in	 the




of	 discovery:	 Angelika	 Hahn,	 Bill	 Brown,	 Joe	 Gilbert,	 Charlie	 Bolton,	 Wilma	 Koopman	 and	 Doug



































I	 located	 and	 reviewed	 the	original	 notes	 and	papers	 that	 I	 used	 to	 assemble	 the	 two	brief	 articles	 on




clinical	material.	Until	 then	steroids	were	used	but	with	 little	confidence	and	a	small	clinical	 trial	had
failed	 to	demonstrate	 efficacy.	 I	was	 at	 the	 right	 place	 at	 the	 right	 time	because	of	 our	well-organized





(Jack)	 Griffin	 of	 Johns	 Hopkins	 as	 he	 was	 eating	 breakfast	 at	 the	 American	 Academy	 of	 Neurology





In	writing	 the	 chapter	 on	 the	history	of	 the	 syndrome	 in	monograph	with	Truax	 and	Wijdicks	 I	was
sensitized	 to	 the	 failure	 by	 Guillain,	 Barré	 and	 Strohl	 to	 acknowledge	 earlier	 papers	 on	 the	 disease,
including	the	famous	one	by	Landry	in	1859.	In	looking	at	the	previously	published	papers	in	my	folder	it
was	clear	 that	others	had	come	across	similar	variants	 to	 the	ones	 I	was	seeing	and	described	 them	in




variant.	 He	 was	 encouraging	 and	 suggested	 that	 I	 contrast	 them	 with	 alternative	 diagnoses	 such	 as

















arms,	 who	 was	 thought	 by	 our	 senior	 clinicians	 (including	 Fisher!)	 to	 have	 botulism	 because	 of
ophthalmoparesis	and	ptosis.	Things	went	as	far	as	to	have	a	deltoid	muscle	biopsy	done,	but	deep	tendon
reflexes	were	 absent	 in	 the	 arms	 and	 she	did	not	 have	 iridoplegia.	The	 idea	 that	Bayes	 theorem	might












Using	 the	 model	 of	 Fisher	 syndrome	 and	 its	 ostensible	 relationship	 to	 GBS,	 I	 looked	 for
commonalities	between	the	variant	syndromes	and	conventional	polyneuritis.	The	criteria	I	established	as
a	 working	 theory	 to	 determine	 if	 a	 syndrome	 was	 part	 of	 the	 GBS	 spectrum	 were	 (A)	 the	 clinical
syndrome	began	with	unusual	features	that	compelled	another	diagnosis	such	as	myasthenia	but	eventually
evolved	to	typical	GBS;	(B)	the	variant	syndrome	was	known	to	occur	as	a	component	of	fully	developed
GBS,	 for	 example	 ophthalmoplegia;	 (C)	 electrophysiologic	 tests	 showed	 conduction	 block,	 proximal
block,	absent	F-waves,	lost	sensory	potentials	or	other	features	typical	of	GBS,	but	these	might	be	present
only	in	one	region	of	 the	body;	(D)	the	CSF	protein	was	elevated	in	a	pattern	and	temporal	course	that
were	 consistent	with	GBS;	 (E)	 the	 illness	was	 acute	 or	 subacute	 and	monophasic,	 with	 recovery	 that




Moreover,	 regarding	 the	 clinical	 utility	 of	 knowing	 these	 variants,	 they	 should	 be	 viewed	 from	 the
perspective	of	Bayes’	theorem.	In	the	patients	I	see	in	a	teaching	hospital	in	Boston,	GBS	is	so	much	more
common	than	diphtheria	and	botulism	that	anything	appearing	to	simulate	these	rarer	diseases	clinically	is
still	 likely	 to	 be	 a	 GBS	 variant.	 This	 is	 even	 true	 when	 there	 is	 pupillary	 paralysis	 and	 dry	 mouth.
Myasthenia	gravis	only	superficially	imitates	the	cranial	and	the	pharyngeal-cervical-brachial	variant	of
GBS,	but	the	distinction	may	become	difficult	when	there	is	ptosis,	as	there	often	is.
These	 variants	 have	 taught	me	 several	 things	 about	 GBS.	 First,	 every	 disease	 process	 has	 to	 start
somewhere	in	the	body.	It	is	conceivable	that	there	is	inflammation	in	every	nerve	during	acute	GBS,	but
the	concentration	of	this	activity	in	a	few	regions	gives	rise	to	special	topographic	syndromes.	Since	some
regional	 variants	 remain	 persistent,	 pure	 and	 profound,	 there	 may	 be	 special	 epitopes,	 which	 are




symptom,	 whereas	 more	 typical	 GBS	 came	 on	 during	 the	 active	 daytime	 hours.	 It	 is	 unlikely	 but
interesting	to	think	that	the	body	position	prior	to	the	onset	of	an	immune	reaction	could	have	an	influence
on	areas	of	blood-nerve	disruption.	This	is	probably	overly	simplistic.
It	 comes	 as	 little	 surprise	 therefore	 that	 Hugh	Willison	 and	 colleagues	 [6]	 and	 more	 profusely	 in
publications	from	Yuki’s	lab,	as	summarized	in	their	Medical	Progress	article	[7],	have	found	that	auto-




Second,	 familiarity	with	 the	variants	 created	 a	 risk	of	 the	misuse	of	 the	 availability	 heuristic	 [8].	 I
referred	above	to	one	glaring	example	of	a	patient	with	spinal	epidural	abscess	that	I	initially	mistook	for
GBS	because	of	quadriparesis	and	coup	du	poignard	between	his	scapulae.	He	was	areflexic	and	was
sent	 to	our	 ICU	 for	 IVIg	 treatments,	 having	had	 a	 lumbar	MRI	 that	was	normal.	 I	 examined	him	 in	 the
middle	of	 the	night	with	my	residents	and	he	was	 in	extreme	pain	 in	 the	back	and	 is	distal	extremities.
He’d	been	given	considerable	narcotics	and	was	intubated	for	respiratory	failure.	I	was	able	to	wake	him
up	enough	to	get	him	to	mouth	words,	close	his	eyes	and	purse	his	lips,	and	I	felt	all	of	these	movements
were	weak	and	 that	 therefore	 the	picture	was	consistent	with	GBS.	An	EMG	the	next	morning	showed
multiple	inexcitable	nerves	as	well	as	absent	late	responses	and	our	electrophysiologist	gave	a	diagnosis
of	GBS.	We	ordered	 the	 IVIg	 and	went	 about	 our	morning	 rounds.	Later	 in	 the	day,	 I	 asked	 to	 see	 the
lumbar	MRI	since	 the	patient	was	 febrile	and	 intermittently	hypotensive.	At	 the	very	upper	edge	of	 the
image	was	a	white	shadow.	It	quickly	became	clear	that	this	was	the	lower	edge	of	a	massive	epidural
abscess.	I	had	put	together	the	interscapular	pain,	with	quadriparesis,	areflexia,	respiratory	failure	and	a
too	 easily	 confirmatory	 EMG,	 all	 as	 GBS.	 We	 made	 the	 diagnosis	 about	 14	 hours	 after	 our	 initial
assessment	 and	 the	 patient	 went	 to	 the	 operating	 room	 but	 his	 spinal	 cord	 was	 already	 necrotic.	 At
autopsy,	there	was	a	massive	staphylococcal	epidural	abscess	extending	from	the	upper	cervical	through
the	 upper	 lumbar	 cord	 that	 I	 recounted	 in	 an	 entire	 chapter	 of	my	book	 for	 the	 public	 on	 neurological
problems,	Reaching	Down	the	Rabbit	Hole	[9].
This	points	out	 the	problem	of	having	 too	much	experience	with	unusual	 clinical	processes	 and	not
having	the	scepticism	and	simplicity	of	a	medical	student.	It	is	reminiscent	of	the	story	of	a	middle-aged
gentleman	who	was	 admitted	 to	 the	 hospital	 with	 severe	 back	 pain	 and	 progressive	wasting.	 He	was
examined	with	every	conceivable	test	and	seen	by	the	most	skilled	clinicians	in	the	hospital.	No	diagnosis
could	 be	made	 and	 he	 died.	 At	 autopsy,	 there	was	 an	 angiosarcoma	 of	 the	 spleen.	When	 the	 chief	 of
medicine	later	reviewed	the	chart,	he	noticed	that	a	medical	student	had	made	the	correct	diagnosis!	He
called	 the	 student	 to	 his	 office	 to	 congratulate	 him	 and	 asked	 how	he,	 a	 beginning	 student,	 could	 have





















































The	 weakness	 spread	 rapidly	 from	 the	 lower	 to	 the	 upper	 parts	 of	 the	 body	 with	 a	 universal	 tendency	 to	 become
generalized.…





























Miller	 Fisher	 described	 3	 patients	 with	 acute	 ophthalmoplegia,	 ataxia	 and	 absent	 tendon	 reflexes	 that
occurred	 acutely	 following	 an	 antecedent	 infection	 in	 1956	 [3].	 These	 patients	 had	 minimal	 or	 no
weakness.	All	 3	 recovered	 spontaneously.	One	out	 of	 the	2	patients	who	had	 spinal	 fluid	 analysis	 had
cyto-albuminogic	dissociation.	Fisher	hypothesized	a	common	etiopathological	link	between	this	disorder



















muscle	 action	potentials	with	normal	velocity	 and	 sensory-nerve	 action	potentials	 on	nerve-conduction
studies.	Two-thirds	of	 the	patients	had	serological	evidence	of	 recent	C.	 jejuni	 infection	 (compared	 to
16%	of	village	controls).	Likewise	a	greater	proportion	of	patients	had	IgG	anti-GM1	antibodies	[6].	In	6
axonal	 GBS	 cases	 that	 were	 autopsied,	 the	 pathological	 findings	 were	 Wallerian	 degeneration	 with
macrophages	within	the	periaxonal	space	that	were	surrounding	or	displacing	the	axons	that	had	an	intact
myelin	 sheath.	 The	 pathological	 changes	 were	 subtle	 in	 some	 of	 the	 patients	 that	 died	 from	 severe














Following	 the	 description	 of	 the	 Miller	 Fisher	 syndrome,	 other	 regional	 variants	 of	 GBS	 are	 being
continuously	 recognized.	 Pharyngeal-cervical-brachial	 weakness	 [10],	 acute	 ataxic	 neuropathy	 [11],
paraparetic	GBS	[12],	facial	diplegia	[10],	acute	ophthalmoplegia	[13],	polyneuritis	cranialis	[14],	acute
oropharyngeal	palsy	[15],	acute	ptosis	[12]	and	acute	mydriasis	[16]	are	some	of	the	sub-types	of	GBS











In	 1984,	 Pryor	 and	 colleagues	 reported	 a	 patient	who	developed	GBS	 after	 a	C.	 jejuni	 infection	with
remarkably	 intact	deep	 tendon	reflexes	 [17].	 In	 the	series	of	AMAN	patients	 from	China,	hyperreflexia
was	 noted	 during	 the	 early	 phase	 of	 recovery	 in	 some	 patients	 [5].	 Kuwabara	 and	 colleagues
corroborated	this	observation	in	13%	of	54	consecutive	GBS	patients.	Most	had	AMAN	and	had	raised














Bickerstaff	 and	 Cloake	 described	 3	 cases	 of	 ophthalmoplegia	 associated	 with	 ataxia	 and	 clouding	 of




wrote	 the	 conclusive	 chapter	 in	 this	 saga	 in	 1997,	 proving	 the	 spectral	 relationship	 between	GBS	and
Bickerstaff	 [21].	 They	 described	 the	 presence	 of	 anti-GQ1b	 antibody	 in	 Bickerstaff	 encephalitis,	 an
antibody	that	by	then	had	been	well	associated	with	MFS.	This	serendipitous	discovery	was	made	when




















than	 15	 years,	 and	 had	 stopped	 eating	 anything	 else	 for	 a	 week	 before	 admission.	 This	 was	 after	 an
apparent	upper	respiratory	infection	(which	further	confused	the	clinical	picture).	Nerve	conduction	study
showed	an	axonal	sensorimotor	polyneuropathy.	The	patient	improved	with	high-dose	thiamine	and	other
vitamin	 supplementation.	 Although	 the	 diagnostic	 serum	 pyruvate	 and	 red	 cell	 transketolase	 were	 not













Other	 pertinent	GBS	mimics	 are	 acute	myelopathy,	 periodic	 paralysis,	HIV	 seroconversion,	 hereditary






































Hughes	 and	 co-workers	 demonstrated	 unequivocally	 the	 ineffectiveness	 of	 corticosteroids,	 used	 in
isolation,	 for	 the	 treatment	 of	 GBS	 [23].	 Subsequently	 2	 seminal	 studies	 have	 established	 the	 role	 of
plasma	exchange	 [24]	and	 intravenous	 immunoglobulin	 [25]	 in	hastening	 the	 recovery	of	GBS	patients,
while	another	showed	the	lack	of	additional	benefit	of	the	combination	[26].
Another	 promising	 therapeutic	 strategy	 is	 the	 inhibition	 of	 complement	 activity.	 Eculizumab	 is	 a
humanized	monoclonal	 antibody	 that	 blocks	 the	 formation	 of	 human	 C5a	 and	 C5b-9	 and	 consequently








co-workers	demonstrated	elevated	 levels	of	 anti-GM1	antibody	and	a	4-fold	 increase	 in	 anti-C.	 jejuni
antibody	[28].	C.	jejuni	was	cultured	from	a	stool	sample	of	this	patient	and	identified	as	the	Penner	19
serotype.	The	 lipopolysaccharide	capsule	 (LPS)	of	 the	 isolated	C.	 jejuni	was	purified	and	analysed.	 It
showed	 binding	 activity	 of	 cholera	 toxin,	 which	 specifically	 recognizes	 the	 GM1-oligosaccharide.
Analysis	 using	 gas-liquid	 chromatography-mass	 spectrometry	 showed	 that	 the	 purified	 LPS	 contained
Gal,	GalNAc	and	NeuAC.	It	was	also	shown	that	this	oligosaccharide	structure	protrudes	from	the	LPS
core	and	its	configuration	is	identical	 to	the	terminal	tetrasaccharide	of	the	GM1	ganglioside.	This	was









































cranial	 nerves.	 The	 illness	 reaches	 its	 peak	 within	 several	 days,	 at	 which	 time	 flaccid	 weakness	 is	 extreme	 and











with	 an	 axonal	 neuropathy.	 Recently,	 Rupp	 and	 colleagues	 demonstrated	 the	 presence	 of	 anti-GM2















































































































Missing	 GBS	 in	 the	 emergency	 department	 (ED)	 is	 common.	 The	 patient	 suddenly	 experiences	 acral
paresthesias	or	numbness,	and	often	back	and	radicular	leg	pain.	He	is	understandably	anxious	and	may
lead	a	clinician	to	a	diagnosis	of	panic	disorder	due	to	anchor	bias,	further	compounded	by	the	potential
for	 gender	 bias	 when	 the	 afflicted	 individual	 is	 an	 otherwise	 healthy	 young	 woman.	 A	 cursory
neurological	examination	is	deemed	‘nonfocal’,	and	the	patient	is	dismissed	with	a	diagnosis	of	anxiety,
hyperventilation	 syndrome,	 ‘neurasthenia’,	 or	 no	 diagnosis	 at	 all,	 and	 discharged	 home.	 Seldom	 is	 a
neurological	consultation	considered	in	those	without	overt	motor	deficits.	The	patient	returns	(often	to	a
different	ED)	days	to	a	week	later	with	progressive	generalized	weakness	and	ventilatory	failure,	and	the




Fully	one-third	of	patients	have	generalized	weakness	of	 the	arms	and	 legs	at	onset,	 and	15%	have
weakness	spreading	in	a	descending	pattern.	This	does	not	include	those	patients	with	the	Miller	Fisher
syndrome	or	pure	sensory	variants.	Sadly,	the	view	that	‘GBS	equals	ascending	paralysis’	is	steadfastly
fixed	 in	 the	 minds	 of	 many	 clinicians	 to	 the	 exclusion	 of	 the	 other	 diagnostic	 features	 of	 GBS.	 For







normal	 in	 an	 otherwise	 healthy	 individual	 with	 acute	 neuropathic	 symptoms;	 GBS	 always	 should	 be
considered.
Nothing	above	the	Neck
Not	 infrequently	 a	patient	with	 rapidly	progressive,	 flaccid,	 areflexic	quadriplegia	 and	 sensory	 loss	 is
transferred	 with	 ‘GBS’.	 Neurology	 trainees	 sometimes	 come	 to	 premature	 diagnostic	 closure	 in	 such






features	 that	 favour	 an	 acute	myelopathy	 include	 complaints	 of	 rapidly	 progressive	 sensory	 loss	 in	 the
legs	extending	proximally	to	the	trunk,	and	early	and	prominent	urinary	retention	or	incontinence	which	is
often	 overlooked,	 as	 virtually	 all	 patients	 now	 have	 urinary	 catheters	 placed	 upon	 ICU	 admission.	 A
bladder	ultrasound	performed	before	catheter	placement	which	demonstrates	high	post-void	residuals	is	a




the	 clavicle;	 pinprick	 testing	 also	 should	 be	 performed	 just	 lateral	 to	 the	 spinous	 processes	 to	 avoid
confusion	with	 escutcheon	 sensory	 loss	 on	 the	 anterior	 trunk,	which	may	be	 present	 in	GBS	and	 acute
ganglionopathies.
What	Does	Not	Belong
Virtually	 all	 major	 reviews	 of	 GBS	 provide	 a	 regurgitation	 of	 a	 long	 list	 of	 diseases	 that	 mimic	 the
disorder.	This	usually	 falls	 into	 two	basic	 categories:	 the	 first	 are	 the	 acute	neuropathic	disorders	 that
share	 the	 rapid	 progression	 of	 a	 paralytic	 peripheral	 neuropathy,	 but	 are	 so	 strikingly	 rare	 as	 to	 be
discussed	almost	exclusively	for	pedagogic	purposes	and	then	promptly	dismissed.	Such	entities	include
diphtheria,	 arsenic	 and	 thallium	 intoxication,	 acute	 intermittent	 porphyria,	 etc.	 My	 mentors	 have
undoubtedly	encountered	a	case	or	two	of	these	oddities	during	their	half-century	careers,	but	I	personally
have	never	seen	a	case	of	diphtheric	demyelinating	polyneuropathy,	or	for	that	matter	arsenic	or	thallium
poisoning.	Additional	 examples	 are	 provided	 in	 Table	17.1.	 These	 exceptionally	 rare	 conditions	 have




acute,	 rapidly	 progressive	 weakness.	 Conditions	 other	 than	 transverse	 myelitis	 include	 basilar	 artery
thrombosis,	myasthenia	gravis,	botulism,	 tick	paralysis,	periodic	paralysis,	 acute	 fulminant	myopathies,
etc.	 (see	 Table	 17.1).	 These	 conditions	 should	 be	 considered	 when	 accompanied	 by	 the	 appropriate
associated	 symptoms	 or	 clinical	 findings,	 but	 the	 typical	GBS	 patient	 usually	 does	 not	 require	 routine
evaluation	 to	exclude	 these	disorders.	Two	of	my	mentors,	Louis	Caplan,	MD,	and	Allan	Ropper,	MD,
frequently	espoused	‘Fisher’s	rules’	on	teaching	rounds,	reflecting	the	clinical	genius	of	their	mentor,	C.





psychiatric	 or	 cognitive	 impairment,	 seizures,	 skin	 or	 hair	 changes,	 central	 nervous	 system	 findings,
multifocality	or	prominent	asymmetry,	pain	disproportionate	to	sensory	findings,	CSF	pleocytosis	(>	50
white	 blood	 cells),	 and	 electrodiagnostic	 findings	 indicative	 of	 a	 primary	 axonopathy	 (allowing	 for




The	 value	 of	 electrodiagnostic	 and	 cerebrospinal	 fluid	 (CSF)	 studies	 are	 covered	 in	 greater	 depth
elsewhere	in	this	volume,	such	that	only	a	few	comments	are	provided.	Both	tests	are	crucial	objective
measures	 that	 establish	 the	 diagnosis	 in	 the	 majority	 of	 GBS	 patients.	 The	 anticipated	 findings	 are
acquired	 demyelination	 on	 nerve	 conduction	 studies	 (NCS)	 and	 cyto-albuminological	 dissociation	 on
CSF	 analysis,	 and	 yet	 these	 studies	 also	 are	 helpful	 when	 neither	 is	 present	 or	 other	 unexpected
abnormalities	are	found	that	point	to	an	alternative	diagnosis.	For	example,	in	paraparetic	patients	where
the	only	NCS	abnormalities	are	prolonged	or	absent	late	responses	limited	to	the	lower	extremities,	other
conditions	 that	 affect	 the	 nerve	 roots	 or	 motor	 neurons	 must	 be	 considered,	 such	 as	 neoplastic	 cell
infiltration,	sarcoidosis,	Lyme	disease,	and	rarely,	acute	infectious	polyradiculitis	due	to	herpes	zoster	or
simplex,	 HIV	 and	West	 Nile	 virus	 infection.	 In	 such	 scenarios	 there	 is	 usually	 a	 CSF	 pleocytosis	 in
addition	to	an	elevated	protein	level.	Conversely,	in	a	validation	study	of	the	Brighton	criteria	for	GBS,
Fokke	and	co-workers	[3]	observed	that	no	GBS	patient	had	a	pleocytosis	greater	 than	50	cells/µl,	but
approximately	 15%	 had	 a	 5	 to	 50	 cells/µl;	 therefore,	 although	 other	 conditions	 should	 be	 thoroughly
investigated,	a	moderate	pleocytosis	does	not	exclude	GBS	in	the	appropriate	clinical	context.	Similarly,




abnormalities.	 Multiple	 conduction	 blocks	 in	 named	 motor	 nerve	 territories	 correlate	 with	 clinical
weakness	 in	 GBS,	 but	 also	 may	 be	 an	 early	 finding	 in	 acute	 mononeuritis	 multiplex	 due	 to	 systemic









demyelinating	 abnormalities	 [4].	 In	 others,	 electrophysiological	 abnormalities	 evolve	 as	 the	 condition
advances	and	diagnostic	criteria	are	fulfilled	upon	follow-up	study.
When	to	Intubate?
GBS	patients	 are	 at	 high	 risk	 for	 developing	medical	 complications	 during	 the	 course	 of	 their	 illness,
most	commonly	pneumonia.	As	weakness	advances,	it	sometimes	can	be	difficult	to	determine	the	exact








reasonable	approximation	 is	60	cc/kg.	With	progressive	weakness	of	 the	diaphragmatic	and	 intercostal
muscles	 there	 is	a	steady	decline	of	 the	vital	capacity,	and	at	20	cc/kg	 the	patient	may	look	reasonably
well	 but	 should	 be	 electively	 intubated	 to	 reduce	 the	 risk	 of	 aspiration,	 prevent	 rapidly	 progressive
ventilatory	 failure	 with	 retention	 of	 carbon	 dioxide,	 and	 prevent	 hypoxia	 eventually	 leading	 to	 a
respiratory	 arrest.	 This	 is	 generally	 the	 reverse	 sequence	 of	 events	 that	 occurs	 in	 most	 patients	 with
parenchymal	lung	disease.	However,	there	are	useful	clinical	clues	that	predict	ventilatory	failure.	Lawn
and	colleagues	have	shown	that	there	seems	to	be	a	correlation	between	rapid	progression	of	GBS	(e.g.,
quadriplegia	 evolving	 over	 a	 few	 days),	 progressive	weakness	 of	 the	 neck	 flexors	 on	 bedside	 testing,
bifacial	 or	 tongue	weakness,	 bulbar	 impairment,	 and	 impending	 ventilatory	 failure	 requiring	 intubation
[5].
When	in	doubt,	intubate.	Intubate	early,	in	a	controlled	situation,	preferably	during	the	day,	when	the
staff	anaesthesiologist	may	leisurely	stroll	 to	 the	ICU	and	the	anxiety	of	 the	patient,	family	and	medical
staff	are	manageable.	I	have	heard	of	innumerable	cases	of	intubation	disasters:	The	patient	initially	looks
fine	on	a	floor	bed,	respiratory	mechanics	and	other	clinical	signs	are	not	followed	properly,	and	hours
later	 the	next	 ‘neuro	check’	 finds	 the	patient	cyanotic	and	not	breathing.	A	code	 is	called,	 followed	by
crash	 intubation	 (usually	 by	 a	 less	 skilful	 anaesthesiologist-in-training)	 and	 the	 requisite	 ventilatory
associated	pneumonia	follows	over	the	next	48	hours.	This	scenario	invariably	occurs	in	the	middle	of	the





rapidly	progressive	ventilatory	 failure	 and	quadriplegia.	However,	 in	 a	non-ventilated	patient	who	has
been	in	the	ICU	for	many	days	or	weeks,	with	a	sudden	onset	of	otherwise	unexplained	tachycardia	with







patients	 were	 critically	 ill	 and	 ventilated	 with	 multi-organ	 failure.	 Most	 were	 heavily	 sedated	 and
received	paralytic	agents	to	facilitate	ventilation.	These	cases	looked	like	severe	GBS;	there	was	severe,
generalized,	 flaccid	 symmetrical	 weakness	 of	 the	 limbs	 with	 areflexia	 and	 sensory	 loss.	 Bolton	 and
colleagues	clarified	our	 thinking	with	 their	 seminal	work	defining	critical	 illness	polyneuropathy	 (CIP)
and	distinguished	this	condition	from	GBS	acquired	in	the	ICU	[6].	In	contrast	to	GBS,	these	patients	are
neurologically	intact	upon	ICU	admission	and	weakness	develops	later	in	the	hospital	course.	The	NCS

















days,	weeks	or	months,	 followed	by	 a	 recovery	phase	 for	weeks	 to	years.	During	 the	plateau	or	 early
recovery	 phase,	 approximately	 10%	 of	 patients	 relapse	with	 recurrent	GBS	 symptoms	 and	 findings	 in
otherwise	 medically	 stable	 patients.	 This	 is	 termed	 a	 treatment-related	 fluctuation	 (TRF),	 and	 most
respond	to	retreatment	with	IVIg	or	plasma	exchange	and	resume	an	otherwise	uncomplicated	recovery.
TRFs	 should	 be	 distinguished	 from	 transient	 worsening	 triggered	 by	 a	 medical	 complication,	 e.g.,
pneumonia,	 urinary	 tract	 or	 other	 infection,	 bowel	 obstruction,	 pulmonary	 embolus,	 etc.	 In	 such
circumstances	 treatment	should	be	directed	at	 the	medical	problem,	not	more	 immunotherapy.	 These
patients	recover	once	the	medical	issue	is	resolved.
There	 are	 occasional	 patients	 who	 have	 multiple	 relapses	 in	 the	 weeks	 that	 follow	 nadir	 without




















Hickam’s	 dictum	 (“Patients	 can	 have	 as	 many	 diseases	 as	 they	 damn	 well	 please”)	 also	 applies	 to
recovered	 GBS	 patients.	 Such	 individuals	 are	 understandably	 anxious	 that	 any	 trivial	 change	 in	 their
residual	 symptoms	 represents	 an	 impending	 recurrence.	 However,	 fluctuations	 of	 paresthesias	 and
numbness	in	otherwise	stable,	recovered	patients	are	more	likely	due	to	unrelated	health	issues,	such	as
dehydration,	infections,	sleep	deprivation,	or	stress,	and	promptly	resolve	when	the	inciting	factors	have
been	 properly	 addressed.	 In	 contrast,	 patients	 are	 entitled	 to	 accumulate	 other	 neurological	 disorders
simulating	 their	 original	 GBS	 symptoms,	 such	 as	 a	 superimposed	 diabetic	 or	 B12	 deficiency-related
polyneuropathy	or	 cervical	 spondylotic	myelopathy.	These	 secondary	 conditions	usually	 evolve	 slowly
and	are	 clarified	with	 careful	 clinical	 assessment	 and	 judicious	 testing.	One	 should	be	mindful	not	 to
routinely	 attribute	 new,	 progressive	 neurological	 symptoms	 to	 a	 remote	 history	 of	 GBS.	 Lastly,
Kuitwaard	 and	 colleagues	 have	 observed	 that	 there	 are	 the	 unlucky	 few,	 as	 many	 at	 6%,	 who	 have
recurrent	GBS	[9].	Recurrences	range	from	2	to	7	attacks	over	years	or	decades,	with	clinical	features
similar	 to	 the	 first	 presentation	and	usually	 triggered	by	an	 infection.	Repeated	attacks	of	GBS	 tend	 to






be	 related	 to	 the	nature	of	medical	care	 in	 the	United	States,	where	patients	are	often	 transferred	great
distances	 to	 medical	 centres	 with	 expertise	 in	 the	 care	 of	 patients	 with	 GBS	 and	 which	 precludes
subsequent	outpatient	follow-up	at	the	treating	facility.	However,	my	personal	observations	suggest	it	also
may	 be	 a	 phenomenon	 of	 ‘the	 forgotten	 patient’	 once	 the	 patient	 has	 been	 stabilized	 and	 transferred
elsewhere.	Many	have	 persistent	 symptoms,	 even	 if	 they	 have	made	 a	 ‘full	 recovery’	 by	 our	 limited
metrics.
Pain	is	common	in	the	recovery	phase,	characterized	as	neuropathic	burning	or	lancinating	pains	in	a
length-dependent	 distribution.	 Persistent	 fatigue	 causes	 substantial	 disability.	Afflicted	 individuals	may
have	normal	strength	but	have	great	trouble	completing	routine	activities	of	daily	living.	Severely	affected




are	 tremendously	 helpful.	 GBS	 patients	may	 continue	 to	 improve	 slowly	 years	 after	 onset.	 It	 is	 these
























Guillain-Barré	 syndrome	 (GBS)	 is	 an	 acute	 polyneuropathy	 that	 reaches	 its	 maximum	 severity	 (by
definition)	 within	 4	 weeks,	 whereas	 the	 maximum	 severity	 in	 chronic	 inflammatory	 demyelinating
polyradiculoneuropathy	(CIDP)	is	reached	after	at	least	8	weeks.	Differentiating	between	GBS	and	CIDP
can	be	difficult	as	 it	 relies	on	arbitrary	clinical	criteria	and	this	separation	may	be	mainly	nosological.







































acute	 idiopathic	 demyelinating	 polyneuropathy	with	 an	 onset	<	 8	 weeks	 (fulfilling	 the	 criteria	 for	 the
diagnosis	of	GBS	[2])	followed	by	a	complete	or	near-complete	recovery.	Because	the	authors	found	a




was	noted	preceding	 the	 first	 episode.	All	patients	were	asymptomatic	or	had	mild	 symptoms	between
episodes.	CSF	protein	level	was	normal	or	only	mildly	elevated	when	obtained	within	1	week	of	onset	of
the	 recurrence	 or	 in	 the	 recovery	 phase.	 In	 all	 patients	 the	 protein	 level	was	 elevated	when	CSF	was
obtained	more	than	1	week	after	onset	of	symptoms	during	a	symptomatic	phase.	One	of	these	12	patients










































the	 pathogenic	 process,	 suppressed	 by	 treatment,	 is	 still	 active	 or	 reactivated	 after	 treatment.	 An
explanation	 for	 the	 fact	 that	 not	 all	 patients	 show	 TRFs	might	 be	 that	 some	 are	 treated	 earlier	 in	 the
disease	course	when	 they	are	still	 in	 the	active	disease	phase.	Another	explanation	could	be	 that	 some
patients	have	a	 longer	 active	disease	course	or	more	prolonged	 immune	attack	 than	others,	 requiring	a
higher	dose	or	longer	treatment	period.
Acute	and	Subacute	CIDP







reported	 a	 respiratory	 infection	 before	 onset	 of	 neurological	 symptoms.	 None	 of	 these	 patients	 had
autonomic	dysfunction	or	required	artificial	ventilation.	All	patients	clearly	responded	to	prednisone	or
showed	a	spontaneous	recovery.	Six	out	of	7	patients	had	an	increased	CSF	protein	level.	Patients	had	a





Sixty	 patients	 (65%)	 had	 a	 relapsing	 course,	 whereas	 32	 patients	 (35%)	 showed	 a	 progressive	 or
monophasic	 course.	 CIDP	 patients	with	 a	 relapsing	 course	 had	 a	 significant	 earlier	 age	 of	 onset.	 The








over	 the	 course	 of	 1	 week	 [12].	 Electrophysiology	 showed	 clear	 evidence	 of	 demyelination.
Electromyography	 showed	 fibrillations	 as	 well	 as	 positive	 sharp	 waves	 in	 all	 muscles.	 The	 clinical
findings	 were	 fully	 compatible	 with	 acute	 canine	 idiopathic	 polyneuropathy	 (ACIP).	 Euthanasia	 was
performed	 because	 of	 rapid	 deterioration.	 On	 postmortem	 examination,	 severe	 enlargement	 and
demyelination	 of	 the	 cervical	 nerve	 roots	 was	 seen.	 Pathology	 showed	 hypertrophic	 changes	 with
formation	 of	 onion	 bulbs,	 and	 hypomyelinated	 fibres	 indicating	 chronic	 de-	 and	 remyelination.
Furthermore,	other	chronic	signs	were	found.	The	owner	of	the	dog	did	not	recall	any	previous	episodes











Distinguishing	 between	 GBS-TRF	 and	 A-CIDP	 early	 in	 the	 course	 of	 the	 disease	 can	 be	 important
because	prognosis	and	treatment	strategy	can	be	different.	Out	of	164	GBS	or	MFS	patients	enrolled	in	a
prospective	study,	16	patients	had	1	or	more	TRFs	(10%)	[13].	The	definition	of	a	TRF	or	exacerbation





















ataxia	 was	 more	 likely	 in	 A-CIDP	 patients	 as	 compared	 to	 GBS	 patients	 (53%	 vs.	 3%,	 P	<	 0.001).














they	 can	 be	 considered	 as	 part	 of	 the	whole	 spectrum	of	 inflammatory	 demyelinating	 polyneuropathies
instead	of	separate	entities.	The	fact	 that	some	patients	may	have	recurrences	of	GBS	or	both	GBS	and
CIDP	 also	 suggests	 that	 some	 individuals	 are	 more	 susceptible	 to	 developing	 these	 inflammatory














































The	 reported	 incidence	 of	 GBS	 in	 children	 is	 variable,	 and	 may	 differ	 between	 age	 categories	 and















of	95	children	fulfilled	 the	diagnostic	 criteria	of	GBS	 (53	boys,	42	girls),	 and	 the	age	 ranged	 from	12
months	 to	 16.5	 years	 (median	 6.2	 years).	Disease	 incidence	 peaked	 during	 the	 cold	months	 (October–










diagnostic	 feature,	 occurring	 in	 one-third	 of	 these	 patients.	The	 study	 also	 describes	minor	 differences
between	GBS	in	children	and	adults	which	should	be	considered	when	treating	a	child	with	GBS.
Natural	History
The	clinical	 course	of	GBS	varies	 between	 countries,	 partly	due	 to	 the	 availability	 of	 treatment.	Most
high-income	 countries	 treat	 adult	 and	 children	 with	 GBS	with	 IVIg	 or	 plasma	 exchange	 and	 have	 the
opportunity	to	provide	ICU	care	and	mechanical	ventilation	if	required.	In	low-income	countries	specific
treatments	and	mechanical	ventilation	may	be	available	only	for	a	minority	of	cases.	Before	the	time	of
plasma	 exchange	 and	 IVIg,	 the	 natural	 history	 of	 Guillain-Barré	 syndrome	 in	 adults	 and	 children	was
documented	in	a	Dutch	cohort	of	68	patients	admitted	between	1975	and	1987	[5]	with	GBS	according	to












82%	 (78	 children)	 of	 patients	 [8].	 The	 predominant	 antecedent	 event	was	 a	 respiratory	 tract	 infection
preceding	 GBS	 in	 37%	 (33)	 of	 all	 children,	 followed	 by	 gastrointestinal	 infections	 in	 15%	 (14)	 of
children.	The	infectious	agents	responsible	for	these	infections	in	children	are	unknown.	In	some	cases	the
preceding	infection	may	be	caused	by	Campylobacter	jejuni,	but	the	frequency	seems	to	be	lower	than	in
adult	patients,	where	C.	 jejuni	 is	 the	predominant	cause	of	preceding	 infection.	Multiple	other	 types	of
preceding	 infections	 have	 been	 reported	 in	 children	 with	 GBS,	 most	 frequently	 with	 coxsackievirus,




are	no	specific	biomarkers	and	 the	nerve	conduction	studies	and	cerebrospinal	 fluid	examination	 in	 the
early	stage	of	GBS	may	be	normal.	The	history	and	neurological	exam,	however,	may	be	problematic	in


















nerve	 conduction	 studies	 [10].	 Twenty-five	 children	 with	 the	 mean	 age	 of	 4	 years	 and	 8	 months,
diagnosed	with	GBS	between	1997	and	2007,	were	retrospectively	reviewed.	Gadolinium-enhanced	MRI
was	 performed	 in	 8	 children	 at	 a	mean	of	 8	 days	 (range	 2–16	days)	 from	 symptom	onset.	 In	 7	 (88%)
children	 there	was	 nerve	 root	 enhancement	 present	 and	 all	 had	 abnormal	CSF	 findings.	 In	 24	 children
NCS	was	performed	and	in	21	children	(88%)	it	was	consistent	with	a	demyelinating	polyneuropathy.	In
20	 children	 a	 lumbar	 puncture	 was	 performed	 and	 in	 16	 children	 (80%)	 cyto-albuminological
dissociation	was	present.	CSF	protein	concentration	was	normal	in	3	children,	at	a	mean	of	3	days	from





the	 gold	 standard	 for	 confirming	 the	 diagnosis	 of	GBS	 in	 children,	 but	 that	 gadolinium-enhanced	MRI
provides	a	valuable	addition	to	NCS	in	the	evaluation	of	children	with	suspected	GBS,	especially	when
the	 presentation	 is	 atypical	 and	 if	 the	 child	 is	 presenting	 to	 a	 peripheral	 centre	 were	 paediatric
neurological	and	paediatric	neurophysiological	expertise	is	unavailable.	After	the	MRI	a	lumbar	puncture
can	 be	 performed	 safely	 to	 exclude	 other	 infectious	 diagnosis.	 A	 disadvantage	 of	MRI	 to	 support	 the




presenting	 feature	of	GBS	 in	children.	Several	 studies	on	 the	occurrence	of	pain	 in	children	with	GBS
have	 been	 published.	 In	 a	 retrospective	 case	 study	 of	 29	 children	 (16	 boys	 and	 13	 girls)	 with	 GBS
younger	than	6	years	old	published	by	Nguyen	and	colleagues,	pain	was	evident	in	23	patients	(79%)	on
admission	and	often	the	most	prominent	symptom	[11].	This	led	to	a	misdiagnosis	in	20	patients	(69%).
The	 prominent	 pain	 syndrome	was	 bilateral	 deep	 lower	 limb	 pain,	 exacerbated	 by	 straight	 leg	 raising
(radicular	pain).	Moreover,	11	patients	(38%)	with	leg	pain	on	examination	were	also	found	to	have	neck








and	 2012	were	 retrospectively	 reviewed.	 Fifty-two	 percent	 of	 the	 patients	 (14)	 developed	 autonomic
dysfunction.	On	average,	autonomic	dysfunction	had	its	onset	at	the	same	time	the	disease	activity	reached
its	 plateau	 phase.	 Twenty-six	 percent	 (7)	 of	 the	 patients	 already	 had	 bladder	 or	 bowel	 sphincter
disturbance	at	 the	 time	of	presentation.	An	additional	3	patients	developed	urinary	 retention	during	 the
course	of	the	disease.	The	development	of	urinary	retention	correlated	significantly	with	weakness	of	all
4	 limbs	 and	 severity	 of	 upper-limb	 weakness.	 Hypertension	 was	 the	 most	 common	 manifestation	 of
autonomic	dysfunction	and	was	seen	in	12	(44%)	patients.	Resolution	or	control	of	the	hypertension	was
statistically	significantly	correlated	with	the	length	of	the	hospital	stay.	Nine	(33%)	patients	required	anti-




This	 article	 confirmed	 previously	 presented	 data	 that	 50%	 of	 children	 with	 GBS	may	 suffer	 from






Bayoumi	 and	 colleagues	 compared	 PE	with	 IVIg	 in	mechanically	 ventilated	 children	with	GBS.	 They
concluded	that	children	with	GBS	requiring	mechanical	ventilation	respond	favourably	to	both	IVIg	and
PE	[7].	A	trial	looking	at	the	treatment	effect	of	different	regiments	of	IVIg	and	the	time	to	start	treatment
has	 been	 conducted	 by	 Korinthenberg	 and	 colleagues	 [13].	 In	 their	 multicentre	 study,	 63	 hospitals




5	days.	Treatment	was	 to	be	 initiated	as	soon	as	possible	after	 the	randomization.	Twenty-one	children
were	included	in	the	early	treatment	study	and	51	children	in	the	late	treatment	study.	The	study	concluded
that	treatment	with	IVIg	before	loss	of	unaided	walking	ability	did	not	give	rise	to	a	less	severe	course,
but	 recovery	 occurred	 somewhat	 faster.	 For	 treatment	 after	 loss	 of	 unaided	 walking,	 there	 was	 no
significant	difference	in	the	effectiveness	of	2g/kg	IVIg	administered	over	2	days	versus	5	days,	but	early
relapses	occurred	more	 frequently	after	 the	 shorter	 treatment	 regimen.	Before	 this	 study,	 children	were
treated	the	same	as	adults	without	the	knowledge	whether	or	not	this	was	also	effective	in	children.	This
study	indicated	that	IVIg	was	also	effective	in	children	and	that	the	currently	used	method	of	starting	with
treatment	 only	 if	 the	 patient	 is	 unable	 to	 walk	 unaided	 is	 also	 sufficient	 in	 children.	 An	 important
remaining	 question,	 however,	 is	whether	 the	 dosage	 regimen	used	 in	 adults	 and	 tested	 in	 this	 paper	 is
optimal	 in	 children	 of	 all	 ages,	 or	 whether	 the	 amount	 of	 IVIg	 should	 be	 adjusted	 based	 on	 body
composition	of	the	growing	child.
The	Future
In	 the	 last	 few	 years	 a	 rise	 in	 the	 number	 of	 publications	 regarding	 childhood	 GBS	 has	 been	 seen,
especially	 from	 low-income	countries.	For	 further	 reading	we	 recommend	a	 review	of	paediatric	GBS
published	 in	 2013	 by	 M.	 Ryan	 that	 describes	 the	 variable	 clinical	 and	 neurophysiologic	 subtypes	 of








There	are	no	models	 to	predict	 the	chance	of	respiratory	failure	or	 long-term	outcome	in	individual
children	with	GBS.












































have	 a	 diagnosis	 other	 than	 GBS	 or	 acute-onset	 chronic	 inflammatory	 demyelinating
polyradiculoneuropathy	 (CIDP).	My	 informal	 survey	 of	 1,192	 patients	 in	 6	 published	 trials	 and	 series








‘chameleons’	 in	which	GBS	mimics	 other	 conditions.	The	 same	 authors	 also	 recently	 proposed	 a	 new






and	 one	 core	 item	 of	 equipment	 to	 back	 up	 his	 personal	 skills.	 Advances	 in	 ultrasound	 [6],	 contrast-
enhanced	MRI	of	nerve	roots	 [7]	and	other	supportive	 tests	have	not	substantially	changed	 the	fact	 that
diagnosis	 of	 GBS	 is	 primarily	 based	 on	 clinical	 history	 and	 examination	 by	 the	 ‘neurologist	 with	 the













lesser	 height	 than	 the	 sky)	 may	 exacerbate	 pre-existing	 subclinical	 spondylotic	 cervical	 myelopathy.
Acute	cord	injury	may	cause	reduced	reflexes,	and	the	time	course	of	transverse	myelitis	is	identical	to
GBS	[10].	Cauda	equina	compression	may	simulate	paraparetic	GBS,	and	radicular	pain	 is	common	in






sufferer	of	GBS.	The	Dutch	GBS	Study	Group	described	how	very	common	pain	 is	 in	GBS	 [11].	 In	 a
cohort	of	156	patients,	36%	had	pain	before	the	onset	of	weakness,	66%	had	pain	within	the	first	month
after	onset	and	38%	still	had	pain	after	one	year.	Pain	at	the	time	of	onset	was	often	severe,	typically	in
the	 extremities,	 especially	 radicular	 pain,	 painful	 paraesthesiae	 and	 muscle	 pain.	 Neuropathic	 pain
medication	may	give	a	small	quantum	of	solace.
However	a	patient	who	 is	weak	and	 in	pain	may	not	have	GBS,	but	 instead	pain-related	 functional
weakness.	A	non-neural	cause	of	back	pain	is	a	common	cause	of	apparent	weakness	in	the	lower	limbs













thyrotoxicosis,	 prolonged	 vomiting	 or	 diarrhoea,	 renal	 tubular	 acidosis,	 hyperaldosteronism,	 and
liquorice	 or	 barium	 toxicity.	 Many	 other	 metabolic	 disturbances	 may	 cause	 acute	 weakness:	 severe
hypophosphataemia	 or	 hypermagnesemia	 may	 cause	 acute	 neuropathy;	 diabetic	 lumbosacral
radiculoplexus	neuropathy	causes	weight	loss,	malaise	and	pain;	and	of	course	the	bedbound	patient	with
sepsis	or	an	acute	general	medical	condition	is	weak,	albeit	not	in	the	conventional	neural	sense.
Porphyria	 should	 be	 suspected	 when	 a	 GBS-like	 syndrome	 is	 accompanied	 by	 encephalopathy
(confusion	and	sometimes	 seizures)	and	abdominal	pain.	There	may	be	proximal	asymmetric	weakness
and	 numbness	 due	 to	 polyradiculopathy	 or	 neuronopathy	 [14].	 Screening	 for	 urine	 porphobilinogen
identified	a	remarkably	high	12	patients	(11%)	with	previously	undiagnosed	acute	porphyria	in	a	Russian
cohort	 of	 108	 patients	 with	 acute	 polyneuropathy	 or	 encephalopathy,	 together	 with	 pain	 (in	 back	 or






infection	 from	 seroconversion	 to	AIDS,	with	CD4	 counts	 ranging	 from	55	 to	 800/µl	 in	 a	 series	 of	 10






prodromal	 febrile	 meningitis	 illness	 with	 myalgia	 or	 diarrhoea,	 with	 CSF	 pleocytosis,	 and	MRI	 may








Thallium	may	be	considered	 the	perfect	poison	due	 to	being	 tasteless,	odourless	and	colourless.	 It	has
been	used	in	many	notorious	cases	of	murder,	by	Saddam	Hussein	against	dissidents	and	in	the	Bond	film
Spectre.	 Thallium	 poisoning	 causes	 acute	 progressive	 sensory-motor	 polyneuropathy	 with	 prominent









a	 week	 or	 two.	 A	 few	 weeks	 after	 initial	 exposure	 and	 recovery,	 some	 patients	 develop	 subacute
‘organophosphate-induced	delayed	polyneuropathy’,	a	distal	predominantly	motor	axonal	neuropathy	with
ataxia	 [22].	 Chronic	 low-dose	 exposure	 to	 organophosphates	 (at	 doses	 insufficient	 to	 cause	 acute
symptoms)	does	not	cause	neuropathy.
Pharmaceutical	 drugs	 occasionally	 cause	 acute	 severe	 axonal	 neuropathy,	 including	 nitrofurantoin,










In	 patients	 on	 an	 intensive	 care	 unit	 (ICU)	 who	 are	 too	 weak	 to	 be	 weaned	 from	 the	 ventilator,	 it	 is
sometimes	 uncertain	whether	 they	 have	GBS	 or	 critical	 illness	 polyneuropathy	 (CIP)	 [24].	 The	 neural
examination	is	similar,	though	CIP	is	distally	predominant	and	only	rarely	affects	cranial	nerves.
Usually	 the	 distinction	 is	 obvious	 from	 the	 history:	 a	 diagnosis	 of	 GBS	 is	 supported	 by	 onset	 of
weakness	before	 ICU	admission,	or	 recovery	of	 any	preceding	 infection	before	 the	onset	of	weakness.
CIP	affects	over	a	 third	of	severely	 ill	patients	 in	 ICU,	especially	 those	with	acute	 respiratory	distress
syndrome,	 sepsis,	or	 systemic	 inflammatory	 response	 syndrome,	 and	almost	100%	of	 those	with	multi-
organ	failure.	Additional	risk	factors	for	CIP	include	hyperglycaemia	and	gram	negative	bacteraemia.	The
pathogenesis	 of	 CIP	 is	 likely	 a	 combination	 of	microcirculatory	 abnormality,	metabolic	 derangements,
reversible	channelopathy,	and	bioenergetic	dysfunction.	Many	patients	also	have	critical	illness	myopathy,
which	is	more	common	following	corticosteroids	and	usually	gives	a	raised	creatine	kinase.	Prolonged
use	 of	 neuromuscular	 blocking	 agents	 (especially	 vecuronium	 bromide)	 also	 may	 lead	 to	 persistent
weakness.	 Where	 the	 distinction	 is	 difficult,	 GBS	 is	 supported	 by	 (usually)	 demyelinating





After	 death,	 many	 of	 our	 organs	 can	 live	 on	 through	 transplantation.	 Demyelinating	 neuropathies
resembling	 GBS	 or	 CIDP	may	 occur	 in	 0.3–0.7%	 of	 patients	 following	 solid	 organ	 or	 bone	 marrow
transplant	[25],	or	indeed	following	chemotherapy	or	biological	drugs	affecting	the	immune	system.	The
time	delay	from	transplant	to	GBS	onset	is	typically	a	few	months,	but	may	range	from	days	to	years.	The






differential	 diagnosis.	 The	 following	 may	 mimic	 MFS,	 Bickerstaff’s	 brainstem	 encephalitis	 or	 the
pharyngo-cervico-brachial	variant	of	GBS.
Botulism	is	an	acute,	toxic,	pure	motor	and	autonomic	syndrome,	with	ophthalmoplegia,	ptosis,	dilated
pupils	 and	 faciobulbar	 weakness,	 and	 later	 descending	 limb	 weakness,	 preceded	 by	 diarrhoea	 and
vomiting	if	the	source	is	foodborne	[26].	Diagnosis	is	by	neurophysiological	demonstration	of	presynaptic
block	 or	 culture	 of	 the	 organism.	 Treatment	 is	 by	 antitoxin.	 Myasthenia	 gravis	 may	 also	 cause	 acute
ophthalmoplegia.
Wernicke’s	 encephalopathy	 is	 characterised	 by	 acute	 confusion,	 ataxia	 and	 nystagmus	 or
ophthalmoparesis,	 due	 to	 thiamine	 deficiency,	 typically	 occurring	 in	 alcoholics	 or	 following	 gastric
surgery	or	chronic	vomiting.	Diagnosis	may	be	confirmed	by	typical	MRI	changes	in	the	medial	thalami,
mamillary	bodies,	midbrain	and	sometimes	cerebellum.




























































































useful	 to	 identify	groups	 that	 respond	poorly	 to	current	 therapies	 [2].	There	are	also	some	patients	 that
need	 to	 know	 their	 statistical	 chance	 of	 making	 a	 full	 recovery.	 Many	 others	 need	 encouragement	 to
improve	with	physiotherapy	and	do	not	need	 their	hope	 for	 recovery	dashed.	Our	models	 for	 recovery
have	wide	error	bars	and	this	is	a	concept	difficult	for	patients	to	grasp.	I	have	seen	patients	with	severe
deficit	 following	C.	 jejuni	with	 rapid	onset	of	weakness	and	worrying	electrics	who	have	made	a	 full
recovery	 despite	 everything.	 These	 are	 probably	 the	 ones	with	 reversible	 conduction	 block	 and	 early
electrical	studies	often	miss	them.	Perhaps	they	are	in	a	minority	but	for	those	individual	patients	that	is
irrelevant.	There	are	some	patients	that	react	to	being	told	they	are	in	a	poor	prognostic	group	by	vowing








taken	 to	 improve	 in	 functional	grades	as	well	 as	 time	 in	an	 intensive	care	unit	 and	other	outcomes.	Of
course	this	does	not	mean	that	all	patients	that	are	treated	will	stop	deteriorating	and	start	to	improve.	In
fact,	 quite	 a	 few	 patients	 do	 show	 some	 deterioration	 after	 treatment	 [3,4]	 and	 still	 end	 up	 having	 a
shorter	 disease	 course	 than	 might	 have	 occurred	 if	 they	 had	 not	 received	 treatment.	 We	 are	 just	 not
comfortable	 if	 any	 patients	 continue	 to	 get	 worse	 after	 we	 have	 treated	 them.	 Hopefully	 we	 will
eventually	know	more	 about	 the	benefit	 of	 repeating	 treatment	 in	 these	patients	 and	we	all	 await	 these
studies	with	expectation.	For	the	moment	we	have	to	balance	the	side	effects	of	a	second	course	IVIg	or

























Twenty-five	 percent	 of	 GBS	 patients	 need	 respiratory	 support,	 and	 recognising	 which	 patients	 need
transfer	 to	 the	 ITU	 is	 critically	 important	 [7,8].	 In	our	unit	we	 try	 to	monitor	 all	patients	who	are	 still
deteriorating	with	a	full	vital	capacity	(FVC)	but	others	use	alternative	measures	of	respiratory	reserve
such	as	 sniff	 pressures.	Getting	 the	message	 across	 to	our	 juniors	 that	 peak-flow	measurements	 can	be
unreliable	is	hard,	and	it	often	just	takes	experience	to	see	when	a	patient	is	struggling	for	breath	when
speaking.	Strangely,	some	patients	with	GBS	have	very	low	vital	capacities	but	do	not	appear	to	be	short
of	 breath	 or	 in	 apparent	 distress.	 I	 have	 always	 wondered	 if	 this	 was	 because	 of	 their	 autonomic
neuropathy	masking	 some	 of	 the	 lung	 receptors	 that	 normally	 create	 dyspnoea.	 Not	 being	 comfortable
lying	flat	is	always	a	worrying	sign.	If	a	GBS	patient	tells	you	they	are	short	of	breath	even	when	they	do
not	look	like	it	I	always	take	it	very	seriously.	Our	juniors	are	tempted	to	give	such	patient	oxygen	but	we
have	 made	 it	 a	 rule	 that	 oxygen	 cannot	 be	 prescribed	 for	 a	 neuromuscular	 patient	 without	 consultant







late	 complications	 of	 the	 disease	 [9].	 Severe	 muscle	 atrophy	 can	 lead	 to	 contractures,	 persistent
hypoventilation,	pain	and	weakness.	A	colleague	with	a	good	knowledge	of	rehabilitation	techniques	and
access	to	innovative	aids	and	supports	can	transform	the	life	of	a	patient	with	residual	deficit.	Hopefully,
the	move	 from	 intensive	 physiotherapy	 to	 rehabilitation	 and	 support	will	 be	 seamless,	 but	 I	 have	 seen
cases	where	the	patient	feels	abandoned	when	the	active	treatment	phase	of	the	disease	is	over	and	this
transition	is	poor.	Pain	is	a	common	problem	in	GBS,	both	in	the	acute	phase	and	during	rehabilitation.






I	 remember	 a	 patient	 from	 the	 early	 1980s	with	 a	 severe	 neuropathy	who	 stayed	 for	 6	months	 in	 ITU











my	GBS	patients	 to	visit	 ITU	when	 they	have	 recovered.	This	gives	 ITU	doctors	an	opportunity	 to	see
how	much	better	recovery	can	occur	in	patients	with	profound	deficit	and	encourages	them	to	still	have
hope	 for	 the	 future.	Otherwise,	 there	 is	 a	 tendency	 for	 doctors	 to	 give	up	on	patients	who	 still	 have	 a












to	 recognise	 the	 illness	more	 promptly	 and	 above	 all	 not	 give	 up	 on	 them	 if	 recovery	 is	 slow.	 In	my
experience	 they	have	been	delighted	 to	contribute	 to	 research	even	when	 it	 is	 invasive	and	unpleasant.




























Guillain-Barré	 syndrome	 (GBS)	 is	 considered	 the	 prototype	 of	 a	 post-infectious	 immune-mediated
disorder.	One	of	the	first	descriptions	of	the	association	between	an	infectious	trigger	and	GBS	dates	back
to	1957,	when	Campbell	reported	that	60%	of	polyneuritis	cases	had	preceding	respiratory	symptoms	like
cough,	 sore	 throat	 and	 fever,	 and	 about	 10%	 to	 20%	had	 recent	 diarrhoea	 [1].	At	 this	 time,	GBS	was
believed	 to	 be	 caused	 by	 a	 virus	 infection	 of	 unknown	 aetiology,	 and	was	 linked	 to	 an	 illness	 in	 cats
(‘feline	enteritis’).
To	 date,	 it	 is	 well	 known	 that	 about	 two-thirds	 of	 GBS	 patients	 experience	 respiratory	 or
gastrointestinal	 symptoms	 days	 to	 weeks	 before	 the	 onset	 of	 neurologic	 symptoms	 [2].	 A	 specific




evidence	 that	C.	 jejuni	 is	 a	 potential	 trigger	 of	 GBS	 and	 is	 associated	 with	 the	 acute	 motor	 axonal
neuropathy	 (AMAN)	 subtype	 and	 IgG	 antibodies	 against	 GM1,	 GM1b,	 GD1a	 or	 GalNAc-GD1a	 [5].
Much	less	is	known	about	the	role	of	preceding	infections	and	the	pathogenesis	in	the	patients	with	GBS
who	did	not	have	a	preceding	C.	jejuni	infection.
Many	 other	 identified	 pathogens	 have	 also	 been	 reported	 in	 association	 with	 GBS,	 including
Mycoplasma	pneumoniae,	Haemophilus	influenzae,	cytomegalovirus	(CMV),	Epstein-Barr	virus	(EBV)
and	influenza	virus	[3].	There	are	even	more	pathogens	reported	in	single	GBS	case	reports	or	series.	The
involvement	 of	 these	 pathogens	 in	GBS	 is	 less	 clear	 and	has	 not	 been	determined	 in	 controlled	 larger
studies.	Here,	we	 focus	 on	 the	 spectrum	of	 these	 preceding	 infections	 in	GBS	beyond	Campylobacter
(Table	22.1).
Detecting	a	Pathogen	in	GBS:	What	Does	It	Mean?
The	demonstration	of	a	causative	pathogen	 in	GBS	 is	 rather	complex.	First,	 there	 is	usually	a	delay	of
days	to	weeks	between	the	infection	and	the	diagnosis	of	GBS.	The	detection	rate	of	a	pathogen	by	culture






pathogens.	Adapted	 from	Jacobs	et	al.	 [3];	 rates	vary	 to	 those	 in	 the	original	publication	because	only	single	positive	 infection
serologies	are	indicated	for	CJ,	CMV,	EBV	and	MP.
Second,	demonstrating	the	presence	of	a	pathogen	in	a	GBS	patient	does	not	necessarily	implicate	that
there	 is	 an	 infection	 that	 triggered	 an	 immune	 response	 to	 the	 nerves.	Many	 pathogens,	 apart	 from	C.
jejuni,	 persist	 or	 are	 carried	 in	 healthy	 asymptomatic	 individuals	 without	 any	 symptoms.	 Multiple,
coexisting	bacterial	and	viral	pathogens	can	be	detected	in	respiratory	samples	of	healthy	asymptomatic
individuals,	particularly	children	 [6].	This	asymptomatic	carriage	of	pathogens	may	also	elicit	 immune
responses	 [6,7].	 It	 is	 unclear	 whether	 these	 immune	 responses	 reflect	 unrecognized	 damage	 by	 the
pathogen	 to	 the	host.	Thus,	 a	positive,	 single-sample	 serological	 result,	 either	 IgM	or	 IgG,	may	simply
reflect	one	or	more	previous	encounters	with	 the	pathogen	and	are	not	necessarily	 related	 to	GBS	 [8].
This	also	applies	to	human	herpes	viruses	that	persist	in	the	host	and	where	the	seroprevalence	in	adults
is	 considerably	high.	Caution	 should	be	 taken	 in	 the	 interpretation	of	 these	diagnostic	 test	 results,	 also
because	some	serological	assays	may	lack	sensitivity	and	specificity.
Third,	GBS	 is	 a	 highly	 heterogeneous	 disorder	with	 respect	 to	 the	 type	 of	 preceding	 infection,	 and
some	infections	may	have	triggered	the	onset	of	disease	only	in	a	small	minority	of	the	cases.







(cross-reactive)	 antibodies	was	 a	 recent	 event.	 This	may	 be	 achieved	 by	 using	 paired	 patient	 sera	 in




antibody	 response	 is	 an	 established	 diagnostic	 method	 to	 prove	 an	 intrathecal	 infection	 with	 M.
pneumoniae,	 CMV,	 EBV,	 influenza	 viruses,	 etc.	 in	 encephalitis	 patients	 [9].	 An	 intrathecal	 antibody
synthesis	can	be	established	either	by	calculation	of	an	antibody	index	or	through	parallel	immunoblotting
of	 simultaneously	 collected	 cerebrospinal	 fluid	 (CSF)	 and	 serum	 samples	 [11,12].	 The	 autoimmune







small.	For	example,	only	one	 in	1,000–5,000	patients	with	C.	 jejuni	 enteritis	will	develop	GBS	 in	 the
subsequent	 2	months	 [13],	 a	 fact	which	 certainly	 also	 applies	 to	 other	 infectious	 pathogens,	where	 the
acute	disease	is	much	more	frequent	than	this	severe	post-infectious	complication.
One	 of	 the	 critical	 steps	 in	GBS	 pathogenesis	 is	 the	 generation	 of	 antibodies	 that	 cross-react	with
specific	gangliosides.	It	has	been	shown	for	C.	jejuni	that	such	cross-reactive	antibodies	are	not	produced
during	uncomplicated	C.	jejuni	enteritis	[5].	The	variety	in	types	of	preceding	infection	is	related	to	the
diversity	 in	 clinical	 presentation	 [14],	 outcome	 [15],	 and	 specificity	 of	 antibodies	 to	 glycolipids	 [3].
Therefore,	 the	 detection	 of	 a	 distinct	 anti-glycolipid	 antibody	 type	 could	 give	 an	 indication	 on	 the
preceding	 infectious	 agent	 that	 triggered	 the	 antibody	 response	 through	 microbial	 mimic	 of	 the	 target














patients.	 There	 is	 no	 distinct	 clinical	 picture	 and	 the	 outcome	 is	 generally	 good,	 although	we	 recently
presented	 a	 case	 series	 of	 children	who	 developed	 severe	 and	 complicated	 disorders	within	 the	GBS
spectrum	after	infection	with	M.	pneumoniae	[10].
In	patients	with	GBS,	 serum	antibodies	 to	M.	pneumoniae	 have	 been	 found	 to	 cross-react	with	 the
myelin	 glycolipid	 galactocerebroside	 (GalC)	 [27,28].	 Interestingly,	 we	 recently	 detected	 anti-GalC
antibodies	 in	 the	CSF	of	a	patient	diagnosed	as	Bickerstaff	brainstem	encephalitis	(BBE)	following	M.
pneumoniae	infection	[29].	Anti-GalC	antibodies	have	been	shown	to	cause	demyelinating	neuropathy	in
rabbits	 that	 were	 immunized	 with	 GalC	 [30],	 and	 have	 been	 associated	 with	 demyelination	 in	 GBS
[28,31],	 encephalitis	 [32]	 and	 acute	 disseminated	 encephalomyelitis	 [33].	 However,	 anti-GalC
antibodies	 could	 also	 be	 detected	 in	 patients	 with	M.	 pneumoniae	 infections	 but	 without	 neurologic





isolated	by	Pfeiffer	 in	1893	during	an	 influenza	outbreak	 (‘influenza	bacillus’)	 [35].	H.	 influenzae	 has
encapsulated	 (type	 a–f)	 and	 unencapsulated	 (nontypeable)	 strains,	 and	 can	 cause	 respiratory	 infections
and	severe	invasive	diseases,	particularly	in	children.	In	the	pre-vaccine	era,	H.	influenzae	type	b	(Hib)
accounted	for	95%	of	all	strains	 that	caused	 invasive	disease.	 It	 is	 this	strain	 that	has	been	reported	 in
association	with	GBS.	The	rates	of	preceding	H.	influenzae	infection	in	GBS	vary	between	1%	and	9%
[3,36,37],	 without	 significant	 differences	 to	 control	 subjects.	 Patients	 with	 GBS	 associated	 with	 H.
influenzae	 presented	with	 respiratory	prodromes,	 less	 frequent	 cranial	 and	 sensory	nerve	 involvement,
pure	motor	 axonal	 dysfunction	 and	 positivity	 for	 anti-GM1	 IgG	 antibodies	 [36].	A	GM1-like	 structure
could	be	identified	in	an	H.	influenzae	isolate	of	a	patient	with	axonal	GBS	[38].




evidence	 of	 a	 recent	H.	 influenzae	 infection	 were	 positive	 for	 serum	 anti-GQ1b	 and	 anti-GT1a	 IgG
antibodies	 [37].	 It	 could	 be	 demonstrated	 that	H.	 influenzae	 isolates	 from	 FS	 patients	 bear	 an	 anti-
GT1a/GQ1b	epitope	[37,40].	Serological	evidence	for	a	recent	H.	influenzae	infection	was	also	found	in
6%	of	BBE	patients	 [41].	Thus,	H.	 influenzae	may	be	 involved	 specifically	 in	 the	development	of	 the












The	 most	 frequent	 virus	 associated	 with	 GBS	 is	 cytomegalovirus	 (CMV),	 which	 emphasizes	 that
molecular	mimicry	may	be	not	restricted	to	bacterial	infections.	CMV	is	the	largest	known	human	herpes
virus	 and	 can	 be	 transmitted	 via	 saliva,	 sexual	 contact,	 placental	 transfer,	 breastfeeding,	 blood
transfusion,	 and	 solid-organ	 or	 haematopoietic	 stem-cell	 transplantation.	 The	 most	 important	 clinical
manifestations	of	CMV	are	congenital	and	neonatal	 infections	and	a	mononucleosis-like	syndrome	[49].
CMV	 establishes	 lifelong	 latency	 after	 primary	 infection	 in	 cells	 of	 the	 myeloid	 lineage.	 The	 overall
seroprevalence	 for	 CMV	 is	 30–70%	 [50].	 Long-term	 immunosuppression	 can	 lead	 to	 uncontrolled
replication	and	serious	disease	[49].	GBS	was	first	associated	with	CMV	in	1967	[51].	Since	then	rates
of	 preceding	 CMV	 infections	 are	 reported	 in	 6–15%	 of	 GBS	 cases	 [3,20,21,52–55].	 GBS	 patients
associated	 with	 CMV	 showed	 distinct	 clinical	 features:	 younger	 age,	 more	 severe	 disease	 course
indicated	 by	 a	 high	 frequency	 of	 respiratory	 insufficiency	 and	 delayed	 recovery,	 cranial	 nerve
involvement	(facial	palsy)	and	severe	sensory	loss	[53].	A	positive	IgM	serology	against	CMV	was	also
found	 in	6%	of	FS	patients	 [52].	The	electrophysiological	subtype	 is	acute	 inflammatory	demyelinating
polyneuropathy	(AIDP)	[21].
CMV	has	been	associated	with	the	occurrence	of	anti-GM2	antibodies	in	GBS	patients,	particularly	of
the	 isotype	 IgM	 [54,56].	 It	 could	 be	 demonstrated	 that	 CMV-infected	 fibroblasts	 express	 a	 GM2-like
epitope	 that	 was	 specifically	 recognized	 by	 anti-GM2	 IgM	 antibodies	 [57].	 However,	 anti-GM2	 IgM
antibodies	could	also	be	found	in	patients	with	positive	CMV	serology	but	without	neurologic	diseases
[21,52].	 Interestingly,	 CMV	 DNA	 was	 detected	 in	 the	 blood	 of	 62%	 GBS	 patients	 with	 a	 positive
serology	[54].	Although	the	presence	of	CMV	DNA	in	blood	did	not	appear	to	be	a	significant	predictive
factor	for	the	outcome,	these	findings	suggested	a	role	of	viral	replication	in	the	development	of	GBS.	In
fact,	CMV	DNA	could	 also	be	detected	 in	 the	CSF	 in	31%	 (13	out	of	42)	of	GBS	patients	 [58].	This
observation,	however,	could	not	be	reproduced	in	another	large	GBS	cohort	(n	=	170),	where	CMV	DNA
was	detected	in	only	one	single	case	(0.6%)	[59].	While	there	may	be	a	role	for	anti-GM2	IgM	antibodies




of	 positive	 IgM	 against	 EBV	 viral	 capsid	 antigen	 in	 GBS	 patients	 has	 been	 reported	 with	 1–10%
[3,20,21,55].	GBS	has	also	been	described	after	EBV	reactivation	in	the	immunocompromised	host	[60].
However,	 since	over	90%	of	adults	are	 infected	with	EBV	[61]	and	because	no	known	anti-glycolipid




simplex	 virus	 (HSV)	 and	 the	 varicella-zoster	 virus	 (VZV)	 persist	 in	 the	 ganglia	 of	 cranial	 nerves	 and
dorsal	 roots,	 and	 are	 present	 in	 virtually	 every	 elderly	 adult	 [62].	 There	 are	 case	 reports	 that	 suggest
these	viruses	as	triggers	of	GBS.	However,	the	association	is	weak	[3].
The	 infection	 with	 VZV	 usually	 occurs	 during	 childhood	 and	 may	 manifest	 as	 chickenpox.	 A
spontaneous	reactivation	of	VZV	can	lead	to	herpes	zoster.	The	pathomechanisms	leading	to	reactivation
of	the	virus	may	be	associated	with	a	derangement	of	the	immunological	status	of	the	host.	Interestingly,	a
recent	 study	 found	 an	18-times	 increased	 risk	 for	 the	 development	 of	GBS	 in	Taiwanese	 patients	with




In	 1967,	 the	 U.S.	 national	 influenza	 immunization	 campaign	 against	 influenza	 A	 (H1N1)	 estimated	 an
attributable	risk	of	vaccine-related	GBS	of	about	one	in	100,000	[64].	These	events	caused	considerable
public	concern.	A	similar	association	was	suggested	for	the	immunization	campaign	against	influenza	A
(H1N1)	 in	2009,	but	extensive	national	and	 international	 studies	 found	 that	vaccination	was	associated











of	 pathologic	 processes,	 such	 as	 immune	 dysregulation	 during	 early	 stages,	 opportunistic	 infections
(CMV,	VZV,	etc.)	in	late	stages,	and	treatment-related	effects	by	antiretroviral	therapy	(ART)	(toxicity	or
aberrant	manifestation	of	immune	reconstitution	after	initiation,	re-initiation,	or	change	of	ART)	[71,72].
GBS	 in	 association	with	HIV	may	 occur	 in	 the	 early	 stage	 of	 infection	 or	 at	 seroconversion	 and	may
present	with	more	frequent	recurrent	episodes	or	the	development	of	chronic	inflammatory	demyelinating
polyneuropathy	(CIDP)	[73].	Although	HIV	infection	was	found	in	55%	of	32	consecutive	GBS	cases	in
Zimbabwe	 [74],	GBS	 has	 not	 been	 observed	 in	 a	 prospective	 study	 of	 1,500	HIV-infected	 patients	 in
Britain	[75].
Hepatitis	E	Virus
The	 latest	discovery	of	 a	preceding	 infection	 in	GBS	 is	hepatitis	E	virus	 (HEV).	HEV	 infection	 is	 the






















































































































































































































During	 the	 First	 World	War,	 2	 French	 military	 doctors,	 Georges	 Guillain	 and	 Jean-Alexandre	 Barré,
together	with	André	Strohl,	all	enlisted	in	the	6th	French	Army,	described	the	case	history	of	2	paralysed
























onset	 of	 the	 polyneuritis.	 In	 another	 10–20%	 of	 the	 cases	 the	 onset	 is	 preceded	 by	 an	 episode	 of
diarrhoea.	He	reports	that	“recent	work	has	tended	to	emphasize	that	the	Landry-Guillain-Barré	syndrome
is	a	non-specific	reaction	to	several	infective	agents	and	is	possibly	due	to	an	abnormal	antigen-antibody





Until	1968,	 the	 isolation	of	Campylobacter	 from	human	stools	was	difficult.	A	breakthrough	discovery
was	made	by	Dekeyser	and	Butzler	and	their	team	in	Brussels,	Belgium.	They	isolated	a	‘related	vibrio’
from	blood	samples	of	a	20-year-old	female	who	was	admitted	to	the	hospital	with	severe	diarrhoea	and
fever.	Using	 a	 newly	 developed	mechanical	 filtration	 technique,	 they	 also	 isolated	 the	 ‘related	 vibrio’
from	the	stools	of	diarrhoeal	patients.	This	first	faecal	isolation	of	‘related	vibrio’	from	human	stools	was
followed	by	the	observation	that	C.	jejuni/C.	coli	were	isolated	from	5.3%	of	3,800	stools	from	children.
By	 the	 mid-1980s,	Campylobacter	 species	 were	 recognized	 as	 the	 most	 common	 cause	 of	 bacterial
enterocolitis	[9].
Skirrow	MB.	Campylobacter	enteritis:	a	‘new’	disease.	BMJ,	1977
The	 filtration	 technique	 was,	 however,	 very	 cumbersome,	 time-consuming	 and	 less	 adapted	 to	 high-
throughput	 diagnostic	 microbiology	 laboratories.	 The	 development	 of	 selective	 media	 containing
antibiotics	 to	 inhibit	 the	 residential	 enteric	 flora	 proved	 to	 be	 a	 real	 breakthrough.	 In	 1977,	 Martin
Skirrow	published	 a	 selective	media	 containing	vancomycin,	 polymyxin	 and	 trimethoprim	and	 isolated
Campylobacter	 spp.	 in	 57	 stool	 samples	 out	 of	 803	 (7.1%)	 patients	 with	 diarrhoea.	 New	 isolation
protocols	 and	 selective	 media	 using	 various	 combinations	 of	 selective	 antibiotics	 were	 rapidly




These	 newly	 developed	 methods	 drew	 the	 attention	 of	 scientists	 trying	 to	 decipher	 the	 aetiology	 of
preceding	infections	in	patients	with	GBS.	However,	no	Campylobacter	spp.	could	be	cultured	from	the
stools	collected	from	these	patients	at	the	onset	of	the	muscular	weakness.	The	first	report	of	a	possible
link	 between	 Campylobacter	 infections	 and	 GBS	 was	 published	 in	 1982.	 Rhodes	 and	 Tattersfield
described	the	case	history	of	a	45-year-old	man	admitted	to	the	hospital	with	severe	diarrhoea,	who,	on
the	10th	day	of	hospitalisation,	developed	a	rapidly	progressive	paresis	with	areflexia	and	was	diagnosed




recent	Campylobacter	 infection.	 The	Campylobacter-associated	 GBS	 cases	 manifested	 a	 significantly
more	 severe	 form	 of	 the	 disease.	 They	 also	 stated	 that	 “antigenic	 similarities	 between	 neural
glycopeptides	 and	 bacterial	 capsules	 may	 be	 the	 possible	 immunological	 link	 in	 the	 case	 of










2	 HS:19	Campylobacter	 strains	 isolated	 from	 GBS	 patients	 showed	 structural	 similarity	 with	 GM1,
GT1a	and	GD3.














They	conducted	a	 serological	 study	among	154	GBS	patients	 and	154	 sex-matched	controls	with	other
neurological	diseases.	Serological	evidence	of	a	recent	Campylobacter	 infection	was	observed	in	32%










As	 the	 molecular	 mimicry	 hypothesis	 was	 considered	 an	 excellent	 paradigm,	 the	 elucidation	 of	 the
biosynthesis	pathways	of	bacterial	ganglioside-like	structures	became	an	area	of	great	interest.	Godschalk
and	van	Belkum	demonstrated	for	the	first	time	that	specific	bacterial	genes	involved	in	the	biosynthesis
and	transfer	of	sialic	acid	were	crucial	 in	determining	specific	LOS	loci	 that	subsequently	 induce	anti-










In	 2004,	 Yuki	 and	 colleagues	 demonstrated	 that	 the	 sensitization	 of	 rabbits	 with	 a	 brain	 ganglioside
mixture	 containing	GM1,	GD1a,	GD1b	 and	GT1b	 leads	 to	 high	 anti-GM1	antibody	 titres	 and	 an	 acute
flaccid	 paralysis	 with	 clinical,	 electrophysiological	 and	 histopathological	 features	 resembling	 GBS.
Experiments	with	purified	Campylobacter	LOS	 led	 to	 similar	 results.	Campylobacter-induced	GBS	 is
currently	the	best-studied	autoimmune	disease	implicating	molecular	mimicry	as	mechanisms	of	disease.













































In	 the	 last	 100	 years	 many	 great	 scientific	 papers	 have	 been	 written	 about	 the	 progress	 made	 in
understanding	the	pathogenesis	of	Guillain-Barré	syndrome.	The	roles	of	antecedent	infection,	molecular
mimicry	and	anti-ganglioside	antibodies	have	been	extensively	described	elsewhere	in	this	monograph.	In




In	GBS	 the	variety	 in	preceding	 infections,	 clinical	 signs	and	symptoms,	and	 severity	of	 the	disease	 is
large.	 Even	 in	 subgroups	 of	 patients	 who	 had	 the	 same	 antecedent	 infection	 the	 clinical	 signs	 and











second-	 or	 third-degree	 relatives.	 The	 prodromal	 illness,	 clinical	 features	 and	 severity	 of	 the	 disease
varied	between	the	affected	members	within	 the	families.	Although	this	 is	 the	 largest	report	of	families
with	GBS,	it	is	not	sufficient	to	prove	the	occurrence	of	GBS	within	families.	Factors	that	may	suggest	a
genetic	 susceptibility	 were	 the	 slightly	 more	 frequent	 occurrence	 of	 GBS	 within	 siblings	 (2.6	 fold








neurological	 symptoms	 or	 antecedent	 infections	were	 similar	 in	 each	 patient	 episode	 and	whether	 the




observations	were	 (A)	 a	 trend	 towards	 shorter	 intervals	 between	 subsequent	 recurrences,	 (B)	 a	more
severe	 deficit	with	 each	 recurrence,	 (C)	 all	 patients	with	 3	 or	more	 episodes	were	 female,	 and	 (D)	 3




















been	 reports	 of	 epidemics	 of	 Campylobacter	 that	 did	 not	 result	 in	 an	 outbreak	 of	 Guillain-Barré
syndrome	[7],	the	estimation	is	that	1	out	of	1,000	will	develop	GBS	after	such	a	Campylobacter	 jejuni
infection	 [8].	 Ang	 and	 colleagues	 reported	 an	 outbreak	 of	 Campylobacter	 jejuni	 within	 a	 family
consisting	of	parents	and	2	sons	[9].	The	father	and	his	sons	had	diarrhoea	and	 the	serology	of	 these	3




and	 brother,	 who	 had	 low	 titres	 of	 IgM	 anti-glycolipid	 antibodies.	 HLA-genotyping	 revealed	 that	 the
father	 and	 unaffected	 son	 had	 HLA-A2/DR4/DQ8	 haplotype,	 which	 the	 patient	 did	 not	 have,	 which
suggests	that	this	haplotype	might	be	protective	for	neurological	sequelae.
Genetic	Susceptibility	Factors
The	 paper	 of	 Ang	 and	 colleagues	 suggests	 that	 a	 certain	 HLA	 haplotype	 might	 be	 protective	 for
neurological	sequelae	after	an	infection	with	agents	associated	with	GBS.	The	highly	polymorphic	human
leucocyte	antigen	(HLA)	system	plays	a	central	role	in	the	immune	responses	by	presenting	antigens	to	the






alleles,	 we	 investigated	 whether	 these	 alleles	 confer	 susceptibility	 to	 GBS	 or	 are	 related	 to	 specific
clinical	and	serological	subgroups	[10].	One	hundred	and	sixty-four	patients	clinically	and	serologically
well	 characterized	 were	 genotyped.	 We	 found	 no	 association	 between	 HLA-DRB1	 and	 HLA-DQB1
alleles	 and	 GBS.	 We	 also	 reviewed	 17	 case-control	 studies	 which	 had	 previously	 investigated	 an
association	 between	 HLA-class	 I	 or	 II	 antigens	 and	 GBS	 susceptibility	 and	 subgroups	 [11–27].	 (See
Table	24.1).	With	regard	to	disease	susceptibility,	most	of	the	studies	did	not	find	any	association	or	at
most	 only	 a	 weak	 association	 that	 could	 not	 be	 confirmed	 by	 other	 studies.	 The	 same	 held	 true	 for
subgroup	 analyses.	 We	 concluded	 that	 the	 HLA-system	 probably	 does	 not	 play	 a	 general	 role	 in






Another	way	 to	 assess	 a	 genetic	 contribution	 to	 the	 pathogenesis	 of	GBS	 is	 to	 study	 single	 nucleotide
polymorphisms	 (SNPs)	 in	 relation	 to	 disease	 susceptibility	 or	 severity.	 These	 SNPs	 are	 widely
distributed	throughout	the	genome	and	are	by	definition	present	in	at	least	1%	of	the	general	population.
Within	a	protein-coding	gene	these	SNPs	can	be	located	in	(A)	the	promoter	region,	which	is	involved	in
the	 transcriptional	 regulation	 of	 the	 gene	 expression,	 (B)	 the	 coding	 region,	 which	 is	 translated	 to	 a
protein,	 (C)	 the	 intron,	 which	 is	 not	 translated	 to	 a	 protein	 but	 is	 involved	 in	 splicing,	 and	 (D)	 the











system,	enzymes	 involved	 in	breakdown	of	blood-brain	barrier,	etc.	The	studies	were	most	of	 the	 time




The	 main	 question	 with	 all	 the	 associations	 between	 SNPs	 and	 disease	 susceptibility	 or	 severity	 is
whether	 it	 leads	 to	 a	 functional	 difference	 in	 vivo.	 In	 this	 study	we	 assessed	 the	 association	 between
polymorphisms	 in	 the	 gene	 encoding	 for	 mannose-binding	 lectin	 (MBL)	 and	 disease	 susceptibility	 or
severity	[29].	MBL	is	a	protein	involved	in	the	activation	of	complement	systems	via	the	lectin	pathway.








Since	 the	small	sample	size,	heterogeneity	of	GBS	and	 the	expected	small	effect	of	 individual	SNPs,	a
meta-analysis	 can	 improve	 the	 power	 of	 genetic	 association	 studies.	 In	 this	meta-analysis	Wu	 and	 his
colleagues	 included	 genetic	 association	 studies	 if	 a	 polymorphism	was	 assessed	 in	more	 than	 2	 case-
control	studies	[30].	The	largest	sample	size	was	for	TNF-alpha	308A/G	polymorphism:	713	cases	and
729	 controls,	 consisting	 of	 4	 Asian	 cohorts	 and	 1	 Caucasian.	 This	 polymorphism	 was	 significantly
associated	with	 disease	 susceptibility	 in	 this	 analysis.	 In	 a	 previously	 performed	 study	 by	 Prasad	 and
colleagues,	the	A-allele	of	this	polymorphism	was	associated	with	higher	circulating	TNF-alpha	levels	in





genome-wide	assays	studies	 (GWAS)	have	been	performed	 in	 infectious	and	autoimmune	diseases,	and
nowadays	 whole-exome	 sequencing	 is	 used	 to	 discover	 genetic	 causes	 of	 diseases.	 Because	 of	 the
complex	 genetic	 traits	 of	GBS	 and	 the	 expected	 small	 effects	 of	 individual	 genes,	 genetic	 association







To	 identify	 gene	 networks	 and	 pathways	 in	Guillain-Barré	 patients,	Chang	 and	 colleagues	 drew	blood
from	Taiwanese	GBS	patients	within	1–2	weeks	after	disease	onset	and	from	7	healthy	volunteers	[32].
They	 performed	 a	 genome-wide	mRNA	 expression	 data	 of	 peripheral	 blood	 leukocytes	 by	Affymetrix
Human	Genome	U133	plus	2.0	Array.	Two	hundred	and	fifty-six	genes	reached	the	minimum	fold	change
(>	2),	of	which	246	genes	were	upregulated	and	10	downregulated.	These	256	genes	were	subjected	to	a
network	 analysis	 clustered	 in	 the	 networks	 by	 (A)	 disease	 and	 disorder,	 (B)	 molecular	 and	 cellular
functions	 or	 (C)	 physiological	 system	 development	 and	 function.	 In	 these	 networks	 they	 found	 several
interesting	genes,	a	few	of	which	I	highlight	with	potential	therapeutic	options.	Matrix	metalloproteinase-
9,	detected	in	damaged	nerves	and	associated	with	disease	severity	and	electrophysiological	changes	in
GBS	patients,	 could	be	 a	potential	 target	molecule	 for	 therapy	 since	 in	 the	 animal	model	 experimental
autoimmune	neuritis	(EAN)	administration	of	a	MMP-9	inhibitor	decreased	the	disease	severity	[33–36].
The	 expression	 of	 a	member	 of	 the	 cyclooxygenase	 family	 encoded	 by	 PTGS2	was	 also	 upregulated.
Since	administration	of	COX	inhibitor	decreased	disease	parameters	at	several	levels	in	EAN	this	could
also	 be	 an	 interesting	 therapeutic	 target	 [37–39].	 With	 regard	 to	 canonical	 pathways,	 I	 highlight	 the
ERK/MAPK	 pathway	 that	 is	 involved	 in	 production	 of	 proinflammatory	 cytokines	 and	 demyelination






















































































the	 nervous	 system	 have	 been	 studied,	 and	 are	 these	 the	 ones	 that	 give	 us	 insight	 into	 the	 formal
pathogenesis	and	pathophysiology	of	GBS?
The	early	reports	starting	some	60	years	ago	include	mostly	postmortem	evaluations	with	very	limited
clinical	 and	 electrophysiological	 data.	With	 the	 advent	 of	 artificial	 ventilation	 and	 other	 advances	 in
intensive	 care	 medicine,	 fortunately,	 fewer	 patients	 run	 a	 lethal	 course	 nowadays	 in	 optimal	 clinical
settings.	 The	 remaining	 lethal	 cases	 are	 autopsied	 very	 rarely.	 This	 causes	 a	 fundamental	 bias	 when
analyzing	older	studies.	Over	the	last	20	years,	patients	fulfilling	contemporary	diagnostic	criteria	do	not
have	sural	biopsies	done	except	with	a	clear	research	protocol.	Hence	few	studies	have	reported	on	the
sural	nerve	 and	only	occasionally	on	motor	nerves.	Technically,	 electron	microscopy	 (EM)	and	 teased
fibre	 preparations	 dominated	 the	 field	 later,	 followed	 by	 light	 microscopic	 immunopathology.	 Most
recently,	skin	biopsies	entered	the	field,	and	findings	were	correlated	to	sural	nerve	pathology.	We	here















Haymaker	 and	 Kernohan’s	 1948	 report	 was	 the	 first	 on	 a	 large	 and	 quite	 heterogeneous	 group	 of	 50
patients	with	an	acute	and	ultimately	lethal	PNS	disease	[1].	More	than	a	quarter	of	the	group	had	findings
that	would	not	be	compatible	with	later	definitions	of	GBS.	These	included	CSF	cell	counts	of	up	to	110
cells	 per	 microlitre	 and	 perivascular	 CNS	 infiltrates;	 some	 had	 meningeal	 lymphocytic	 infiltrates.
Haymaker	 and	 Kernohan	 in	 their	 50	 autopsy	 cases,	 most	 of	 whom	 had	 died	 of	 respiratory	 failure,
described	 perivascular	 lymphocytes	 in	 the	white	matter	 in	 25%	 of	 their	 cases	 [1,2].	 They	 found	mild




Since	 their	 patients	 had	died	between	2	 and	46	days	 after	 the	onset	 of	 disease,	 the	 authors	 had	 the
chance	 to	 look	at	early	and	 late	pathology	and	 to	speculate	on	 the	sequence	of	events	 in	 the	peripheral
nervous	system.	They	describe	nerve	oedema	during	the	first	3	to	4	days,	focal	swelling	of	myelin	sheaths
and	 irregularity	 of	 axon	 cylinders	 on	 day	 5,	 lymphocyte	 infiltration	 on	 day	 9	 and	 the	 presence	 of
macrophages	on	day	11.	Schwann	cell	proliferation	was	observed	on	day	13.	In	their	patients	with	a	pure
motor	phenotype,	only	the	anterior	roots	were	affected;	in	those	with	sensorimotor	deficits,	they	found	the
same	pathology	 in	 anterior	 and	posterior	 roots.	 Interestingly,	 the	 authors	 interpreted	 the	 late	 and	 rather












The	 first	 comprehensive	 review	 of	 the	 histopathology	 GBS	 and	 other	 types	 of	 acute	 inflammatory
polyneuropathies	was	published	by	Wilhelm	Krücke	in	1955	[4],	with	the	inclusion	of	several	personal
cases.	The	 author	 discusses	 in	 detail	 the	 paper	 by	Haymaker	 and	Kernohan	 but	 also	 elaborates	 on	 the
extensive	 pathology	 literature	 from	France,	Germany,	England	 and	 the	United	States	 on	 reported	 cases
back	to	1898.	In	his	treatise	he	favours	an	‘allergic’	hypothesis	because	of	the	type	of	lesions,	but	points






‘neuritis’	after	all	 [5].	The	authors	 find	 that	both	 the	 temporal	course	and	 the	basic	pathology	are	well
modelled	by	EAN	as	described	in	the	same	institution	[3].	They	show	massive	lymphocyte	infiltration	in
the	radial	and	femoral	nerve	of	1	patient,	 lymphocytic	and	polymorphonuclear	 infiltrates	 in	 the	anterior
roots	of	another,	and	lymphocytic	and	polymorphonuclear	infiltrates	in	the	cranial	and	peripheral	nerves
of	others.	Even	 in	muscle	sections,	 they	 found	 inflammatory	 infiltrates	around	 the	 terminal	motor	nerve
branches.	Myelin	 breakdown	 was	 observed	 in	 motor	 and	 sensory	 nerves.	 Retraction	 of	 myelin	 at	 the
nodes	 of	 Ranvier	 led	 to	 nodal	 gaps,	 indicating	 focal	 demyelination.	 In	 a	 patient	 with	 severe	 root
inflammation,	anterior	and	posterior	horn	cells	were	pathologic,	and	there	was	astroglial	proliferation	in
the	 spinal	 cord.	 Inflammatory	 infiltrates	 had	 a	 perivascular	 preference	 in	 several	 cases.	 Of	 interest,
several	patients	 survived	 the	GBS	and	died	of	other	causes	 later.	Denervation	atrophy	of	muscles	was
seen	 in	 those	 that	 survived	 the	 longest.	One	 lady	had	 recovered	 from	GBS	and	was	able	 to	walk	with
crutches.	 She	 had	 lived	 5	 more	 years	 before	 dying	 from	 a	 stroke.	 Her	 autopsy	 showed	 segmental
demyelination	 with	 insufficient	 remyelination,	 and	 there	 were	 still	 focal	 inflammatory	 infiltrates
surrounding	endoneurial	vessels.	These	consisted	of	lymphocytes	and	occasional	plasma	cells.	A	similar
pathological	 picture	was	observed	 in	 a	 patient	 surviving	 for	 6	years.	The	 authors	 conclude	 from	 these
observations	 that	 low-grade	 inflammatory	 activity	may	 persist,	 and	 that	 a	 hypothetical	 flare-up	 of	 this
process	might	underlie	recurrent	polyneuritis.	The	authors	also	conclude	that	GBS,	like	EAN,	is	a	“cell-









Wiśniewski	 and	 colleagues	 reported	 on	 a	 young	 female	 patient	 who	 had	 progressive	 tetraparesis	 and
eventually	respiratory	failure	[6].	She	died	from	acute	cardiac	arrest	and	had	a	postmortem	examination
only	 4	 hours	 after	 her	 death.	No	 pathology	was	 seen	 in	 the	CNS	 (vide	 supra,	 report	 by	Haymaker	&
Kernohan	 [1]).	 In	 the	PNS	 intermodal	demyelination	was	 found,	with	macrophages	 entering	 the	myelin
sheath,	 phagozytosing	 myelin	 debris,	 and	 presumably	 activated	 lymphocytes	 were	 identified	 near	 the
lesions.	 In	 addition,	 net-like	 and	 vesicular	 myelin	 changes	 were	 noted.	 These	 authors	 cite	 the	 earlier







myelin	 debris	 as	 small	 and	 aligned	 along	 the	 nerve	 fibre,	 with	 myelin	 phagocytosed	 by	 an	 invading
mononuclear	cell	leaving	the	axon	intact.	Prineas	named	this	‘active	primary	demyelination’.	On	EM	the
pivotal	findings	were	macrophages	penetrating	the	myelin	sheaths	through	gaps	in	the	basement	membrane
and	 leading	 to	 lysis	 of	 major	 dense	 lines	 while	 stripping	 away	 the	 outermost	 laminae	 of	 the	 myelin
sheaths.	The	same	cells	then	phagocytosed	this	myelin,	such	that	debris	could	be	seen	in	their	cytoplasm.
Macrophage	 processes	 were	 found	 particularly	 to	 be	 burrowing	 their	 way	 along	 minor	 dense	 lines
(intraperiod	lines).	The	less	commonly	observed	vesicular	dissolution	of	myelin	appeared	to	be	mediated
by	 macrophages	 in	 the	 presence	 of	 lymphocytes.	 Demyelinated	 axons	 were	 then	 surrounded	 by
polymorphic	 mononuclear	 cells.	 Prineas	 concludes	 that	 amongst	 the	 possible	 pathomechanisms,	 an
antibody-mediated	 process	 and	 a	 direct	 cytotoxic	 attack	 by	 lymphocytes	were	 both	 unlikely,	while	 the











Ranvier	and	amputate	part	of	 the	Schwann	cell	 (bottom)	as	compared	 to	a	primary	Schwann	cell	disease	 (top).Modified	with
permission	from	[8].
Figure	25.2		Simplified	scheme	showing	some	major	putative	mechanisms	in	immune-inflammatory	polyneuropathies.	APC,	=
antigen	presenting	cell;	TH	=	T-helper	 lymphocyte;	B	=	B-lymphocyte	coated	with	antibodies	and	once	 transformed	 to	plasma






The	 question	 as	 to	 whether	 the	 autonomic	 nervous	 system	 is	 also	 part	 of	 GBS	 was	 addressed	 by
several	authors.	In	the	study	by	Asbury,	Adams	and	Arnason	(vide	supra)	and	in	a	report	by	Matsuyama
and	Haymaker,	inflammatory	cell	infiltrates	were	described	in	sympathetic	ganglia	[12].
Much	 later,	 pathological	 studies	 on	 GBS	 sural	 nerves	 and	 numerous	 rat	 EAN	 experiments	 led	 to
several	 new	 observations	 which	 allowed	 putative	 immune	 mechanisms	 to	 be	 proposed	 including














Patients	with	 clinical	 sensory	 involvement	 or	with	 a	 later	 time	 point	 of	 biopsy	 had	 higher	 lymphocyte
numbers	 in	 the	 sural	 nerve	 than	 their	 counterparts.	Also,	macrophage	numbers	were	higher	 in	biopsies
taken	 later	 in	 the	 disease.	 Surprisingly,	 the	 numbers	 of	macrophages	 were	 not	 higher	 in	 patients	 with
hyperacute	 courses.	 On	 the	 contrary,	 those	 cases	 had	 fewer	 macrophages	 than	 patients	 with	 acute	 to
subacute	 GBS.	 Thus,	 the	 old	 idea	 of	 inflammatory	 cells	 being	 involved	 first	 in	 degeneration	 and
subsequently	in	regeneration	[1,2]	might	be	supported	by	these	findings.	One	permanently	disabled	patient
slowly	 deteriorated	 after	 10	 years	 at	 which	 time	 the	 other	 sural	 nerve	 was	 biopsied.	 Numbers	 and
patterns	of	inflammatory	cells	were	in	about	the	same	order	as	during	the	acute	stage.
Infiltrating	macrophage	clusters	as	observed	here	were	also	seen	in	sural	nerves	from	the	13	patients





Given	 that	 GBS	 is	 clinically	 more	 a	 motor	 than	 a	 sensory	 neuropathy,	 a	 motor	 nerve	 might	 be	 more
informative	 as	 to	 the	 pathophysiology	 than	 a	 sensory	 nerve.	 Along	 these	 lines,	 Hall	 and	 colleagues





16.	 Demyelination	 was	 patchy,	 with	 one	 fascicle	 much	 more	 affected	 than	 the	 second	 one.	 Some
lymphocytes	 could	 be	 detected,	 but	 the	 majority	 of	 inflammatory	 cells	 in	 the	 endoneurium	 and	 in	 the
epineurium	 were	 macrophages.	 These	 were	 laden	 with	 myelin	 debris.	 Direct	 myelin	 stripping	 by















In	 the	series	by	Schmidt	and	colleagues	([14],	vide	supra)	 immunohistochemistry	 techniques	were	 first
included	in	a	large	series	of	biopsies.	This	was	within	a	period	when	researchers	searched	for	relevant
cofactors	in	the	immunopathogenesis	of	GBS.
The	 direct	 demonstration	 of	 the	 role	 of	 circulating	 ganglioside	 antibodies	 and	 of	 complement	 is
covered	in	the	chapters	by	Plomp	and	Willison,	by	Yuki	and	by	Uncini	and	Kuwabara.	This	field	started






investigated	 the	presence	of	complement	 in	GBS	by	 light	and	electron	microscopy	[21].	Three	subjects
with	GBS	 (AIDP)	 and	 early	 death	 (3	 to	 6	 days	 after	 onset)	were	 autopsied	 and	 showed	 a	 rim	 of	 the
complement	 activation	marker	 C3d	 and	 the	 terminal	 complement	 complex	 neoantigen	 C5b-9	 along	 the
outer	surface	of	the	Schwann	cells.	On	EM	of	the	positive	fibres	showed	mild	vesicular	changes	of	the
outermost	 myelin	 lamellae.	 Of	 note,	 in	 the	 hyperacute	 patient	 this	 was	 seen	 in	 some	 fibres	 with	 no
macrophages	as	yet.	Vesicular	degeneration	was	 seen	before	 the	 invasion	of	macrophages.	The	authors
proposed	complement	activation	as	a	definite	mechanism	in	GBS.

























in	 the	 acute	 phase	 of	 the	 disease	 and	 the	 second	 at	 a	 6-month	 visit.	 Patients	 in	 the	 acute	 phase	were
biopsied	 between	 week	 1	 and	 week	 3	 after	 disease	 onset.	 Twenty-four	 patients	 were	 available	 for
follow-up.	Assessing	 the	density	of	 intraepidermal	nerve	 fibres,	 that	are	generally	considered	 to	be	C-
fibres,	 the	 authors	 found	 a	 reduction	 of	 intraepidermal	 nerve	 fibre	 density	 (IENFD)	 in	 41%	 of	 their










Since	 the	 dermis,	 particularly	 from	 proximal	 regions,	 contains	myelinated	 nerve	 fibres,	 the	 authors
were	 also	 able	 to	 assess	 myelination	 and	 the	 morphology	 of	 Ranvier	 nodes.	 As	 expected	 in	 a
demyelinating	disease,	the	stain	for	myelin	basic	protein	was	weaker	than	in	control	nerves.	Intriguingly,
T	 lymphocytes	and	macrophages	were	seen	surrounding	dermal	nerve	bundles	with	degenerated	myelin






Some	 patients	 experience	 an	 acute	 polyradiculoneuropathy	 fulfilling	 all	 features	 of	 GBS;	 they	 even
improve	upon	the	standard	treatments,	but	they	later	have	relapses	or	a	chronic	progressive	neuropathy.





responded	 to	 IVIg	 as	 primary	 treatment	 for	 their	 assumed	GBS,	 but	 then	 relapsed,	 and	 later	 had	 good
responses	mainly	to	plasmapheresis	and	Rituximab,	that	is,	treatments	which	reduce	the	autoantibody	load
from	the	system.	Skin	biopsies	were	available	from	2	and	sural	nerve	biopsies	from	3	of	the	patients.	The
sural	nerve	biopsies	 showed	 signs	of	 axonal	degeneration	and	numerous	endoneurial	macrophages,	but




complete	 depletion	 of	 myelinated	 fibres.	 Furthermore,	 in	 the	 patients	 with	 contactin-1	 antibodies,	 the
nodal	 and	paranodal	 architecture	was	profoundly	altered.	These	patients	had	 loss	or	destruction	of	 the
immunoreactivity	for	caspr	and	neurofascin,	which	was	found	neither	in	the	21	patients	with	GBS	nor	in
49	patients	with	CIDP.	Sodium	channels	were	no	 longer	clustered	at	 the	node.	 In	summary,	 in	a	patient
with	 a	GBS-like	 disease	 that	 later	 turns	 out	 to	 have	 a	CIDP-like	 course,	 paranodal	 antibodies	may	be
involved	in	the	underlying	pathology.	Sural	nerve	biopsy	may	show	a	misleading	‘axonal’	pattern.
Summary	and	Conclusions
There	 is	abundant	evidence	 that	GBS	is	an	 immune-mediated,	acute	or	subacute	PNS	disorder.	Several
immunological	markers	have	been	identified,	some	of	which	are	strong	candidates	as	pathogenic	factors.
At	various	meetings,	the	indication	for	nerve	biopsy	has	been	discussed	between	experts	in	the	field.
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Guillain-Barré	 syndrome	 (GBS)	 has,	 ironically,	 declined,	 whilst	 the	 diagnostic	 value	 of
electrophysiological	tests	have	been	on	the	rise.	The	irony	here	is	that	the	CSF	examination	was	the	test













Quincke	himself	gave	credit	 to	Essex	Wynter	 for	publishing	 the	 first	description	of	 the	 technique	of




Hospital	 in	London	 [3].	The	 first	 time	Essex	Wynter	 tried	 the	 technique	was	 in	 a	 3-year-old	 boy	with
tubercular	meningitis	 in	February	1889.	Four	drachms	of	 liquor	were	collected,	besides	what	was	 lost
due	 to	 leakage.	 Following	 the	 procedure	 the	 boy	 transiently	 improved	 before	 passing	 away.	 Autopsy
showed	an	intact	spinal	equina,	but	no	trace	of	the	LP	in	the	theca.	Such	traces	were	found	in	the	next	3
cases,	 none	 of	 whom	 survived	 due	 to	 the	 primary	 disease,	 tuberculosis.	 Based	 on	 the	 results	 of	 the























Zealand	 divisions	made	 their	 debut,	whilst	 the	 French	 attacked	Frégicourt	 and	Rancourt,	 there	were	 3
French	 neurologists	 discussing	 CSF	 results	 from	 2	 LPs	 taken	within	 24	 hours	 with	 results	 which	 had
never	been	observed	before.	The	term	‘dissociation	albumino–cytologique’	was	coined.
Later,	Guillain	refers	 to	the	“hyperalbuminosis	of	 the	CSF	in	the	absence	of	cytologic	reaction”	[5].
He	 believes	 this	 to	 be	 such	 a	 consistent	 feature	 of	 the	 disease	 that	 he	 states,	 “I	 refuse	 to	 recognize
radioculoneuritis	 with	 hyperlymphocytosis	 or	 hypernucleosis	 as	 belonging	 to	 the	 syndrome”	 [5].	 He
concludes	 that	 “because	 the	virus	of	polyradiculoneuritis	with	albuminocytologic	dissociation	does	not
destroy	nerve	paths,	progressive	improvement	and	eventual	recovery	of	the	patient	will	be	observed”	[5].








Not	 everyone	 found	 the	CSF	 total	 protein	 to	 be	 elevated	 consistently.	But	 already	 the	 detailed	 French
observations	on	the	first	2	patients	permitted	to	hypothesise	that	the	sensitivity	of	this	test	was	less	in	a
very	early	LP	compared	to	a	later	LP	[4],	an	observation	shared	by	a	retrospective	study	from	the	Mayo
















of	 GBS	 with	 quantitative	 clinical	 follow-up	 data	 over	 6	 months.	 Some	 did	 not	 make	 as	 excellent	 a
recovery	as	Guillain	would	have	 insisted	 to	be	 the	case	 in	GBS.	These	patients	were	not	able	 to	walk
without	 problems	 and	were	 classified	 as	 having	 a	 poor	 outcome.	The	 authors	 compared	 the	CSF	 data
from	those	with	good	outcome	(n	=	20)	with	those	with	poor	outcome	(n	=	6).	The	first	interesting	finding











concentration	 will	 not	 permit	 one	 to	 be	 absolutely	 certain	 about	 the	 cellular	 origin	 [22].	 It	 will	 be
interesting	 to	 learn	 if	 future	 studies	 will	 investigate	 post-translational	 modifications	 and	 proteolytic
breakdown	products	of	this	fascinating	protein.
London,	UK,	20th	December	2001:	CSF	Neurofilament	Proteins
Personally,	 I	 find	 it	 paradoxical	 to	 write	 now	 about	 neurofilaments	 in	 the	 Top	 10	 of	 GBS	 because	 it
relates	 to	 a	 moment	 of	 complete	 despair	 just	 before	 Christmas	 2001.	 After	 4	 years	 of	 work	 with
neurofilament	 proteins	 I	 finally	 had	 completed	 collecting	 the	 reference	 population	 data	 for	 the
neurofilament	heavy	chain	(NfH).	After	analysing	the	data	I	was	disappointed	(Figure	26.1).	There	was	a
large	 scatter	 of	 CSF	NfH	 data	 [23].	 The	 reason	 for	my	 disappointment	was	 that	 I	 had	 hoped	 to	 have
chosen	an	excellent	control	group,	a	well-defined	demyelinating	peripheral	nervous	disease,	 to	 test	 the
hypothesis	 that	CSF	NfH	 levels	were	 a	biomarker	 for	neuroaxonal	degeneration	of	 the	 central	nervous
system.	In	GBS	I	had	expected	normal	CSF	NfH	levels.	Did	I	have	to	accept	the	null	hypothesis	and	did
this	mean	that	the	test	I	had	spent	the	last	4	years	on	developing	was	of	little	value?









sclerosis	 (ALS),	 disc	 prolapse	 (DP),	 demyelinating	 disease	 (DM),	 Guillain-Barré	 syndrome	 (GBS)	 and	 subarachnoid














Glial	 fibrillary	 acidic	 protein	 (GFAP)	 and	S100B	 are	 2	 biomarkers	which	 have	 been	 used	 to	 provide
indirect	evidence	for	glial	pathology	in	GBS	[22,28,30].	Both	proteins	are	elevated	in	the	CSF	in	GBS.	It







to	presence	of	anti-myelin	protein	antibodies.	 In	fact,	over	half	of	 the	GBS	patients	 from	one	study	did
have	CSF	anti-myelin	basic	protein	(MBP)	IgG	and	IgM	auto-antibodies	[33].	Findings	of	auto-antibodies
directed	against	myelin	proteins	have	been	regarded	as	nonspecific,	because	they	are	also	found	in	many
other	 diseases.	Accepting	 that	 some	 auto-antibodies	 (anti-MBP)	 are	 of	 little	 diagnostic	 value	 in	GBS,
there	 are	 others	 which	 are	 of	 high	 diagnostic	 value	 [34].	 It	 will	 be	 interesting	 learning	 about	 the




CSF.	With	 the	 exception	 of	 IgG	 specific	 to	 neuroinvasive	 infections	 and	 their	 complications,	 such	 as
subacute	sclerosing	panencephalitis	(SSPE),	the	yield	is	generally	low	in	autoimmune	disease.
It	almost	seems	a	paradox	that	even	in	a	specific	CNS	disease	such	as	neuromyelitis	optica,	the	use	of










Post-translational	modifications	 govern	 the	 interface	 between	 protein	 transcription	 and	 translation.	 For
neurofilaments,	undoubtedly	phosphorylation	 is	of	key	 relevance	 [24],	but	 I	would	be	hesitant	 to	place
this	among	the	Top	10	for	GBS.	A	much	more	promising	mechanism	for	GBS	is	glycosylation	[36].
Glycosylation	mainly	targets	Asp→Asp-glycan,	Ser→Ser-glycan,	Thr→Thr-glycan,	Hyl→Hyl-glycan,
Hyp→Hyp-glycan.	 Of	 the	 3	 types,	 only	 N-	 and	O-glycosylation	 occur	 in	 humans.	 Importantly,	 protein
glycosylation	 is	 a	 hallmark	 in	 autoimmune	 disease.	 A	 change	 of	 protein	 glycosylation	 may	 trigger	 an
autoimmune	 attack	 [37].	 Interestingly,	 glycolysation	 can	 differ	 between	 tissues	with	 evidence	 for	CNS
specific	 glycosylation	 patterns.	 Would	 it	 not	 be	 wonderful	 if	 there	 were	 an	 anatomical	 map	 of
glycosylation	patterns	of	the	PNS	and	CNS	for	those	protein	biomarkers	thought	to	be	of	relevance	in	the
disease?	 Therefore	 post-translational	 modifications	 which	 only	 occur	 in	 vivo,	 such	 as	 glycosylation,
phosphorylation,	citrullination,	N-	and	C-terminal	modifications	will	be	in	my	future	Top	10.
The	 interpretation	 of	 body	 fluid	 Nf	 levels	 will	 need	 to	 consider	 at	 least	 5	 proteins	 (α-internexin
(blue),	 NfL	 (light	 red),	 NfM	 (bright	 red),	 NfH	 (dark	 red)	 and	 peripherin	 (yellow)	 in	 2	 body	 fluid
compartments	(CSF,	blood).	In	the	acute	phase,	proximal	axonotmesis	within	the	CSF	compartment	leads
to	 high	 CSF	 NfL,	 NfM	 and	 NfH	 levels	 indicate	 early	 axonal	 loss.	 In	 cases	 of	 where	 trans-synaptic
retrograde	axonal	degeneration	follows,	one	should	also	test	for	CSF	α-internexin	levels.	A	rise	of	CSF
α-internexin	level	should	precede	visible	atrophy	on	structural	imaging	modalities.	In	contrast,	high	blood
peripherin	 levels	 in	 the	 absence	 of	 high	 CSF	 Nfl,	 NfM	 and	 NfH	 levels	 are	 indicative	 of	 distal
axonotemesis	 only.	 In	 those	 cases	 where	 axonal	 sprouting	 does	 not	 occur,	 distal	 axonotemesis	 may
continue	to	develop	to	retrograde	axonal	degeneration.	This	should	result	in	a	late	increase	of	CSF	levels.
Once	the	motor	neuron	is	lost,	trans-synaptic	retrograde	axonal	degeneration	may	follow.	There	is	also	the
possibility	 for	 a	 relapsing	 or	 chronic	 disease	 course	 to	 develop,	 which	 should	 be	 paralleled	 by	 a













































































This	 chapter	 is	 reflections	 on	 the	 Guillain-Barré	 syndrome	 (GBS)	 with	 an	 emphasis	 on	 the
electrophysiologic	 aspects	 and	 comes	 from	 the	 exciting	 time	 when	 we	 were	 all	 at	 the	 University	 of
Pennsylvania	 under	 the	 chairmanship	 of	 Professor	Arthur	K.	Asbury.	This	was	 a	 time	 and	 place	when
investigations	 of	 GBS	 flourished,	 and	 electrophysiology	 was	 a	 major	 component	 of	 this	 exploration.
Although	we	 each	 subsequently	moved	 to	 different	 institutions,	 we	 continue	 to	 share	 an	 excitement	 in
investigating	and	thinking	about	the	physiologic	aspects	of	GBS	and	other	inflammatory	neuropathies.
The	physiologic	hallmark	of	GBS	is	conduction	block.	The	rapid	onset	of	symptoms	and	the	frequently
observed	 early	 recovery	 of	weakness	 can	 be	 attributed	 to	 the	 development	 and	 reversal	 of	 conduction







demyelinative	 polyneuropathies	 [1].	 The	 extreme	 dispersion	 of	 dorsal	 root	 responses	 illustrated	 that
individual	axons	conducted	at	a	wide	range	of	velocities	indicative	of	the	heterogeneity	of	demyelination
across	the	population	of	axons.	It	also	demonstrated	that	demyelination	was	distributed	multifocally	along
the	 length	of	peripheral	nerves,	 thought	 to	be	a	consequence	of	variations	 in	blood-nerve	permeability,
particularly	in	nerve	roots	and	nerve	terminals.	Differential	effects	on	motor	versus	sensory	axons	were



















In	 the	 early	 1980s,	 a	 series	 of	 papers	 appeared	 which	 changed	 the	 field	 [6,7,8,13,14,15].	 Using	 the
intraneural	injection	technique,	it	was	possible	to	show	first	that	sera	from	various	animal	models	(EAN,
EAE	and	anti-GalC)	and	second	that	sera	from	GBS	patients	produced	an	acute	lesion	characterized	by
conduction	 block	 associated	 with	 minor	 pathological	 features,	 which	 evolved	 to	 complete	 conduction
block	and	a	demyelinative	lesion	with	recovery	over	time.	This	experimental	approach	provided	crucial
insights	into	the	pathophysiology	of	GBS.	It	was	a	remarkable	experience	to	observe	the	development	of
conduction	 block	 as	 the	 earliest	 electrophysiologic	 consequence	 of	 the	 intraneural	 injection	 of	 these
antibodies	(Figure	27.1)	as	well	as	the	restoration	of	conduction	which	corresponded	at	around	8	to	14







As	 the	 pathophysiology	 of	 GBS	 was	 being	 investigated,	 clinical	 electrodiagnosis	 of	 GBS	 was
evolving	with	 recognition	 of	 the	 importance	 of	 conduction	 block,	 that	 early	 changes	were	 particularly
found	in	the	most	distal	(low	compound	motor	action	potential	[CMAP]	amplitudes	and	prolonged	distal
motor	latencies	[DML])	and	most	proximal	segments	(absent	or	prolonged	F-wave	responses).










by	Lambert	 and	Mulder	 [17]	 and	McLeod	 [18],	 and	 showed	 that	 in	 the	 first	 2	weeks	motor	 amplitude
reductions	 were	 the	 most	 conspicuous	 early	 change	 but	 by	 week	 5,	 87%	 of	 patients	 had	 conduction







physiologically	 and	pathologically	 there	was	no	 evidence	of	 segmental	 demyelination	or	 inflammation.
Many	considered	that	this	may	have	been	the	result	of	severe,	aggressive	demyelinating	GBS	and	that	the
findings	represented	the	sequel	of	this	rapidly	progressive	disease.	However,	the	dramatic	findings	from
northern	 China	 made	 it	 clear	 that	 there	 was	 clearly	 an	 axonal	 form	 of	 Guillain-Barré	 syndrome	 (see









more	 chronic	 disorders	 such	 as	 multifocal	 motor	 neuropathy	 and	 forms	 of	 chronic	 inflammatory









28]	has	 forced	us	 to	 reconsider	electrodiagnostic	criteria	 for	GBS	from	the	days	when	GBS	and	AIDP
were	synonymous	 [29,30]	 to	 those	 that	attempt	 to	differentiate	 the	axonal	 forms	 from	 the	demyelinating






forms	of	GBS	from	 the	AIDP	form	of	GBS	 in	 the	 first	week	after	disease	onset	 [33].	Some	propose	2




Electrodiagnostic	 studies	 remain	 a	 crucial	 investigation	 of	 patients	 with	 suspected	 GBS.	 They	 have










































































The	 term	 ‘nodo-paranodopathy’	was	 originally	 proposed	 to	 better	 characterize	 neuropathies	with	 anti-
gangliosides	antibodies	and	overcame	some	inadequacies	of	the	classical	dichotomous	classification	into
demyelinating	and	axonal	[1].	More	recently	this	categorization	has	been	extended	to	include	neuropathies
of	 different	 aetiology	 (dysimmune,	 inflammatory,	 ischaemic,	 nutritional	 and	 toxic)	 in	 which	 the
involvement	of	 the	nodal	 region	 is	central	 in	 the	pathogenesis	 [2].	The	 following	studies	epitomize	 the
research	 journey	 that	 has	 led,	 over	 the	 past	 20	 years,	 to	 the	 conceptualization	 of	 dysimmune	 nodo-





(acute	 motor	 axonal	 neuropathy	 [AMAN]),	 preceding	 Campylobacter	 jejuni	 infection	 and	 anti-
ganglioside	 antibodies	were	becoming	 clearer.	The	 Johns	Hopkins	University	group	produced	detailed
pathological	studies	of	fatal	GBS	cases	from	the	Hebei	Province	in	China	providing	remarkable	insights
into	 the	 pathogenesis.	 In	 3	 seminal	 papers	 the	 authors	 described	 extensive	Wallerian-like	 degeneration
(with	only	minimal	demyelination	and	inflammation),	almost	exclusively	of	motor	fibres,	and	showed	that
the	earliest	and	mildest	changes	consisted	of	lengthening	of	the	node	of	Ranvier	with,	in	some	instances,
involvement	 of	 paranodal	 myelin	 [3,4].	 Most	 importantly,	 they	 demonstrated	 IgG	 and	 complement
deposition	 along	 the	 axolemma	 of	 motor	 fibres,	 particularly	 at	 the	 nodes	 of	 Ranvier,	 prior	 to	 the
development	of	Wallerian-like	degeneration	[5].	It	was	suggested	that	“simple	binding	of	antibody,	alone
or	with	 subsequent	 activation	 of	 complement	 at	 the	 nodes	 of	motor	 fibres,	 can	 be	 sufficient	 to	 impair
conduction”.	These	findings	could	well	explain	the	puzzling	observations	of	fatal	AMAN	cases	showing
only	minimal	pathologic	changes	and	why	some	patients	 rapidly	 recovered	 in	 spite	of	an	 initial	 severe
paralysis.	The	foundation	for	the	concept	of	nodo-paranodopathy	was	laid.
Figure	28.1		(A)	Anatomical	organisation	of	myelinated	nerve	fibre	and	its	subdomains.	(B)	Simplified	molecular	organisation	at







action	 potential	 (CMAP)	 amplitudes	 (Figure	 28.2A)	 [6].	 In	 1998	 Kuwabara	 and	 colleagues	 reported
AMAN	patients	with	antibodies	against	ganglioside	GM1	who	had	conduction	block	(CB)	in	distal	and
intermediate	nerve	segments	and	conduction	slowing	which	promptly	resolved	without	 the	development
of	 excessive	 temporal	 dispersion	 (TD)	 (Figure	 28.2C,	 28.2D)	 [7].	 This	 feature,	 named	 ‘reversible
conduction	 failure’	 (RCF)	 to	 distinguish	 it	 from	 demyelinating	 CB,	 mimics	 demyelination	 on	 early









GM1,	 GD1a	 and	 GD1b	 who	 acutely	 developed	 symmetric	 weakness	 without	 sensory	 symptoms.
Electrophysiology	showed	a	reduction	of	distal	CMAP	amplitudes	and	early	partial	motor	CB	with	focal
conduction	slowing	in	intermediate	nerve	segments	[8].	In	these	patients	distal	CMAPs	normalized,	and
CB	 and	 conduction	 slowly	 resolved	 in	 2	 to	 5	 weeks	 in	 parallel	 with	 strength	 recovery	 without	 the
development	 of	 excessive	 TD	 or	 denervation	 at	 electromyography.	 These	 patients	 were	 initially
considered	a	rare	GBS	subtype	named	acute	motor	conduction	block	neuropathy	(AMCBN).	AMAN	and
AMCBN	have	 in	 common	 antecedent	C.	 jejuni	 enteritis	 and	 anti-ganglioside	 IgG	 antibodies.	AMCBN
patients	 show	 the	 RCF	 pattern	 in	 most	 nerves.	 Therefore,	 it	 was	 hypothesized	 that	 AMCBN	 was	 an
‘arrested	AMAN’,	in	which	anti-ganglioside	antibodies	bind	to	the	nodal	axolemma	and	induce	RCF	not
progressing	to	axonal	degeneration	[8].	Similar	patients	were	reported	under	different	names	(reviewed
in	 Uncini	 and	 Kuwabara,	 2012)	 [9].	 The	 description	 of	 patients	 with	 conduction	 failure	 evolving	 to
axonal	degeneration	(Figure	28.2B)	or	showing	RCF	and	axonal	degeneration	co-occurring	in	the	same	or
different	nerves	 confirms	 that	AMCBN,	AMAN	with	RCF	and	AMAN	with	 axonal	 degeneration	 are	 a
pathophysiological	continuum	[10–12].	This	explains	why	 recovery	 in	AMAN	may	be	either	 rapid	and
complete	or	prolonged	with	poor	outcome	in	a	dichotomous	pattern	according	to	the	relative	amount	of
axonal	degeneration	and	RCF	in	each	patient	[13].
At	 this	 point	AMAN	was	 electrophysiologically	 characterized	 not	 only	 by	 axonal	 degeneration	 but
also	by	a	reversible	failure	of	conduction,	and	that	both	processes	could	be	due	to	an	immune	mediated
attack	to	the	nodal	axolemma	became	quite	certain.




anti-GM1	 and	 anti-GD1a.	 (B)	 AMAN	with	 conduction	 failure	 followed	 by	 axonal	 degeneration.	 Ulnar	 nerve.	 Note	 on	 day	 3	 the
gradual	reduction	of	CMAP	amplitudes	from	elbow	and	axilla	stimulation	followed	on	day	7	by	reduced	amplitudes	of	all	CMAPs.
The	 patient	 had	 IgG	 anti-GM1.	 (C)	AMAN	with	 reversible	 distal	 conduction	 failure	 pattern.	Median	 nerve.	On	 day	 6	 distal	 and
proximal	CMAP	amplitudes	were	 reduced	 (2.6	mV).	On	day	12	distal	CMAP	was	142%	 increased	 returning	within	 the	normal
range.	There	was	no	excessive	temporal	dispersion	of	proximal	or	distal	CMAP	in	all	recordings.	The	patient	had	IgG	anti-GD1b.
(D)	AMAN	with	reversible	conduction	failure	pattern	in	intermediate	nerve	segments.	Ulnar	nerve.	On	day	10	there	was	a	partial













population,	 at	 first	 test,	 the	 electrodiagnosis	 was	 almost	 identical	 with	 both	 criteria	 sets:	 65–67%	 of
patients	were	classifiable	as	acute	inflammatory	demyelinating	polyradiculoneuropathy	(AIDP)	and	18%
as	 axonal	 GBS;	 14–16%	were	 equivocal	 [15].	 At	 follow-up,	 24%	 of	 patients	 changed	 classification:
AIDP	decreased	 to	58%,	axonal	GBS	 increased	 to	38%,	and	equivocal	patients	decreased	 to	4%.	The
majority	of	 shifts	were	 from	AIDP	and	equivocal	groups	 to	 axonal	GBS,	 and	 the	main	 reason	was	 the
recognition	by	serial	recordings	of	the	RCF	as	expression	of	axonal	pathology.	All	patients	who	shifted	to
the	axonal	group	had	antibodies	to	gangliosides.	Similar	results	were	reported	in	Japanese	series	[11,16].
These	 studies	 demonstrate	 that	 in	 early	 GBS	 it	 may	 be	 impossible	 to	 distinguish	 between	 AIDP	 and
axonal	GBS	in	some	patients	and	indicate	that	the	lack	of	distinction	between	demyelinating	CB	and	RCF
by	 serial	 conduction	 studies	 may	 fallaciously	 classify	 patients	 with	 axonal	 GBS	 as	 having	 AIDP.


















nodes	 and	 paranodal	 detachment	 of	 myelin	 sheath	 identical	 to	 the	 early	 pathology	 found	 in	 AMAN
patients.	 Anti-GD1a	 antibodies	 disrupt	 the	 nodes	 by	 the	 same	 mechanisms.	 In	 an	 ex	 vivo	 mouse




the	 terminal	 complement	 complex),	 whereas	 inhibition	 of	 the	 protease	 calpain	 preserved	 the
immunostaining	profiles	of	nodes	of	Ranvier	without	protecting	nerve	conduction.
The	above	findings	 indicate	 that	 the	early	 immunopathologic	stage	of	AMAN	is	characterized	by	an
attack	 to	 the	nodal	region	and	failure	of	nerve	conduction	which	may	still	be	promptly	reversible	as	 in
AMAN	with	 RCF	 or	 AMCBN.	 If	 the	 immune	 reaction	 progresses,	 calcium	 entry	 in	 the	 axon	 triggers
protease	 activation	 and	 consequent	 axonal	 damage	 and	 Wallerian-like	 degeneration.	 Macrophages
subsequently	move	from	the	nodes	into	the	periaxonal	space,	scavenging	the	injured	axons	(Figure	28.3).
Experimental	models	 have	 thus	 confirmed	 that	 in	AMAN	 the	major	 injury	 site	 of	 the	 antibodies	 is	 the







mediated	 dysfunction	 and	 disruption	 of	 the	 nodes	 of	 Ranvier	 [20].	 In	 recent	 years	 evidence	 has
accumulated	that	dysfunction/disruption	of	the	nodal	region	is	a	pathogenic	mechanism	not	only	in	AMAN
but	also	in	other	acute	neuropathies	with	antibodies	to	gangliosides.	RCF	has	been	described	in	motor	and
sensory	 fibres	of	patients	with	acute	motor	 and	 sensory	axonal	neuropathy	 (AMSAN)	and,	 similarly	 to
AMAN,	abnormally	 elongated	nodes	were	 found	 in	 the	dorsal	 roots	of	patients	with	AMSAN	[21,22].
RCF	in	motor	and	sensory	fibres	has	also	been	reported	in	patients	with	the	pharyngeal-cervical	brachial
subtype	 of	 GBS	 [23].	 RCF	 restricted	 to	 sensory	 fibres	 has	 been	 reported	 in	 patients	 with	 promptly
reversible	 acute	 sensory	 ataxic	 neuropathy	 and	 IgG	 anti-GD1b	 or	 -GQ1b	 antibodies	 and	 in	 the	Miller
Fisher	 syndrome	which	 is	 also	known	 to	have	 a	good	prognosis	 [24,25].	Moreover,	 the	 sensory	nerve
biopsy	of	an	anti-GQ1b	positive	patient	with	the	Miller	Fisher	syndrome	showed	lengthening	of	nodes	of








The	 traditional	 classification	 of	 neuropathies	 into	 axonal	 or	 demyelinating	might	 generate	 confusion	 in
diagnosing	GBS	 subtypes.	AMAN	 is	 classified	 as	 an	 axonal	 neuropathy	 because	 the	 primary	 attack	 is
directed	 towards	 the	 nodal	 axolemma,	 leading	 ultimately	 to	 axonal	 degeneration.	 However,	 the	 term
‘axonal’	 may	 be	 misleading	 as	 in	 common	 neurological	 knowledge	 it	 is	 linked	 to	 Wallerian-like
degeneration	and	evokes	poor	prognosis,	and	not	everybody	agrees	on	an	axonal	scenario	characterized
by	transitory	dysfunction	and	prompt	recovery	as	in	AMAN	with	RCF	or	AMCBN.	On	the	other	hand,	in





Figure	28.3	 	The	 immunopathologic	cascade,	 the	electrophysiologic	and	clinical	correlates	 in	acute	motor	axonal	neuropathy
(AMAN).	 (A–D)	Acute	nodal	disruption.	 (A)	Cartoon	showing	 the	normal	node	 (top),	 the	early	 (middle)	and	advanced	 (bottom)
phase	of	nodal	disruption.	Caspr,	contactin-associated	protein;	Nav,	voltage-gated	sodium	channel.	(B)	Immunostaining	of	ventral
roots	 from	normal	 (top)	or	AMAN	 rabbits	with	 IgG	anti-GM1	antibodies.	Autoimmune	attack	 (blue,	membrane	attack	 complex)
occurs	at	 the	nodes	first	 then	extends	to	the	paranodes.	Clusters	of	nodal	Nav	channels	(red)	or	paranodal	Caspr	(green)	are
destroyed	and	eventually	disappear.	(C)	Toluidine	blue	staining	of	ventral	roots	from	AMAN	rabbits.	The	arrow	indicates	a	normal
node	 (top).	 The	 bracket	 indicates	 an	 abnormally	 elongated	 node	 (bottom).	 (D)	 Electron	 microscopy	 showing	 abnormally










elongated	 nodal	 gaps	 progressing	 to	 axonal	 degeneration.	 (I)	 Electron	 microscopy	 of	 ventral	 root	 from	 AMAN	 rabbit.	 A
macrophage	(M)	is	in	the	periaxonal	space	with	an	injured	axon	(A)	in	presence	of	intact	myelin	sheath.	(J)	Toluidine	blue	staining
of	sciatic	nerve	from	AMAN	rabbit.	Arrowheads	indicate	the	degenerated	nerve	fibres.	(K)	Serial	motor	conductions	of	the	ulnar
nerve	 from	an	AMAN	patient	with	high	 titre	of	 IgG	anti-GM1	and	-GD1a	antibodies.	On	day	3	 there	 is	only	a	slight	 reduction	of
proximal	 CMAP	 amplitude	 across	 the	 elbow	 segment.	 On	 day	 6	 CB	 is	 present	 across	 the	 elbow	 segment	 (proximal	 CMAP
amplitude	 is	 78%	 reduced).	 At	 day	 22	 a	 reduction	 of	 all	 CMAP	 amplitudes	 is	 evident,	 indicating	 the	 evolution	 to	 axonal
degeneration.	The	cartoon	on	the	right	details	the	possible	events	leading	to	axonal	degeneration.	Antibodies	bind	to	gangliosides






Figures	 B,	 D	 and	 F	 used	 with	 permission	 from	 [18].	 Figures	 G	 and	 K	 used	 with	 permission	 from	 [10].	 Figure	 I	 used	 with
permission	from	[42].
To	 overcome	 these	 nosologic	 difficulties	 and	 avoid	 misclassification	 the	 new	 category	 of	 nodo-
paranodopathies	was	proposed	[1].	Figure	28.4	summarizes	 the	association	of	dysimmune	neuropathies
with	 antibodies	 to	 gangliosides	 and	 to	 axo-glial	 proteins	 and	 the	 evidence	 supporting	 the	 nodal	 and
paranodal	involvement.
Acute	neuropathies	with	anti-ganglioside	antibodies	can	be	classified	as	nodopathies	because	of	 the















may	 induce	 increased	Na+	 influx,	 intra-axonal	Na+	 accumulation,	 reversal	 of	 the	 axolemmal	Na+/Ca2+
exchanger,	 intra-axonal	 Ca2+	 accumulation,	 and	 Ca2+-mediated	 axonal	 degeneration.	 All	 of	 the	 above
findings	 suggest	 that	 MMN	 could	 be	 better	 classified	 as	 a	 chronic	 dysimmune	 nodo-paranodopathy
(Figure	28.4).
Figure	28.4	 	Dysimmune	nodo-paranodopathies.	The	association	of	neuropathies	with	antibodies	to	gangliosides	and	axo-glial
proteins	and	 the	evidences	supporting	 the	nodal	and	paranodal	 involvement	are	shown.	Strength	 in	association	and	evidence:










Chronic	 inflammatory	 demyelinating	 polyradiculoneuropathy	 (CIDP)	 is	 thought	 to	 be	 an	 autoimmune
disorder	 with	 heterogeneous	 clinical	 phenotypes.	 The	 proteins	 of	 the	 compact	 myelin	 have	 long	 been





30%	 of	 CIDP	 patients	 bound	 at	 the	 nodal	 region	 of	 rat	 sciatic	 nerve	 recognizing,	 in	 some	 instances,
contactin-1	 (CNTN-1),	 neurofascin-186,	 gliomedin	 [35].	 The	 following	 year	 Querol	 and	 colleagues
showed	that	6.5%	of	45	CIDP	patients	had	IgG	to	CNTN-1	or	CNTN-1	and	contactin-	associated	protein
(Caspr)	[36].	These	patients	shared	a	phenotype	characterized	by	aggressive	onset,	motor	predominance
and	poor	 response	 to	 IVIg.	The	 same	Spanish	group	 reported	4	patients	with	antibodies	 to	neurofascin
155,	 predominantly	 of	 the	 IgG4	 isotype,	 presenting	with	 severe	distal	weakness,	 disabling	 tremor	 in	 3
patients	 and	poor	 response	 to	 IVIg	 [37].	Anti-CNTN-1	antibodies,	 exclusively	or	predominantly	of	 the
IgG4	 isotype,	were	 found	 in	 2.4%	 of	 500	 Japanese	CIDP	 patients	 presenting	with	 subacute	 onset	 and
sensory	ataxia,	and	in	8%	of	53	German	patients	showing	acute	onset,	prevalently	motor	neuropathy	and	a
high	occurrence	of	tremor	[38,39].	The	axonal	cell	adhesion	molecules	CNTN-1	and	Caspr,	and	the	glial





antibody	 showed	 loss/destruction	 of	 paranodal	 Caspr	 and/or	 neurofascin	 immunoreactivity,	 elongated
nodes	and	axonal	damage	but	not	demyelination	[39].	The	authors	concluded	that	anti-CNTNI	antibody-
associated	neuropathy	“does	not	meet	morphological	criteria	of	demyelinating	neuropathy	and	therefore










and	 function	 of	 the	 axo-glial	 protein	 and	 the	 lack	 of	 true	 segmental	 demyelination	 at	 pathology,	 the
neuropathy	with	antibodies	to	CNTN-1,	Caspr,	or	neurofascin	155	could	be	better	classified	as	a	chronic
paranodopathy.	 Compared	 to	 acute	 nodopathy	 associated	 with	 anti-ganglioside	 antibodies	 this	 chronic
paranodopathy	 seems	 to	 show	 the	 electrophysiological	 features	 of	 de-remyelination,	 even	 though





primary	 nerve	 injury	 and	 avoids	 the	 confusing	 situation,	 as	 in	 neuropathies	 associated	 with	 anti-
ganglioside	 antibodies,	 that	 in	 spite	 of	 the	 common	 site	 of	 nerve	 damage	 and	 pathophysiological
mechanism,	some	patients	might	be	classified	as	having	a	demyelinating	and	others	as	having	an	axonal
neuropathy.	 In	 our	 opinion	 the	 nodo-paranodopathy	 category	 seems	 appropriate	 for	 various	 dysimmune
acute	 and	 chronic	 neuropathies	 associated	 with	 antibodies	 to	 gangliosides	 and	 to	 paranodal	 axo-glial



























































































The	 development	 of	 electrophysiology	 started	 in	 the	 18th	 century	 with	 Galvani’s	 discovery	 of	 animal






The	 first	 modern	 electromyography	 (EMG)	 machine	 was	 constructed	 by	 Jasper	 in	 1942	 at	 McGill
University,	Montreal,	Canada,	and	in	1950	the	first	commercially	available	EMG	system	was	introduced.
This	 technical	 progress	 and	 a	 better	 understanding	 of	 disease	 processes	 led	 to	 an	 increased	 use	 of
electrical	investigations	and	has	led	to	our	extensive	knowledge	of	the	human	peripheral	nervous	system.
Even	in	this	day	and	age	new	techniques	are	being	developed	and	old	techniques	are	being	rediscovered
and	 adjusted	 for	 new	 purposes	 to	 study	 the	 various	 aspects	 of	 the	 human	 nerve	 and	 muscle.	 In	 this




His	 pioneering	 techniques	 have	 improved	 our	 understanding	 of	 the	 electrical	 properties	 of	 nerve
membranes	and	their	alterations	in	various	diseases.	One	paragraph	about	his	work	is	not	doing	justice	to
the	 enormous	 impact	 he	 has	 had	 on	 the	 neurophysiological	 world,	 and	 is	 not	 sufficient	 to	 explain	 his
brilliant,	albeit	complex	threshold	tracking	technique.	However,	in	this	short	overview	I	will	try	to	give
an	impression	of	the	basic	principles	of	this	sophisticated	technique.
In	 the	 1990s,	 Professor	Bostock	 developed	 a	 semiautomatic	 program	 called	QTRAC	 [1].	With	 this
program	various	nerve	excitability	tests	assessing	nerve	membrane	properties	in	vivo	can	be	performed.
It	 provides	 information	 about	 motor	 or	 sensory	 axons	 complementary	 to	 the	 information	 provided	 by
conventional	 nerve	 conduction	 studies	 (NCS).	 Nerve	 excitability	 testing	 provides	 information	 on	 ion
channels	and	 the	 functions	of	energy-dependent	pumps	 in	 the	nodal	and	 internodal	membrane,	and	 their
changes	during	disease.	In	threshold	tracking	a	resting	threshold	is	compared	to	a	threshold	produced	by
changes	in	the	nerve	environment.	First,	the	resting	threshold	has	to	be	established.	This	is	the	threshold
that	 produces	 a	 predefined	 compound	 muscle	 action	 potential	 (CMAP)	 size	 (often	 40%	 of	 maximum
CMAP	 amplitude).	 Then	 nerve	 excitability	 is	 changed	 by	 different	 manoeuvres	 (by	 altering	 the	 nerve
environment	or	by	applying	additional	currents).	The	current	that	is	then	required	to	elicit	the	predefined
CMAP	amplitude	will	be	determined	automatically.	For	example,	when	axons	are	hyperpolarized,	the	test
potential	 becomes	 smaller	 and	 the	 computer	will	 increase	 stimulus	 intensity	 until	 the	 test	 potential	 has
returned	to	its	target	size.	In	clinical	practice,	the	nerve	is	stimulated	using	a	computerized	protocol	and
takes	 approximately	 15	 minutes.	 With	 this	 protocol	 several	 indices	 of	 axonal	 excitability,	 such	 as
refractoriness,	strength–duration	properties,	threshold	electrotonus,	supernormality	and	late	subnormality






to	 measure	 axonal	 excitability	 in	 acute	 motor	 axonal	 neuropathy	 (AMAN)	 and	 acute	 inflammatory
demyelinating	polyneuropathy	 (AIDP)	patients.	Axonal	excitability	properties	were	different	 in	AMAN
patients	than	in	those	with	AIDP.	AMAN	patients	had	a	greater	refractoriness	during	the	acute	phase	of	the
disease	 that	 normalised	 during	 follow-up.	 The	 recovery	 cycle	 data	 suggest	 a	 critically	 reduced	 safety
factor	for	impulse	conduction	in	distal	nerve	terminals	of	AMAN	patients	[2].
The	Electrophysiological	Muscle	Scan
In	 2007,	 2	 publications	 were	 published	 more	 or	 less	 simultaneously	 about	 the	 clinical	 potential	 of	 a






electrical	 stimulation.	Each	MU	has	 a	 different	 stimulus	 intensity	 (SI)	 at	which	 it	will	 be	 activated.	A
gradual	increase	in	SI	from	threshold	(the	SI	at	which	the	MU	with	the	lowest	threshold	is	activated)	to
supramaximal	values	 (the	SI	 that	 elicits	 a	maximum	CMAP)	will	 result	 in	 successive	 activation	 of	 all




quantification	 of	 steps.	 Steps	 are	 clearly	 visible	 size	 differences	 in	 the	 CMAP	 amplitude	 between
consecutive	stimuli.	They	appear	as	abrupt	jumps	in	the	usually	sigmoid	curve	and	result	from	the	firing	of
large,	newly	recruited	MU	potentials.	They	are	a	sign	of	reinnervation	and/or	MU	loss.	The	presence	and
properties	 of	 steps	 differ	 significantly	 between	 normal	 subjects	 and	 patients	 with	 amyotrophic	 lateral
sclerosis	(ALS).	Furthermore,	this	curve	can	be	used	to	study	basic	excitability	properties	of	peripheral
nerves.	 In	Miller	 Fisher	 patients,	 subclinical	 limb	motor	 nerve	 dysfunction	 can	 be	 identified	with	 this





number	 of	MUs	 have	 to	 be	 estimated.	 Various	MU	 number	 estimation	 (MUNE)	 techniques	 have	 been
proposed.	Each	method	has	its	own	shortcomings	regarding	reliability	and	reproducibility.	Most	methods
are	 also	 very	 time	 consuming.	 The	 paper	 of	 Bostock	 [6]	 describes	 a	 new	 technique,	 based	 upon	 the
CMAP	 scan.	 It	 is	 a	 very	 quick	method	 and	 consists	 of	 fitting	 a	 recorded	CMAP	 scan	 into	 a	 simulated





assumption	 that	 the	 contribution	 of	 each	 MU	 to	 the	 maximum	 CMAP	 amplitude	 is	 constant.	 Another
simplification	 is	 that	 the	 spread	 of	 thresholds	 is	 assumed	 equal	 for	 all	MUs	 and	 based	 on	 findings	 in
healthy	human	MUs.	For	diseases	such	as	ALS	and	GBS,	these	spread	in	thresholds	are	unknown.	Despite




A	 more	 time-consuming,	 but	 elegant	 method	 to	 estimate	 the	 number	 of	 MUs	 is	 the	 multiple	 point
stimulation	technique	with	high-density	surface	EMG	(HDsEMG)	[7].	MUNE	is	based	upon	the	division
of	 the	maximal	CMAP	amplitude	by	 an	 estimate	of	 the	mean	MU	potential	 (MUP)	 size	 [8].	This	mean
MUP	 is	 calculated	 by	 averaging	 a	 number	 of	 individual	MUPs	 that	 have	 been	 sampled	 using	 one	 of	 a
variety	 of	 approaches.	 In	 MUNE	 with	 HDsEMG,	 the	 nerve	 is	 stimulated	 and	 the	 MU	 responses	 are
recorded	with	an	array	of	126	densely	spaced	electrodes	positioned	over	the	muscle.	Using	such	an	array
provides	spatiotemporal	profiles	(‘fingerprints’)	of	individual	MUs,	which	facilitates	the	detection	of	MU










in	 various	 stages	 of	 a	 disease	 yield	 only	 indirect	 evidence	 of	 changes	 occurring	 in	 individual	 MUs.
Following	individual	MUs	over	time	(tracking)	can	overcome	this	problem	and	provides	insight	into	the
functional	 and	morphological	 properties	 of	 these	MUs.	 It	 allows	 investigation	 of	 how	 these	MUs	 are
influenced	over	time	by	neuromuscular	disorders	or	treatment.
Similar	to	the	MUNE	technique	described	in	the	paragraph	above,	MU	tracking	uses	an	array	of	126
densely	spaced	electrodes	positioned	over	 the	muscle	 [11].	Since	each	MU	has	a	distinct	 ‘fingerprint’,
this	allows	for	detection	of	these	individual	MUs	in	different	sessions,	which	are	months	or	even	years
apart.	To	‘track’	MUs	and	identify	the	same	MU	in	different	sessions,	it	is	essential	that	the	high-density
electrodes	 are	 placed	 in	 the	 same	 position.	 To	 adjust	 for	 potential	 translational	 and	 rotational





Permanent	 axonal	 loss	 is	 possibly	 responsible	 for	 long-term	motor	 impairment	 in	 various	GBS	 forms
[13].	Motor	axonal	loss	is	often	compensated	by	reinnervation	and	is	hard	to	identify	with	conventional
electrophysiological	 techniques.	 The	 macroelectromyography	 (macro-EMG)	 signal	 can,	 in	 contrast	 to
conventional	EMG,	be	used	as	a	measure	of	the	MU	size	including	the	number	of	fibres	[14].	Thus,	it	can
evaluate	reinnervation.	In	macro-EMG,	the	recording	electrode	is	the	cannula	of	a	modified	single	fibre
electromyography	 electrode.	 By	 means	 of	 spike-triggered	 averaging,	 the	 contribution	 from	 all	 muscle
fibres	in	a	MU	is	extracted.	The	resulting	signal	reflects	the	number	and	size	of	muscle	fibres	in	one	MU
and	is	called	macro	MU	potential	(macro-MUP).	In	the	current	paper,	[13]	it	was	shown	that	the	macro-
MUP	 amplitudes	 of	 GBS	 patients	 were	 clearly	 larger	 compared	 to	 healthy	 controls.	 Furthermore,	 the





to	 the	 misdiagnosis	 of	 a	 potentially	 treatable	 neuropathy.	 The	 electrodiagnostic	 features	 of	 acquired
demyelination,	such	as	the	presence	of	conduction	blocks	and	focal	temporal	dispersion,	are	sometimes
not	detected	due	to	the	occasionally	very	proximal	location	of	these	features.	The	transcranial	magnetic
stimulation	 (TMS)	 technique,	 using	 collision	 (the	 triple	 stimulation	 technique	 (TST))	 is	 a	 quantitative









paraparetic	 form.	 In	 these	cases	 finding	demyelination	might	 aid	 the	diagnosis.	TST	might	be	useful	 to
detect	proximal	demyelination.
Cauda	Equina	Conduction	Time	in	Guillain-Barré	Syndrome
As	 described	 in	 the	 paragraph	 above,	 proximal	 nerve	 segments	 are	 not	 easily	 accessible	 with


















cortical	 responses	 in	 GBS	 patients	 had	 longer	 latencies	 and	 lower	 amplitudes	 than	 those	 in	 healthy




30	 years.	 New	 neurophysiological	 techniques	 have	 been	 developed	 and	 are	 now	 being	 used	 in	 daily










































or	 produced	 during	 host	 defence	 against	 infections,	 erroneously	 attack	 peripheral	 myelin	 or	 axonal
components	with	 ensuing	 demyelination	 and/or	 axonal	 injury.	GBS	 encompasses	 a	 number	 of	 different
clinical	manifestations	with	 a	predominant	demyelinating	or	 axonal	phenotype.	Electroneurography	and




in	particular	magnetic	 resonance	 imaging	(MRI),	while	 in	peripheral	nerve	disorders	 imaging	has	been
restricted	 to	 conditions	 in	which	 a	mass	 lesion	 compressing	 nerves	 or	 roots	was	 expected	 on	 clinical
grounds.	This	 restraint	approach	has	changed.	 In	1993,	Filler	and	colleagues	presented	 the	 first	 ‘image
neurogram’	 showing	 a	 human	 nerve	 graft	 by	 commercial	 MRI	 [1].	 They	 coined	 the	 term	 ‘magnetic
resonance	 neurography’	 (MRN).	During	 the	 last	 20	 years	 peripheral	 nerve	 imaging	 developed	 into	 an
innovative	 scientific	 subspecialty	 with	 growing	 clinical	 impact.	 In	 this	 chapter	 I	 review	 advances	 in




pulse	sequences	 to	distinguish	peripheral	nerves	 from	 the	surrounding	soft	 tissue.	Technical	details	are
described	 elsewhere	 [1,2].	 Briefly,	 fat-saturated,	 heavily	 T2-w	 (T2*-w)	 sequences	 are	 applied	 for
detection	of	pathological	signal	alterations	in	nerves.	In	addition,	unenhanced	T1-w	MRI	scans	are	taken
for	 anatomical	 orientation,	 and,	 finally,	 gadolinium	 (Gd)-DTPA-enhanced	 and	 fat-suppressed	 T1-w
images	are	required	 to	distinguish	pathological	nerve	signals	from	vessels	which	also	appear	bright	on
T2-w	sequences.	For	correct	interpretation	of	the	imaging	data	it	is	mandatory	to	apply	these	sequences
with	 the	 same	 slice	 thickness	 and	 anatomical	 orientation.	MRN	mainly	 exploits	 alterations	 of	 the	 T2-
signal	of	peripheral	nerves	upon	injury.	Intact	nerves	cannot	be	discriminated	on	T2-w	MRI	because	they
are	 isointense	 to	 the	 surrounding	 tissue.	 The	 intrinsic	 nerve	 signal,	 however,	 profoundly	 changes	 upon
nerve	injury	[1,2]:	nerve	segments	with	axonal	damage	undergoing	Wallerian	degeneration	(WD)	become
hyperintense	 on	 T2-W	 MRI,	 and	 this	 hyperintensity	 disappears	 after	 nerve	 regeneration.	 T2-
hyperintensities,	 however,	 are	 not	 specific	 for	 axonal	 injury.	 Nerves	 undergoing	 demyelination	 also
display	 T2-signal	 increases	 which,	 in	 contrast	 to	 nerves	 undergoing	WD,	 are	 patchy	 and	 focal.	 Thus,
MRN	 can	 disclose	 areas	 of	 axonal	 damage	 as	well	 as	 demyelination.	As	 a	 note	 of	 caution,	 the	 nerve




The	 diagnosis	 of	 inflammatory	 neuropathies	 such	 as	 GBS	 and	 chronic	 inflammatory	 demyelinating
polyneuropathy	 (CIDP)	 is	 usually	 based	 on	 the	 history	 of	 onset	 and	 course,	 clinical	 evaluation	 of
neurological	 signs	 and	 characteristic	 electrophysiological	 findings	 which	 in	 typical	 cases	 reveal
conduction	block	and/or	slowing	of	nerve	conduction.	Thus,	imaging	is	not	required	for	the	diagnosis,	but
may	 be	 extremely	 useful	 in	 the	 diagnostic	 workup	 of	 patients	 with	 suspected	 focal	 mononeuritis	 (see
below).	MRI	in	GBS	patients	revealed	thickening	and	Gd-DTPA-enhancement	of	spinal	nerve	roots	and




more	 likely	 to	have	back	or	 leg	pain	and	 lower	functional	GBS	scores	 than	 those	with	mild	or	no	root
enhancement	 [3].	Other	 studies	 showed	 that	mostly	 anterior	 spinal	 nerve	 roots	were	 affected,	 and	 that
imaging	abnormalities	regressed	upon	clinical	recovery.	Similarly	to	GBS	patients,	CIDP	patients	show








these	 patients	 underwent	 a	 fascicular	 biopsy	 which	 revealed	 focal	 inflammation	 and	 nerve	 lesions
responded	 to	 anti-inflammatory	 treatments.	 Thus,	 from	 a	 clinical	 standpoint	 MRI	 could	 dramatically
improve	the	diagnostic	yield	if	we	were	able	to	(A)	specifically	identify	inflammatory	foci	(see	below),
and	 (B)	 cover	 larger	 parts	 of	 the	 PNS	 than	 with	 conventional	 MRI.	 In	 2009,	 a	 technique	 termed
‘diffusion-weighted	 whole	 body	 imaging	 with	 suppression	 of	 body	 signal’	 (DWIBS)	 was	 introduced,
which	 allows	 selective	 visualization	 of	 peripheral	 nerves	 over	 long	 trajectories.	 This	 reconstruction
magnetic	neurography	was	recently	applied	to	CIDP	patients	in	a	proof-of-concept	study,	and	disclosed
widespread	symmetric	and	root-dominant	nerve	hypertrophy	[6].	Interestingly,	patients	with	the	multifocal
acquired	 demyelinating	 sensory	 and	motor	 (MADSAM)	 variant	 of	CIDP	 displayed	multifocal	 fusiform
hypertrophy	 only	 in	 some	 nerve	 trunks.	 This	 novel	 imaging	 technique	 may	 dramatically	 improve	 our
diagnostic	yield	in	inflammatory	neuropathies,	similar	to	another	emerging	technology,	nerve	ultrasound.
Figure	 30.1	 	 (A)	 MRI	 abnormalities	 in	 a	 CIDP	 patient.	 Note	 hyperintense	 (white),	 swollen	 nerve	 roots	 and	 plexus	 cervico-





Nerve	 signal	 alterations	 as	 revealed	 by	 conventional	 MRN	 are	 nonspecific,	 and	 the	 extractable
information	is	limited	to	the	distribution	of	nerve	lesions.	In	both	GBS	and	CIDP,	the	pathophysiological
hallmark	is	macrophage-mediated	demyelination	or,	less	frequently,	axonal	injury,	but	inflammation	itself









oxide	core	of	4–8nm	 in	 superparamagnetic	 iron	oxide	 (SPIO)	particles	or	 a	 smaller	 core	 in	ultrasmall
superparamagnetic	 iron	 oxide	 (USPIO)	 particles,	 both	 of	 which	 are	 surrounded	 by	 a	 variable	 coating
affecting	biological	properties	such	as	half-life	within	the	blood.	In	tissues,	iron	oxide	particles	shorten
both	 the	 T1	 and	 T2	 relaxation	 time.	Mostly,	 SPIO	 particles	 have	 been	 used	 to	 study	 inflammation	 in
experimental	animals	 in	 the	PNS.	When	SPIO	particles	are	 injected	systemically	 into	 the	circulation	of
mice	 or	 rats,	 they	 are	 avidly	 phagocytosed	 by	monocytes/macrophages,	 before	 free	SPIO	particles	 are
cleared	 by	 the	 reticuloendothelial	 system.	 Since	 this	 occurs	 rapidly,	 within	 30	 to	 60	 minutes,	 most
remaining	 SPIO	 particles	 in	 the	 circulation	 are	 cell-	 (macrophage)	 bound	 thereafter,	 and	 blood	 pool
effects	can	be	neglected.	This	is	in	contrast	to	free	USPIO	particles	which	have	an	extended	half-life	of
around	 24	 hours.	 When	 SPIO-laden	 macrophages	 are	 attracted	 to	 tissues	 during	 inflammation,	 they
become	visible	due	to	a	signal	loss,	appearing	as	hypointensity	on	T2	and	T2*-w	MR	images.
In	a	 seminal	MRI	study,	Bendszus	and	Stoll	 injected	SPIO	particles	 into	 rats	 at	various	 time	points
after	 sciatic	 nerve	 crush	 and	 could	 follow	 macrophage	 infiltration	 in	 vivo	 [9].	 Blood-derived
macrophages	first	 infiltrated	 the	 lesion	site	 (figure	30.2).	Thereafter,	 the	entire	distal	 stump	undergoing






















by	 some	 specificity	 issues:	 (A)	 small	 local	 haemorrhages	 can	 also	 cause	 signal	 loss	 and	 erroneously








(black	 dots)	 representing	 infiltrating	 blood-derived	 macrophages.	 Adapted	 with	 permission	 from	 Stoll	 et	 al.,	 Journal	 of
Neuroimmunology	149	(2004)	142–146.
Recently,	19F-MRI	 emerged	 as	 a	 novel	 imaging	modality	 for	 inflammation	 [8].	 19F	markers	 such	 as
PFC	compounds	provide	a	unique	signal	in	vivo	due	to	the	negligible	19F	background	signal	of	the	body.
Similar	 to	 SPIO/USPIO	 particles,	 PFC	 nanoparticles	 are	 preferentially	 phagocytosed	 by
monocytes/macrophages	in	the	circulation	and,	thus,	the	fluorine	signal	in	inflamed	organs	is	mainly	due
to	macrophage	infiltration	carrying	intracellular	PFC	nanoparticles.	In	addition	to	19F	images,	1H	images
are	 acquired	 by	 MRS,	 which	 aid	 in	 placing	 the	 PFC-labelled	 cells	 into	 their	 anatomical	 context.
Currently,	 there	 is	 only	 one	 study	 on	 1H/19F	 MRS	 in	 the	 PNS.	 In	 a	 pilot	 study,	 we	 induced	 focal
demyelination	in	sciatic	nerves	of	rats	by	the	chemical	lysolecithin.	At	a	certain	concentration	lysolecithin
dissolves	 myelin	 sheaths	 while	 sparing	 the	 axons,	 and	 thereby	 induces	 a	 robust	 local	 inflammatory






barriers.	 Although	 the	 BNB	 becomes	 leaky	 during	WD,	 patients	 and	 experimental	 animals	 with	 acute
axonal	nerve	 lesions	often	do	not	 show	Gd-DTPA-enhancement.	 In	contrast,	 as	described	above,	nerve
roots	from	GBS	and	CIDP	patients	often	show	Gd-DTPA-enhancement.	Thus,	it	appears	that	Gd-DTPA-
enhancement	 can	 be	 taken	 as	 a	 biomarker	 for	 inflammatory	 activity	 in	 the	 nervous	 system	 as	 widely




DTPA	or	Gf)	and	areas	with	acute	macrophage	 infiltration	 (iron-particle	 induced	hypointensities)	often
did	not	correspond.	It	appeared	that	leakage	of	the	BBB/BNB	for	soluble	factors	such	as	contrast	agents,
and	leukocyte	infiltration	were	timely	and	locally	discordant	[10].	This	notion	is	supported	by	numerous
histological	 studies	 showing	 that	 immune	 cells	 mainly	 enter	 the	 nervous	 system	 by	 trans-endothelial
migration,	 and	 not	 through	 the	 extracellular	 space	 due	 to	 destruction	 of	 tight	 junctions.	 Taken	 together,
these	studies	emphasize	the	necessity	to	develop	specific	cellular	MR	contrast	agents	for	clinical	use	that
allow	us	to	monitor	inflammatory	activity	directly.	A	breakthrough	in	this	field	could	help	to	improve	the


























Schwann	 cells,	 like	 the	 Guillain-Barré	 syndrome,	 have	 been	 victims	 of	 the	 lumpers	 and	 splitters
phenomenon—the	 lumpers	proclaim	 ‘A	Schwann	 cell	 is	 a	Schwann	 cell	 is	 a	Schwann	 cell’,	while	 the
enlightened	such	as	Emily,	myself	and	all	the	other	Schwann	cell	aficionados,	consider	it	to	be	a	wonder
of	 the	cellular	world,	complex,	multifunctional	and	multiphenotypic.	And	so	 this	cell	has	had	an	 image





do	 more	 than	 merely	 myelinate.	 In	 1878	 Ranvier	 mooted	 that	 the	 perisynaptic	 cells	 at	 the
neuromuscular/tripartite	synapse	were	in	fact	Schwann	cells	and	not	part	of	the	muscle	fibres	[1].
So	now	to	the	next	century	and	the	defining	of	GBS	in	its	many	subtypes	via	a	long	and	winding	road	to
the	 ‘Rise	 of	 the	 Schwannopathies’.	 The	 light	 and	 electron	 microscope	 study	 by	 Wiśniewski,	 Terry,
Whitaker,	Cook	and	Dowling	in	1969	of	the	‘spinal	nerve	roots,	spinal	ganglia	and	sciatic	nerve’	from	a
patient	 with	 GBS	 (then	 called	 Landry-Guillain-Barré	 syndrome	 but	 now,	 like	 Strohl,	 Landry	 has
disappeared)	 [2]	 was	 pivotal.	While	 the	 light	 microscopy	 showed	 no	 CNS	 abnormalities,	 in	 the	 EM
~15%	 of	 the	 sciatic	 nerve	 showed	 no	 evidence	 of	 axonal	 degeneration	 and	 for	 the	 first	 time	 clearly
demonstrated	severely	damaged	myelin	lamellae,	sometimes	with	adjacent	normal	myelin	lamellae.	They
go	on	to	describe	macrophage	infiltration	through	the	Schwann	cell	basal	lamina	and	invasion	of	the	outer
mesaxon	 of	 the	 damaged	 Schwann	 cell.	 So	 now,	 for	 maybe	 the	 first	 time,	 comes	 recognition	 that	 the
compact	 myelin-forming	 Schwann	 cells	 are	 more	 than	 their	 compacted	 spiralling	 lamellae;	 that	 the
Schwann	cell	itself	can	be	the	primary	target	pre-empting	the	rise	of	the	Schwannopathies.
It	is	interesting	that	John	Prineas	in	his	perspicacious	GBS	paper	of	1981	acknowledges	that	of	GBS
“the	 precise	 mechanism	 that	 leads	 macrophages	 to	 seek	 out	 and	 amputate	 a	 specialized	 region	 of	 the
Schwann	 cell	 plasma	membrane	 remains	 unexplained”	 [3].	 It’s	 rather	 scary	 to	 think	 about	 ‘amputated’





Innsbruck	 Peripheral	 Nerve	 Society	 meeting,	 where	 he	 presented	 the	 drawing	 of	 the	 myelin-forming
Schwann	cell	in	all	its	architectural	wonder,	at	the	nodes	of	Ranvier,	the	uncompacted	paranodal	swirls
with	 their	 microvilli	 stretching	 out	 to	 the	 axolemma,	 the	 Nav	 channels	 clustering	 together,	 the
juxtaparanode	 harbouring	 the	K	 channels.	 These	 show	 so	 clearly	 the	 importance	 of	 the	 organisational
basis	of	the	Schwann	cell/axonal	relationship	and	the	importance	of	maintaining	this	channel	organisation
for	salutatory	conduction	(see	Figure	31.1)	[4].	This	really	nailed	the	concept	that	diseases	such	as	GBS
and	 chronic	 inflammatory	 demyelinating	 polyneuropathy	 (CIDP)	 are	 diverse	 syndromes,	 subsets	 of
specific	effects	on	not	only	 the	neurons	but	 the	conversation	between	 the	axon,	cell	body	and	Schwann
cell	 compartments.	 Although	 the	 focus	 of	 neuropathologists	 and	 electrophysiologists	 has	 been	 on	 the
damaged	 compact	 myelin	 regions	 of	 the	 Schwann	 cell	 and	 the	 associated	 significant	 slowing	 of
conduction,	 it	 is	 also	 crucial	 to	 consider	 how	 maintenance	 of	 the	 axon/Schwann	 cell	 relationship
underpins	 normal	 conduction.	 Because	 of	 the	 complex	 organisation	 of	 the	 node	 of	 Ranvier	 with	 its
Schwann	cell	microvilli	and	tightly	organised	suites	of	molecules	associated	with	the	node,	paranode	and
juxtaparanode,	the	role	of	the	Schwann	cell	in	all	its	forms	and	architecture	is	being	examined	for	clues	as
to	 subtypes	 of	 GBS;	 especially	 the	 demyelinating	 subtype,	 acute	 inflammatory	 demyelinating
polyneuropathy	(AIDP).
That	 said,	 although	AIDP	may	 be	 considered	 to	 be	 a	 demyelinating	 disease,	 it	 also	 affects	 the	 so-
called	unmyelinated	fibres	such	as	the	autonomic	postganglionic	axons.	As	Jack	Griffin	has	pointed	out,
approximately	80%	of	peripheral	nerve	is	made	up	of	unmyelinated	axons	[5].	However,	even	these	axons







the	demyelinating	 form	of	GBS.	However,	 the	major	myelin	proteins	have	not	proven	 to	be	 significant
targets.	Hafer-Macko	and	colleagues	[6]	examined	3	autopsies	taken	3,	8	and	9	days	after	disease	onset	in









depicted	 as	 2	 continuous	 (green)	 lines;	 these	 form	 a	 circumferential	 belt	 and	 are	 also	 found	 in	 incisures.	Gap	 junctions	 are
depicted	as	orange	ovals;	these	are	found	between	the	rows	of	tight	junctions	and	are	more	numerous	in	the	inner	aspects	of
incisures	and	paranodes.	Adherens	 junctions	are	depicted	as	purple	ovals;	 these	are	more	numerous	 in	 the	outer	aspects	of
incisures	and	paranodes.	The	nodal,	paranodal	and	juxtaparanodal	regions	of	the	axonal	membrane	are	coloured	blue,	red	and
green,	 respectively.	 (B)	 The	 proteins	 of	 compact	 and	 noncompact	 myelin.	 Compact	 myelin	 contains	 P0,	 PMP22	 and	 MBP;
noncompact	myelin	contains	E-cadherin,	MAG,	Cx32,	Cx29	and	claudins	1	and	5.	Schwann	cells	can	make	as	many	as	100
spiral	turns	around	an	axonal	 length	so	that	their	 longitudinal	 length	far	exceeds	that	of	the	axon	they	ensheathe.	To	put	this	 in
perspective,	 an	 unwrapped	 Schwann	 cell	 from	 an	 axon	 with	 a	 hypothetical	 diameter	 of	 6mm	 would	 be	 39m	 in	 length	 if
unwrapped.	Used	with	permission	from	Scherer	and	Arroyo	[4].
Whereas	 the	 identities	 of	 the	 target	 antigens	 in	 the	 axonal	 form	 of	 GBS	 have	 been	 identified	 and




significant	 response	 against	 antigens	not	 present	 in	 the	 compact	myelin.	The	 reason	 the	 target(s)	 of	 the
immune	response	remain	elusive	in	AIDP	is	unclear,	but	it	may	be	that	for	decades	we	have	been	barking
up	the	wrong	tree	 in	 looking	for	 targets	 in	 the	compact	myelin.	The	fact	 that	compact	myelin	 is	but	one
component	of	the	complex	cellular	arrangement	of	the	Schwann	cell	has	often	been	overlooked.	In	reality,
the	 perinodal	 loops,	 Schmidt	 Lanterman	 incisures	 and	 transverse	 processes	 interdigitated	 between	 the
compact	myelin	 lamellae	and	 the	outer	and	 inner	mesaxon	are	all	 in	continuity	with	each	other	and	 the
compact	myelin	spiral.	Immune-mediated	injury	to	any	of	these	areas	has	the	potential	to	cause	problems
with	maintenance	of	myelin	integrity	and	possibly	signal	transduction.
This	 can	 be	 demonstrated	 by	Willison’s	 finding	 that	 in	 the	 Miller	 Fisher	 variant	 of	 GBS	 the	 non
myelin-forming	membranes	 of	 the	 perisynaptic	 Schwann	 cells	 [9]	 as	well	 as	 the	motor	 nerve	 terminal
membranes	 are	 targeted.	 This	 shows	 that	 the	 pathophysiology	 is	 antibody-mediated,	 with	 both	 the
Schwann	 cells	 and	 the	 terminals	 specifically	 targeted	 and	 damaged	 by	 the	 binding	 of	 the	 anti	 GQ1b
















neurodegeneration	only	 in	Schwann	cells	 [10].	Knocking	out	 the	LKB1	pathway	in	Schwann	cells	 from
birth	 led	 to	 progressive	 degeneration	 of	 both	 myelinated	 and	 unmyelinated	 axons,	 where	 small
unmyelinated	sensory	fibres	were	amongst	the	worst	affected.	Deleting	LKB1	from	mature	Schwann	cells
after	 they	 had	 completed	 myelination	 also	 led	 to	 axonal	 loss,	 while	 the	 myelin	 remained	 ostensibly









as	 the	 devil	 facial	 tumour	 disease	 (DFTD),	 its	 origin	 appears	 to	 have	 arisen	when	 a	 single	 cell	 in	 a
female	 devil	 transformed	 into	 a	 cancerous	 clonal	 cell	 line.	 This	was	 then	 transmitted	 to	 another	 devil
during	 a	 facial	 biting	 session	 (the	 bad	 dining	 manners	 of	 Tasmanian	 devils	 are	 legendary—see
https://www.youtube.com/watch?v=SU44KwIfBXM).
DFTD	 is	 one	of	 only	 2	 currently	 known	 transmissible	 tumours	 and	 the	 only	 one	 that	 is	 fatal.	 It	 has
almost	forced	the	Tasmanian	devil	population	into	extinction.	Because	the	disease	spread	geographically
over	time,	epidemiologists	assumed	that	the	cause	was	an	infectious	agent,	but	they	could	not	identify	a


































The	 node	 of	Ranvier	 is	 the	 anatomical	 substrate	 for	 saltatory	 conduction.	 Just	 as	 interactions	 between
myelinating	 glial	 cells	 and	 axons	 are	 required	 for	 the	 development	 of	 myelin	 sheaths,	 the	 molecular
anatomy	of	nodes	is	based	on	specific	molecular	interactions	between	these	2	cell	types.
1:	Ranvier,	Paris,	1876–1878
In	 1878,	Louis-Antoine	Ranvier	 published	 “Leçons	 sur	 l’Histologie	 du	 Systeme	Nerveux”	which	was
based	on	a	series	of	lectures	he	had	given	between	1876	and	1877	[1].	In	that	book,	he	reported	the	thin
(~1	micron)	periodic	interruptions	between	adjacent	myelin	internodes	in	the	peripheral	nerves	of	frogs
and	mammals.	He	 called	 these	 structures	 ‘étranglement	 annulaire’	 (Figure	32.1),	 but	 subsequently	 they








filled	with	a	material	 that	could	be	stained	with	silver	nitrate	 that	 is	 then	reduced	by	exposure	 to	 light,
revealing	 the	 ‘discs	of	Ranvier’	 (Figure	32.2A).	The	paranodes	 illustrated	 in	Figure	32.2B	 showed	 “a








AB:	 “Node	of	nerve	fibres.	A,	axonic	 impregnation	often	found	 in	diluted	and	quick-acting	silver	solutions;	B,	 impregnation	with
silver,	after	 fixation	 in	 formol-pyridine-manganese;	a,	spinous	bracelets	of	Nageotte;	b,	disc	of	Ranvier;	d,	axon;	e,	Schwann’s
membrane.”	C:	“Schematic	drawing	of	the	nerve	fibre	at	the	level	of	the	node.	a,	fine	oblique	neurofibrils;	b,	cementing	discs;	c,




wire	 immersed	 in	 nitric	 acid	 [3].	 He	 introduced	 the	 term	 ‘saltatory’	 conduction,	 and	 emphasized	 the
analogy	to	myelinated	axons:	“Whether	conditions	analogous	to	those	just	described	enter	in	the	case	of
nerve	 and	 other	 transmitting	 structures	 in	 living	 organisms	 is	 difficult	 to	 determine	 experimentally,	 but
seems	not	improbable.	We	observe,	for	example,	that	in	the	most	rapidly	conducting	protoplasmic	tracts
known,	 the	medullated	 nerves	 of	 vertebrates,	 the	 conducting	 element	 (axone)	 is	 enclosed	 by	 a	 tubular
sheath	of	apparently	high	electrical	resistance,	the	medullary	sheath,	which	is	constricted	or	interrupted	at
regular	 intervals.	 The	 medullated	 nerve	 transmits	 impulses	 at	 about	 10	 times	 the	 velocity	 of	 the
nonmedullated	nerve,	in	which,	except	for	the	absence	of	the	segmented	sheath,	the	structure	is	similar.”
4:	Huxley	and	Stämpfli,	Cambridge	and	Berne,	1949
Erlanger	 and	Gasser,	 pioneers	of	peripheral	nerve	 electrophysiology	 (for	which	 they	 shared	 the	Nobel
Prize	 in	 1944),	 appreciated	 that	 nodes	 likely	 “regenerated”	 action	 potentials	 [4]	 “It	 seem	much	more
reasonable	to	suppose	that	a	nerve	fiber	conducts	by	means	of	a	self-contained	mechanism	…”	This	was
directly	demonstrated	by	Huxley	 and	Stämpfli	 in	1949	 [5],	who	 isolated	 single	myelinated	 axons	 from
frog	sciatic	nerves	and	measured	the	amplitude	of	the	current	as	a	function	of	position	along	the	internode



















Beginning	 in	 the	 1980s,	 the	 molecular	 architecture	 of	 nodes	 of	 Ranvier	 has	 been	 built,	 molecule-by-
molecule,	 with	 antibodies	 that	 recognized	 its	 molecular	 constituents.	 The	 intramembranous	 particles











In	 the	 1990s,	 Bennett	 and	 colleagues	 identified	 isoforms	 (270	 and	 480	 kDa)	 of	 ankyrinG,	 that	 were
localized	 to	 nodes	 of	Ranvier	 and	 axon	 initial	 segments	 [7].	This	 group	 also	 discovered	 that	 two	 cell






KCNQ23	 channels	 and	Nav	 channels	 β	 subunits,	 as	well	 as	Nav	 channels	 α	 subunits,	 tenascin-R,	 and	 tenascin-C,	 and	 the
spectrin	 cytoskeleton.	 Nr-CAM,	 NF186,	 and	 β	 subunits	 may	 interact	 in	 trans	 with	 CAMs	 on	 the	 Schwann	 cell	 microvilli.	 At
paranodes,	 Caspr	 and	 contactin	 heterodimers	 interact	 in	 trans	 with	 NF155.	 At	 juxtaparanodes,	 TAG-1	 dimers	 interact
homophilically	in	trans.	Axonal	TAG-1	forms	a	complex	with	Caspr2,	tetramers	of	Kv1.1/Kv1.2	channels,	and	PSD-93,	PSD-95.
Protein	4.1B	 links	 the	cytoplasmic	 tail	of	Caspr	and	Caspr2	 to	 the	spectrin	cytoskeleton.	Homotypic	gap	 junctions	comprised
Cx32	link	the	paranodal	membranes	of	the	myelin	sheath.
8:	Peles	lab,	Tel	Aviv,	2005–2010
The	 Peles	 lab	 [8]	 identified	 gliomedin	 as	 a	 binding	 partner	 for	 NF186	 and	 Nr-CAM,	 showed	 that
gliomedin	is	expressed	by	myelinating	Schwann	cells	and	is	localized	to	nodes,	and	is	required	to	form






that	 contain	 septate-like	 junctions	 (Figure	 32.5).	 Septate-like	 junctions	 limit	 the	 diffusion	 of	 large




deletion	 of	 contactin,	 Caspr,	 or	 NF155	 results	 in	 the	 failure	 to	 form	 septate-like	 junctions,	 and	 is
associated	with	neurological	deficits.
10:	Scherer	and	Paul,	Philadelphia	and	Boston,	1995









form	of	Guillain-Barré	 syndrome	 [14].	More	 recently,	 antibodies	 against	nodal	 (NF186,	Nr-CAM,	and
gliomedin),	 paranodal	 (contactin,	 NF155),	 and	 juxtaparanodal	 (TAG-1/contactin-2	 and	 Caspr2)	 have
been	found	in	small	subsets	of	patients	with	chronic	inflammatory	demyelinating	neuropathy	and	Guillain-









































GBS	 and	 its	 pathological	 correlates,	 and	 subsequently	 focus	 on	 progress	 in	 understanding	 the
pathophysiology	 of	 this	 pain.	 There	 has	 been	 a	 recent	 convergence	 between	 the	 pain	 and	 immunology
fields	 in	 recognising	 that	 immune	mechanisms	 have	 an	 important	 part	 to	 play	 in	 the	 development	 and
persistence	of	neuropathic	pain	whatever	 the	cause.	These	 innate	and	adaptive	 immune	mechanisms	not
only	 impinge	on	neurons	but	 also	have	 a	major	 impact	 on	myelinating	 and	non-myelinating	glia.	 I	will
discuss	not	only	what	we	have	learnt	about	the	specifics	of	pain	aetiology	in	GBS	but	also	how	this	has





Of	 course	 the	 first	 question	 in	 relation	 to	 pain	 and	 GBS	 is	 how	 common	 is	 it	 and	 what	 are	 the
characteristics	of	 the	pain?	In	fact	pain	was	noted	 in	 the	 initial	cases	described	by	Guillain,	Barré	and
Strohl	and	in	subsequent	case	reports/series.	However,	 it	was	not	until	 the	publication	of	 this	paper	by
Haymaker	 and	 Kernohan	 that	 a	 more	 systematic	 approach	 was	 employed	 in	 elucidating	 sensory
dysfunction	 in	GBS	 [1].	Many	 of	 their	 comments	 chime	with	 our	 experience	 of	 pain	 suffered	 by	GBS
patients	 in	 the	21st	century.	They	reviewed	a	clinicopathological	series	of	50	cases	from	the	American






majority	of	 cases,	 in	 a	 significant	group	 it	 persisted.	The	authors	note	 that	 the	majority	of	patients	had
demonstrable	evidence	of	sensory	loss,	usually	in	a	‘glove	and	stocking’	distribution	but	 in	some	cases
also	affecting	the	trunk.	Not	only	is	impaired	sensibility	described	on	examination	(to	touch,	pinprick	and
vibration	 sense),	 but	we	 also	 see	 descriptions	 of	 sensory	 abnormalities	which	we	 now	 associate	with













transient;	other	affected	areas	were	 flanks	and	shoulders,	with	 the	hands	and	 feet	being	 less	commonly
affected.	 There	was	 very	 little	 correlation	 between	 clinical	 signs,	 electrophysiological	 findings	 or	 the
presence	of	inflammation	within	the	DRG	and	the	presence	of	pain.	The	lack	of	correlation	between	the









most	 common	 pain	 distribution,	 consistent	with	 the	 findings	 of	Ropper	 and	 colleagues,	was	 the	 lower
back	 and	 upper	 legs,	 although	 a	 significant	 group	 reported	 pain	 in	 the	 extremities.	 One	 means	 of
explaining	 such	 a	 distribution	 would	 be	 dorsal	 root	 inflammation,	 which	 is	 commonly	 reported	 in
pathological	series	of	GBS	(see	Haymaker	and	Kernohan	above)	resulting	in	lumbar	back	pain	and	pain








In	 the	1990s	 it	became	clear	 that	 the	 free	nerve	endings	of	C-fibres	and	 thin	myelinated	A-delta	 fibres
could	be	visualised	and	quantified	within	the	epidermis	by	immunostaining	for	the	pan-neuronal	marker
PGP-9.5.	 These	 represent	 the	 terminals	 of	 nociceptors	 and	 thermoceptors,	 and	 this	 technique	 is	 now
widely	used	in	both	research	and	clinical	practice.	This	has	been	a	major	advance	given	that	the	function
of	 these	 fibres	 is	 not	 interrogated	 with	 standard	 electrophysiological	 testing.	 Pan	 and	 colleagues	 [6]
applied	 this	 technique	 to	 a	 group	 of	 GBS	 patients,	 showing	 that	 there	 was	 a	 significant	 reduction	 in
intraepidermal	nerve	fibre	density	(IENFD)	in	the	distal	leg	as	compared	to	matched	controls.	There	was
a	correlation	between	the	reduction	in	IENFD	and	raised	thermal	thresholds	in	GBS	patients.	There	was	a










In	 a	 cohort	 of	 32	GBS	 patients	 these	 authors	 showed	 a	 significant	 reduction	 in	 IENFD	 in	 the	 lumbar
region	 in	 61%	of	 patients,	 and	 at	 the	 distal	 leg	 in	 60%	of	 patients	 in	 the	 acute	 phase	 of	GBS	 (first	 3
weeks)	 [8].	 One	 important	 implication	 is	 that	 injury	 to	 small	 fibres	 is	 not	 length	 dependent	 given	 the










It	 is	 common,	 severe	 and	 in	 a	 significant	 group	 of	 patients	 persistent	 even	 at	 1	 year	 and	 affects	 both
proximal	 regions	such	as	 lower	back	as	well	as	 the	extremities.	With	pathological	correlations	we	can









our	 understanding	 of	 peripheral	 neuropathic	 pain	 [9].	 We	 now	 take	 for	 granted	 the	 fact	 that	 sensory
neurons	develop	ectopic	or	 spontaneous	activity	 following	nerve	 injury;	 this	paper	was	 the	 first	direct
demonstration	of	these	phenomena.	Prior	to	this	report	it	had	been	shown	that	cutting	a	nerve	would	lead
to	 an	 acute	 ‘injury	 discharge’	 within	 seconds,	 which	 would	 then	 subside;	 however,	 there	 was	 no
knowledge	 as	 to	what	would	 happen	 to	 the	 electrophysiological	 properties	 of	 primary	 afferents	 in	 the
subsequent	days	and	weeks,	which	was	the	topic	of	this	paper.
The	authors	 ligated	 the	sciatic	nerve	 to	generate	a	neuroma	and	 then	 recorded	 from	 individual	units
within	 fine	 filaments	 of	 the	 teased	 dorsal	 root	 at	 up	 to	 40	 days	 post-injury.	 They	 noted	 ongoing
spontaneous	 activity	 in	 myelinated	 afferents	 terminating	 in	 the	 neuroma.	 The	 fact	 that	 application	 of
lidocaine	 to	 the	neuroma	could	block	 this	ongoing	activity	was	provided	as	evidence	 that	 the	 impulses
arose	from	the	neuroma	itself;	subsequent	studies	have	shown	that	ectopic	activity	can	also	arise	at	 the
level	of	the	cell	body	within	the	DRG	[10].	The	sensory	neurons	also	adopted	a	novel	mechanosensitivity.
In	 the	 conclusion	 the	 authors	 presciently	 argue	 that	 this	 ongoing	 activity	 would	 be	 an	 important
pharmacological	target	for	novel	analgesics.	A	recent	study	using	peripheral	nerve	blocks	in	man	suggests







question	 for	 the	 demyelinating	 variants	 of	GBS	 is	whether	 primary	 demyelination	 in	which	 the	myelin
sheath	is	removed	while	the	axon	remains	intact	can	result	 in	neuropathic	pain.	Wallace	and	colleagues
showed	 clearly	 in	 their	 work	 that	 this	 is	 in	 fact	 the	 case;	 they	 also	 went	 on	 to	 provide	 mechanistic









The	 authors	 show	 that	 primary	 demyelination	 results	 in	 increased	 expression	 of	 the	 voltage-gated
sodium	 channel	 NaV1.3,	 which	 is	 normally	 only	 expressed	 during	 development	 and	 is	 absent	 in
adulthood.	Others	had	previously	demonstrated	 that	demyelination	of	axons	 leads	 to	 radical	 changes	 in
ion	channel	distribution:	for	instance,	voltage-gated	sodium	channels,	which	would	normally	be	confined
to	the	node	of	Ranvier,	now	spread	along	the	axolemma	and	could	act	as	ectopic	‘generators’.	This	study






paper	 provides	 a	 mechanistic	 link	 between	 ganglioside	 autoantibodies	 and	 the	 development	 of
neuropathic	pain	[13].	The	‘B’	series	gangliosides	(such	as	GD2)	in	particular	are	known	to	be	expressed
by	 sensory	 neurons	 at	 the	 surface	 of	 the	 cell	 body	 and	 along	 the	 axolemma.	An	 example	 of	 the	 direct
effects	 of	 antiganglioside	 antibodies	 is	 that	 a	 monoclonal	 antibody	 directed	 against	 GD2	 used
therapeutically	 in	 the	 treatment	of	neuroblastoma	was	noted	 to	cause	pain	and	mechanical	 allodynia	as
side	effects.
To	 understand	 the	 pathogenic	 effects	 of	 anti-GD2	 antibodies,	 Xiao	 and	 colleagues	 systemically
administered	anti-GD2	antibody	to	rats.	These	antibodies	resulted	in	the	rapid	development	of	mechanical
hypersensitivity	 in	 the	 rat	 which	 mirrored	 the	 development	 of	 mechanical	 allodynia	 in	 patients
administered	 these	 antibodies.	 On	 electrophysiological	 recording	 (performed	 on	 the	 same	 day	 as	 the
behavioural	 assessment)	 both	 C-fibres	 and	 A-delta	 sensory	 fibres	 developed	 spontaneous	 activity.	 In
addition,	 their	 threshold	 to	mechanical	stimuli	dropped.	In	summary,	antibodies	 to	 the	GD2	ganglioside
known	 to	 be	 expressed	 by	 sensory	 neurons	 could	 acutely	 sensitise	 primary	 afferents	 leading	 to
spontaneous	 activity,	 reduced	 mechanical	 thresholds	 and	 the	 development	 of	 spontaneous	 pain	 and




Experimental	 allergic	 neuritis	 is	 an	 animal	 model	 in	 which	 an	 acute,	 inflammatory	 demyelinating
neuropathy	develops	and	is	used	as	a	model	of	the	AIDP	variant	of	GBS.	A	number	of	groups	(including
Moalem-Taylor	and	colleagues	[12]),	have	recently	shown	that	the	development	of	experimental	allergic
neuritis	 (EAN)	 is	associated	with	 the	development	of	pain-related	hypersensitivity.	 In	 this	paper	Zhang
and	colleagues	study	the	effects	of	minocycline—a	second-generation	tetracycline	with	anti-inflammatory
properties—in	 this	model	 [14].	EAN	was	 induced	by	a	neuritogenic	peptide	of	P2.	EAN	results	 in	 the
recruitment	 of	 inflammatory	 infiltrate	 to	 peripheral	 nerve	 and	 increased	 inflammatory	 cytokine	 (TNF-
alpha)	 expression.	 This	 inflammatory	 environment	 is	 likely	 to	 sensitise	 primary	 afferents,	 and	 indeed
individual	 cytokines	 such	 as	 TNF	 can	 produce	 spontaneous	 activity	 and	 sensitise	 primary	 afferent
nociceptors.	Although	EAN	results	 in	peripheral	nerve	 injury,	maladaptive	plasticity	within	 the	CNS	is
also	 likely	 to	 have	 a	 role	 in	 neuropathic	 pain	 development.	 Indeed,	 as	 has	 also	 been	 noted	 following
traumatic	nerve	injury,	microglia	within	the	spinal	cord	transform	to	a	pro-inflammatory	phenotype	[15]
and	express	the	purinoceptor	P2Rx4.	These	pro-inflammatory	(P2RX4	+ve)	microglia	within	the	dorsal
horn	 release	 brain-derived	 neurotrophic	 factor	 (BDNF),	 which	 sensitises	 nociceptive	 signalling.
Minocycline	treatment	reduces	the	severity	of	EAN	as	assessed	by	motor	function	and	ameliorates	all	of
the	 inflammatory	 changes	 described	 above,	 resulting	 in	 reduced	 pain-related	 hypersensitivity.	 This
produces	an	important	illustration	of	how	pro-inflammatory	process	engaged	by	EAN	(and,	by	inference,
in	GBS)	can	act	to	sensitise	the	nociceptive	system.	Disease-modifying	therapy	in	GBS	is	likely	to	reduce





Association	 for	 the	 Study	 of	 Pain	 (IASP)	 is	 a	 comprehensive,	 systematic	 review	 and	meta-analysis	 of
pharmacotherapy	 for	 neuropathic	 pain	 [16].	 There	 have	 been	 a	 number	 of	 small	 studies	 of	 analgesic
therapy	in	GBS;	however,	a	recent	Cochrane	review	pointed	out	that	the	quality	of	the	evidence	was	poor
and	it	was	not	possible	to	draw	definitive	conclusions	[17].	One	of	the	emerging	themes	in	neuropathic
pain	 is	 that	 pathophysiological	 mechanisms	 (for	 instance	 ectopic	 activity	 in	 primary	 afferents	 or
sensitisation	 within	 the	 CNS)	 are	 not	 aetiology	 specific	 and	 in	 general	 pharmacological	 agents	 show
efficacy	across	a	range	of	causes	of	neuropathic	pain.	In	fact,	an	aspiration	for	the	future	is	that	we	should
use	somatosensory	phenotyping	rather	than	aetiology	to	stratify	patients	and	target	treatment.	The	authors
of	 this	 paper	 point	 out	 that	 their	 analysis	 and	 guidance	 should	 be	 applicable	 to	 a	 wide	 range	 of
neuropathic	causes	(and	we	hope	this	includes	GBS).	One	caveat	is	that	most	large	randomised	controlled
trials	 for	 neuropathic	 pain	 are	 performed	on	patients	with	 painful	 diabetic	 neuropathy	or	 post-herpetic
neuralgia.	Based	on	efficacy	and	tolerability,	recommended	first-line	agents	for	neuropathic	pain	are	the
gabapentinoids,	 tricyclic	 antidepressants	 (TCAs)	 or	 serotonin/noradrenaline	 reuptake	 inhibitors.	 In	 the
acute	phase,	care	would	need	to	be	taken	with	the	use	of	TCAs	if	there	were	autonomic	involvement.	The
second-line	 agents	 which	 were	 recommended	 included	 lidocaine	 plasters	 and	 high-dose	 capsaicin
patches;	however,	the	regions	of	neuropathic	pain	may	well	be	too	extensive	for	topical	therapy	in	GBS.










sensory	 axons	 and	dysfunction	of	 ion	 channels	 resulting	 in	 ectopic	 activity.	 Interestingly,	 there	 is	 some
experimental	 evidence	 that	 antiganglioside	 antibodies	 (anti-GD2)	 can	 trigger	 spontaneous	 activity	 in
sensory	neurons.	Currently	the	best	treatment	algorithms	will	use	generic	guidelines	on	the	management	of
neuropathic	pain	such	as	those	recently	developed	by	NeuPSIG;	however,	future	trials	are	needed	to	test
analgesic	efficacy	specifically	 in	GBS.	A	key	aspiration	of	 the	neuropathic	pain	field	 is	 to	use	sensory
profiling	 in	 order	 to	 stratify	 patients,	 with	 the	 hope	 that	 such	 stratification	 will	 reveal	 particular







































to	write	 a	 chapter	 based	 on	 complement	 and	 its	 role	 in	Guillain-Barré	 syndrome.	Given	 our	 different























When	 first	 approached	 to	 contribute	 to	 this	 publication,	 I	 knew	 without	 doubt	 that	 one	 of	 Professor
Morgan’s	publications	had	to	be	featured	in	my	list	of	notable	papers.	The	only	problem	was	which	one	to







(including	GBS),	 infections,	 neurodegenerative,	 acute	 injuries	 and	neuropsychiatric.	The	 importance	of
understanding	 the	 disease	 process	 in	 these	 diseases	 has	 become	 increasingly	 important	 of	 the	 last	 few









mouse	 antibody	 deposits	 were	 present	 on	 the	 presynaptic	 membranes	 after	 passive	 immunisation.	My
naive	understanding	of	the	mouse	immune	system	led	me	in	search	of	an	explanation,	and	I	came	across
this	publication	which	shed	light	on	this	conundrum.
In	 this	 article	Ong	 and	Mattes	 acknowledge	 that	 “common	 laboratory	mouse	 strains	 have	 very	 low










Because	 this	 article	 provided	 a	 valuable	 insight	 into	 the	 issue	 of	 mouse	 complement,	 we	 were












reported	 that,	 compared	 to	 wild	 type	mice,	 knocking	 out	 the	 gene	 for	 the	 complement	 regulator	 DAF,
which	 accelerates	 the	 breakdown	 of	 both	 the	 classical	 and	 alternative	 pathway	 derived	 C3	 and	 C5
convertases,	 resulted	 in	 mice	 with	 exacerbated	 disease	 pathology.	 This	 was	 measured	 both




didn’t	 reveal	 an	 acute	model	 of	GBS	 in	 these	mice.	 However,	 this	 presented	 us	with	 a	 new	 tactic	 to









to	 amplify	 the	 complement	 cascade	 subsequent	 to	 classical	 pathway	 activation.	 In	 this	 article	 treating
cells	with	neuraminidase	(which	cleaves	sialic	acid	residues	from	cells)	converted	a	non-activator	into
an	activator	of	alternative	complement.	 It	 is	now	understood	 that	 the	 fluid	phase	complement	 regulator,
Factor	H	(β1H),	 readily	binds	 to	 sialic	 acid	 and	other	polyanionic	molecules,	 thereby	protecting	 cells
from	complement	by	decay	accelerating	activity	of	 the	alternative	pathway	C3	convertase	and	cofactor
activity	 for	 Factor	 I	 mediated	 C3b	 cleavage.	 While	 this	 principal	 suggests	 a	 relative	 protective






damage	 in	 many	 neurological	 diseases.	 Pharmaceutical	 companies	 are	 aware	 of	 the	 great	 need	 to
modulate	or	inhibit	complement	activity,	yet	until	recently	there	has	been	a	void	of	clinical	complement
therapeutics.	It	was	in	2007	that	the	FDA	approved	the	use	of	eculizumab	for	the	treatment	of	patients	with
paroxysmal	 nocturnal	 hemoglobinuria	 (PNH)	 and	 to	 date	 it	 has	 been	 approved	 for	 use	 in	 50	 other





of	 the	 PIG-A	 gene	 in	 pluripotent	 hematopoietic	 stem	 cells,	 which	 encodes	 a	 protein	 essential	 for	 the
synthesis	of	glycosylphophatidyllinositol	(GP1,	a	lipid	component	which	anchors	a	variety	of	proteins	in
the	plasma	membrane)	[5].	Two	of	these	GPI-anchored	proteins	that	are	absent	in	PNH	patients	are	the



























attack	 complex	 (MAC),	 in	 those	with	GBS,	 but	 none	 in	 the	 normal	 control	 group	 [6].	 Their	 work	 on
kinetic	 studies	 for	 complement-fixing	 antibodies	 showed	 a	 correlation	 between	 decreasing	 levels	 of
circulating	antibody	and	SC5b-9,	and	an	improvement	in	muscular	strength.	Immunostaining	of	peripheral





With	my	appetite	whetted,	 I	delved	further	 into	 the	work	of	Griffin	 ,	Hafer-Macko	and	 their	colleagues
during	 the	 1990s,	 who	 characterised	 pathological	 findings	 in	 GBS	 and	 formed	much	 of	 the	 basis	 our
modern	understanding	of	the	AMAN	variant	[7].	These	2	papers	explore	the	immunopathology	of	axonal
GBS	 through	 autopsy	 pathological	 samples.	 The	 former	 demonstrates	 Wallerian-like	 degeneration	 in
affected	 nerves,	 showing	 macrophage	 infiltration	 in	 the	 peri-axonal	 space,	 and	 uses	 its	 discussion	 to
postulate	links	between	severity	of	nodal	damage	and	activation	of	complement	in	the	nodal	region.	The
Hafer-Macko	 paper	 describes	 nodal	 complement	 deposition,	 and	 highlights	 the	 differences	 in	 patterns
between	what	we	see	 in	AIDP	and	AMAN	[8].	Together	 these	papers	began	 to	unpick	 the	 relationship
between	 complement	 and	 AMAN,	 allowing	 me	 to	 get	 a	 further	 handle	 on	 not	 only	 the	 complex




Jumping	 forward	 somewhat,	 to	 a	 time	 when	 pathogenic	 anti-ganglioside	 antibodies	 thought	 to	 drive
axonal	GBS	were	characterised,	McGonigal	and	colleagues’	paper	not	only	demonstrated	the	deposition
of	 membrane	 attack	 complexes	 at	 nodes	 of	 Ranvier,	 but	 also	 offered	 a	 functional	 analysis,	 using
electrophysiological	assessments	to	show	lack	of	current	flow	once	the	MAC	had	bound,	and	conversely
showing	that	inhibiting	complement	activation	could	also	be	protective	to	the	nodes	of	Ranvier,	which	of






of	 anti-GQ1b	 antibody	 and	 normal	 human	 serum,	 to	 show	 the	 antibody-driven,	 complement-derived
respiratory	paralysis	could	be	abrogated	by	intravenous	injections	of	C5	inhibitor	eculizumab	[10].	The
in	 vitro	 work	 performed	 in	 parallel	 showed	 application	 of	 Eculizumab	 completely	 prevented	 MAC







have	 received	 doses	 of	 eculizumab	 for	 their	GBS,	 and	 time	will	 tell	 if	we	 can	 replicate	 the	 fantastic




As	with	 all	 good	 scientific	 research,	 our	 research	was	not	 performed	 in	 isolation—it	 has	 truly	been	 a
collaborative	affair.	We	would	like	to	acknowledge	the	contributions	of	our	past	and	present	colleagues
based	at	the	University	of	Glasgow	and	the	Greater	Glasgow	NHS	trust	and	our	key	collaborators	across




























Adoptive	 transfer	 studies	 demonstrate	 that	 the	 minimal	 requirement	 to	 initiate	 inflammation,
demyelination	and	axonal	 loss	 in	 the	peripheral	nervous	system	(PNS)	 is	a	 tissue-specific	CD4+	T-cell
response.	This	observation	marked	my	first	foray	into	neuroimmunology	and	prompted	speculation	that	a
similar	mechanism	contributed	 to	 the	pathogenesis	of	Guillain-Barré	 syndrome	 (GBS).	This	 concept	 is
now	 largely	discounted	with	 respect	 to	GBS,	but	 increasing	evidence	 indicates	 the	T-cell	 compartment
plays	 important	 roles	 in	 other	 diseases	 affecting	 the	 PNS,	 in	 particular	 Charcot-Marie-Tooth	 disease





Adams	 and	 Waksman	 developed	 the	 first	 model	 of	 experimental	 allergic	 neuritis	 (EAN)	 in	 which
inflammatory	 demyelination	 was	 restricted	 to	 the	 PNS	 by	 immunising	 rabbits	 with	 sciatic	 nerve
homogenates	 emulsified	 in	 Freund’s	 complete	 adjuvant	 [1].	 They	 noted	 that	 the	 structure	 and	 cellular
composition	of	 these	 lesions	resembled	 that	seen	 in	some—but	not	all—cases	of	GBS,	 leading	 them	to
state	 these	 were	 “sufficiently	 impressive	 to	 justify	 a	 further	 exploration	 of	 the	 possibility	 that	 acute
‘infectious’	polyneuritis	may	have	an	immunologic	basis”.	Moreover,	as	similar	lesions	could	be	induced
by	 immunizing	 rabbits	 with	 CNS	 tissue	 homogenates,	 they	 concluded	 “there	 must	 clearly	 exist	 in	 the








in	 man	 prompted	 an	 intense	 effort	 to	 determine	 the	 nature	 of	 the	 immune	 response	 responsible	 tissue
damage	in	the	PNS.	Initial	interest	focused	on	the	possible	role	of	antibodies,	but	passive	transfer	of	EAN
with	 serum	 from	 sensitised	 animals	 was	 ineffective.	 This	 led	 Åström	 and	 Waksman	 to	 consider	 the
possibility	 it	 was	 mediated	 by	 a	 cellular,	 delayed	 hypersensitivity	 response	 within	 the	 PNS	 [2].	 The
ability	 of	 lymph	 node	 cells	 derived	 from	 a	 sensitized	 animal	 to	 induce	 hypersensitivity	 responses	 in
normal	 recipients	 had	 been	 established	 some	 40	 years	 earlier	 by	 Landsteiner	 and	 Chase,	 so	 it	 was	 a
logical	step	to	extend	this	concept	to	the	pathogenesis	of	tissue	specific	‘allergic’	diseases	such	as	EAN.
In	 this	 paper	 Åström	 and	 Waksman	 describe	 the	 ability	 of	 lymph	 node	 cells	 isolated	 from	 donors
immunised	with	bovine	sciatic	nerve	homogenate	in	adjuvant	to	induce	in	naïve	recipients	a	disease	that
was	 indistinguishable	 from	actively	 induced	EAN.	This	 study	was	performed	 in	New	Zealand	 rabbits,
and	perhaps	not	surprisingly,	in	view	of	our	current	understanding	of	immunology,	disease	penetrance	and
severity	 were	 low.	 Nonetheless,	 cells	 from	 donors	 immunised	 with	 kidney	 homogenates	 or	 adjuvant







the	mechanistic	basis	of	EAN	[3].	The	authors’	 success	was	dependent	 largely	on	 their	 selection	of	an
appropriate	combination	of	antigen	source	and	species,	but	they	also	note	“clinical	disease	produced	by
the	 pure	 neuritogen	 was	 slightly	 less	 severe	 than	 that	 induced	 by	 whole	 myelin”,	 an	 observation	 that










CD4+	 T	 cells	 and	 macrophages,	 breakdown	 of	 the	 blood-nerve	 barrier	 and	 primary	 demyelination.
However,	 the	 intensity	 of	 this	 inflammatory	 response	 increased	 in	 proportion	with	 the	 dose	 of	T	 cells
transferred,	 reaching	 a	 threshold	 beyond	which	 axonal	 degeneration	was	 the	 primary	 pathologic	 effect
which	 resulted	 in	 widespread	 secondary	 demyelination	 that	 in	 many	 cases	 extended	 into	 the	 dorsal
columns	of	the	spinal	cord.	This	study	established	that	the	minimal	requirement	to	initiate	EAN	in	a	naïve,
immunocompetent	 host	 was	 a	 neuritogenic	 CD4+	 T-cell	 response,	 and	 it	 initiated	 a	 number	 of	 studies
exploring	effector	mechanisms	 that	were	ultimately	 responsible	 for	 loss	of	 function	and	 tissue	damage.






that	 autoantibody-dependent	 pathomechanisms	were	 involved	 in	many	 peripheral	 neuropathies,	 and	 not
surprisingly	this	was	paralleled	by	a	concurrent	decline	in	interest	in	T	cell-dependent	mechanisms.	That
was	until	the	serendipitous	and	completely	unexpected	finding	that	the	B7-2	blockade	in	the	NOD	mouse
initiates	 a	 spontaneous	 autoimmune	 peripheral	 polyneuropathy	 (SAPP)	 which	 reproduces	 many	 of	 the
clinical,	 electrophysiological	 and	 pathological	 features	 of	 CIDP	 [7].	 The	 mechanistic	 basis	 by	 which
ablation	of	the	CD28/B7-2	co-stimulatory	pathway	unleashed	this	previously	cryptic	neuritogenic	CD4+
T-cell	 response	 in	 the	 context	 of	 this	 particular	 genetic	 background	 remains	 unclear,	 but	 it	 rekindled





the	major	 target	 for	 the	 neuritogenic	T-cell	 response	 [4].	Using	P0-specific	T-cell	 hybridomas	derived
from	 T	 cells	 infiltrating	 the	 PNS	 of	 affected	 mice,	 the	 authors	 then	 generated	 a	 P0	 T-cell	 receptor
transgenic	mouse	 line	(POT)	 to	explore	 the	development,	 regulation	and	pathogenicity	of	P0-specific	T
cells	 in	 vivo.	 This	 revealed	 that	 P0-specific	 T	 cells	 can	 survive	 thymic	 selection	 to	 populate	 the
periphery,	 but	 their	 neuritogenic	 potential	 in	 immunocompetent	 wild	 type	 mice	 is	 then	 held	 in	 check,
primarily	by	CD4+	Foxp3+	regulatory	T	cells.	This	regulatory	checkpoint	is	lost	when	POT	mice	are	bred






The	 low	 prevalence	 of	 CIDP	makes	 it	 difficult	 to	 obtain	 sufficiently	 large	 patient	 cohorts	 to	 identify
disease-associated	 changes	 in	 immune	 cell	 function.	 However,	 several	 research	 groups	 took	 on	 this
challenge,	 including	 Hughes	 and	 colleagues,	 who	 provide	 evidence	 that	 CIDP	 is	 associated	 with	 a
functional	defect	in	regulatory	CD4+CD25high	T	cells	[8].	However,	this	defect	does	not	occur	in	isolation
as	 immunophenotyping	 revealed	 circulating	 monocytes	 were	 increased	 whilst	 NK	 cell	 numbers	 were
decreased	 between	 patients	 and	 controls.	 In	 contrast,	 there	 were	 no	 significant	 differences	 in	 the








[4,7],	 and	 many	 may	 be	 persuaded	 this	 is	 also	 the	 case	 in	 CIDP	 [8].	 However,	 while	 these	 studies
highlight	the	ability	of	CD4+	T	cells	to	trigger	inflammatory	disease	activity	in	the	PNS,	they	do	not	rule




the	 inflammatory	 response	 induced	by	a	 low	dose	of	neuritogenic	CD4+	T	cells	 is	 sufficient	 to	disrupt
BNB	integrity	enough	 to	 facilitate	access	of	pathogenic	neurofascin-specific	antibody	 into	 the	PNS	and
exacerbate	 clinical	 disease	 [6].	 Extrapolating	 this	 concept	 to	 human	 neuropathies	 raises	 a	 simple	 but
rather	important	question:	what	are	the	threshold	values	for	antigen-specific	T	cells	and/or	autoantibodies
to	induce	a	clinically	relevant	effect	in	the	PNS?	This	is	important	as	progressively	more	sensitive	cell-
based	 assays	 are	being	 introduced	 to	detect	 ‘potentially’	pathogenic	 autoantibody	 responses	 in	 clinical
samples.
Montreal,	2014:	At	Last	Something	about	CD8+	T	Cells
EAN	 [5]	 and	 SAPP	 [4,7]	 established	 a	 pre-eminent	 role	 for	 CD4+	 T	 cells	 in	 the	 pathogenesis	 of
inflammatory	demyelinating	peripheral	neuropathies,	but	as	 stated	by	Salomon	 in	2001	 these	 results	do
not	 rule	out	 the	possibility	pathogenic	CD8+	T	cells	may	play	a	 role	 in	 the	aetiology	of	 these	diseases
after	longer	periods	of	time.	Thirteen	years	later	evidence	is	now	available	that	this	is	indeed	the	case,	as
demonstrated	by	the	development	of	a	spontaneous	autoimmune	peripheral	polyneuropathy	(SAPP)	in	L31
transgenic	mice	bred	onto	a	CD4-/-	 background	 [9].	These	mice	develop	a	 range	of	motor	 and	 sensory
deficits	 that	 are	 associated	with	 large	 numbers	 of	macrophages	 and	CD8+	 T	 cells	 infiltrating	 the	 PNS
accompanied	by	demyelination	and	varying	degrees	of	axonal	loss.	This	model	indicates	that	disruption	of
immune	 homeostasis	 due	 to	 constitutive	 overexpression	 of	 B7.2	 can	 trigger	 a	 profound	 CD4+	 T	 cell-




The	 rather	 eclectic	 collection	 of	 papers	 discussed	 above	 map	 the	 development	 of	 the	 concept	 that
adaptive	 T-cell	 responses	 play	 significant	 roles	 in	 the	 pathogenesis	 of	 acquired	 inflammatory




cross	 these	 mutants	 onto	 a	 RAG-1-deficient	 background	 to	 determine	 whether	 this	 response	 had	 any
functional	significance	[10].	This	proved	to	be	the	case	as	tissue	damage	was	significantly	ameliorated	in






































Guillain-Barré	 syndrome	 (GBS)	 encompasses	 a	 group	 of	 related	 neuropathic	 disorders,	 considered
autoimmune	in	nature,	that	commonly	share	endoneurial	inflammation	(cellular	and	noncellular)	as	a	key
feature.	 That	 a	 synergism	of	 cellular	 and	 humoral	 immune	 elements	 is	 involved	 in	 the	 pathogenesis	 of
these	disorders	is	a	commonly	favoured	hypothesis	but	not	accepted	universally.	That	antigen	specificity
and	 nature	 of	 adaptive	 autoimmune	 responses,	 especially	 T-cell	 responses,	 are	 not	 well	 defined,




including	 monocytes/macrophages	 to	 induce	 target	 tissue	 inflammation	 and	 injury	 in	 autoimmune
disorders.	 The	 pathologic	 studies	 in	 demyelinating	 and	 axonal	 GBS	 indicate	 a	 central	 role	 for
macrophage	 populations,	 which	 are	 the	 key	 components	 of	 innate	 immune	 system	 and	 endoneurial
inflammation.	 Macrophage-mediated	 myelin	 stripping	 and	 nodal	 and	 periaxonal	 macrophage-mediated





constitute	 endoneurial	 inflammation	 and	 mediate	 nerve	 (myelin	 and	 axonal)	 injury	 exist	 in	 individual
inflammatory	neuropathies	grouped	under	GBS	and	what	their	key	components	are.	The	current	discussion
narrowly	 focuses	 on	 the	 role	 of	 inflammation	 and/or	 inflammatory	 milieu,	 downstream	 of	 known	 or
unknown	adaptive	nerve-specific	immune	responses,	in	mediating	nerve	injury	in	GBS,	highlighting	some







Waksman	 and	Adams’	 landmark	 paper	 is	 highly	 likely	 to	 feature	 in	 several	monographs	 in	 the	 current
collection	[1].	The	authors	provide	fundamental	and	comprehensive	experimental	animal	data	that	support
the	concept	of	 inflammatory	neuropathic	disease.	In	 this	study,	 the	experimental	allergic	neuritis	(EAN)
was	generated	in	rabbits	by	immunizing	with	homologous	and	heterologous	sciatic	nerves.	These	animals
developed	 clinical	 disease	 approximately	 2	 weeks	 after	 immunization.	 There	 was	 elevation	 of	 CSF
protein	without	pleocytosis.	Notably,	spinal	roots,	dorsal	root	ganglion,	and	peripheral	nerves	developed
endoneurial	 histiocytic/monocytic	 and	 lymphocytic	 inflammation	 and	 nerve	 fibre	 demyelination	 with
variable	secondary	axonal	injury.	Importantly,	the	authors	emphasize	the	close	relationship	of	histiocytes
with	 demyelination,	 including	 the	 presence	 of	 myelin	 debris	 in	 post-phagocytic	 monocytes.	 Based	 on
these	 clinical,	 CSF	 and	 pathologic	 findings,	 Waksman	 and	 Adams	 postulated	 that	 this	 disease	 model
resembles	 the	 clinical	 conditions	 grouped	 under	 Landry’s	 paralysis,	 GBS	 and	 acute	 infectious
polyneuritis,	and	represents	one	of	 the	earliest	models	of	 inflammatory	disease	of	peripheral	nerves.	In
the	 context	 of	 the	 current	 discussion,	 this	 is	 one	 of	 the	 earliest	 studies	 noting	 endoneurial
histiocytic/monocytic	cell	populations	as	 immune	effectors	mediating	myelin	 injury	and	clearance.	This




mononuclear	 cells	 in	demyelination	 [3].	He	 reported	 that	mononuclear	 cells	 traverse	 the	Schwann	 cell
sheath,	penetrate	the	outer	mesaxon,	push	the	Schwann	cells	aside,	contact	the	myelin	sheath,	and	strip	and
dissolve	 myelin	 sheath.	 These	 studies	 imply	 mononuclear	 cellular	 contact-dependent	 inflammatory
demyelination.	In	contemporaneous	ultrastructural	studies,	Ballin	and	Thomas	reported	early	disruption	of
contacts	 formed	 by	 myelin	 terminal	 loops	 and	 paranodal	 axolemma	 at	 the	 nodes	 of	 Ranvier	 after







MGH	 cohort	 of	 19	 GBS	 patients,	 at	 all	 stages	 of	 the	 disease	 [5].	 Analogous	 to	 EAN,	 primary
demyelination,	including	early	nodal	changes,	and	secondary	axonal	injury	was	found	in	almost	all	cases.
The	 authors	 opined	 “the	 role	 of	 macrophages	 in	 EAN	 and	 in	 idiopathic	 polyneuritis	 is	 uncertain.
Macrophages	 in	 both	 diseases	 are	 particularly	 prominent	 at	 sites	 of	 extensive	 myelin	 breakdown	 and
contain	 fragments	 of	 degenerating	 myelin.	 Whether	 they	 have	 some	 primary	 role	 in	 initiating	 myelin
breakdown	or	act	purely	to	clean	up	myelin	destroyed	by	lymphocytes	is	not	known.”
Whether	 demyelination	 and	 T-cell	 inflammation	 are	 universal	 pathologic	 features	 of	 all	 patients
grouped	under	GBS	was	unclear	at	 that	 time.	Haymaker	and	colleagues,	prior	 to	 the	publication	of	 the
Asbury	study,	reported	that	T-cell	inflammation	was	not	a	constant	early	pathologic	feature	in	their	GBS
cases	with	 demyelinating	 pathology	 [6].	 In	 the	mid	 1990s,	Hafer-Macko	 and	 colleagues	 also	 reported
demyelinating	GBS	cases	with	sparse	endoneurial	T-cell	inflammation	[7].	Overall,	these	clinical	studies
suggest	heterogeneity	in	T-cell	inflammation	and	pathogenesis	of	demyelinating	GBS.
In	 a	 related	 series	 of	 experimental	 studies,	 Saida	 and	 colleagues	 showed	 that	 inflammatory
demyelinating	neuropathy	can	be	induced	in	experimental	animals	without	prominent	T-cell	inflammation
[8,9,10].	 In	 their	 studies,	 rabbits	 immunized	 with	 galactocerborside	 (GalC)	 developed	 anti-GalC
antibody-mediated	 demyelinating	 neuropathy,	 which	 was	 complement	 dependent.	 Notably,	 macrophage
recruitment	and	macrophage-mediated	myelin	phagocytosis	was	prominent	in	these	studies	as	well.
In	 sum,	 T-cell	 inflammation	 could	 significantly	 vary	 in	 demyelinating	 GBS	 and	 both	 T	 cells	 and





Heininger	 and	 colleagues’	 important	 study	 showed	 that	 macrophages	 are	 essential	 to	 endoneurial
inflammation	and	nerve	fibre	damage	in	adoptive	EAN	[11].	A	number	of	studies	prior	to	this	publication
had	 shown	 the	 effector	 role	 of	macrophages	 in	 active	 EAN	 [12].	 Active	 EAN	with	myelin	 or	myelin
protein	 immunization	 include	an	 induction	phase	of	 the	autoimmune	response	 to	myelin	antigens,	during
which	 macrophages	 play	 an	 important	 role	 as	 antigen-presenting	 cells	 to	 the	 lymphocytes	 (adaptive
immune	 arm).	 The	 AT-EAN	 paradigm	 precludes	 the	 antigen-presenting	 role	 of	 macrophages	 as	 a
mechanism	 of	 protection	 in	 this	 model.	 This	 Heininger	 study	 supports	 the	 hypothesis	 that	 adoptively
transferred	T	cells	interact	with	macrophages	at	amplification	and	effector	phases	in	this	paradigm,	and
thus	 that	macrophages	are	key	components	of	endoneurial	 inflammation	 that	mediate	myelin/nerve	 fibre
injury.	This	and	other	EAN	studies	by	the	same	group	support	the	notion	that	macrophages	induce	myelin




Spies	 and	 colleagues’	 influential	 study	 demonstrates	 that	 local	 inflammatory	 milieu	 is	 important	 in
mediating	 antibody-induced	 demyelination	 [15].	 Myelin	 protein	 P2	 reactive	 T	 cells	 were	 injected
intraneurally	and	 rabbit	EAN	serum	containing	anti-GalC	activity	was	administered	systemically	 (i.p.),
which	 led	 to	 focal	 demyelination	 detected	 by	 electrophysiology	 and	 pathology.	 Similar	 changes	 in
endoneurial	 milieu	 could	 be	 obtained	 with	 activated	 T	 cells	 specific	 for	 non-neural	 antigens,	 again




Introducing	 the	 concept	 of	 axonal	 GBS	 in	 the	 absence	 of	 T-cell	 inflammation,	 Feasby	 and	 colleagues
describe	7	patients	with	acute	neuropathic	illness	with	motor	predominant	phenotype	(similar	to	Landry’s
cases)	and	axonal	electrophysiology	and	pathology	[16].	The	detailed	pathological	studies	on	autopsied
materials	 in	 one	 case	 showed	 primary	 axonal	 degeneration	 without	 significant	 demyelination	 or
lymphocytic	 inflammation.	Predominant	motor	 axonal	 involvement	was	confirmed	by	electrophysiology
(inexcitable	motor	 nerves)	 and	 anterior	 root	 and	 phrenic	 (motor)	 nerve	 pathology.	 Notably,	 this	 study
directly	 correlated	 the	 severity	 of	 axonal	 injury	 with	 poor	 recovery.	 The	 authors	 opined	 that	 one
mechanism	for	 inexcitable	motor	nerves	 is	an	 increase	 in	 the	 threshold	of	excitation	of	 the	nerve	fibres





Nobuhiro	 Yuki	 and	 colleagues	 reported,	 for	 the	 first	 time,	 a	 triad	 of	 acute	 axonal	 motor	 neuropathy,
preceding	Campylobacter	 infection,	 and	 IgG	 anti-GM1	 antibodies	 [18].	 This	 small	 but	 pivotal	 study
(based	 on	 2	 cases)	 wielded	 huge	 influence	 in	 this	 area	 of	 research.	 The	 triad	 recognized	 in	 this
observational	 study	 forms	 the	 basis	 of	 the	 now	well-accepted	 hypothesis	 of	molecular	mimicry	 as	 the
pathogenetic	mechanism	for	axonal	and	Fisher	variants	of	GBS.	A	large	number	of	experimental	studies
have	 established	 that	 Campylobacter	 jejuni	 lipooligosaccharides	 carry	 ganglioside-like	 moieties










consisted	 of	 lengthening	 of	 the	 node	 of	 Ranvier	 with	 distortion	 of	 the	 paranodal	myelin,	 and	 in	 some
instances	 breakdown	 of	 the	 outermost	 myelin	 terminal	 loops.	 At	 this	 stage	many	 nodes	 had	 overlying
macrophages	which	extended	 their	processes	 through	 the	Schwann	cell	basal	 lamina	covering	 the	node
and	 apposed	 the	 axolemma.	 At	 later	 time	 points	 macrophage	 processes	 extended	 beneath	 the	 myelin
terminal	 loops	 and	 the	 whole	 macrophage	 entered	 the	 periaxonal	 space	 at	 the	 paranode.	Macrophage
processes	 dissected	 the	 axon	 from	 the	 adaxonal	 Schwann	 cell	 plasmalemma	 and	 the	 macrophages
advanced	 into	 the	 internodal	periaxonal	 space,	where	 they	 typically	 surrounded	a	condensed-appearing
axon.	 This	 association	 of	 macrophage	 and	 axons	 appeared	 to	 be	 stable	 for	 some	 time,	 and	 the	 axons









time	 points	 after	 the	 onset	 of	 the	 disease	 [20].	 Whether	 early	 complement	 component(s)	 deposits	 at
structural	 specializations	 along	 myelinated	 axons	 originate	 from	 circulation	 or	 adjacent
microglial/macrophage	 cells	 in	 the	 endoneurium	 and/or	 perinodal	 and	 periaxonal	 spaces	 is	 not
established.	It	has	been	shown	previously	that	macrophage	populations	can	synthesize	and	secrete	various







In	 this	 study	 Yuki	 and	 colleagues	 report	 an	 animal	 model	 of	 post-infectious	 autoimmune	 neuropathy
induced	by	immunization	of	rabbits	with	C.	jejuni	 lipooligosaccharide-bearing	GM1-like	moieties	[21].
These	 animals	developed	 IgG	anti-GM1	antibodies,	which	were	 associated	with	paralytic	disease	 and
peripheral	 neuropathy	 with	 overlapping	 pathological	 features	 with	 axonal	 GBS,	 including	 periaxonal
macrophages	characteristic	of	 the	human	disorder.	These	studies	provide	strong	support	for	 the	concept
that	axonal	GBS	are	post-infectious	disorders	 in	which	humoral/antibody	directed	against	carbohydrate
antigens	 shared	 by	 peripheral	 nerve	 fibres	 and	 infectious	 agents	 induce	 axonal	 neuropathy.	 Whether
autoantibodies	against	gangliosides	are	by	themselves	sufficient	to	induce	nerve	damage	or	require	other
effectors	 of	 the	 innate	 immune	 system	 was	 not	 established	 in	 this	 study.	 The	 presence	 of	 periaxonal




The	 background	 for	 the	 study	 by	 Zhang	 and	 colleagues	 is	 that	 our	 translational	work	 initially	 focused
narrowly	on	establishing	reproducible	passive	transfer	animal	models	of	AGA-mediated	nerve	injury	in
the	context	of	axonal	GBS	[22].	Reproducing	human	pathology	in	mouse	models	has	been	daunting.	Early
on	we	 learned	 that	 passive	 transfer	 of	AGAs	 in	 small	 laboratory	 animals	 did	 not	 produce	neuropathic
disease.	This	 led	us	 to	 study	 the	pathogenic	 effects	 of	AGAs	 in	 a	nerve	 crush	model,	 as	nerve	 stumps
distal	 to	 the	crush	site	have	an	inflammatory	milieu	due	to	recruitment	of	macrophages	and	virtually	no
BNB	integrity.	We	showed	that	passive	transfer	of	AGAs	(experimental	and	human)	impair	nerve	repair
and	 severely	 inhibit	 axon	 regeneration	 [23,24].	 The	 primary	 intent	 of	 these	 studies	 was	 to	 show	 that
passive	transfer	of	AGAs	has	deleterious	effects	on	nerve	fibres	and	this	antibody-mediated	nerve	fibre
injury	 is	 dependent	 upon	 endoneurial	 inflammatory	 milieu	 (including	 recruited	 macrophages).	 An
implication	of	 these	findings	was	 that	 they	echo	the	clinical	association	of	AGAs	and	poor	recovery	in
GBS.
The	 goal	 of	 the	Zhang	 and	 colleagues	 study	was	 a	 careful	 dissection	 of	 a	 nerve	 crush	model	 using
various	 mutant	 and	 transgenic	 mice	 with	 an	 altered	 expression	 of	 specific	 FcγRs	 and
macrophage/microglia	 populations	 and	 nerve	 transplant	 strategy,	 to	 demonstrate	 that	 the	 presence	 of
AGAs	in	the	injured	mammalian	peripheral	nerves	switch	the	proregenerative	inflammatory	environment
to	 growth	 inhibitory	 milieu	 by	 engaging	 specific	 activating	 FcγRs	 on	 recruited	 monocyte-derived
macrophages	to	cause	severe	inhibition	of	axon	regeneration.	A	fundamental	principle	learned	from	this
series	 of	 nerve	 crush	 studies	 was	 that	 inflammatory	 milieu,	 primarily	 consisting	 of	 activated	 FcγR-
bearing	 macrophage/microglia,	 are	 critical	 mediators	 of	 Ab-mediated	 nerve	 injury.	 These	 data
demonstrate	 that	 the	 passive	 transfer	 of	 AGAs	 can	 induce	 neuropathic	 injury,	 but	 endoneurial




The	 ‘inflammatory	milieu’	hypothesis	 stemming	 from	 the	 crush	model	discussed	 above	was	 tested	 in	 a
new	 AGA-mediated	 passive	 transfer	 mouse	 model	 induced	 by	 L5	 spinal	 nerve	 transection	 (L5SNT;
modified	 Chung’s	 model)	 to	 study	 AGAs	 effects	 on	 intact	 nerve	 fibres	 [25].	 L5SNT	 causes	 the
degeneration	of	a	small	proportion	of	 fibres	 that	constitute	 the	sciatic	nerve	and	 its	branches,	but	more
importantly	sets	up	an	 inflammatory	milieu	 in	 the	endoneurium.	Our	studies	 indicate	 that,	 in	 this	mouse
model,	AGAs	 induce	 sequential	 nodal	 (early)	 and	 then	 axonal	 (late)	 injury	 of	 intact	myelinated	 nerve
fibres,	recapitulating	pathologic	features	of	human	disease.	Notably,	macrophages	were	seen	adjacent	to
widened	 nodes	 of	Ranvier	 at	 early	 time	 points.	 Importantly,	 our	 studies	 showed	 that	 immune	 complex
formation,	macrophage/microglia	 and	 the	 activating	 FcγRs	were	 involved	 in	 the	AGA-mediated	 nodal








injury	 to	 the	 nodes	 of	 Ranvier	 in	 both	 demyelinating	 and	 axonal	 variants	 of	 the	 disease.	 Although
macrophages	in	the	vicinity	of	the	nodes	are	well	documented	in	axonal	cases,	whether	the	nodal	injury	is
macrophage	contact-dependent	and/or	 -independent	and	 the	 the	precise	molecular	mechanisms	of	nodal
injury	in	this	situation	are	not	well	defined	for	either	axonal	or	demyelinating	cases	of	GBS.	Monocyte-
derived	macrophages	appear	to	be	important	effectors	of	nerve	injury	in	experimental	studies	of	EAN	and
anti-ganglioside	 antibody-mediated	 nerve	 injury	 models.	 T-cell	 inflammation	 orchestrates	 endoneurial
inflammation	and	macrophage	recruitment	in	EAN	and	probably	in	AIDP	cases	with	T-cell	inflammation.
How	macrophages	mediate	Schwann	cell/myelin	 injury	 is	not	 completely	understood.	The	pathological
studies	 favour	 both	 chemical	 (cell	 contact-independent)	 and	 phagocytic	 (cell	 contact-dependent)
macrophage-mediated	 injury	 to	myelin	 compartment	 in	demyelinating	variants	of	GBS,	but	mechanisms
and	 molecular	 actors	 involved	 in,	 perhaps,	 the	 dichotomous	 injury	 to	 Schwann	 cells/myelin	 are	 not
completely	understood.
How	endoneurial	 inflammation	and	macrophage	 recruitment	 is	accomplished	 in	AIDP	cases	without
prominent	 T-cell	 inflammation	 and	 axonal	 variants	 of	 GBS	 is	 a	 key	 question,	 which	 to	 a	 large	 part
remains	 unaddressed.	 Could	 endoneurial	 glia	 (including	 microglia)	 be	 activated	 by	 soluble	 signals
diffusing	from	systemic	immune	compartment	and	subsequently	set	up	endoneurial	inflammation	including
macrophage	 recruitment	 in	 these	 situations?	 Our	 studies	 in	 Chung’s	 (L5SNT)	model	 show	 that	 partial
nerve	 injury	 generates	 endoneurial	 signals	 that	 recruit	 macrophages	 from	 circulation	 and	 set	 up
inflammatory	milieu	 in	 the	nerve.	Moreover,	our	experimental	 studies	 in	 the	context	of	anti-ganglioside
antibodies	and	axonal	injury	indicate	that	activating	FcγRs	on	macrophage	populations	are	key	molecular
effectors	mediating	nerve	injury.	Whether	the	macrophage	and	activating	FcγRs	interactions	with	immune
complexes	 formed	on	nerve	 fibres	are	 random	or	other	molecular	 signals	abet	 in	 this	process	 (such	as
complement	 activation	 products)	 acting	 as	 chemoattractants	 for	 directing	 the	 macrophages	 within
endoneurium	to	specific	sites	along	the	nerve	fibres	remains	to	be	established.	Moreover,	the	kinetics	and
evolving	 phenotype(s)	 (pro-inflammatory,	 anti-inflammatory	 or	 in	 between	 these	 polarized	 states)	 of
macrophage/microglial	cells	in	the	endoneurial	compartment	of	intact	and	injured/diseased	nerves	are	not
well	defined.	The	molecular	effectors	of	nerve	fibre	injury	downstream	of	macrophage-immune	complex
interactions	are	also	not	elucidated.	 It	appears	more	 than	one	 inflammatory	pathway	at	 the	motor	nerve
terminal	 and	 in	 the	 endoneurium	can	produce	 similar	pathologic	 reactions	 (nodal	 and	axonal	 injury)	 in
experimental	models,	as	indicated	by	a	series	of	elegant	studies	with	AGAs	and	complement	[26,27,28].









































































(the	 authors)	 started	 investigating	 the	 possibility	 that	 Guillain-Barré	 syndrome	 (GBS)	 associated	 anti-
ganglioside	antibodies	could	injure	the	motor	nerve	terminal,	we	marshalled	our	thoughts	around	existing
studies	that	might	support	such	an	idea,	of	which	there	were	many.	We	gathered	techniques	and	reagents
that	had	been	previously	developed	and	used	 to	 study	neuromuscular	 synaptic	 function	 in	 experimental
mouse	preparations,	and	applied	them	to	investigate	our	hypotheses.	In	doing	so	we	quickly	realised	that
pretty	much	everything	we	thought	about	had	already	been	thought	about	by	someone	before	us,	and	we
















is	 greatly	 aided	 by	 the	 logical	 layout	 of	 the	 members	 of	 the	 complex	 and	 large	 ganglioside	 family
described	 by	 Lars	 Svennerholm,	 one	 of	 the	 founding	 fathers	 of	 ganglioside	 biochemistry	 [3].	 His
classification,	 based	 on	 the	 migration	 pattern	 seen	 on	 thin	 layer	 chromatography,	 is	 still	 widely	 used








this	 system	 to	 work	 out	 key	 aspects	 of	 the	 quantal	 theory	 of	 neurotransmission	 [5]	 for	 which	 he	 was
awarded	 the	 Nobel	 Prize	 for	 Physiology	 or	Medicine	 in	 1970	 (jointly	 with	 Ulf	 von	 Euler	 and	 Julius
Axelrod).	Our	studies	on	the	electrophysiological	effects	of	anti-ganglioside	antibodies	at	neuromuscular
junctions,	 first	performed	with	 the	Miller	Fisher	syndrome	sera	 in	Oxford,	and	subsequently	 in	Leiden,
relied	heavily	on	the	classical	technical	and	theoretical	knowledge	of	this	process	provided	by	Katz.	The





tetanus	 neurotoxins	 exert	 their	 paralytic	 effects	 by	 first	 binding	 to	 the	 presynaptic	 membrane	 at
neuromuscular	 junctions;	 (B)	 that	 these	 toxins	bind	complex	gangliosides	 [6];	and	(C)	 that	gangliosides




be	 the	 case	 was	 a	 lot	 more	 complicated	 than	 developing	 the	 idea.	 Similarly,	 the	 development	 of
knowledge	about	botulinum	neurotoxin	binding	to	cholinergic	nerve	terminals	was	a	longstanding	process
that	 has	 gradually	 evolved	 since	 the	 1960s	 and	 still	 remains	 an	 interesting	 area	 for	 research	 today,
particularly	 with	 the	 booming	 use	 of	 botulinum	 neurotoxins	 in	 medical	 and	 cosmetic	 applications.
Specific	 ganglioside	 binding	 sites	 have	 now	 been	 identified	 on	 the	 neurotoxin	molecule,	 as	well	 as	 a
mechanism	 of	 secondary	 binding	 to	 synaptic	 vesicles	 proteins	 when	 they	 become	 exposed	 to	 the
extracellular	 environment	 during	neuroexocytosis.	Contemporaneous	 studies	 on	 cholera	 toxin	B	 subunit
binding	to	GM1	ganglioside,	and	its	use	for	localisation	of	GM1	including	nerve	terminals	and	nodes	of




Continuing	 on	 the	 toxin	 theme,	 the	 use	 of	 a	 wide	 range	 of	 neurotoxins	 has	 been	 germane	 to
electrophysiological	 studies	 on	 both	 neuromuscular	 synapse	 and	 nodal	 function	 over	 many	 decades.
Professor	Chang	from	National	Taiwan	University,	Taipei,	clearly	merits	 recognition	for	his	discovery,
reported	 in	 the	early	1960s	 (with	CY	Lee),	 that	 a	 fraction	 in	 the	venom	of	 the	banded	krait,	Bungarus
multicinctus,	 irreversibly	 blocked	 nicotinic	ACh	 receptors	 [7].	 The	 reference	we	 include,	 rather	 than
reverting	 to	 the	 primary	 literature	 (which	 at	 the	 time	 was	 rejected	 by	 the	 Journal	 of	 Physiology!),
comprises	a	delightfully	 insightful	and	very	 funny	 retrospective	account	of	Professor	Chang’s	 scientific
adventures	 that	 we	 recommend	 as	 a	 must-read	 for	 all	 interested	 in	 this	 area.	 The	 fraction,	 called	 α-













The	 recurring	 theme	 of	 toxins	 must	 include	 reference	 to	 the	 electrophysiological	 and	 morphological
effects	of	α-Latrotoxin,	a	neurotoxic	component	of	the	venom	of	the	black	widow	spider	venom.	Frontali
and	colleagues	[8]	purified	a	protein	fraction	from	the	venom	that	was	highly	toxic	for	mice	and	showed
that	 this	 factor	 was	 responsible	 for	 the	 depletion	 of	 synaptic	 vesicles	 from	 motor	 nerve	 terminals,
associated	with	a	tremendous	increase	in	the	frequency	of	miniature	endplate	potentials,	shown	before	by
others	with	the	whole	venom.	Later	studies	showed	that	one	of	the	toxin’s	mechanisms	of	action	is	to	form
a	 tetrameric	pore	 that	 causes	uncontrolled	presynaptic	 influx	of	Ca2+,	 stimulating	 neuroexocytosis.	 The
similarity	 between	 the	 effects	 of	 this	 α-Latrotoxin	 and	 the	 action	 of	 anti-ganglioside	 autoantibody
containing	 the	Miller	 Fisher	 syndrome	 sera	 (and	 later,	 acute	motor	 axonal	 neuropathy	 sera	 as	well	 as
corresponding	 anti-ganglioside	monoclonal	 antibodies	 generated	 by	 us)	 in	 the	 presence	 of	 complement
activation	is	remarkable.	It	allowed	us	to	build	up	a	model	of	presynaptic	membrane	injury	resulting	from
pore	 formation	 with	 aberrant	 Ca2+	 influx.	 The	 electron	 micrographs	 of	 nerve	 terminals	 are	 virtually
identical	 between	 the	 2	 conditions,	 i.e.,	 swollen	 terminals	 devoid	 of	 synaptic	 vesicles.	 Similarly,	 the
electrophysiological	phenotypes	are	identical,	i.e.	the	‘explosion’	of	miniature	endplate	potentials	for	tens





other	 autoantibody-mediated	 disorders.	 Clearly	 this	 especially	 refers	 to	 the	 complement-fixing
immunoglobulin	isotypes	and	subclasses,	notably	IgM	and	IgG1-3.	Elucidating	the	role	of	complement	in




an	autoimmune	situation,	at	nerve	membranes	 in	particular,	 it	 appears	 to	be	highly	 toxic,	disturbing	 the
ionic	 balance	 between	 intra-	 and	 extracellular	 compartments	 and	maintenance	 of	 the	 resting	membrane
potential.	 In	 this	 review	 paper,	 Podack	 and	 Tschopp	 presented	 beautiful	 ultrastructural	 images	 and	 a






We	 are	 only	 now	beginning	 to	 understand	why	 anti-glycolipid	 antibody-containing	 sera	 collected	 from
clinically	affected	GBS	cases	may	not	be	the	best	source	of	antibodies	for	investigating	neurotoxic	effects
in	 GBS.	 Very	 early	 on	 in	 our	 joint	 studies	 we	 invested	 considerable	 time	 in	 isolating	 monoclonal
antibodies	 reactive	 with	 neural	 gangliosides,	 also	 relying	 heavily	 on	 the	 GM2/GD2	 synthase	 mice




trawling	 through	 panels	 of	 our	 anti-ganglioside	monoclonal	 antibodies	 trying	 to	 understand	 why	 some
have	 effects	 whereas	 others	 do	 not.	 The	 ability	 to	 accurately	 apply	 fixed	 concentrations	 of	 known









The	development	of	 transgenic	mice	 that	 lack	glycosyltransferases	 involved	 in	ganglioside	biosynthesis
has	 allowed	 researchers	 to	 uncover	 hitherto	 unknown	 functions	 of	 gangliosides.	A	 preplanned	meeting
with	Koichi	 and	Keiko	Furukawa	 at	 the	Gordon	Research	Conference	on	Glycolipid	 and	Sphingolipid
Biology	in	2000	provided	the	opportunity	for	us	 to	use	 the	GM2/GD2	synthase	knockout	mice	 they	had
recently	 developed	 that	 lacked	 complex	 gangliosides	 [11].	No	 other	 single	 animal	 tool	 has	 been	more
important	 to	 us	 than	 these	mice.	 Similar	 studies	 have	 been	 conducted	 by	 other	GBS	 researchers	 using
mice	 generated	 contemporaneously	 by	 the	 Proia	 group	 at	 NIH.	 GM2/GD2	 synthase	 knockout	 mice
develop	sensory	and	motor-coordination	deficiencies	upon	aging.	Despite	prior	suggestions	that	complex
gangliosides	 were	 key	 components	 of	 the	 presynaptic	 apparatus,	 it	 turned	 out	 that	 gangliosides	 are
remarkably	 redundant	 in	 supporting	 neurotransmitter	 release	 at	 the	 neuromuscular	 junction.	 Even	 total
ganglioside	 ablation	 (obtained	 by	 crossing	GM2/GD2	 synthase	KO	mice	with	GD3	 synthase	 knockout
mice	 and	 treating	 their	 nerve-muscle	 preparations	 with	 neuraminidase	 to	 destroy	 the	 only	 remaining
ganglioside	 GM3)	 resulted	 in	 only	mild	 changes	 in	 ACh	 release	 from	 the	motor	 nerve	 terminal.	 This







Monoclonal	 antibodies	 targeted	 against	 tumour	 cell-specific	 antigens	 have	 long	 been	 considered	 to	 be
magic	 bullets	 for	 therapy	 development.	Whilst	 the	GBS	 field	 has	 been	working	 out	 how	 to	 stop	 anti-









antibodies,	 showing	 that	 some	 of	 these	 can	 only	 exert	 neuropathophysiological	 effects	 at	 motor	 nerve









studying	this	field,	making	us	realise	 that	 the	motor	nerve	 terminal	was	a	highly	dynamic	structure	with
very	rapid	rates	of	membrane	turnover	[13].	Once	a	ligand,	in	our	case	a	GBS-associated	anti-ganglioside
autoantibody,	in	another	case	perhaps	a	neurotoxin	or	virus,	has	landed	on	the	presynaptic	membrane,	how
quickly	 is	 it	 endocytosed?	 Is	 it	 then	 recycled	 to	 the	 plasma	 membrane	 or	 destined	 for	 a	 retrograde
trafficking	pathway?	This	remains	an	area	of	great	interest,	almost	30	years	after	this	beautiful	paper	was





has	been	a	 totally	engaging	and	 interesting	aspect	of	GBS	research.	Perhaps	most	 importantly,	we	each
also	gained	 a	highly	 trusted	 and	 lifelong	 friend.	We	are	 the	 first	 to	 acknowledge	 the	 limitations	of	 our
experiments	and	have	regularly	been	challenged,	quite	 rightly,	about	 the	clinical	 relevance	of	 the	nerve
terminal	as	a	site	of	 injury	in	GBS	patients	and	its	variants.	Now	is	not	 the	time	to	argue	a	case	for	or
against.	Perhaps	more	 simply	 it	 is	 the	 time	 to	quote	 the	 immortal	 lines	 from	 ‘The	Adventure	of	Silver






Paraphrased	 for	 the	 current	 context,	 hypothesis-driven	 scientific	 enquiry	 perhaps	 provides	 more
information	when	the	results	are	negative,	than	when	they	are	positive.
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In	 the	 100	 years	 since	GBS	was	 first	 described,	GBS	 research	 has	 advanced	 significantly	 from	 basic
electrophysiology	studies	 to	 the	 identification	of	 the	pathological	pathways	 involved	 in	 the	onset	of	 the
disease.	Arguably,	one	of	the	most	important	discoveries	in	the	history	of	GBS	was	the	association	of	the










first	 researcher	 to	describe	gangliosides,	which	he	 isolated	 from	 the	organs	of	patients	with	Niemann-
Pick	 and	 Tay-Sachs	 disease	 [1],	 but	 his	work	was	 reinforced	 by	 that	 of	 a	 Swedish	 researcher	 named
Gunnar	Blix,	who	was	the	first	person	to	identify	sialic	acid	[2].
Klenk	 initially	 called	 his	 unknown	 lipid	 ‘Substanz	X’and	 found	 that	 it	 formed	black	 humin	when	 it
underwent	acid	hydrolysis	and	produced	a	purple	colour	when	heated	with	Bial’s	reagent.	Blix,	following
on	 from	his	 sialic	 acid	 discovery,	 also	 isolated	 a	 compound	 from	bovine	 brain	 that	 he	 believed	 to	 be
‘Substanz	X’,	but	he	also	noted	the	similarities	between	this	compound	and	sialic	acid	[3].
As	 a	 result	Blix	 compared	 both	 compounds	 using	Bial’s	 and	Ehrlich’s	 reagents	 and	 found	 that	 they
produced	 the	 same	 colours.	 Based	 upon	 this	 observation,	 he	 postulated	 that	 sialic	 acid	 was	 a	 major
component	 of	 ‘Substanz	 X’,	 but	 Klenk	 disagreed.	 He	 had	 isolated	 a	 similar	 compound,	 termed
‘neuraminic	acid’,	which	he	believed	to	be	a	major	component	of	the	lipid	[4].




The	rivalry	between	Klenk	and	Blix	persisted	for	several	years	as	 they	 investigated	 the	structure	of
gangliosides.	 Ultimately,	 both	 competitors	 were	 proven	 right,	 as	 Klenk	 demonstrated	 that	 N-acylated
neuraminic	acid	was	a	major	component	of	gangliosides,	whilst	Blix	showed	that	all	acylated	neuraminic
acids	 were	 sialic	 acids	 [6].	 Regardless	 of	 their	 competitiveness,	 both	 scientists	 made	 important
contributions	to	ganglioside	research,	which	helped	set	the	topic	on	the	right	path.
What	Is	in	a	Name?
Following	 on	 from	 the	 fiery	 beginnings	 of	 gangliosides,	 our	 focus	 shifts	 to	 one	 of	 the	 lipids’	 more
important	 aspects,	 its	 nomenclature.	As	more	 gangliosides	were	 discovered	 it	 became	 apparent	 that	 a
unified	naming	system	was	required	to	simplify	their	identification	in	the	literature.	This	task	was	taken





size	 of	 the	 oligosaccharide	 chain.	 Finally,	 a	 lowercase	 letter	 denotes	 the	 isometric	 arrangement	 of	 the
sialic	acids	on	the	headgroup;	for	example	GQ1b	[8].
GM1	and	Cholera	Toxin:	A	Toxic	Relationship


















tissue	 from	 these	mice	 indicated	 that	 the	 complex	 gangliosides	 did	 not	 have	 roles	 in	 organogenesis	 or
morphogenesis.	 However,	 there	 was	 a	 reduction	 in	 neuronal	 conduction	 velocity,	 suggesting	 that
gangliosides	had	a	role	in	normal	neuronal	function.














It	 was	 discovered	 through	 biochemical	 analysis	 and	 immunofluorescence	 studies	 that	 GQ1b	 was
enriched	 in	 the	 oculomotor	 and	 cranial	 nerves	 in	 humans	 [14,15].	 The	 close	 association	 of	 these







As	 the	 use	 of	 ELISAs	 increased	 as	 a	 diagnostic	 tool,	 it	 became	 apparent	 that	 discrepancies	 existed
between	 different	 laboratories.	 Although	 both	 clear	 positive	 and	 negative	 results	 tended	 to	 remain
consistent,	 intermediate	 signals	 could	 vary	 25-fold,	 which	 raised	 questions	 about	 the	 validity	 of	 the
results.
In	 an	 attempt	 to	 address	 this	 problem,	Willison	 and	 colleagues	 produced	 a	 standardised	 ELISA	 in
conjunction	with	 the	 other	 laboratories	 that	 formed	 the	 European	 Inflammatory	Neuropathy	 Cause	 and
Treatment	 (INCAT)	 group	 [16].	 Using	 this	 method,	 they	 were	 able	 to	 reduce	 the	 variation	 between
laboratories;	however,	there	was	an	internal	laboratory	error	rate	of	41%.









was	 not	 until	 the	 discovery	 of	 anti-ganglioside	 antibodies	 that	 researchers	 were	 able	 to	 adequately
explain	 this	 link.	Based	upon	 the	 similarities	 between	 the	 lipooligosaccharide	 (LOS)	 coats	 of	 bacteria








proved	 that	 the	 antibodies	 detected	 in	 patient	 sera	 were	 relevant	 to	 the	 induction	 of	 GBS.	 This	 also
supported	 the	 research	 being	 performed	 by	 other	 groups	 and	 substantiated	 the	 use	 of	 monoclonal
antibodies	in	GBS	models.
A	Little	More	Complication,	a	Little	More	Action
Following	 the	 discovery	 of	 anti-GQ1b	 antibodies	 in	 MFS,	 researchers	 began	 screening	 other	 GBS
patients	for	anti-ganglioside	antibodies.	Whilst	a	number	of	these	were	found	against	a	variety	of	targets,
they	were	rarely	found	in	as	high	numbers	as	in	MFS.	In	an	attempt	to	overcome	this	problem	and	improve
antibody	detection,	 a	 Japanese	 research	group	 screened	patient	 sera	 against	 complexes	 composed	of	 2
different	gangliosides	[20].
They	found	that	a	number	of	patients	had	antibodies	which	bound	to	GD1a:GT1b	complexes	without
binding	 to	 the	single-constituent	gangliosides.	The	authors	proposed	 that	 these	antibodies	differed	 from
regular	anti-ganglioside	antibodies	in	that	they	likely	bound	to	clustered	epitopes	formed	by	components
of	both	gangliosides	rather	than	to	an	epitope	expressed	by	just	one.
This	 was	 a	 completely	 novel	 concept	 that	 opened	 up	 new	 avenues	 in	 GBS	 research.	 Antibodies
specifically	 targeting	 ganglioside	 complexes	 were	 found	 in	 other	 autoimmune	 neuropathies	 and	 were
linked	to	different	clinical	outcomes	[21,22,23].	In	addition,	antibody	detection	increased	in	patient	sera
which	improved	the	performance	of	clinical	assays.
This	 discovery	 also	 changed	 researcher’s	 viewpoints	 of	 how	 gangliosides	 exist	 in	 the	 membrane.
Rather	 than	 being	 expressed	 in	 standalone	 formations,	 gangliosides	 are	 likely	 to	 form	 complexes	with
neighbouring	 lipids	and	proteins,	which	will	affect	 their	presentation	 to	 the	 immune	system.	The	use	of








This	 was	 shown	 in	 particular	 with	 GD1a,	 which,	 due	 to	 its	 terminal	 sialic	 acid,	 prevented	 the
exposure	of	certain	epitopes	on	the	GM1	molecule.	When	the	tissue	was	treated	with	neuraminidase	this




assessing	 the	 sites	 of	 injury	 in	 different	 autoimmune	 neuropathies	 and	 determining	 the	 relevance	 of
clinical	data	in	disease	pathogenesis.	The	work	derived	from	this	research	is	therefore	ongoing.
Conclusion
Gangliosides	 are	 an	 essential	 component	 of	 life	 and	 have	 important	 roles	 in	 neuroregulation,	 signal
transduction,	and	maintenance	and	repair	of	the	nervous	system.	As	a	result	they	are	abundantly	expressed


























































Ever	 since	 intravenous	 immunoglobulin	 (IVIg)	 proved	 to	 have	 an	 elusive	 immune	modulatory	 effect	 in
many	 inflammatory	diseases,	 there	has	been	an	ongoing	 rat	 race	 (quite	 literally,	given	 the	many	animal
studies)	to	find	the	mechanism	of	action.	IVIg	has	pleiotropic	effects	on	the	activated	immune	system,	and
every	 year	 more	 and	 more	 potential	 mechanisms	 are	 added	 to	 the	 list.	 One	 may	 wonder	 if	 all	 these
reported	effects	of	IVIg	actually	hold	true	in	all	the	numerous	disorders	it	is	prescribed	for,	and	in	every
single	 patient.	 In	 spite	 of	 this	 continuous	 quest	 to	 decipher	 the	 pharmacodynamics	 of	 IVIg,	 its





high	 levels?	Where	 does	 IVIg	 in	 the	 body	 go?	 Should	we	 dose	 higher	 or	 lower?	 Should	we	 base	 our
dosage	 on	 something	 other	 than	 bodyweight?	 Answering	 these	 basic	 questions	 regarding	 the	 dosing,
distribution	and	metabolism	of	 IVIg	 is	prudent	 to	 fine-tuning	 this	 therapy.	So	where	do	we	stand	 today
regarding	the	pharmacokinetics	of	IVIg?
Intravenous	Immunoglobulin
IVIg	 is	 not	 a	 typical	 pharmaceutical	 drug,	 but	 a	 preparation	of	 pooled	human	 immunoglobulin	G	 (IgG)
obtained	 from	 thousands	 of	 blood	 donors.	 Depending	 on	 the	 product,	 IVIg	 mostly	 consists	 of	 IgG	 (>
95%),	with	 the	 addition	of	 sodium	and/or	 stabilizers,	 and	 trace	 amounts	 of	 other	molecules	 [2].	 Since
treatment	 of	 GBS	 with	 IVIg	 proved	 equal	 to	 plasma	 exchange	 [3],	 the	 products	 underwent	 several
modifications.	Currently	most	products	are	in	liquid	form,	which	has	the	advantages	of	being	storable	at
room	temperature,	a	longer	shelf-life,	an	increased	infusion	rate	and	possibly	fewer	adverse	events	[4,5].





in	 selecting	 a	 particular	 product	 [11].	 However,	 sufficient	 data	 on	 clinical	 efficacy	 of	 different	 IVIg
products	are	lacking	[12],	and	products	are	known	to	differ	from	each	other	in	various	aspects.	Regarding
IVIg	 as	 just	 a	 generic	 product	 is	 therefore	 an	 oversimplification;	 choosing	 a	 product	 that	 is	 readily
available	(or	least	expensive)	can	very	well	impact	efficacy	and/or	responsiveness	to	treatment	[13].	One




the	 finding	 that	 increases	 in	 IgG	 levels	 2	weeks	 following	 the	 start	 of	 a	 5-day	 course	 impacts	 clinical
outcomes	[14].	Patients	that	seem	to	clear	the	IVIg	faster	were	worse	off;	however,	an	explanation	for	this
large	 variation	 in	 pharmacokinetics	 is	 lacking.	 Identifying	 these	 patients,	 preferably	 before	 the	 start	 of







































Concurrent	 to	 all	 the	 work	 done	 on	 the	 catabolism	 of	 IgG,	 a	 different	 revolution	 occurred	 with
immunoglobulins	as	treatment,	either	as	pooled	polyvalent	immunoglobulins	or	eventually	as	monoclonal
antibody	(mAb).	The	former	was	successfully	used	as	replacement	therapy	in	an	immune-deficient	patient
lacking	 IgG	 in	 1952	 [30].	 Next	 to	 replacement	 therapy,	 an	 additional	 beneficial	 factor	 in	 fresh-frozen
plasma	 was	 suspected	 by	 several	 authors	 studying	 immune	 thrombocytopenia	 (ITP),	 typically	 a	 post-
infectious,	 acute	 but	 self-limiting,	 predominantly	 antibody	 mediated	 disease	 against	 glycoproteins	 on
platelets.	As	early	as	1933	it	was	noted	that	blood	transfusions	could	induce	disease	remission	in	acute
ITP,	 whilst	 stressing	 the	 necessity	 of	 repeated	 transfusions	 [31].	 Almost	 20	 years	 later	 it	 was	 first
speculated	 (to	my	 knowledge)	 that	 some	 factors	 in	 the	 transfused	 blood,	 other	 than	 platelets,	might	 be
responsible	for	the	beneficial	effect	(an	increase	in	platelets)	[32].	Closing	down	on	this	elusive	factor
was	 carried	 out	 by	 work	 from	Mila	 Pierce	 and	 colleagues,	 when	 she	 contemplated	 that	 the	 transient
beneficial	 effect	 in	a	patient	 (lasting	20–23	days)	 correlates	with	blood	 infusions	and	 that	 fresh-frozen
plasma	 (FFP,	 devoid	 of	 platelets)	 could	 also	 elicit	 this	 response	 [33].	 The	 authors	 discontinued




But	 IVIg’s	 current	 claim	 to	 fame	 came	 with	 successful	 treatment	 with	 intravenous	 immunoglobulin
(IVIg)	 of	 patients	 with	 ITP	 by	 Imbach	 and	 colleagues,	 causing	 a	 surge	 of	 interest	 in	 high-dose
immunomodulatory	 functions	 [1].	 Based	 on	 previous	 observations,	 the	 decision	 was	 made	 to	 treat	 a
patient	 refractory	 to	all	other	 treatments	with	a	course	of	 IVIg	 [35].	The	proposed	working	mechanism
was	the	requirement	of	a	large	amount	of	IgG	to	overload	and	block	the	reticuloendothelial	system	by	its
catabolism.	The	treatment	with	0.4	g/kg	of	bodyweight	(BW)	a	day	was	deduced	from	the	use	of	IVIg	as


















effect	 in	 ITP,	 there	 is	 a	 correlation	with	 a	 better	 effect	 and	 higher	 response	 rate	with	 increased	 doses
[44,45].	 Furthermore,	 for	 ITP,	 IgG	 levels	 within	 the	 normal	 range	 values	 (~6	 g/L—16	 g/L)	 seem
inadequate	to	halt	the	disease	[46].
Another	 disease	 treated	 with	 IVIg	 is	 Kawasaki’s	 disease	 (KD),	 suspected	 to	 be	 post-infectious	 in




rather	 than	 spreading	 the	 IVIg	 course	 over	multiple	 days.	 This	 also	 underscores	 the	 importance	 of	 the
pharmacokinetics	of	IVIg:	one	massive	boost	in	IgG	is	more	efficacious	here	than	multiple	smaller	peaks
[48].	Further	progress	 in	 this	 field	discriminates	between	patients	 requiring	either	1,	2	or	even	4	gr/kg
(for	initial	IVIg-resistant	patients)	of	IVIg	all	given	at	a	rate	of	1	gr/kg	BW	an	hour	[49].	The	‘luxury’	that
these	IVIg-treated	diseases	have	in	common	for	comparative	studies	are	relatively	easy	to	measure	and
are	 reliable	 clinical	 and	 physiological	markers	 for	 IVIg	 response,	 things	 sorely	 lacking	 in	 the	 field	 of
GBS	[50].
Nonetheless,	speculation	on	a	potentially	increased	efficacy	for	a	shorter	treatment	duration	was	made
immediately	 after	 proof	 of	 IVIg’s	 effectiveness	 in	 GBS	 [51].	 A	 small	 number	 of	 studies	 have	 been
performed	assessing	different	IVIg	regimens.	The	only	study	in	adults	compared	a	3-day	regimen	versus	a





no	 difference	 between	 2g/kg	 over	 2	 days	 versus	 the	 exact	 same	 amount	 over	 5	 days.	While	 the	 2-day
course	was	 safe,	 increased	 treatment-related	 fluctuations	were	 reported,	 and	 the	 authors	 speculated	 on
still	ongoing	disease,	not	sufficiently	covered	by	the	2	days	of	treatment	[53].	Yet,	this	hypothesis	could
not	be	proven	 since	 IgG	 serum	 levels	were	not	 available.	Also,	 this	 study	was	performed	 in	 children,
thought	to	have	a	relative	mild	disease	course	compared	to	adults	[54].	Children,	of	course,	also	differ
from	adults	in	their	body	composition	and	subsequently	in	a	key	pharmacokinetic	parameter:	the	volume
of	 distribution	 [55].	Dosing	 of	 IVIg	 however,	 is	 still	 based	 on	 actual	 bodyweight	 for	 all	 patients	 (NB





It	 seems	 that	 almost	 every	 aspect	 of	 GBS	 seems	 challenging	 to	 resolve,	 and	 this	 certainly	 applies	 to
treatment	with	IVIg.	Even	in	2016,	we	at	least	know	that	IVIg	works	and	that	a	prolonged	increment	in	IgG
levels	after	IVIg	seems	to	positively	affect	outcome	in	GBS.	Have	we	then	made	no	further	advancement
these	past	3	decades	of	 IVIg	 treatment	for	GBS?	That	 is	definitely	not	 the	case.	The	coming	years	will
allow	us	 to	clarify	 some	mysteries	concerning	 immunoglobulin	 therapy	 in	GBS.	Will	 a	 second	dose	of
IVIg	 be	 beneficial	 in	 severe	 patients?	 Will	 subcutaneous	 IgG,	 providing	 a	 more	 favourable
pharmacokinetic	profile	over	time,	offer	new	therapeutic	options?
In	addition,	improvements	and	alternatives	to	polyvalent	immunoglobulin	therapy	are	well	underway.
This	will	allow	us	 to	 finally	decrease	 the	enormous	 list	of	postulated	IVIg	working	mechanisms.	Some
promising	developments	with	 IgG-based	mAbs	 are	 eculizumab	 in	GBS,	 an	 IgG2/4	hybrid	 blocking	 the
complement	 cascade;	 a	mAb	 targeting	 the	 FcRn	 receptor,	 increasing	 the	 catabolism	 of	 auto-antibodies
[58];	and	mAbs	directed	against	FcyRIIb,	the	inhibitory	Fc-receptor	with	the	potential	to	enhance	existing
therapies	[59,60].	Alternatively	to	a	mAb	against	FcyRIIb,	a	recombinant	soluble	variant	of	this	receptor
is	 currently	 being	 tested	 for	 its	 anti-inflammatory	 effects	 [61].	 IVIg	 itself	 is	 also	 subject	 to	 potential
improvement:	 a	 highly	 sialylated	 version	 has	 been	 developed,	 aiming	 to	 exploit	 the	 anti-inflammatory
effects	described	when	this	carbohydrate	is	present	on	the	IgG	molecule	[62].	The	cationization	of	IVIg	is
also	being	explored,	which	should	increase	the	bio-distribution,	making	it	easier	for	IgG	to	enter	organs
or	cross	 the	blood-brain/nerve	barrier	 [63].	A	very	appealing	alternative	 is	an	 IVIg	biomimetic,	which
does	 not	 focus	 on	 one	mechanism	 of	 action,	 but	 rather	 is	 capable	 of	 binding	 or	 blocking	 a	 number	 of
receptors	and	complement	factors	[64].	It	is	hoped	that	one	of	these	directions	or	other	developments	not















































































































































Ganglioside	 research	 developed	 at	 the	 beginning	 of	 the	 20th	 century;	 however,	 it	was	 necessary	 to
wait	until	the	1960s	to	have	their	structures	elucidated.	Then,	this	family	of	glycoconjugates	immediately
attracted	 the	 interest	 of	 several	 scientists,	 whose	 work	 convincingly	 showed	 that	 gangliosides	 are
important	physiological	regulators	of	a	variety	of	neuronal	processes,	like	neuritogenesis,	synaptogenesis
and	cell-cell	interactions	such	those	involved	in	the	migration	of	neuronal	precursors	and	the	wrapping	of
myelin	around	axons.	 In	particular,	 the	 finding	 that	 the	administration	of	ganglioside	mixtures	 to	animal
models	 of	 peripheral	 sympathetic	 regeneration	 and	 reinnervation	 was	 able	 to	 improve	 the	 recovery
processes	 of	 both	 cholinergic	 and	 adrenergic	 nerve	 fibres	 was	 extremely	 appealing,	 suggesting	 that
gangliosides	 might	 play	 a	 relevant	 role	 in	 neural	 regeneration	 after	 injuries	 that	 could	 be
pharmacologically	exploited	[1].	Subsequently,	and	up	to	today	[2],	a	great	number	of	basic,	preclinical











of	 pure	 ganglioside	molecules,	GM1	and	polysialylated	 gangliosides,	 following	 the	 introduction	 in	 the
drug	market	of	ganglioside-containing	formulations.
In	1973,	the	drug	Cronassial,	containing	the	highly	purified	ganglioside	mixture	from	calf	brains,	was
launched	 in	 Italy	 and	 prescribed	 for	 peripheral	 neuropathies	 and	 back	 pain.	 From	 1976,	 the	 drug	was
commercialized	 under	 several	 different	 names	 in	 20	 countries	 in	 Europe,	 South	 and	Central	 America,
Asia	 and	 Africa.	 Later,	 in	 1985,	 the	 drug	 Sygen,	 containing	 highly	 purified	 GM1	 and	 prescribed	 for
neurodegenerative	 diseases	 and	 cerebral	 and	 spinal	 injuries,	 flanked	 Cronassial	 in	 Italy	 and	 later	 in




Sygen	was	 entered	 in	 new	 trials	 for	 the	 treatment	 of	 central	 nervous	 system	 diseases	 like	 cerebral




the	 occurrence	 of	 GBS,	 due	 to	 their	 interaction	 with	 the	 axonal	 surface	 at	 the	 node	 of	 Ranvier.	 This
opened	a	fierce	debate	on	 the	safety	of	gangliosides	as	drugs.	Some	scientists	were	against	 the	 therapy
and	others	in	favour.	The	discussion	also	involved	the	Italian	drug	committee	that,	after	over	16	million
prescriptions	 and	 a	 few	 cases	 of	 GBS	 claimed	 to	 be	 derived	 by	 the	 therapy,	 decided	 to	 withdraw
gangliosides	at	the	end	of	1993,	in	Italy.	The	same	occurred	later	in	other	countries.	However,	Brazil	and
China	 still	 prescribe	 Sygen	 and	 a	 generic	 ‘monosialotetrahexosylganglioside	 sodium’,	 respectively.	 In
some	countries,	GM1	is	still	involved	in	clinical	trials	at	different	stages.
After	over	20	years	since	 the	withdrawal	of	 the	ganglioside-containing	drugs	 in	many	countries,	 the




do	 not	 display	 immunogenic	 properties,	 as	 do	 not	 the	 soluble	 gangliosides.	 On	 the	 other	 hand,
gangliosides	become	immunogenic	when	carried	by	an	adjuvant,	such	as	a	microorganism.
The	 production	 of	 antisera	 against	 gangliosides	 in	 experimental	 animals	 invariably	 requires	 heavy
manipulation	of	the	material	used	for	immunization.	All	procedures	reported	in	the	literature	are	based	on
the	mixing	or	coupling	of	gangliosides	with	a	variety	of	strongly	immunogenic	carrier	substances,	such	as





is	 very	 rare.	 In	 addition,	 this	 was	 obtained	 by	 injection	 of	 liposomes	 composed	 of	 gangliosides,	 egg
lecithin	and	cholesterol,	and	methylated	bovine	serum	albumin.	In	addition,	liposomes	were	emulsified	in
complete	 Freund’s	 adjuvant	 [4].	No	 reports	 are	 available	 on	 the	 onset	 of	 an	 autoimmune	 neurological
syndrome	 following	 controlled	 ganglioside	 injections	 in	 a	 large	 cohort	 of	 humans	 that	 exceeds	 15,000
units.
On	 the	 other	 hand,	 convincing	 proof	 that	 highly	 purified	 gangliosides	 are	 not	 immunogenic	 when
injected	in	patients	comes	from	the	extensive	use	of	gangliosides	for	20	years,	and	by	the	clinical	trials
developed	 to	 understand	 some	 pharmacological	 properties	 of	 gangliosides	 on	 neurodegenerative
diseases,	as	neuro-protective	compounds	and	as	promoters	of	spinal	cord	recovery	following	injury:
Five	 Alzheimer’s	 disease	 patients	 received	 up	 to	 30	 mg/day	 of	 GM1	 ganglioside	 by	 continuous
injection	 into	 the	 brain	 lateral	 ventricles	 for	 12	 months.	 None	 of	 these	 patients	 developed	 serum
antibodies	recognizing	gangliosides	in	an	ELISA	test.	None	developed	GBS	or	any	other	neurological
autoimmune	 syndrome.	 Instead,	 these	 patients	 became	 more	 active,	 had	 improved	 reading
comprehension	 and	 were	 able	 to	 perform	 activities	 such	 as	 writing	 reports	 and	 short	 letters	 on	 a
computer	[5].
In	2	trials,	about	100	Parkinson’s	disease	patients	received	100mg	of	GM1	daily,	both	intravenously




Oxaliplatin	is	a	very	powerful	drug	against	gastrointestinal	 tumours;	however,	 it	 is	characterized	by
severe	peripheral	neurotoxicity.	Sixty	patients	with	gastrointestinal	tumours	were	injected	daily	with











raw	 or	 undercooked	 poultry,	 unpasteurized	milk	 or	 contaminated	water,	 is	 the	most	 common	 cause	 of
bacterial	gastroenteritis.	The	 isolation	rate	of	C.	 jejuni	 from	stool	culture	of	GBS	patients	 ranges	 from
8%	to	50%.	Some	of	these	patients	developed	serum	antibodies	recognizing	gangliosides	by	ELISA	or	by
immune-TLC	staining.
The	 above-mentioned	microorganisms	 display	 complex	 glycoconjugates	with	 terminal	 carbohydrate






The	 above-mentioned	 studies	 in	 our	 opinion	 convincingly	 demonstrate	 that	 there	 has	 never	 been	 any





with	 ganglioside	 treatment	 [11].	A	 subsequent	 study	 found	 42	 cases	 of	GBS	 among	579,725	 discharge
codes	 referring	 to	 the	year	 1989	 in	3	 Italian	districts.	 In	 another	 Italian	district,	 9	 cases	of	GBS	were
reported	 in	 subjects	 receiving	 ganglioside	 treatment	 from	 1981	 to	 1993;	 among	 those	 9	 patients,	 7
received	gangliosides	after	 the	diagnosis	of	GBS;	 the	 risk	of	GBS	 in	subjects	exposed	 to	gangliosides
was	 not	 significantly	 higher	 as	 compared	with	 nonexposed	 subjects.	 A	 Spanish	 study	 showed	 that	 the
incidence	of	GBS	was	not	higher	 in	geographical	areas	where	gangliosides	were	frequently	prescribed
than	 in	 those	 in	which	 they	were	not	prescribed	 [12].	The	 local	health	district	 (LHD)	of	Ferrara,	 Italy
reported	an	epidemiological	 investigation	on	the	possible	relationship	between	ganglioside	therapy	and
GBS	by	a	systematic	comparison	of	the	incidence	of	GBS	in	the	period	between	1988	and	1993	(when




gangliosides	were	withdrawn	 from	 the	 Italian	market.	When	 extending	 case	 ascertainment	 up	 to	 2001,
only	a	small	decline	in	the	incidence	of	GBS	was	found	that	might	be	better	explained	by	fluctuations	in
GBS	incidence	than	by	the	withdrawal	of	ganglioside	treatment.
In	 the	 LHD	 of	 Ferrara	 the	 resident	 mean	 population	 was	 165,239,	 with	 77,630	 men	 and	 87,609
women,	in	the	years	1994–2001.	The	cases	of	GBS	were	24.3	in	the	years	1981–1987,	20.1	in	the	years
1988–1993	and	25.4	in	the	years	1994–2001.
In	 the	years	1981–1993	 there	was	an	 incidence	rate	of	GBS	of	1.87	per	100,000	population,	which
become	 2.30	 for	men	 and	 1.48	 for	women.	 In	 the	 years	 1994–2001,	 after	 ganglioside	withdrawal,	 the


































As	 the	 old	 adage	 goes,	 ‘A	 picture	 is	worth	 a	 thousand	words’,	 and	 I	 think	 this	 is	 particularly	 true	 in
scientific	 research.	We	might	 not	 fully	 digest	 or	 remember	 the	 exact	 text	 in	 every	 article	we	 read,	 but















and	 41.3)	 in	 a	 subsequent	 review	 of	 human	 immune-mediated	 neuropathies	 [4]	 so	 I	 wasn’t	 forced	 to
choose.	Animal	models	have	of	course	been	indispensable	in	furthering	our	understanding	of	GBS,	but	I
think	where	 possible	 it’s	 beneficial	 that	we	 use	 patient	 autopsy	 tissue	 as	 a	 reference	 point,	 and	 these




is	 likely	 involved	 in	 membrane	 disruption	 and	 vesiculation,	 respectively.	 Complement	 activation	 is
followed	by	subsequent	macrophage	invasion	at	each	respective	membrane	where	they	likely	participate
in	opening	of	 the	periaxonal	 space	 and	degeneration	of	 axons	 (AMAN),	 and	 removal	of	myelin	debris





sequence	of	events	 in	AIDP.	 (C)	Macrophages	attracted	by	complement	activation	remove	myelin.	 (D)	Schematic	depiction	of





proposed	 pathogenesis	 in	 AMAN,	 showing	 antibody	 binding	 to	 the	 axonal	 targets	 followed	 by	 complement	 activation	 and
macrophage	 invasion	 through	 the	 node	 of	 Ranvier.	 Images	 A	 and	 D	 adapted	 with	 permission	 from	 [4].	 Images	 B	 and	 C
reproduced	with	permission	from	[2].
Complexities	of	Ganglioside	Distribution	and	Membrane	Interactions
The	 blots	 in	 Figure	 41.4	 are	 wonderfully	 simple	 images,	 but	 the	 information	 that	 they	 convey	 both
individually	 and	 together	 fundamentally	 changes	 the	 way	 ganglioside-antibody	 interactions	 are
understood.	 Anti-ganglioside	 antibodies	 are	 found	 in	 approximately	 60%	 of	 patient	 sera	 and	 are
























A	 decade	 later,	 Kaida	 and	 colleagues	 observed	 another	 new	 feature	 of	 patient	 anti-ganglioside
antibodies	[6].	 It	 is	possible	 to	find	antibodies	 in	patient	sera	 that	bind	to	gangliosides	 in	complex	and
their	 newly	 formed	 glycoepitopes,	 rather	 than	 single	 ganglioside	 epitopes.	 In	 the	 TLC	 blot	 from	 this
article,	 lanes	 2	 (single	 GD1a)	 and	 3	 (single	 GD1b)	 show	 no	 or	 weak	 bands	 when	 patient	 serum	 is
overlaid,	while	lane	4	(GD1a	+	GD1b)	shows	prominent	binding.	Gangliosides	can	form	clusters	in	the











that	 gangliosides	 are	 not	 homogenously	 expressed	 and	 that	 not	 all	 characteristics	 of	 anti-ganglioside
antibody	binding	can	be	revealed	by	array.	Indeed,	it	is	now	known	that	antibodies	binding	similarly	on
array	can	bind	differently	in	processed	or	living	tissue	[9].
It	has	been	known	 for	many	years	 that	 anti-ganglioside	antibodies	 are	 found	at	high	 titres	 in	patient
serum,	and	that	some	of	these	antibodies	are	associated	with	clinical	symptoms	implying	specific	nerves
or	 sites	 are	 targeted	 (e.g.	 anti-GD1a	 Ab	 in	 AMAN).	 Why	 are	 some	 membranes	 (e.g.	 motor	 axons)
preferentially	targeted	when	gangliosides	are	comparably	expressed	in	myelin	and	axon	fractions?	Does
localisation	 of	 gangliosides	 differ,	 just	 as	 the	 density	 of	 GQ1b	 differs	 among	 nerves?	 Detailed	 and





normal	 nerve.	 However,	 binding	 is	 not	 so	 restricted	 in	 transverse	 cryosections	 where	 Schwann	 cell
membrane	and	compact	myelin	are	also	positive.	Tissue	was	processed	differently	 for	 immunoelectron
microscopy	and	cryosectioning	and	that	likely	underlies	these	slightly	different	results.	Additional	binding
is	 found	along	 the	 internode	 in	areas	of	 thinned	myelin	and	all	 the	way	along	unmyelinated	 fibres	 from
amyelinated	 dystrophic	mice	 indicating	 that	GM1	 is	 present	 on	 the	 entire	 axon	 but	 its	 accessibility	 is
restricted	 under	 normal	 conditions.	 Taken	 together,	 these	 results	 raised	 awareness	 that	 there	 are	many
technical	considerations	to	be	made	when	interpreting	binding	and	localisation	data.	And	unfortunately	a
beautiful	image	does	not	reflect	the	whole	story!
In	 Figure	 41.6,	 the	 authors	 used	 high-affinity	 mouse	 monoclonal	 antibodies	 raised	 against	 the	 four
major	brain	complex	gangliosides	 to	probe	 the	peripheral	nerve	and	produce	 these	memorable	 images.
The	 immunohistochemical	 results	 clearly	 demonstrate	 that	 antibodies	 can	 differentially	 bind	motor	 and
sensory	fibres,	and	in	this	scenario	axonal	but	not	myelin	membranes.	This	indicated	that	gangliosides	can
be	inaccessible	to	circulating	antibody	binding	(e.g.	in	compact	myelin),	displayed	within	the	membrane
in	 an	unfavourable	manner	 for	 binding,	 and	 that	 individual	 antibodies	 can	 exhibit	 fine	 specificity.	This




GBS	 [10,11].	 It	 has	 also	 helped	 to	 establish	 the	 node	 of	Ranvier	 as	 a	 primary	 site	 for	 immune	 attack
associated	with	dysfunction.	Figure	41.7,	from	Susuki	and	colleagues	[12],	clearly	indicates	Na	channel
disruption	 at	 the	 node	 of	Ranvier	 associated	with	 complement	 deposition	 and	 nodal	 lengthening	 in	 the
acute	disease	phase.	Disruption	to	Na	channel	clustering	critically	impairs	saltatory	conduction	and	aligns
with	the	motor	nerve	conduction	block	observed	in	rabbits	and	humans.	This	finding	forms	the	foundation













for	 live-imaging	 experiments	…	 and	 also	 produce	 rather	 eye-catching	 images!	 Here,	 the	 authors	 used
these	mice	to	show	the	effect	of	blocking	the	formation	of	the	complement	cascade’s	terminal	MAC	pore
on	 peripheral	 intramuscular	 nerve	 bundles	 subjected	 to	 anti-ganglioside	 antibody	 and	 a	 source	 of
complement	 [14].	 The	 fluorescent	 signal	 (white)	 is	 absent	 from	 the	 most	 terminal	 branches	 of	 the
intramuscular	 nerve	 bundles	 and	 weak	 more	 proximally,	 indicating	 a	 severe	 disruption	 to	 the	 nerve
membrane	 that	 coincided	with	 loss	of	 function.	This	 is	 completely	prevented	by	 the	blockade	of	MAC
pore	formation	by	anti-C5	antibody,	eculizumab	(Alexion	Pharmaceuticals	Ltd).
Figure	 41.8	 	 Complement	 inhibition	 with	 eculizumab	 attenuates	 nerve	 injury	 in	 an	 animal	 model	 of	 GBS.	 Antiganglioside
antibodies	and	complement	injure	distal	nerves	resulting	in	axonal	injury	and	loss	of	fluorescent	signal	(bottom	panel;	NMJs	are














Figure	41.9	 	 The	 binding	 of	 Guillain-Barré	 syndrome	 (GBS)	 and	 chronic	 inflammatory	 demyelinating	 polyneuropathy	 (CIDP)
patients’	IgG	to	nodes	of	Ranvier	is	blocked	by	soluble	antigens.	Mouse	sciatic	nerve	fibres	were	incubated	with	sera	(red)	from
(A,	B)	acute	 inflammatory	demyelinating	polyneuropathy	(AIDP)	or	 (C,	D)	acute	motor	axonal	neuropathy	(AMAN)	patients	and





Schematic	drawing	shows	some	of	 the	molecular	 components	of	 the	peripheral	 nervous	system	nodal	 region,	which	 can	be
divided	into	the	node,	paranode,	and	juxtaparanode.	At	the	node,	gliomedin,	Nr-CAM,	and	neurofascin	(NF)	186	link	the	Schwann
cell	microvilli	to	the	nodal	axolemma.	In	the	paranode,	NF155	interacts	with	Caspr	and	contactin	heterodimers	to	link	the	glial	and




Schematics	 themselves	 have	 become	 more	 sophisticated	 over	 the	 years	 and	 form	 a	 really	 important




that	we	 need	 to	 look	 at	 the	whole	 picture	 and	 not	 isolated	 elements.	 The	 node	 of	Ranvier	 is	 a	 highly
specialised	 structure	 with	 a	 critical	 role	 in	 nerve	 conduction.	 It	 is	 a	 known	 site	 of	 antibody	 binding,






be	 unequivocally	 identified,	 autoantibodies	 may	 bind	 to	 myelin	 antigens	 and	 activate	 complement.	 This	 is	 followed	 by	 the
formation	of	membrane-attack	complex	(MAC)	on	the	outer	surface	of	Schwann	cells	and	the	initiation	of	vesicular	degeneration.
Macrophages	 subsequently	 invade	 myelin	 and	 act	 as	 scavengers	 to	 remove	 myelin	 debris.	 Panel	 B	 shows	 the
immunopathogenesis	of	acute	motor	axonal	neuropathy.	Myelinated	axons	are	divided	into	four	functional	regions:	the	nodes	of
Ranvier,	 paranodes,	 juxtaparanodes,	 and	 internodes.	 Gangliosides	 GM1	 and	 GD1a	 are	 strongly	 expressed	 at	 the	 nodes	 of
Ranvier,	where	the	voltage-gated	sodium	(NaV)	channels	are	localized.	Contactin	associated	protein	(Caspr)	and	voltage-gated
potassium	 (KV)	 channels	 are	 respectively	 present	 at	 the	 paranodes	 and	 juxtaparanodes.	 IgG	 anti-GM1	 or	 anti-GD1a
autoantibodies	bind	to	the	nodal	axolemma,	leading	to	MAC	formation.	This	results	in	the	disappearance	of	NaV	clusters	and	the





















































Guillain-Barré	 syndrome	 (GBS)	 is	 an	 acute,	 self-limited	 peripheral	 neuropathy	 often	 preceded	 by	 an
infection.	 The	 pathogenetic	 mechanism	 of	 GBS	 is	 considered	 to	 be	 autoimmunity.	 Antibodies	 against
glycolipids,	including	gangliosides,	have	been	reported	to	be	present	in	around	60%	of	the	sera	from	GBS









Nagai	and	colleagues	 investigated	 the	modulation	of	 the	 immunologic	 response	 to	myelin	basic	protein
(MBP)	by	the	formation	of	a	conjugate	of	MBP	and	acidic	sphingoglycolipids	[1].	During	the	course	of
their	 investigations,	 they	 noticed	 that	 rabbits	 intensively	 immunised	 with	 total	 brain	 gangliosides
sometimes	 developed	 neurologic	 symptoms	 and	 signs.	 They	 then	 immunised	 rabbits	 with	 purified
gangliosides.	As	a	result,	4	of	the	8	rabbits	which	had	been	injected	with	GD1a	ganglioside	developed
neurological	symptoms	and	signs.	When	they	immunised	rabbits	with	GM1	ganglioside,	the	rabbits	were
also	 affected	 with	 neurological	 disease,	 although	 the	 rate	 of	 induction	 of	 neurological	 problems	 was
lower	than	it	had	been	with	GD1a.	The	rabbits	injected	with	GM1	had	high	titres	of	antibody	activities	to
GM1,	but	 those	 injected	with	GD1a	produced	a	small	or	negligible	amount	of	antibody	activities.	This
paper	 is	 the	 first	 to	 describe	 the	 animal	model	with	 robust	 neurological	 symptoms	 and	 signs	with	 the
sensitisation	 with	 ganglioside.	 However,	 descriptions	 of	 the	 neurological	 symptoms	 and	 signs,	 the
serological	examinations,	and	pathological	investigations	were	not	sufficient	enough	to	evaluate	in	detail.
They	 described	 that	 the	 rabbits	 injected	with	 GD1a	 ganglioside	 developed	 a	 state	 of	 rigid	 or	 spastic
paralysis	whereas	 those	 injected	with	GM1	ganglioside	 developed	 flaccid	 paralysis.	 If	 so,	 the	 rabbits
injected	with	GD1a	ganglioside	might	develop	a	central	nervous	system	disease.	But,	in	any	case,	it	can





Saida	and	colleagues	 immunised	 rabbits	with	galactocerebroside	 (GalC),	 a	major	glycolipid	 in	central
and	peripheral	nervous	systems	[2].	They	reported	that	13	of	31	sensitised	rabbits	showed	flaccid	paresis
and	 hypesthesia	 of	 4	 limbs.	 Some	 of	 the	 rabbits	 showed	 respiratory	 paresis.	 Electrophysiologically,









antiserum	was	 removed	by	preincubation	with	GalC	 and	was	 lost	when	 the	 serums	were	 heated	 at	 56
degrees	centigrade	 for	30	minutes,	 indicating	 that	 the	pathogenetic	mechanism	was	anti-GalC	antibody-
dependent	 and	 complement-mediated.	 Although	 the	 pathogenetic	 roles	 of	 anti-GalC	 antibodies	 were









of	 the	 animal	model	was	 the	 differences	 in	 the	 distribution	 of	 individual	 gangliosides	 from	 species	 to
species.	It	was	reported	that	antibody	activities	to	gangliosides	with	disialosyl	residue,	including	GD1b,
were	associated	with	sensory	ataxic	neuropathy.	Kusunoki	and	colleagues	found	that	GD1b	was	densely
localised	 in	 the	 large	 neurons	 in	 human	 dorsal	 root	 ganglia.	 Because	 such	 localisation	 of	 GD1b
ganglioside	was	 also	 seen	 in	 rabbits,	 they	 hit	 upon	 an	 idea	 that	 the	 effective	 animal	model	would	 be
developed	by	the	sensitisation	of	the	rabbits	with	GD1b	ganglioside.	They	then	immunised	rabbits	with
GD1b	 ganglioside	 and	 succeeded	 in	 developing	 the	 animal	model	 with	 robust	 neurological	 signs	 [5].




induced	SAN),	was	 the	 first	established	animal	model	of	autoimmune	neuropathy	 targeting	ganglioside.
The	 titres	 of	 the	 anti-GD1b	 antibodies	 were	 increased.	 In	 contrast,	 no	 lymphocytic	 infiltration	 was









the	 titres	 of	 the	 antibodies	 specific	 to	 GD1b	 and	 found	 that	 the	 titres	 were	 significantly	 higher	 in	 the
affected	rabbits	than	in	the	unaffected	ones.	This	shows	that	the	antibodies	specific	to	GD1b	are	required
to	induce	sensory	ataxic	neuropathy	in	rabbits.	It	was	reported	in	another	paper	that	passive	transfer	of	the
antiserum	caused	neuropathological	changes	similar	 to	 the	GD1b-induced	SAN	[7].	Taken	 together,	 the







a	 controversy	 over	 whether	 or	 not	 immunisation	 of	 the	 animals	 with	 GM1	 ganglioside	 would	 cause
neurological	 problems.	 Yuki	 and	 colleagues	 sensitised	 rabbits	 with	 bovine	 brain	 ganglioside	 mixture
(BBG)	containing	GM1	or	purified	GM1	according	to	the	procedure	of	GD1b-induced	SAN	model	[10].
Results	 showed	 that	all	of	 the	13	 rabbits	 inoculated	with	BBG	and	9	of	 the	11	 rabbits	 inoculated	with
purified	 GM1	 developed	 acute	 motor	 neuropathy.	 The	 rabbits	 inoculated	 with	 BBG	 had	 anti-GM1
antibodies.	 Pathological	 findings	 showed	 axonal	 degeneration	with	 neither	 lymphocytic	 infiltration	 nor
demyelination.	This	study	indicated	that	anti-GM1	antibody	is	a	causative	factor	and	this	model	should	be
a	 useful	 animal	 model	 for	 investigation	 of	 AMAN.	 The	 authors	 used	 functional	 grades	 (FG)	 from	 0
(normal)	 to	 5	 (dead).	 In	 BBG-inoculated	 rabbits,	 9	 of	 13	 rabbits	 showed	 FG	 of	 4	 (showing	 severe
weakness	of	the	4	limbs,	which	were	spread	out)	at	the	nadir	and	one	rabbit	showed	FG	of	3	(showing
moderate	weakness	of	 the	4	 limbs	and	unable	 to	walk).	Therefore	10	of	 the	13	 rabbits	were	unable	 to
walk	at	the	nadir.	In	contrast,	in	GM1-inoculated	rabbits,	only	3	of	11	rabbits	were	FG	of	3	or	more	(2









paranodal	 axo-glial	 junctions.	 This	 paper	 revealed	 the	 precise	molecular	 pathogenetic	mechanisms	 of
BBG-induced	motor	axonal	neuropathy	and	clearly	showed	that	 it	was	a	complement-mediated	disease.




In	a	GD1b-induced	SAN	model,	axonal	degeneration	with	macrophage	 infiltration	was	observed	 in	 the
dorsal	root	and	in	the	dorsal	column	of	the	spinal	cord.	However,	in	spite	of	the	looseness	of	the	blood-
nerve	 barrier	 in	 DRG,	 there	 were	 no	 significant	 pathological	 changes	 in	 DRG.	 It	 was	 possible	 that
apoptosis	of	 the	 large	 sensory	neurons	occur	 in	 this	animal	model.	To	 find	out,	Takada	and	colleagues
performed	a	TUNEL	assay	of	the	DRG	from	the	affected	rabbits	and	discovered	that	a	subset	of	neurons
were	 TUNEL	 positive	 [12].	 Anti-caspase	 3	 antibody	 also	 immunostained	 some	 of	 the	 DRG	 neurons.
TUNEL	positivity	was	found	in	the	neurons	with	large	diameter.	Therefore,	apoptosis	of	the	large	primary






In	order	 to	develop	passive	 transfer	model	 of	 anti-ganglioside	 antibody-mediated	neuropathies,	Sheikh
and	 colleagues	 performed	 intraperitoneal	 implantation	 of	 hybridoma-secreting	 anti-ganglioside
antibodies,	 reacting	with	GD1a	 ganglioside,	 in	mice	 [13].	As	 a	 result,	 approximately	 half	 the	 animals
implanted	with	the	hybridoma	developed	a	patchy,	predominantly	axonal	neuropathy	in	a	small	proportion
of	 nerve	 fibres.	 Passive	 transfer	 with	 systemically	 administered	 antibodies	 did	 not	 cause	 such
pathological	changes.	The	authors	discussed	whether	hybridoma	implantation	might	make	the	blood-nerve
barrier	leaky.	Even	in	the	mice	implanted	with	the	hybridoma,	neuropathological	changes	were	mild.	This
study	 showed	 that,	 in	 addition	 to	 the	 antibodies,	 other	 factors	 such	 as	 antibody	 accessibility	 were





motor	 nerve	 terminals	 at	 the	 neuromuscular	 junction	 (NMJ)	 using	mouse	 hemi-diaphragm	model	 [14].
Based	 on	 this	 finding,	Halstead	 and	 colleagues	 injected	 balb/c	mice	 intraperitoneally	with	 anti-GQ1b
antibody,	 followed	 by	 an	 intraperitoneal	 injection	 of	 normal	 human	 serum.	Mice	 treated	 as	 described
above	showed	breathing	difficulties	 [15].	Anti-GQ1b	antibodies	are	detected	 in	about	90%	of	 the	sera
from	patients	with	Miller	Fisher	syndrome	(MFS)	in	the	acute	phase.	Breathing	difficulty	is	not	observed
in	MFS.	However,	when	anti-GQ1b	antibody	is	positive	in	patients	with	GBS	with	ophthalmoplegia,	the
patients	more	 frequently	need	mechanical	ventilation	 than	 anti-GQ1b-negative	patients	 [16].	Therefore,
this	 mouse	 model	 is	 a	 nice	 model	 of	 GBS	 with	 respiratory	 insufficiency.	 Halstead	 and	 colleagues
reported	 that	 eculizumab,	 which	 blocks	 the	 formation	 of	 human	 C5a	 and	 C5b-9,	 protected	 mice	 from
respiratory	paralysis	 in	 this	model	by	preventing	complement-mediated	damage	at	 the	NMJ.	This	work









































Animal	 models,	 in	 spite	 of	 their	 limitations,	 are	 essential	 research	 tools	 for	 deciphering	 disease
mechanisms	 in	 autoimmune	 diseases.	 The	 use	 of	 animal	 models	 has	 facilitated	 the	 discovery	 of	 new
susceptibility	 genes,	 detailed	 immunologic,	 and	 morphologic	 and	 functional	 studies	 as	 well	 as	 the
development	 of	 novel	 therapeutic	 strategies.	Within	 the	 context	 of	 Guillain-Barré	 syndrome	 and	 other
autoimmune	neuropathies,	these	models	include	experimental	autoimmune	neuritis	(EAN),	antibody	(Ab)-
mediated	experimental	 autoimmune	neuropathy	and	 spontaneous	autoimmune	polyneuropathy	 (SAP).	As










EAN	was	 first	 induced	 in	 rabbits	by	Waksman	and	Adams	 in	1955	by	 immunization	with	sciatic-nerve






findings	 of	 19	 fatal	 cases	 of	 human	 GBS	 had	 led	 to	 conclusions	 that	 cellular	 immunity	 to	 myelin
components	is	the	underlying	culprit	in	GBS	[2–4].	Of	note,	Dr	Waksman	has	also	been	recognized	for	his













via	 CD40L-CD40	 interactions,	 regulatory	 mechanisms	 and	 production	 of	 auto-Abs.	 B	 cells	 play	 a









Weakness	 in	GBS	and	EAN	arises	 from	either	axonal	 loss	or	conduction	 failure.	Conduction	 failure	 in
demyelinated	fibres	occurs	as	a	consequence	of	capacitance	impedance	mismatch,	leakage	of	currents	and
exposure	 of	 internodal	K+	 channels.	However,	 conduction	 failure	 in	 EAN	 and	GBS	 often	 precede	 the
onset	 of	 demyelination,	 and	 is	 attributed	 to	 paranodal	 retraction	 and	 disruption	 of	 nodal	Na+	 channels
[11,12].
Whether	axonal	or	demyelinating	 features	predominate	 in	EAN	depends	on	 the	disease	severity	and
method	of	disease	 induction.	Adoptive	 transfer	 of	P2-reactive	T	 cell	 lines	 in	Lewis	 rats	 led	 to	 axonal
dysfunction	or	degeneration	with	minimal	demyelination,	whereas	adoptive	transfer	of	myelin-sensitized
lymph	 node	 cells	 (T	 cells	 and	 B	 cells)	 led	 to	 prominent	 demyelinating	 features	 [13].	 Interestingly,
disappearance	 of	 adhesion	 molecules	 neurofascin	 186	 and	 gliomedin,	 thought	 to	 be	 mediated	 by	 Abs
against	these	proteins,	was	observed	in	EAN	induced	by	peripheral	myelin,	but	not	in	EAN	induced	by	P2
[12].	These	 findings	 indicate	 that	 the	 antigenic	 targets	of	 immune	attack	extend	 to	nodal	 and	paranodal
proteins	 and	 is	 not	 restricted	 to	 myelin	 proteins.	 Indeed,	 immunization	 with	 gliomedin	 induces	 a
progressive	 neuropathy	 that	 is	 characterized	 by	 nodal	 disruption	 and	 demyelination	 [14].	 In	 addition,
antibodies	 to	 neurofascin	 cause	 exacerbation	 and	 prolongation	 of	 adoptive	 transfer	 EAN	 [15].	 Taken
together,	 these	 results	 suggest	 that	early	conduction	 failure	 in	EAN	and	GBS	 is	due	 to	nodal/paranodal




sera	 from	EAN	 and	GBS	 had	 been	 demonstrated,	 albeit	 not	 correlating	well	with	 clinical	 severity.	A
possible	 role	 of	Abs	 or	 other	 serum	 factors	 in	 the	 pathogenesis	 of	 EAN	 is	 supported	 by	 the	work	 of
Antony	and	colleagues	demonstrating	the	beneficial	effect	of	plasma	exchange	in	rabbits	when	given	prior
to	 the	 establishment	 of	 clinical	 disease	 [16].	 The	 effectiveness	 of	 IVIg	 as	 a	 treatment	 of	 EAN	 was
published	 in	 1997,	 the	 same	 year	 that	 results	 of	 the	 Plasma	 Exchange/Sandoglobulin	 Guillain-Barré
Syndrome	 Trial	 were	 published	 in	 The	 Lancet	 [17,18].	 The	 study	 by	 Gabriel	 and	 colleagues
demonstrated	 that	 the	 Ig	 treatment	 from	 disease	 onset	 was	 more	 beneficial	 than	 treatment	 from
immunization	 and	was	 associated	with	 a	 decrease	 in	 rat	 anti-myelin	Abs	 [17].	Miyagi	 and	 colleagues
found	that	the	intact	IVIg,	but	not	F(ab′)2	ameliorated	the	clinical	course	of	EAN	induced	by	P2	[18].
Because	 of	 the	 natural	 history	 of	 GBS	 and	 the	 favourable	 response	 to	 intravenous	 Ig	 and	 plasma
exchange,	many	studies	on	experimental	therapeutics	in	EAN	were	not	translated	to	clinical	trials	or	use
for	 this	 disorder.	 I	 was	 involved	 in	 a	 study	 demonstrating	 the	 suppressive	 effect	 of	 a	 β2	 adrenergic
agonist	 terbutaline	 on	 EAN	 in	 Lewis	 rats	 even	 when	 given	 after	 disease	 onset	 [19].	 The
immunomodulatory	 effect	 of	 cAMP-elevating	 agents	 in	 EAN	 was	 demonstrated	 by	 another	 agent,
Rolipram,	 a	 phosphodiesterase-4	 inhibitor,	 which	 induced	 downregulation	 of	 interferon-γ	 and	 pro-

















model	 of	 spontaneous,	 organ-specific	 autoimmunity	 is	 the	 NOD	 mouse,	 which	 exhibits	 increased




and	homeostasis	of	 regulatory	T	cells	 (Tregs)	 [25,26].	The	B7-2	knockout	NOD	mouse	was	originally
generated	in	Dr	Bluestone’s	laboratory	to	study	the	role	of	costimulatory	molecules	in	type	1	diabetes.	He
was	 still	 at	 the	 University	 of	 Chicago	 at	 that	 time.	 One	 of	 his	 postdocs,	 Dr	 Salomon,	 observed	 that
elimination	 of	 B7-2	 (CD86)	 in	 NOD	mice	 led	 to	 protection	 against	 type	 1	 diabetes	 but	 triggered	 the
development	of	progressive	weakness	at	6	to	7	months	of	age.	I	was	asked	to	help	with	the	analysis	of	the
clinical	phenotype.	Electrophysiological	and	histological	studies	revealed	features	of	demyelination	and
axonal	 loss,	 and	 inflammatory	 infiltrates	 in	 sciatic	 nerves	 and	 dorsal	 root	 ganglia,	 as	 can	 be	 seen	 in
progressive	form	of	CIDP	[24,27].	 I	was	 intrigued	by	 the	concept	 that	elimination	of	one	molecule	can
alter	the	manifestation	of	autoimmune	disease	in	susceptible	animals.	Because	my	main	research	interest
at	 that	 time	was	 in	 oligodendrocyte	 and	 Schwann	 cell	 biology	 rather	 than	 neuroimmunology,	 I	 did	 not
pursue	 further	 investigations	 until	 6	 years	 later.	Using	 different	 approaches,	 both	Bluestone’s	 group,	 at
University	of	California	San	Francisco,	and	my	group,	at	the	University	of	Chicago,	found	that	myelin	P0
is	 the	 antigenic	 target	 in	 SAP	 in	 NOD	mice.	 SAP	 is	 mediated	 by	 IFN-γ-secreting	 Th1	 cells	 that	 are
reactive	against	myelin	P0,	and	at	least	2	pathogenic	P0	epitopes	are	involved,	P0	(1–25)	and	P0	(180–
199)	 [28–30].	Myelin	 P0	 is	 an	Aire-regulated,	 tissue-specific	 self-Ag	 in	 the	 thymus.	Maureen	 Su	 and







to	 induce	 tolerance	 to	 P0,	which	 can	 be	 rescued	 by	 preconditioning	with	 IL-10	 [33].	Another	way	 to
overcome	impaired	DC	function	is	by	transduction	with	lentiviral	vectors	expressing	vasoactive	intestinal
peptide	(LV-VIP-BCD11b+	DCs),	which	delays	 the	onset	 of	 disease	 and	 attenuates	 clinical	 severity	 in
SAP	[34].
Of	note,	P0	is	expressed	not	only	in	the	PNS	myelin	but	also	by	peri-islet	Schwann	cells,	suggesting	a





triggered	 by	 changes	 in	 costimulatory	 molecules/pathways.	 It	 is	 tempting	 to	 speculate	 that	 similar
mechanisms	occur	in	humans	in	that	GBS	is	monophasic	in	most	patients	but	can	switch	to	relapsing	and
remitting	 CIDP	 or	 progressive	 CIDP	 when	 regulatory	 mechanisms	 are	 impaired	 due	 to	 altered
costimulatory	or	cytokine	milieu.
Conclusions







There	 are	 many	 investigators	 who	 have	 contributed	 significantly	 to	 the	 advancement	 of	 our
understanding	of	pathogenesis	of	GBS.	Within	the	context	of	EAN	and	SAP,	my	top	10	publications	were
chosen	based	on	 their	 impact	or	 implications	on	 the	field	of	neuroimmunology	of	PNS.	The	 three	early
publications	 by	 investigators	 at	Harvard	 (Waksman,	Adams,	Arnason,	Asbury	 and	Webster)	 led	 to	 the
decades	of	emphasis	on	the	role	of	PNS-reactive	T	cells	and	other	effector	mechanisms	in	GBS.	Brostoff
and	 colleagues	were	 the	 first	 to	 show	 that	 EAN	 can	 be	 induced	 by	 a	 peripheral	myelin	 peptide.	 The
pathology	 of	 EAN	 consists	 of	 inflammatory	 infiltrates,	 demyelination	 and	 varying	 degrees	 of	 axonal
degeneration.	 The	 realization	 that	 nodal	 and	 paranodal	 dysfunction	 plays	 an	 important	 role	 in	 the
pathophysiology	of	EAN	is	highlighted	by	the	work	of	Shrager’s	group,	and	Lonigro	and	Devaux.	Last	but






















































































Spontaneous	conditions	similar	 to	 those	of	Guillain-Barré	syndrome	(GBS),	 leading	 to	acute	ascending
paralysis	 and	 associated	 with	 polyradiculoneuropathies	 of	 unknown	 origin,	 have	 been	 reported	 in	 a
number	of	different	animal	species.	Unfortunately,	in	many	cases,	comparison	and	interpretation	of	these
reports	 is	 challenging,	 since	 depending	 on	 when	 these	 examinations	 were	 conducted	 and	 whether	 the
animals	survived,	the	extent	and	modality	of	investigations	carried	out	often	varies.
The	majority	 of	 descriptions	 focus	 on	 dogs,	 cats	 and	 chickens.	 Individual	 case	 reports	 include	 the
description	 of	 a	 chimpanzee	with	 acute	 onset	 of	 ascending,	 symmetrical,	monophasic	 flaccid	 paralysis












14	 days	 of	 being	 bitten	 by	 a	 racoon,	 these	 dogs	 exhibited	 an	 acute,	 symmetrical,	 ascending	 paralysis,
occasionally	also	involving	the	tail,	neck	and	trunk.	Hyperaesthesia,	involvement	of	cranial	nerves,	death
(presumed	 to	 be	 caused	 by	 respiratory	 failure)	 and	 multiple	 episodes	 after	 repeated	 bites	 were	 also
observed.	It	does,	however,	need	to	be	noted,	 that	only	a	few	dogs	bitten	by	raccoons	actually	develop
coonhound	paralysis.
The	 detailed	 histological	 investigations	 conducted	 in	 dogs	 succumbing	 to	 the	 disease	 revealed	 the
most	striking	changes	to	be	in	the	ventral	roots	(Figure	44.2)	with	lumbosacral	areas	more	involved	than
thoracic	or	 cervical	 areas,	 and	 the	myelin	 sheaths	 affected	more	 than	 the	 axons.	The	 extent	 of	 changes
varied	in	peripheral	nerves;	however,	both	in	nerves	and	nerve	roots	predominantly	large-diameter	nerve
fibres	were	affected.	The	myelin	damage	exhibited	a	segmental	pattern	with	the	myelin	appearing	either
swollen	or	pale,	or	 fragmented	 into	globules.	Complete	 loss	of	myelin	 resulted	 in	empty	Schwann	cell
sheaths.	Associated	axons	ranged	from	appearing	quite	normal	to	undergoing	degeneration.	In	other	cases,
the	 axons	 were	 more	 frequently	 involved	 when	 compared	 to	 the	 myelin	 sheaths	 [4].	 The	 intraneural




of	 sparse	 or	 absent	 inflammation.	 Similar	 to	 reports	 in	 GBS,	 macrophages	 were	 present	 within	 the
periaxonal	spaces.
Figure	44.1		Redbone	coonhound	in	the	recovery	phase	of	coonhound	paralysis
Note	 the	 marked	 muscle	 atrophy	 and	 decubital	 ulcers	 acquired	 during	 the	 paralytic	 phase	 of	 disease.	 Reproduced	 with
permission	from	[21].







further	 investigations	 by	 other	 groups	 examining	 dogs	 with	 similar	 clinical	 presentation	 in	 which,









motor	 neuron	 tetraparesis	 or	 flaccid	 paralysis	 [6].	 Symptoms	 usually	 start	 in	 the	 hind	 limbs	 and	 then
progress	 to	 the	 forelimbs;	 the	 progressive	 phase	 tends	 to	 last	 for	 roughly	 5	 days,	 occasionally	 longer.
Some	dogs	continue	 to	exhibit	voluntary	movement	of	all	4	 limbs	 throughout	 the	disease,	whilst	others
suffer	 complete	 paralysis	 of	 limbs	 and	 neck,	 and	 may	 experience	 respiratory	 compromise,	 requiring
mechanical	ventilation.	Muscle	atrophy	develops	within	7	to	10	days	and	hypo-	or	areflexia,	a	decrease
or	 loss	of	muscle	 tone	and	 in	many	cases	hyperesthesia	of	 the	 limbs	and	 trunk	are	noted.	Owners	often
recognize	a	change	or	loss	in	bark	and	some	dogs	develop	bilateral	facial	paralysis	and	tongue	weakness.
Generally,	however,	dogs	remain	alert	and	responsive	 throughout	 the	disease,	continue	 to	eat	and	drink
normally	and	 in	 the	vast	majority	of	cases	 remain	 in	control	of	 their	urination	and	defecation	and	even
continue	to	wag	their	tail.
In	 electrophysiological	 investigations,	 ACP	 dogs	 exhibit	 signs	 both	 for	 demyelinating	 and	 axonal
neuropathies,	 combined	with	 evidence	 of	muscle	 denervation	 (Figure	 44.3).	 Some	 investigations	 have
revealed	 demyelinating	 and	 axonal	 changes	 in	 the	 ventral	 roots,	 with	 a	 prominent	 axonopathy









Nerve	 biopsies	 exhibit	 no	 changes	 or	 mildly	 reduced	 myelinated	 fibre	 density,	 occasional	 myelin
ovoids	 and	 mild	 inflammatory	 infiltrates,	 whilst	 muscles	 exhibit	 changes	 consistent	 with	 denervation
atrophy	[5,8].
Routinely,	 ACP	 patients	 receive	 no	 treatment	 and	 all	 efforts	 are	 put	 into	 supportive	 care	 and
rehabilitation.	Dogs	need	to	be	turned	every	few	hours	to	prevent	pressure	sores,	and	ventilated	and	hand

















could	 only	 be	 induced	 in	 offspring	 from	 coonhound-type	 dogs	 who	 had	 recovered	 from	 coonhound







extension	 of	 the	 pilot	 study,	 at	 this	 stage	 incorporating	 10	 institutions	 from	 4	 European	 countries	 and
including	 dogs	 with	 other	 cranial	 and	 peripheral	 neuropathies	 of	 unknown	 origin,	 myopathies	 and
neuromuscular	disorders	(OMN	group),	which	altogether	are	examining	162	canine	sera.	Here,	32	of	73
ACP	dogs	exhibited	anti-GM2	Abs,	4	of	73	exhibited	anti-GA1	Abs	and	13	of	73	exhibited	both	(overall
67%),	whilst	 only	 3	 of	 40	 (7.5%)	OMN	 dogs	 and	 5	 of	 49	 (10%)	with	 non-neurological	 control	 sera
exhibited	such	Abs	(Figure	44.4).
The	concurrent	staining	investigations	carried	out	with	anti-GM2	Ab-containing	canine	sera	on	murine
sciatic	nerves	and	murine	monoclonal	anti-GM2	Abs	on	canine	 sciatic	nerves	 indicated	 that	GM2	was
localized	to	the	abaxonal	Schwann	cell	surface	and	multifocally	in	the	axonal	areas.	Experimental	support
for	potential	demyelinating	properties	of	ACP	serum	is	lent	by	the	observation	that	intraneural	injection	of
canine	 ACP	 serum	 into	 rat	 sciatic	 nerves	 in	 conjunction	 with	 a	 source	 of	 complement	 induces
demyelination	at	a	higher	frequency	when	compared	to	control	serum	[12].	Also	the	observation	that	the
application	 of	 IVIg	 in	ACP	 dogs	 has	 shown	 a	 clear	 trend	 towards	 treated	 dogs	 recovering	 faster	 than
nontreated	dogs	[8]	provides	a	further	potential	pathophysiological	link	between	ACP	and	GBS.
Chickens:	Marek’s	Disease




The	 infection	 of	 chickens	with	Marek’s	 disease	 virus,	 a	 cell-associated	 lymphotropic	 herpes	 virus,
results—in	its	classic	form—in	a	paralytic,	demyelinating	peripheral	neuropathy,	with	affected	chickens
exhibiting	asymmetrical,	partial	paresis	of	the	wings	and	legs,	progressing	to	complete	paralysis	of	one	or
more	 extremities,	 torticollis,	 paralysis	or	 dilation	of	 the	 crop	 and	 respiratory	distress.	Grossly,	 one	or
more	peripheral	nerves	are	enlarged,	usually	involving	the	brachial	and	sciatic	plexus	and	nerve	trunks,







control	 sera	exhibited	such	Abs.	Black	corresponds	 to	Ab-negative	signals.	The	 intensity	of	Ab	 reactivity	 increases	of	blue	 to
green	and	red,	with	red	indicating	the	strongest	signals.












juvenile	 White	 Leghorn	 chickens	 apparently	 not	 associated	 with	 Marek’s	 disease	 virus	 (MDV)	 and
characterised	by	cell-mediated,	inflammatory	demyelination	present	in	cranial	nerves,	spinal	nerves	and
nerve	 roots.	Clinically,	 these	 animals	 exhibit	 progressive	 asymmetric	 paresis	with	 intermittent	 relative
extensor	hypertonicity.	Grossly,	cranial	nerves	and	spinal	nerve	roots	are	 thickened,	whilst	histological
examinations	 reveal	multifocal	 lymphohistiocytic	 infiltrates	within	 the	proximal	 aspects	of	 some	of	 the
cranial	 nerves	 as	 well	 as	 the	 dorsal	 and	 ventral	 roots,	 which	 colocalise	 with	 demyelinated	 and
hypomyelinated	 axons.	 Similar	 to	 findings	 in	 GBS,	 electron	 microscopical	 investigations	 reveal
macrophages	 invading	 the	 myelin	 sheaths	 (Figure	 44.5).	 Additionally,	 a	 genetic	 susceptibility	 factor
confined	to	the	avian	major	histocompatibility	complex	was	found.	Whether	this	syndrome	corresponds	to








Cats	 are	 only	 rarely	 affected	 by	 acute	 idiopathic	 poly(radiculo)neuropathies	 and	 in	 this	 species	 the
comparison	to	GBS	is	hindered	most	by	the	inconsistency	of	the	examinations	carried	out	in	each	report.
The	 largest	 case	 series	 describes	 9	 young	 (4-month-old	 to	 4-year-old)	 cats	 with	 acute	 ascending
tetraparesis	or	tetraplegia,	a	loss	of	spinal	reflexes,	and	variable	dyspnoea	and	involvement	of	the	cranial
nerves	 [17].	 The	 nadir	 of	 clinical	 signs	 was	 reached	 3	 days	 after	 onset	 and	 7	 out	 of	 9	 cats	 made	 a
complete	recovery	with	supportive	treatment	over	the	following	4–6	weeks,	whilst	the	remaining	2	cats







of	muscles	 and	 nerves	 revealed	 changes	 consistent	 with	 generalised	 axonal	 neuropathy	 predominantly
affecting	the	ventral	nerve	roots,	and	in	an	adult	domestic	shorthair	cat	who	presented	with	acute	pelvic
limb	weakness	 progressing	 to	 nonambulatory	 tetraparesis	 over	 3	 days,	 proprioceptive	 deficits,	 cranial
nerve	involvement,	absent	spinal	reflexes	and	absent	superficial	pain	perception	[19].	Whilst	the	latter	of
these	 cats—euthanized	 following	 progressive	 respiratory	 compromise—exhibited	 an	 acute	 motor	 and








the	 chronic	 course	 of	 this	 disease,	 the	 aetiology	 of	which	 remains	 unknown,	 is	 considered	 to	 possibly
represent	an	immunogenic	response	to	a	persisting	herpes	virus	infection,	an	infection	of	other	aetiology
or	 antigens	 released	 by	 trauma	 or	 infection.	 This	 contrasts	 with	 GBS,	 making	 this	 disease	 a	 less
compatible	model.
Conclusion
Spontaneous	 animal	models	 of	GBS	 are	 present	 in	 numerous	 animal	 species,	with	 the	most	 promising
models	 at	 this	 stage	 represented	 by	 chickens	 and	 dogs,	 the	 former	 of	 which	 (chickens)	 recommend
themselves	due	to	the	numerical	availability	of	subjects	for	examination,	whilst	the	latter	of	which	(dogs)
are	 more	 amenable	 to	 more	 detailed	 and	 advanced	 investigations,	 including	 neurological,
electrophysiological	and	CSF	examinations,	which	combined	with	the	heterogeneity	of	the	canine	strains
involved	is	likely	to	mimic	the	situation	in	human	GBS	patients	better.
Following	 a	 relatively	 long	 period	 of	 paucity	 of	 reports	 on	 the	 subject	 of	 acute




















































diagnosis	 and	 pathogenesis	 of	Guillain-Barré	 syndrome	 and	 of	 its	 variants.	A	 large	 number	 of	 studies










a	 reactivity	 to	 a	 ganglioside	 that	 ultimately	 proved	 not	 to	 be	 a	 ganglioside.	 Ilyas	 and	 colleagues	 first
reported	in	1984	[1]	that	sera	from	3	patients	with	neuropathy	and	IgM	monoclonal	gammopathy	reacted
with	 the	 nerve	 antigen	myelin-associated	 glycoprotein	 (MAG)	bound	 to	 an	 antigen	 in	 the	 carbohydrate
moiety	of	this	molecule,	which	was	also	present	in	a	glycolipid	of	peripheral	nerve	that	was	deemed	to	be
a	 ganglioside.	 This	 cross-reacting	 glycolipid	 was	 later	 found	 not	 to	 be	 a	 ganglioside	 but	 2
glycosphingolipids	 named	 sulfoglucuronylparagloboside	 (SGPG)	 and
sulfoglucuronyllactosaminylparagloboside	(SGLPG)	[2].	The	same	or	a	closely	related	reactive	epitope
was	 reported	 the	 previous	 year	 to	 react	 with	 the	 mouse	 IgM	monoclonal	 antibodies	 H-NK1	 directed
against	 a	 surface	 epitope	 expressed	 by	 human	 natural	 killer	 cell	 and	 by	 several	 neural	 cell	 adhesion
molecules	 [3].	This	 study	opened	 the	way	 to	 the	 search	 for	 antibodies	 to	gangliosides	 in	patients	with





The	 real	 start	 of	 the	 association	 of	 anti-gangliosides	 antibodies	 and	Guillain-Barré	 syndrome	was	 the
fundamental	1990	study	by	Yuki	and	colleagues	[6]	that	reported	on	2	patients	who	developed	an	acute
axonal	polyneuropathy	after	Campylobacter	 jejuni	 enteritis.	Both	patients	 had	high	 titres	 of	 serum	 IgG
antibodies	to	the	gangliosides	GM1	that	progressively	decreased	during	recovery.	Despite	its	relevance,
this	 manuscript	 was	 accepted	 at	 Neurology	 only	 as	 a	 brief	 communication,	 and	 there	 were	 many
discussions	 about	 this	 study.	 I	 remember	 that	 in	 those	 days	 there	was	 some	 scepticism	 among	 experts
about	the	existence	of	an	axonal	form	of	GBS	that	was	considered	to	be	only	a	demyelinating	neuropathy,
and	 indeed	 the	 term	 ‘GBS’	 did	 not	 appear	 in	 the	 title.	 Even	 though	 a	 previous	 study	 by	 Feasby	 and
colleagues	in	1986	[7]	had	already	described	5	patients	with	an	acute	axonal	form	of	GBS,	I	remember	an
expert	at	a	meeting	saying	that	“there	is	no	such	thing	as	an	axonal	Guillain-Barré”.	This	may	also	explain
why	 the	 concomitant	 report	 of	 an	 epidemic	 among	 people	 living	 in	 the	 country	 in	 northern	China	 of	 a
disease	 that	 is	 now	 considered	 to	 be	 axonal	GBS	was	 originally	 postulated	 to	 be	 a	 different	 disease,
termed	 ‘acute	 motor	 axonal	 neuropathy’	 (AMAN)	 [8,9]	 which	 was	 only	 later	 included	 under	 GBS
[10,11].
To	make	 things	more	 complicated,	 during	 those	years	 an	 influential	 Italian	pharmaceutical	 company
was	 producing	 therapeutic	 agents	 for	 neuropathy	 containing	 a	 mixture	 of	 gangliosides	 (GM1,	 GD1a,
GD1b	and	GT1b;	Cronassial)	or	GM1	alone	(Sygen)	so	that	the	association	of	antibodies	to	gangliosides
and	GBS	was	quite	disturbing,	considering	that	some	reports	of	GBS	after	treatment	with	this	therapy	had
started	 to	 appear	 [12].	 It	 is	 now	 accepted	 by	 the	 neurological	 community	 that	 the	 paper	 by	 Yuki	 and
colleagues	 included	most	 of	 the	 current	 knowledge	 that	 a	 predominantly	 axonal	 form	 of	 GBS	may	 be
induced	by	an	antecedent	infection	by	Campylobacter	jejuni	 that	by	a	mechanism	of	molecular	mimicry










characterized	 by	 the	 concomitant	 presence	 of	 ophthalmoplegia,	 ataxia	 and	 areflexia.	 Since	 then	 this
reactivity	has	been	 reported	 in	 approximately	90%	of	patients	with	MFS	 [19,20],	 and	 in	patients	with
Bickerstaff’s	brain-stem	encephalitis	[21]	which	differs	from	MFS	in	the	presence	of	concomitant	signs	of
central	nervous	system	(CNS)	involvement,	including	impairment	of	consciousness	or	pyramidal	signs,	in
some	patients	with	GBS	and	ophthalmoplegia	 [22]	or	with	acute	ophthalmoparesis	 (reviewed	 in	 [23]).
This	has	also	led	to	the	proposal	of	the	term	‘anti-GQ1b	syndrome’	for	patients	with	these	antibodies	and
a	number	of	 acute	 clinical	 syndromes	characterized	by	 the	presence	of	oculomotor	 impairment	with	or
without	ataxia.	I	have	to	say	that	the	close	association	of	these	antibodies	with	this	syndrome	has	led	to	an
amazing	 increase	 in	 the	 diagnosis	 of	 MFS,	 at	 least	 in	 Italy,	 where	 a	 number	 of	 patients	 with
ophthalmoparesis	 and	 these	 antibodies	where	 diagnosed	 to	 have	MFS	 even	when	 tetraplegic	 and	with







with	 different	 clinical	 and	 electrophysiological	 presentations	 of	 GBS,	 different	 antecedent	 events	 and
possibly	 pathogenetic	mechanisms,	 and	 to	 the	 definition	 of	 a	 number	 of	 new	 functional	 or	 topographic
variants	of	GBS.	In	1992	Yuki	and	colleagues	reported	2	patients	with	an	explosive,	motor	GBS	rapidly
evolving	 into	 respiratory	 insufficiency	and	mainly	axonal	 impairment	who	had	high	 titres	of	anti-GD1a
IgG	 antibodies	 [25].	 Subsequent	 studies	 showed	 that	 these	 antibodies	 are	 present	 in	 approximately	 5–
20%	of	patients	with	GBS,	most	of	whom	have	a	severe	axonal	form	[26–28].	Studies	also	reported	an
association	 of	 this	 reactivity	 with	 an	 antecedent	 infection	 by	 Campylobacter	 jejuni	 [29].	 A	 closely
related	 reactivity	 against	N-acetylgalactosaminyl	GD1a	 (GalNAcGD1a)	 [30]	 and	often	with	 the	 cross-
reacting	GM1b	ganglioside	[31]	was	subsequently	reported	in	approximately	20%	of	patients	with	GBS
and	was	 initially	 associated	with	 an	 axonal	motor	 form	of	GBS	 and	 antecedent	Campylobacter	 jejuni
infection	 [32]	 and	 occasionally	 with	 Mycoplasma	 pneumoniae	 infection	 [33].	 More	 heterogeneous




New	 antibody	 reactivities	were	 also	 associated	with	 demyelinating	 forms	 of	GBS.	 In	 1996	 Irie	 et	 al.
reported	3	patients	with	GBS	and	an	acute	cytomegalovirus	(CMV)	infection	revealed	by	increased	anti-
CMV	IgM	antibodies	who	had	high	 titres	of	anti-GM2	IgG	and	IgM	antibodies	 [34].	Subsequent	series
reported	 this	 reactivity	 in	up	 to	10%	of	patients.	These	antibodies	were	 later	 found	to	cross-react	with
CMV-infected	 fibroblasts,	 supporting	 the	 hypothesis	 of	 a	 possible	 mechanism	 of	 molecular	 mimicry
between	 the	 pathogen	 and	 the	 ganglioside	 [35].	 These	 studies	 opened	 the	 way	 to	 the	 possible
understanding	 of	 the	 pathogenesis	 of	 demyelinating	 GBS	 since	 most	 patients	 with	 GBS	 after	 CMV
infection	appeared	to	have	a	demyelinating	GBS	with	more	prominent	sensory	impairment	 than	patients
with	 an	 antecedent	 Campylobacter	 jejuni	 infection	 or	 without	 a	 known	 infection	 [36].	 The	 relation
between	 anti-GM2	 antibodies	 and	 CMV-associated	 GBS	 was	 not,	 however,	 always	 confirmed	 in
subsequent	studies	[37,38].
Another	 infrequent	 reactivity	 with	 ganglioside	was	 described	 in	 1994	 by	Willison	 and	 colleagues,
who	reported	a	patient	with	an	acute	sensory	neuropathy	without	ophthalmoplegia	with	IgG	antibodies	to
GD1b	 and	GD3	 but	 not	 to	GQ1b,	 distinguishing	 him	 from	MFS	 [39].	A	 few	 other	 patients	with	 acute
ataxic	neuropathy	and	a	selective	reactivity	to	GD1b	were	later	reported	[40,41].	A	more	extensive	study




Another	 peculiar	 association	 is	 that	 of	 a	 selective	 IgG	 reactivity	 with	 GT1a	 with	 or	 without
concomitant	 reactivity	 with	 GQ1b	 in	 a	 form	 of	 GBS	 with	 prominent	 or	 exclusive	 cervico-brachial-
oropharyngeal	 impairment.	This	was	 initially	 reported	 in	 a	patient	with	 a	pharyngeal-cervical	 brachial
variant	 of	 GBS	 with	 a	 separate,	 concomitant	 lower	 reactivity	 with	 GD1a	 [43].	 A	 similar	 selective
reactivity	with	GT1a	was	subsequently	reported	in	a	few	other	patients	with	oropharyngeal	palsy,	neck
weakness	or	polyneuritis	cranialis	[44,45],	while	in	the	majority	of	positive	patients	the	correlation	was
difficult	 to	ascertain	considering	the	frequent	concomitant	reactivity	 to	GQ1b.	The	difficulty	 in	defining
the	 clinical	 correlate	 of	 this	 reactivity	 also	 derives	 from	 another	 study	 confirming	 the	 frequent
concomitant	reactivity	with	GQ1b	[46].	Other	reactivities	were	subsequently	reported	in	a	small	number







an	 antecedent	 Campylobacter	 jejuni	 infection	 but	 it	 was	 unclear	 how	 the	 same	 pathogen	 could	 be
associated	with	different	clinical	conditions.	Kuroki	and	colleagues	were	the	first	to	relate	the	presence
anti-GM1	IgG	antibodies	in	GBS	with	an	antecedent	infection	by	Campylobacter	jejuni	of	the	Penner	19













a	minority	of	patients	with	Campylobacter	 jejuni	 infection	 develop	GBS	 (1.17/1000,	 77	 times	 greater
risk	than	in	the	general	population)	and	that	the	probability	of	developing	GBS	in	the	2	months	following
Campylobacter	jejuni	is	less	than	2/10,000	[51].	The	hypothesis	that	the	immunologic	predisposition	of
the	 host	may	 also	 contribute	 to	 this	 susceptibility	 has	 also	 been	 investigated	with	 inconclusive	 results
[52,53].
The	In	Vitro	Effect	of	Anti-GM1	Antibodies.	Buchwald	et	al.	1998
The	 possible	 mechanism	 by	 which	 anti-GM1	 antibodies	 may	 affect	 peripheral	 nerve	 function	 was
examined	in	an	 in	vitro	model	by	Buchwald	and	colleagues,	who	adopted	 the	same	macro-patch-clamp
system	used	to	study	neuromuscular	transmission	in	myasthenia	gravis	[54].	Using	this	model	the	authors












of	 miniature	 endplate	 potentials	 followed	 by	 a	 complete	 block	 of	 neuromuscular	 transmission.	 In	 a
subsequent	 study	 [57]	 they	 showed	 that	 anti-GQ1b	 antibodies	 bind	 at	 the	 neuromuscular	 junctions,
inducing	 a	 massive	 quantal	 release	 of	 acetylcholine	 from	 nerve	 terminals	 followed	 by	 a	 block	 of
neuromuscular	 transmission.	 This	 effect	 resembled	 that	 of	 the	 neurotoxin	α-latrotoxin,	 a	 component	 of
black	 widow	 spider	 venom,	 raising	 the	 possibility	 that	 the	 antibodies	 bound	 to	 the	 same	 receptor	 as
bound	 by	 this	 toxin.	 The	 effect	 of	 anti-GQ1b	 antibodies	 was	 strictly	 dependent	 on	 the	 activation	 of
complement	components	but	neither	the	classical	pathway	activation	nor	the	formation	of	membrane	attack
complexes	was	required,	supporting	the	possibility	of	the	activation	of	the	alternative	pathway.




antibodies	 (see	above)	 [59,60].	They	 found	 that	 IgG	from	patients	with	MFS	had	a	combined	pre-	and
postsynaptic	action	blocking	the	neuromuscular	transmission	sera.	In	this	case,	however,	a	similar	effect
was	 obtained	with	 sera	 from	 patients	 in	whom	 anti-GQ1b	 antibodies	were	 not	 found.	 In	 general	 both






Three	of	 the	6	 immunized	 rabbits	developed	a	 sensory	neuropathy	without	motor	 involvement	 that	was
associated	with	axonal	 loss	 in	 the	dorsal	 roots	and	sciatic	nerve	and	with	 loss	of	nerve	cell	bodies	 in
dorsal	 root	ganglia.	All	animals	developed	antibodies	 to	GD1b.	This	presentation	was	similar	 to	what
had	been	observed	 in	some	patients	with	anti-GD1b	antibodies	and	an	acute	sensory	ataxic	neuropathy
(see	above).	A	similar	model	of	anti-ganglioside	neuropathy	was	later	induced	in	rabbits	by	immunization
with	 a	 mixture	 of	 ganglioside	 containing	 GM1	 or	 with	 GM1	 alone	 [62].	 In	 this	 case	 the	 animals
developed	high	 titres	of	 anti-GM1	antibodies	 associated	with	 the	 acute	onset	of	 flaccid	paresis	with	a
monophasic	illness	course.	Pathological	studies	revealed	axonal	degeneration	with	deposits	of	IgG	on	the
axons	of	anterior	roots.	This	animal	model	strictly	resembled	human	axonal	GBS.	In	addition,	similar	to
what	 had	 been	 observed	 in	 human	 GBS,	 treatment	 of	 the	 immunized	 rabbits	 with	 intravenous
immunoglobulin	induced	a	faster	recovery	of	GBS	compared	to	untreated	animals	[63].	A	similar	axonal
neuropathy	was	induced	in	mice	by	intraperitoneal	implantation	of	hybridoma-secreting	antibodies	to	the
gangliosides	 GD1a/GT1b-2b	 [64].	 This	 experimental	 model	 may	 explain	 the	 already	 mentioned
neuropathy	induced	in	humans	by	treatment	with	gangliosides;	subsequent	studies	revealed	the	ability	to
induce	 an	 acute	 axonal	 GBS	 by	 sensitization	 with	 the	 lipooligosaccharide	 of	 Campylobacter	 jejuni
isolated	 from	patients	with	GBS	 [65,66].	 Immunized	animals	developed	high	 titres	of	 serum	anti-GM1
antibodies,	 followed	 by	 an	 acute	 flaccid	 paresis.	 Pathological	 studies	 revealed	 signs	 of	 Wallerian
degeneration	 in	 some	 animals	 with	 deposits	 of	 IgG	 in	 the	 nerve.	 In	 addition,	 the	 same	 pathological
features	 observed	 in	 some	patients	with	 acute	GBS	of	macrophage	 infiltrating	 between	 the	myelin	 and
axon	were	found	in	some	animals	[65].	I	think	that	these	experiments	clearly	showed	how	exposure	of	the
animals	 to	Campylobacter	 jejuni	 may	 induce	 the	 development	 of	 anti-GM1	 antibodies	 and	 an	 acute
axonal	GBS.
A	Personal	View
I	 think	 that	 there	 is	 considerable	 evidence	 from	 the	 above-mentioned	 studies	 that	 anti-ganglioside
antibodies	play	an	important	role	in	the	pathogenesis	of	GBS	and	MFS.	As	neurologists,	however,	we	are
a	little	bit	spoiled	by	what	we	observed	in	myasthenia	gravis,	where	80–90%	of	patients	have	antibodies





with	 GBS	 or	 MFS	 have	 antibodies	 to	 a	 complex	 of	 gangliosides	 [67,68]	 even	 if	 these	 patients	 only
represent	a	minority.	It	remains	unclear	why	a	difference	in	the	prevalence	of	antecedent	infection	from
country	 to	country	does	not	 result	 in	consistent	differences	 in	 the	 incidence	of	GBS	[69]	nor	 is	 it	clear
why	 a	 similar	 proportion	 of	 patients	 in	 different	 countries	 eventually	 develop	 the	 same	 disease	 from
different	triggering	events.	Even	if	we	now	have	fantastic	evidence	on	how	the	mechanism	of	molecular




















































































































































In	 Guillain-Barré	 syndrome	 (GBS)	 and	 its	 variants,	 antibodies	 to	 glycolipids,	 especially	 N-
acetylneuraminic	 acid-	 (sialic-acid)	 bearing	glycosphingolipids,	which	 are	 referred	 to	 as	 gangliosides,
have	been	 tested	 in	acute	phase	sera	as	diagnostic	markers.	Generally,	 to	detect	pathogenic	antibodies,
purified	single	substances	have	been	used	as	test	antigens.	Thorough	purification	of	natural	substances	and
avoidance	 of	 antigen	 contamination	 provide	 accurate	 and	 reliable	 results.	 It	 has	 been	 the	 same	 in
measurement	of	anti-ganglioside	antibodies.	Over	10	years	ago,	we	detected	IgG	antibodies	specifically
reacting	 with	 a	 mixture	 of	 2	 different	 gangliosides	 in	 sera	 from	 patients	 with	 GBS,	 and	 named	 such
mixture	as	ganglioside	complex	(GSC).	In	thin-layer	chromatogram	(TLC)	immunostaining	assay,	the	anti-
GSC	 antibodies	 do	 not	 bind	 to	 each	 constituent	 ganglioside,	 but	 bind	 to	 overlapping	 portions	 of	 2





reacted	with	 unknown	 antigens	 just	 below	 a	 level	 of	GD1a	 in	TLC	 immunostaining	 assay	 using	 crude
bovine	 brain	 ganglioside	 fraction	 which	 was	 obtained	 through	 DEAE	 Sephadex	 A-25	 column	 by
extraction	 with	 0.1M	 ammonium	 acetate.	 Conventional	 ELISA	 screening	 for	 serum	 anti-ganglioside
antibodies	showed	negative	results	for	GD1a,	GalNAc-GD1a,	and	GD1b.	Identification	of	the	invisible
targets	 for	 the	 immunoreaction	on	a	TLC	plate	was	one	of	 tasks	 the	visionary	 supervisor	Dr	Kusunoki
assigned	to	a	graduate	student.	In	spite	of	considerable	laboratory	work	with	use	of	various	purification





Considering	 that	 glycosphingolipids	 form	 a	 cluster	 with	 other	 glycolipids	 in	 lipid	 rafts,
glycosphingolipid-enriched	membranes,	 it	 is	 no	 wonder	 that	 clustered	 glycol-epitopes	 in	 the	 rafts	 are
targeted	 by	 anti-ganglioside	 antibodies.	 Ligands	 of	 adhesion	 molecules	 such	 as	 selectins	 and	 siglecs
(sialic	 acid-recognizing	 immunoglobulin-superfamily	 lectins)	 are	 assumed	 to	 comprise	 complex






putative	 antigenic	 epitopes	 for	 anti-GSC	 antibodies.	 In	 TLC	 immunostaining,	 the	 developing	 solvent	 consisted	 of	 chloroform,
methanol	and	0.2%	CaCl2·2H2O	(50:45:10,	v/v).	Lower	 left	panel:	TLC	results	visualised	by	orcinol	 reagent;	 lower	 right	panel:







into	 2	 patterns:	 reactivity	 against	 a	 combination	 of	 [Galβ1-3GalNAc]	 and	 [NeuAcα2-8	 NeuAc	 α	 2-
3Galβ1-3GalNAc]	 in	 terminal	 residues	 of	 ganglio-N-tetraose	 structures,	 or	 reactivity	 against	 a
combination	 of	 [NeuAcα2-3Galβ1-3GalNAc]	 and	 [NeuAcα2-8	 NeuAcα	 2-3Galβ1-3GalNAc]	 in
terminal	residues	(Figure	46.2).	Such	antibodies	to	GSC	containing	GQ1b	or	GT1a	are	also	found	in	half
of	GBS	patients	with	ophthalmoplegia	[5].	Regarding	anti-GSC	antibodies,	MFS	is	different	from	GBS	in
that	 there	 are	 no	 IgG	 antibodies	 to	 GSCs	 consisting	 of	 2	 of	 GM1,	 GD1a,	 GD1b	 and	 GT1b	 in	MFS.
Colocalization	of	GQ1b,	GM1	and	GD1a	remains	to	be	proved	in	nerve	membranes	of	oculomotor	nerves
and	dorsal	root	ganglion	neurons.















GSC	 antibodies	 was	 17%	 in	 GBS	 [7].	 In	 target	 GSC,	 the	 combination	 of	 gangliosides	 appears	 to	 be
governed	 by	 a	 principle	 that	 a	 target	 molecule	 is	 an	 epitope	 formed	 by	 a	 combination	 of	 [Galβ1-
3GalNAc]	 and	 [NeuAcα2-3Galβ1-3GalNAc]	 in	 terminal	 moieties	 of	 ganglio-N-tetraose	 structures
(Figure	 46.1).	 GBS	 patients	 with	 such	 anti-GSC	 antibodies	 were	 characterized	 by	 having	 had	 an
antecedent	gastrointestinal	infection,	lower	cranial	nerve	deficits	and	severe	disability.	The	association	of
anti-GSC	 antibodies	 with	 severe	 disability	 should	 be	 confirmed	 in	 future	 prospective	 studies.	 The
severity	may	be	explained	by	tighter	interactions	between	anti-GSC	antibodies	and	GSC	with	multivalent







selectins	 and	 Siglecs	 (sialic-acid-recognizing	 immunoglobulin-superfamily	 lectins),	 based	 on	 a	 cis-	 or
trans-carbohydrate-to-carbohydrate	 interaction	 [8,9].	 Ganglioside	 complexes	 providing	 clustered
carbohydrate	epitopes	are,	 therefore,	 likely	 to	be	 influential	on	 the	cell	 adhesion	process.	Research	by
Todeschini	 and	 colleagues	 exhibited	 that	 a	 GM2/GM3	 complex	 more	 efficiently	 inhibits	 cell	 motility
through	blocking	of	c-Met	activation	than	GM2	or	GM3	alone	[10].	This	was	the	first	report	showing	that
GSCs	play	a	functional	role	in	the	cell	function.	One	future	task	is	to	amass	convincing	evidence	proving





of	 GBS	 patients.	 Anti-GM1/GalNAc-GD1a-positive	 patients	 usually	 develop	 a	 pure	 motor	 variant	 of
GBS	 with	 preserved	 cranial	 and	 sensory	 nerves	 and,	 contrary	 to	 expectations,	 are	 characterized	 by
experiencing	a	preceding	respiratory	infection	and	early	conduction	block	(CB)	in	motor	nerves.	The	CB
arises	at	intermediate	nerve	segments	of	motor	nerves,	but	not	at	common	compression	sites	such	as	the
wrists	 and	elbows.	 In	view	of	 the	 rapid	 recovery	of	CB	and	no	evidence	of	 remyelination	 and	axonal
degeneration	 in	 subsequent	 electrophysiological	 studies,	 the	 CB	 is	 likely	 to	 result	 from	 reversible
conduction	failure	caused	by	temporary	blockade	of	voltage-gated	sodium	channels	(NaV)	at	the	nodes	of
Ranvier.	GM1	and	GalNAc-GD1a	may	assemble	and	form	a	GM1/GalNAc-GD1a	complex	in	the	vicinity




In	 the	 routine	 measurement	 of	 anti-GSC	 antibodies	 in	 sera	 from	 GBS	 patients,	 some	 IgG	 anti-GD1b
antibodies	revealed	prominent	decrease	of	anti-GD1b	activities	by	the	addition	of	gangliosides	with	2	or
more	sialic	acids	to	GD1b.	In	a	larger	number	of	GBS	patients,	we	confirmed	that	such	GD1b-specific
antibodies	 were	 significantly	 associated	 with	 development	 of	 ataxia,	 whereas	 GBS	 patients	 without
ataxia	had	anti-GD1b	antibodies	which	equally	reacted	against	a	mixture	of	GD1b	and	other	gangliosides,







In	 a	 sophisticated	 ex	 vivo	 study	 using	GalNAc	 transferase-deficient	 and	GD3	 synthase-deficient	mice,
Greenshields	and	colleagues	clearly	showed	that	the	glycolipid	environment	governs	the	accessibility	and
the	avidity	of	anti-ganglioside	antibodies	[13].	A	monoclonal	anti-GM1	antibody	(DG2)	with	activity	not
attenuated	 by	 GSC	 was	 found	 to	 bind	 to	 motor	 nerve	 terminals.	 In	 contrast,	 a	 monoclonal	 anti-GM1
antibody	 (DG1)	 with	 activity	 that	 was	 attenuated	 by	 GSC	 could	 not	 bind	 to	 motor	 nerve	 terminals.
Conversion	of	GD1a	to	GM1	by	neuraminidase	treatment	made	it	possible	for	DG1	to	access	to	GM1	in
the	 motor	 terminal	 axons.	 These	 study	 results	 clearly	 indicate	 that	 the	 glycolipid	 environment	 and
antibody	 specificity	 are	 influential	 factors	 in	 antibody-antigen	 interactions.	 Based	 on	 the	 binding
specificity,	finally,	the	anti-ganglioside	antibodies	are	classified	into	3	types:	complex-attenuated	(DG1),
complex-independent	(DG2),	and	complex-enhanced.	Neighbour	glycolipids	as	well	as	anti-ganglioside





Complement	 activation	 is	 considered	 to	 play	 a	 key	 role	 in	 anti-ganglioside	 antibody-mediated	 nerve
injury	 in	GBS	 and	 its	 variants,	 as	 shown	 in	 vitro	 and	 ex	 vivo.	 Zitman	 and	 colleagues	 showed,	 in	 the
nerve-muscle	co-culture	ex	vivo	model,	that	anti-GSC	antibodies	from	patients	with	GBS	and	its	variants
had	a	neurophysiological	blocking	effect	at	motor	nerve	terminals	and	induce	complement-mediated	nerve
damage	 through	an	antigen-antibody	 interaction	 [14].	 In	addition,	 the	authors	 showed	 that	GSC	such	as





ELISA	 plate	 are	 not	 enough	 to	 test	 antibody	 reactivity	 against	 a	 multitude	 of	 glycolipid	 complexes.
Rinaldi,	Brennan	and	Willison	(2012)	developed	a	new	screening	method—combinatorial	glycoarray—
which	is	appropriate	for	testing	antibody	activities	to	many	heteromeric	complexes	consisting	of	various
lipids	 as	 well	 as	 glycolipid	 complexes	 [15].	 Their	 method	 can	 test	 antibodies	 to	 many	 glycolipid
complexes	simultaneously,	discover	new	anti-glycolipid	antibodies	and	save	scarce	reagents.
As	 reported	 elsewhere	 [16],	 in	 multifocal	 motor	 neuropathy,	 IgM	 anti-GM1	 antibodies	 revealed	 a
stronger	binding	ability	to	GM1	ganglioside-containing	lipid	mixture	than	to	GM1	alone.	A	recent	study
using	 the	 combinatorial	 glycoarrays	with	 polyvinylidene	 difluoride	 (PVDF)	membrane	 has	 pointed	 out
that	 glycol	 epitopes	 newly	 formed	 in	 a	mixture	 of	 glycolipid	 and	 lipid	 can	 be	 novel	 targets	 [17].	We
should	 note	 that	 the	 sensitivity	 and	 the	 specificity	 of	 antibodies	 to	 such	 heteromeric	 complexes	 may





Reconstructing	 biological	 membrane	 models	 faithfully	 is	 an	 urgent	 issue.	 It	 is,	 however,	 difficult	 at
present	to	artificially	reproduce	the	same	lipid	environment	as	lipid	rafts	of	the	plasma	membrane.	It	is
unclear	how	GSCs	are	 formed,	 are	distributed	and	 function	 in	 the	nervous	 system.	 In	2012,	Mauri	 and
colleagues	provided	a	dimeric	GM1-GD1a	hybrid	ganglioside	derivative,	which	contains	2	structurally
different	 oligosaccharide	 chains	 [19].	 Such	 synthetic	 dimeric	 hybrids	 mimic	 GSCs	 and	 are	 useful	 for
studies	 on	 anti-GSC	 antibody-mediated	 immunoreaction	 to	 carbohydrates.	 The	 combinatory	 glycoarray
systems	 are	 important	 tools	 for	 extensively	 investigating	 anti-ganglioside	 antibody-mediated
glycoconjugate	 recognition,	 as	well	 as	 for	 detecting	 novel	 anti-GSC	 antibodies.	 It	 is,	 however,	 nearly
impossible	 to	 adjust	 the	 condition	 of	 the	 glycoarray	 systems	 regarding	 their	 glycolipid	 density	 and	 the
clustering	of	sugar	ligands.	Antibody-mediated	carbohydrate	recognition	on	the	cell	surface	is	regulated
by	 the	chemical	property	of	 the	constituents	of	glycoconjugates	 in	 the	cell	membrane.	Additionally,	 the
nature	 of	 the	 glycoconjugates	 is	 governed	 by	 parameters	 consisting	 mainly	 of	 multivalency	 of	 sugar
epitopes,	 their	 orientation	 and	 conformational	 flexibility	 of	 their	 presentation,	 and	 ligand	 density	 and
spacing	of	 interaction	partners	 [20]	 (figure	46.3).	Synthetic	 clustered	glycolipids	of	different	valencies
vary	 in	 carbohydrate	density	on	 a	PVDF	or	 a	 polystyrene	 surface	 and	 are	useful	 to	 adjust	 some	of	 the
above	parameters	and	to	make	efficient	use	of	the	present	glycoarray	systems.
Perspectives
In	 addition	 to	 the	GM1-GD1a	hybrid,	 a	dimeric	GM1	hybrid	 (GM1-GM1	dimer)	 and	a	dimeric	GD1a
hybrid	(GD1a-GD1a	dimer)	are	also	important	tools	for	analysing	anti-ganglioside	antibody-carbohydrate
interaction	 on	 the	 cell	 surface	 [21].	 We	 should	 equip	 a	 series	 of	 synthetic	 mono-,	 di-,	 and	 trivalent





A	 recent	 study	 has	 shown	 that	 GM1-like	 and	 GD1a-like	 lipooligosaccharides	 may	 form	 a	 GM1b
epitope,	inducing	the	development	of	anti-GM1b	antibodies	[22].	This	result	indicates	that	the	complex	of
2	 different	 structures	 may	 form	 a	 new	 molecular	 mimicry,	 although	 it	 is	 unclear	 whether	 the	 anti-




























































a	role	 in	 the	pathogenesis	of	GBS,	 is	from	Cook	and	colleagues	[2].	The	paper	reports	 the	presence	of
atypical	basophilic	mononuclear	cells	in	the	blood	of	patients	with	GBS,	so-called	atypical	leukocytes	or
circulating	 immunocytes.	 They	 found	 many	 of	 these	 cells	 proliferating,	 as	 indicated	 by	 the	 uptake	 of
tritiated	 thymidine,	 demonstrating	 DNA	 synthesis.	 This	 was	 analysed	 cell-by-cell	 (imagine	 all	 the
counting	that	it	required!).	Sixty-four	percent	of	the	GBS	patients,	mostly	in	the	acute	stage	of	the	disease,
had	 increased	 numbers	 of	 these	 DNA-synthesizing	 cells.	 The	 numbers	 subsequently	 declined	 to	 basal
levels.	Importantly,	there	was	a	correlation	between	the	number	of	DNA-synthesizing	cells	and	the	onset
of	 clinical	 recovery.	The	 responses	 in	peripheral	blood	were	 reminiscent	of	 the	 responses	 seen	during
immune	 reactions	 in	 man	 and	 animals	 immunised	 with	 peripheral	 nervous	 system	 tissue	 in	 complete
Freund’s	adjuvant	 (CFA)	[3].	Building	further	onto	 the	 landmark	histopathology	study	[4],	showing	 that
mononuclear	 infiltrates	 are	 present	 in	 demyelinating	 areas	 of	 peripheral	 nerves	 of	 GBS	 patients,	 the







After	 the	 discovery	 that	 antibodies	 in	 GBS	 patients	 were	 recognising	 glycolipids	 [5],	 an	 important
question	arose	as	to	what	subclasses	were	produced.	Since	antibodies	to	lipopolysaccharides	(LPS)	and
bacterial	capsular	polysaccharides	are	predominantly	of	the	IgG2	subclass	[6,7],	Hugh	Willison	and	co-
workers	 must	 have	 been	 surprised	 to	 find	 that	 the	 antibodies	 were	 actually	 of	 the	 IgG1	 and	 IgG3
subclasses	 [8].	 Interestingly,	 some	patients	with	MFS,	but	not	GBS,	did	have	 low	 levels	of	 IgG2	anti-
GQ1b,	 suggesting	 that	 a	 typical	 carbohydrate	 antibody	 response	 to	 glycolipids	 can	 occur	 in	 some
instances.	 The	 ‘atypical	 immune	 response’,	 as	mentioned	 in	 the	 discussion	 of	 the	 paper	 [8],	 has	 been
confirmed	 by	 many	 other	 groups	 and	 was	 found	 to	 be	 related	 to	 preceding	 infections,	 where
gastrointestinal	 infections	 were	 linked	 to	 IgG1	 and	 respiratory	 infections	 to	 both	 IgG1	 and	 IgG3	 [9].
Immunisation	 of	 humans	 with	 GM2	 combined	 with	 Bacillus	 Calmette-Guérin	 also	 resulted	 in	 the









focussed	on	 the	 in	vitro	production	of	anti-GM1	IgM,	and	 this	was	also	 found	 in	some	disease	control
patients,	 in	 2	 GBS	 cases	 evidence	 was	 found	 for	 the	 production	 of	 anti-GM1	 IgG.	 In	 addition,	 in	 2
patients	 in	 vitro	 IgM	 anti-GM1	 production	was	 found	 early	 in	 the	 disease	 course	 and	 in	 unstimulated











was	also	present	 in	nude	mice,	 lacking	a	thymus.	Upon	each	booster,	 there	was	an	increase	in	antibody
levels,	 suggesting	a	 step-wise	expansion	of	GM1-specific	B	cells.	Hence	 the	data	nicely	 indicates	 that











The	 ‘antigenic	stimulation’	 in	GBS	patients,	as	observed	by	Cook	and	colleagues,	 is	now	known	 to	be
caused	by	various	pathogens,	most	frequently	Campylobacter	jejuni	[15].	Therefore	the	Norman	Latov’s
group	wondered	whether	 immunisation	with	 lipooligosaccharides	 (LOS)	derived	 from	C.	 jejuni	 would
give	rise	to	anti-glycolipids	[16].	They	were	able	to	induce	high	titres	of	anti-GM1	IgM	antibodies	in	rats
that	were	immunised	with	keyhole	limpet	hemocyanin	(KLH)	prior	to	injection	with	C.	jejuni	LOS.	The













following	 immunisation	 with	 C.	 jejuni	 LOS	 [18].	 In	 this	 model,	 ‘intermolecular’	 T-cell	 help	 was
provided	by	the	addition	of	ovalbumin	to	the	ganglioside	liposomes,	or	by	the	use	of	CFA.	This	resulted
in	class	switching	to	IgG1	and	IgG2a/b.	In	the	same	paper	it	was	shown	that	in	ganglioside-sufficient,	but
TLR4	 hyporesponsive	 mice,	 no	 anti-glycolipid	 antibodies	 could	 be	 induced.	 This	 experiment	 clearly
demonstrates	the	important	role	of	TLR4	activation.	Mice	immunised	with	LOS	devoid	of	a	ganglioside
mimic	 did	 not	 produce	 cross-reactive	 antibodies,	 indicating	 that	 the	 exact	mimic	must	 be	 present.	The





In	 the	quest	 for	 a	mouse	model	 for	 anti-GM1	antibody-mediated	neuropathy,	 the	 laboratory	of	Norman
Latov	generated	a	transgenic	mouse	with	a	population	of	B	cells	expressing	an	anti-GM1	B-cell	receptor
[20].	The	 sequence	of	 the	antibody	was	derived	 from	a	patient	with	multifocal	motor	neuropathy	 [21].
One	of	the	most	striking	observations	to	me	is	that	the	B	cells	with	anti-GM1	reactivity	were	not	deleted






occurred	 (mainly	 IgG3	and	 IgG2b).	 Immunisation	with	GM1	alone	or	E.	coli	 LPS	did	 not	 induce	 anti-







The	 studies	 in	 rodents,	 discussed	 above,	 in	 which	 glycolipids	 predominantly	 induce	 antibodies	 with
thymus-independent	 characteristics,	 suggest	 that	 T	 cells	 are	 required	 for	 switching	 to	 the	 isotypes
associated	with	GBS.	So	what	is	known	about	T-cell	responses	in	GBS?	Evidence	for	involvement	of	γδ
T	cells	in	GBS	is	provided	by	the	2000	study	by	Borsellino	and	colleagues	[23].	Most	importantly,	the
percentage	 of	 Vδ1	 cells	 was	 significantly	 increased	 in	 the	 peripheral	 blood	 of	 GBS	 patients,	 and
approximately	half	of	the	cells	also	expressed	the	NK	cell	marker	NKRP1A.	T-cell	clones	derived	from








The	 final	 ‘missing	 link’	 experiment,	 to	 prove	 that	 cross-reactive	 antibodies	 are	 generated	 through	 a
process	of	molecular	mimicry	and	cause	neuropathy,	was	reported	by	Yuki	and	colleagues	in	2004	[25].
Rabbits	were	 immunised	 at	 3-week	 intervals	with	C.	 jejuni	 LOS	 dissolved	 in	KLH	 and	 emulsified	 in
CFA.	In	the	high-dose	group,	all	animals	developed	antibodies	to	GM1	and	flaccid	paralysis	occurred	at
various	time	points.	The	rabbit	model	pathologically	resembles	human	acute	motor	axonal	neuropathy.	Of
note,	 the	 anti-GM1	 titres	 gradually	 increased	 following	booster	 immunisations,	 and	 the	majority	 of	 the
animals	 developed	 paralysis	 within	 3	 weeks	 after	 the	 anti-GM1	 titre	 peak	 was	 reached.	 One	 animal














I	 joined	 the	 laboratory	of	Bart	 Jacobs.	The	project	underscores	 the	 long-standing	 fruitful	 collaboration








innate	 immune	cells	 is	 facilitating	 the	 initiation	of	 subsequent	 adaptive	 immune	 responses.	Recent	data





clear	 now	 that	 GBS	 is	 a	 post-infectious	 disease,	 mediated	 by	 B	 cells	 and	 antibodies	 that	 are	 cross-
reactive	 with	 glycolipids	 in	 the	 peripheral	 nerve.	 Although	 B	 cells	 can	 be	 activated	 to	 produce	 anti-
glycolipid	 antibodies	 in	 a	 thymus-independent	manner	 in	 rodents,	 and	most	 likely	 also	 in	 humans,	 for
class	 switching	 to	 IgG1	 and	 IgG3	 additional	 B-cell	 help	 seems	 to	 be	 required.	 The	 exact	 cellular
mechanism,	 however,	 remains	 to	 be	 determined.	 Both	 the	 presence	 of	 a	 carbohydrate	 mimic,	 which










































































it	was	 that	 discovery	which	provided	 the	 first	 indication	 that	myelin	might	 be	 selectively	destroyed	 in
GBS.	 Prior	 to	 that	 date,	 pathological	 studies,	 even	 the	 landmark	 report	 of	Haymaker	 and	Kernohan	 in
1949,	 which	 examined	 50	 fatal	 cases,	 did	 not	 mention	 demyelination,	 although	 the	 extent	 of	 nerve
devastation	was	thoroughly	documented	[2].	The	first	major	study	to	recognise	specific	myelin	destruction




myelin	was	 targeted	 in	 these	 disorders.	Wisniewski,	Terry,	Whitaker,	Cook	 and	Dowling	published	 an
autopsy	 study	 which	 showed	 that	 myelin	 dissolution	 occurred	 in	 immediate	 proximity	 to	 invading
macrophages	and	that	lymphocytes	were	not	present	within	the	basal	lamina	of	affected	fibres	[4].	Similar
macrophage-mediated	 demyelination	 in	 EAN	 was	 reported	 by	 Lampert	 in	 1969	 [5].	 In	 1972	 Prineas
described	changes	 in	GBS	of	 stripping	and	phagocytosis	of	compact	myelin	by	macrophages	 following
displacement	of	normal	appearing	Schwann	cell	cytoplasm	away	from	the	sheath	[6].	(See	Figure	48.1.)
These	dramatic	illustrations	suggested	that	if	GBS	and	EAN	were	homologous	autoimmune	disorders















Over	 the	 next	 few	 decades	 researchers	 screened	 patient	 sera	 for	 antibodies	 to	 the	 major	 myelin
proteins—particularly	for	those	that	could	induce	EAN,	including	P2,	P0	and	PMP-22.	There	have	been
numerous	studies	screening	sera	for	antibody	reactivity	to	these	major	myelin	proteins,	but	thus	far	they
have	 not	 proven	 to	 be	 key	 targets	 and	 there	 is	 no	 consensus	 as	 to	 their	 pathogenic	 relevance	 in	 those
patients	in	whom	antibodies	have	been	detected.
P0	Protein








neuropathy.	 PMP-22	 is	 also	 neuritogenic	 in	 the	 Lewis	 rat,	 and	 antibodies	 to	 synthetic	 peptides
representing	either	the	first	or	second	extracellular	domains	of	PMP-22	have	been	reported	in	58%	of	19
GBS	 patients	 and	 4%	 of	 51	 normal	 subjects	 [9].	 Other	 groups	 have	 failed	 to	 detect	 such	 a	 clear






















mechanisms	of	molecular	mimicry	 in	AIDP.	Recently	Sawai	and	colleagues	 identified	antibodies	 to	 the
protein	 moesin	 in	 5	 out	 of	 6	 AIDP	 patients	 who	 had	 antecedent	 CMV	 infections	 [16].	 Moesin	 was
identified	as	a	 target	 in	 this	case	by	using	a	proteomic	approach	 to	screen	sera	with	proteins	extracted
from	schwannoma	cells	and	identify	proteins	that	bound	IgG	using	mass	spectrometry.	Moesin	is	part	of
the	ERM	(ezrin,	 radixin,	moesin)	 family	expressed	on	Schwann	cell	microvilli	at	 the	nodes	of	Ranvier
and	is	among	a	growing	group	of	proteins	that	may	be	relevant	to	demyelinating	neuropathies	but	are	not









cache	 as	 new	methods	 of	 detection	 became	 available,	 and	 by	 2010	 there	 were	 about	 40	 known	 PNS
myelin	proteins.
In	 2011	 the	 first	 proteomic	 analysis	 of	 PNS	myelin	 identified	 545	 proteins	 in	mouse	 sciatic	 nerve,
















































triggered	 by	 molecular	 mimicry	 [2]:	 (A)	 establishment	 of	 an	 epidemiological	 association	 between	 an
infectious	 disease	 and	 immune-mediated	 diseases;	 (B)	 identification	 of	 T	 cells	 or	 antibodies	 directed
against	 human	 target	 antigens;	 (C)	 identification	 of	 microbial	 mimics	 of	 the	 target	 antigen;	 and	 (D)
reproduction	of	the	disease	in	an	animal	model.
Guillain–Barré	syndrome	(GBS)	is	the	first	disease	to	fulfil	all	the	4	criteria:	(A)	an	epidemiological
association	 between	 GBS	 and	 Campylobacter	 jejuni	 infection	 [3]	 has	 been	 established;	 (B)	 auto-
antibodies	against	GM1	or	GD1a	in	patients	with	GBS	subsequent	to	C.	jejuni	enteritis	[4,5]	have	been
identified;	(C)	Molecular	mimicry	between	GM1	or	GD1a	and	lipooligosaccharides	(LOSs)	of	C.	jejuni
isolated	 from	 GBS	 [6,7]	 has	 been	 demonstrated;	 and	 (D)	 a	 disease	 replica	 has	 been	 produced	 by
sensitizing	 rabbits	with	GM1	or	GM1-like	LOS	of	C.	 jejuni	 and	passive	 transfer	of	 anti-GM1	or	anti-











impairment.	 Feasby	 and	 colleagues	 had	 reported	 “an	 acute	 axonal	 form	 of	 Guillain-Barré
polyneuropathy”	 in	 1986	 [12],	 but	 at	 that	 time	 most	 clinicians	 believed	 GBS	 to	 be	 a	 demyelinating
peripheral	nerve	disease.	Repeated	nerve	conduction	study	results	in	our	patient	supported	a	diagnosis	of
axonal	 degeneration,	 and	 not	 demyelination.	 Although	 our	 patient	 complained	 of	 subjective	 distal
paresthesia,	his	clinical	and	electrophysiological	 features	were	similar	 to	amyotrophic	 lateral	sclerosis
(ALS).	I	recalled	a	paper	I	had	read	by	Latov’s	group	published	in	1986	in	which	his	group	reported	a
patient	 with	 ALS-like	 disorder	 who	 had	 IgM	 M-protein	 against	 GM1	 and	 who	 improved	 after
immunotherapy	 [13],	 suggesting	 what	 we	 know	 now	 as	 multifocal	 motor	 neuropathy.	 Their	 report
prompted	 me	 to	 consider	 the	 possibility	 that	 our	 patient	 might	 also	 have	 anti-GM1	 antibodies.	 Our
investigations	 revealed	 IgG,	 not	 IgM,	 antibodies	 reacting	with	GM1	 [4].	The	 titres	 decreased	with	 the
course	 of	 the	 illness.	 A	 second	 patient	 with	 GBS	 who	 carried	 anti-GM1	 IgG	 antibodies	 was	 later
identified.	This	patient	also	had	antecedent	diarrhoea	and	pure	motor	weakness.	Nerve	conduction	studies
suggested	axonal	degeneration	in	motor	nerves,	but	no	demyelination.
The	 presence	 of	 watery	 diarrhoea	 prior	 to	 the	 illness	 in	 both	 patients	 provided	 the	 clue	 that	 a
microbial	 agent	 might	 be	 the	 trigger	 for	 the	 development	 of	 GBS.	 There	 had	 been	 a	 few	 reports	 of
association	of	GBS	with	diarrhoea	or	C.	jejuni	enteritis	[14,15].	Although	C.	jejuni	had	not	been	widely
recognized	 as	 an	 antecedent	 infectious	 agent	 of	GBS	 at	 that	 time,	 both	 our	 patients	were	 serologically














Administration	 of	 bovine	 brain	 gangliosides	 (BBG)	 was	 widely	 used	 in	 Western	 Europe	 and	 South











with	a	GM1	epitope.	The	LOS	was	 separated	by	column	chromatography,	 and	 fractions	were	obtained
that	 showed	 reactivity	 to	 rabbit	 anti-GM1	 antibodies	 and	 cholera	 toxin	 B-subunit.	 By	 gas-liquid
chromatography	mass	spectroscopy,	I	found	that	 the	purified	LOS	contained	D-galactose,	D-glucose,	N-
acetyl-D-galactosamine,	 N-acetyl-D-glucosamine	 and	 N-acetyl	 neuraminic	 acid,	 which	 are	 sugar
components	of	GM1	ganglioside.	1H	nuclear	magnetic	resonance	showed	that	the	terminal	tetrasaccharide
of	 the	purified	LOS	was	 identical	 to	 that	of	GM1	(Figure	49.1)	 [7].	The	bacterial	strain	also	carried	a
GD1a-like	LOS	[25].
As	 there	were	 reported	 cases	 of	MFS	 subsequent	 to	C.	 jejuni	 enteritis	 [26],	 I	 postulated	 that	 there
were	some	strains	of	C.	jejuni	that	had	the	GQ1b	epitope.	In	1993,	when	I	investigated	the	presence	of	the
GQ1b	epitope	 in	C.	 jejuni	 strains	 isolated	 from	patients	with	 enteritis,	 clinicians	 requested	me	 to	 test
anti-GQ1b	 antibodies	 in	 2	 patients	 with	 MFS	 from	 whom	 C.	 jejuni	 was	 isolated	 [27].	 I	 therefore
performed	 thin-layer	 chromatography	 immunostaining	 to	 show	 the	 presence	 of	 GQ1b-like	 LOS	 of	C.
jejuni	 from	 the	 patients	 using	 monoclonal	 anti-GQ1b	 antibody.	 In	 1994,	 we	 reported	 the	 results,
suggesting	 the	 existence	 of	 molecular	 mimicry	 between	 GQ1b	 and	 the	C.	 jejuni	 LOS	 [28].	 In	 1997,


















(A)	Molecular	mimicry	 exists	 between	 gangliosides	 (GM1	 and	GD1a)	 and	Campylobacter	 jejuni	 lipooligosaccharides	 (LOSs).
Infection	by	C.	jejuni	bearing	GM1-like	or	GD1a-like	LOSs	may	induce	the	production	of	anti-GM1	or	anti-GD1a	IgG	antibodies	in
certain	patients.	Modified	from	44	with	permission.
(B)	Myelinated	 axons	 are	 divided	 into	 4	 functional	 regions:	 the	 nodes	 of	 Ranvier,	 paranodes,	 juxtaparanodes	 and	 internodes.
Gangliosides	GM1	and	GD1a	are	strongly	expressed	at	the	nodes	of	Ranvier,	where	the	voltage-gated	sodium	(NaV)	channels	are
localized.	Contactin-associated	protein	 (Caspr)	and	voltage-gated	potassium	(KV)	 channels	are	present	at	 the	paranodes	and
juxtaparanodes,	 respectively.	Anti-GM1	or	anti-GD1a	 IgG	antibodies	bind	 to	 the	nodal	 axolemma,	 leading	 to	membrane	attack
complex	(MAC)	formation.	This	results	in	the	disappearance	of	NaV	clusters	at	the	nodes,	mislocalization	of	KV	clusters	at	 the
paranodes	and	the	detachment	of	paranodal	myelin,	which	can	lead	to	nerve-conduction	failure	and	muscle	weakness.	Axonal






















white	 rabbits	 with	 0.5	 mg	 of	 GD1b	 together	 with	 keyhole	 limpet	 hemocyanin	 and	 complete	 Freund’s
adjuvant	[32].	I	postulated	that	when	we	inoculated	Japanese	white	rabbits	with	2.5	mg	of	a	BBG	mixture
(GM1	21%,	GD1a	40%,	GD1b	16%,	GT1b	19%;	Cronassial®)	according	to	their	protocol	[32],	at	least
some	 rabbits	 might	 develop	 flaccid	 paralysis	 or	 ataxia	 associated	 with	 anti-GD1a	 or	 anti-GD1b
antibodies	because	the	mixture	contained	0.5	mg	of	GM1,	1	mg	of	GD1a	or	0.4	mg	of	GD1b.
When	we	started	our	animal	experiments	in	1998,	I	was	very	sceptical	as	to	whether	the	rabbits	would
develop	 muscle	 weakness.	 Surprisingly,	 all	 13	 rabbits	 inoculated	 with	 the	 ganglioside	 mixture






the	disease.	We	started	 inoculating	rabbits	with	Sygen®	 (isolated	GM1)	when	a	 few	rabbits	developed
anti-GM1	 IgG	antibodies	 and	 acute	 flaccid	 paralysis	 [9].	Nine	 of	 11	 rabbits	 developed	 anti-GM1	 IgG
antibodies	 and	 acute	 flaccid	 paralysis.	 Pathological	 findings	 in	 the	 rabbit	 peripheral	 nerves	 were
predominantly	Wallerian-like	 degeneration	with	 neither	 lymphocytic	 infiltration	nor	 demyelination.	 IgG
was	deposited	at	 the	nodal	or	 intranodal	 axolemma	 in	 the	 spinal	 anterior	 roots.	Anterior	 spinal	nerves
showed	macrophage	 infiltration	 in	 the	 periaxonal	 space,	 but	 the	 surrounding	 myelin	 sheaths	 remained
almost	 intact	 [34].	 In	 addition	 to	 these	 pathological	 findings,	 neurophysiological	 findings	 also
corresponded	well	with	those	in	human	acute	motor	axonal	neuropathy	(AMAN),	an	axonal	form	of	GBS.
We	 repeatedly	 injected	 Japanese	 white	 rabbits	 with	 C.	 jejuni	 LOS	 isolated	 from	 a	 patient	 with
AMAN,	which	 consisted	 of	GM1-like	 and	GD1a-like	LOSs	 [6,8].	We	 started	 this	 experiment	 in	 1999
when	a	few	rabbits	developed	the	disease	by	sensitization	with	the	BBG	mixture.	First,	we	used	2.5	mg	of
C.	jejuni	LOS,	as	well	as	the	BBG	mixture	experiment.	Only	4	of	10	rabbits	developed	flaccid	paralysis,
suggesting	 that	 sensitization	had	 to	be	more	 frequent.	Next,	we	 sensitized	10	 rabbits	with	10	mg	of	C.
jejuni	 LOS,	 and	 all	 the	 rabbits	 developed	 flaccid	 paralysis.	 The	 diseased	 rabbits	 had	 anti-GM1	 IgG
antibodies,	 but	 not	 anti-GD1a	 antibodies.	 The	 pathological	 findings,	 compatible	 with	 the	 features	 of
human	 AMAN,	 were	 evidence	 that	 rabbits	 inoculated	 with	C.	 jejuni	 LOS	 constitute	 a	 valid	 AMAN
model.
I	postulated	that	anti-GM1	IgG	antibodies	block	voltage-gated	sodium	(NaV)	channels	at	the	nodes	of
Ranvier	 [35].	 Susuki	 and	 I	 began	 these	 series	 of	 experiments	 in	 2004.	We	 showed	 that	 in	 the	 spinal
anterior	 roots	 of	 AMAN	 rabbits,	 IgG	 antibodies	 bound	 to	 nodes	 of	 Ranvier,	 where	 GM1	was	 highly
expressed,	and	activated	complement,	resulting	in	the	formation	of	membrane	attack	complex	at	the	nodal
axolemma	 [36].	 NaV	 channel	 clusters	 disappeared	 at	 lengthened	 nodes	 with	 complement	 deposition.
There	 was	 paranodal	 detachment	 along	with	 nodal	 lengthening,	 which	was	 seen	 at	 the	 early	 phase	 in
patients	 with	 AMAN	 [37].	 These	 pathological	 changes	 are	 able	 to	 produce	 muscle	 weakness.








GD1a	IgG	antibodies	 [6,8];	 (B)	 these	autoantibodies	bind	 to	GM1	or	GD1a	at	 the	nodes	of	Ranvier	 in
peripheral	motor	nerves	[36];	(C)	bound	anti-GM1	or	anti-GD1a	IgG	antibodies	induce	local	complement
activation,	 resulting	 in	 the	 formation	 of	membrane	 attack	 complex;	 (D)	 the	 autoimmune	 attack	 disrupts

















the	51st	determining	 its	enzymatic	activity	 [38].	Cst-II	 (Thr51)	has	only	α-2,3-sialyltransferase	 activity
(mono-functional)	and	produces	GM1-like	and	GD1a-like	LOSs	(Figure	49.2).	In	contrast,	cst-II	(Asn51)
has	 both	 α-2,3-	 and	 α-2,8-sialyltransferase	 activities	 (bi-functional),	 and	 synthesizes	 GT1a-like	 or
GD1c-like	LOSs,	mimicking	GQ1b.	When	I	read	their	paper,	I	postulated	that	C.	jejuni	isolates	from	GBS
had	cst-II	(Thr51)	and	that	the	isolates	from	MFS	had	cst-II	(Asn51).	Koga	and	I	began	experiments	using
the	 relevant	 isolates.	We	 found	 that	 neuropathic	 strains	 were	 more	 frequently	 found	 to	 have	 cst-II,	 in
particular	 cst-II	 (Thr51),	 than	 did	 enteritic	 ones	 (82%	 versus	 52%)	 [40],	 whereas	 strains	 with	 cst-II
(Thr51)	 had	 the	 GM1	 and	 GD1a	 epitopes,	 strains	 with	 cst-II	 (Asn51)	 regularly	 expressed	 the	 GQ1b
epitope.	The	presence	of	 these	bacterial	 epitopes	 in	neuropathic	patients	corresponded	 to	autoantibody
reactivity.	Patients	 infected	with	C.	 jejuni	 (cst-II	Asn51)	more	 often	were	 positive	 for	 anti-GQ1b	 IgG
antibodies	 and	had	ophthalmoparesis	 and	 ataxia.	 In	 contrast,	 patients	who	 had	C.	 jejuni	 (cst-II	 Thr51)
were	more	frequently	positive	for	anti-GM1	and	anti-GD1a	IgG	antibodies	and	had	limb	weakness.
Why	a	microbial	 infection	 leads	 to	 the	development	of	different	 autoimmune	diseases	has	yet	 to	be
clarified.	For	example,	 the	mechanism	of	how	group	A	streptococcal	 infection	 induces	acute	 rheumatic





to	GM1	or	GD1a	expressed	on	 the	motor	nerves	of	 the	 limbs,	producing	AMAN.	In	contrast,	C.	 jejuni
strains	that	carry	cst-II	(Asn51)	expresses	GT1a-like	or	GD1c-like	LOS	on	its	cell	surface,	and	infection



























































































































the	 eponym	Guillain-Barré	 syndrome	 should	be	 applied	only	 to	patients	without	 atypical	 signs	 such	 as
incomplete	recovery	[3].	However,	in	1968,	Pleasure,	Lovelace	and	Duvoisin	described	a	cohort	of	49
patients	 and	 found	 no	 differences	 in	 the	 clinical	 picture	 between	 patients	 with	 GBS	 and	 ‘atypical







[5].	 The	 children	were	 followed	 until	 full	 recovery	 or	 for	 at	 least	 3	 years	without	 full	 recovery.	 Full
recovery	was	defined	as	good	and	normal	strength	of	all	muscle	groups	(grading	scale:	zero,	trace,	poor,
fair,	good	and	normal)	in	the	first	3	years	after	GBS.	Thirty-six	children	(77%)	made	a	full	recovery,	but
all	 47	 children	 were	 ambulant	 after	 3	 years,	 even	 in	 the	 incomplete	 recovery	 group.	 Eberle	 and
colleagues	found	muscle	weakness	of	the	upper	and	lower	extremities,	absence	of	deep	tendon	reflexes	in
lower	extremities,	low	protein	level	in	cerebrospinal	fluid,	long	hospitalization	time	and	longer	time	from









differences	 in	 prognosis	 between	 patients	 who	 had	 no	 fibrillation	 potentials	 (81%	 good	 prognosis),
indicating	pure	demyelinating	disease,	and	patients	with	fibrillation	potentials,	with	or	without	conduction








was	 the	 first	 paper	 that	 analysed	 prospectively	 collected	 trial	 data	 (on	 prednisolone	 [8]	 and	 plasma
exchange	[9])	of	71	patients	to	discover	early	predictors	of	poor	prognosis.	Mechanical	ventilation,	time
to	 improvement	 of	 more	 than	 1	 month	 and	 a	 plateau	 time	 of	 more	 than	 3	 weeks	 were	 identified	 as
significant	 predictors	 of	 poor	 outcome	 (restricted	 in	manual	 activities	 at	 12	months;	 see	 Table	 50.1).




After	 their	analysis	of	 trial	data,	Winer	and	colleagues	set	up	a	prospective	cohort	 study	 to	answer	all
kinds	of	questions	about	GBS,	including	identifying	predictors	of	outcome	[10].	This	study	was	published

















Immune	 therapy	 with	 IVIg	 and	 plasmapheresis	 undoubtedly	 improved	 the	 prognosis	 of	 GBS	 patients;
however,	not	all	patients	do	well	after	therapy.	Kuitwaard	and	colleagues	searched	for	an	explanation	and
found	 that	 there	 is	 a	 large	 variability	 in	 IgG	 rise	 after	 IVIg	 treatment	 [12].	 A	 multivariate	 analysis,
correcting	for	known	prognostic	factors,	indicated	that	a	low	rise	in	serum	IgG	after	IVIg	therapy	was	an
independent	 predictor	 for	 poor	 outcome.	This	may	 suggest	 that	 some	 patients	 need	 a	 higher	 dosage	 of
IVIg.	 Confirmation	 of	 this	 finding	would	 be	 a	 first	 step	 towards	 personalized	medicine	 in	 GBS;	 IVIg




Figure	50.2	 	Predicted	 fraction	of	 patients	unable	 to	walk	 independently	at	 6	months	after	 randomization	on	 the	basis	of	 the
Erasmus	GBS	outcome	score	(n	=	762).	Vertical	bars	indicate	95%	CI.	Point	sizes	proportionate	to	the	number	of	patients	with	a





a	 longer	 period	 of	 time.	 In	 this	 study	Walgaard	 and	 colleagues	 constructed	 a	 simple	 clinical	model	 to
predict	 respiratory	 insufficiency;	 the	model	 can	be	 applied	 at	 hospital	 admission	 and	 is	 therefore	very
useful	in	clinical	practice	[13]	(Table	50.4).	Patients	with	a	high	risk	of	respiratory	insufficiency	need	to
be	monitored	closely,	possibly	in	an	intensive	care	unit,	to	take	precautions	when	the	need	for	mechanical





and	 even	 years.	 When	 a	 long	 duration	 of	 mechanical	 ventilation	 is	 expected,	 tracheotomy	 should	 be
considered.	Fourrier	and	colleagues	analysed	40	mechanically	ventilated	GBS	patients	and	found	that	the








Mark	 Twain	 is	 still	 right	 in	 his	 quote	 and	 inspires	 professors	 today	 to	 conduct	 large	 studies.	 The
International	 GBS	 Outcome	 Study	 (IGOS),	 a	 large	 international	 prospective	 study	 set	 up	 by	 the
International	Neuropathy	Consortium	included	>	1,000	GBS	patients	worldwide	(www.gbsstudies.org).
Final	goals	of	the	IGOS	are	to	be	able	to	better	inform	patients	and	relatives	about	the	prognosis	of	GBS,






































In	a	recent	paper	 it	was	stated	 that	 the	development	of	outcome	measures	 in	 inflammatory	neuropathies
has	 received	 little	 attention	when	 compared	 to	 the	 efforts	 taken	 in	 understanding	of	 the	many	 facets	 of
inflammatory	 neuropathies	 [1].	 Capturing	 the	 history	 of	 scoring	 in	 neurology	 brings	 us	 to	 Dr	 Henry








[3,4,5].	 ‘Quantitative’	 (e.g.	 neurological)	 observations	 are	 based	 on	 counting	 observed	 events,	 while
meaningful	measurements	 are	 based	 on	 the	 arithmetical	 properties	 of	 interval	 or	 ratio	measures	 [3,6].
Observations,	like	muscle	strength	assessment	at	bedside	using	Plummer’s	modified	tool,	provide	a	good
description	of	the	clinical	question	of	interest.	The	problem	arises	when	we	create	sum	scores	from	these
observations,	 treating	 these	 scores	 as	 linear,	 and	 make	 assumptions	 from	 the	 findings	 [4,7].	 We,	 as
physicians,	tend	to	hold	on	to	the	‘known	truth’	and	provide	information	regarding	‘the	best	way’	to	assess
clinical	changes	 in	a	particular	 illness	of	 interest,	 thereby	assuming,	often	 incorrectly,	 that	we	have	 the
proper	 knowledge	 to	 do	 so	 [8].	What	 we	 ‘know’	 often	 tends	 to	 limit	 our	 ability	 to	 look	 at	 the	 same
construct	from	a	different	perspective.	We	irrationally	apply	fixed	decision-making	to	our	use	of	outcome







neurologists	 in	 general	 [2].	 The	 history	 of	 scoring	 neurological	 observations	 like	 muscle	 weakness,
sensory	deficit,	and	tendon	reflexes	are	being	highlighted	in	an	elegant	way	in	this	paper,	starting	from	the
19th	century	when	Mitchel	and	Lewis	initiated	the	practice	of	alphanumeric	scoring	of	neurological	signs





Its	weakness	 relates	 to	 the	 relatively	 ‘unknown’.	As	 an	 example,	 the	NIS,	 introduced	 in	 1991,	 is	 a
composite	 score	 of	 various	 neurological	 observations	 such	 as	 muscle	 weakness,	 sensory	 deficit	 and
changes	 in	 tendon	 reflexes,	 and	 has	 been	 the	 primary	 outcome	 measure	 in	 a	 large	 number	 of
neuromuscular	 studies	 [12,13].	Despite	 its	 broad	 use,	 the	 obtained	 scores	 from	 the	NIS	 are	 used	 as	 if
these	 observations	 represent	 a	 ruler	with	 a	 fixed	 unit,	which	 is	 highly	 unlikely.	Others	 have	 suggested
using	great	caution	when	 interpreting	changes	 in	 scores	coming	 from	ordinal-based	scales	 like	 the	NIS








patients	 entered	 the	 trial	 and	 the	 primary	 outcome	 measure,	 the	 Functional-score	 was	 introduced	 that
ranged	from	0	(healthy)	to	6	(dead).	The	authors	concluded	that	steroid	treatment	is	not	beneficial	and	can
even	 be	 detrimental	 in	 GBS.	 The	 functional	 score	 (F-score),	 a	 ranked	 ordinal-based	 scale,	 has	 been
slightly	modified	through	the	years,	introducing	the	ability	to	walk	5	or	10	meters	and	was	later	named	the
































unit,	 thus	having	no	 intrinsic	numerical	value	[24].	Hence,	 this	brings	us	back	 to	 the	concept	of	 type	of




The	MRC	 grading	 system	 is	 the	most	 commonly	 used	method	 of	 evaluating	muscle	 strength	 clinically
[2,24].	Despite	 the	power	of	 its	simplicity,	with	great	 reliability	scores	 reported,	 this	method	has	been
criticized	due	to	the	unequal	width	of	its	ordinal	constructed	categories.	In	particular,	the	inequality	of	the
MRC	grades	(grades	1,	2	and	3	being	too	narrow,	and	4	being	too	broad)	has	been	extensively	discussed
by	 comparison	 with	 a	 dynamometer	 (data	 at	 the	 ratio	 level)	 for	 assessing	 strength	 [25,26,27,28,29].
Attempts	to	modify	the	scale	even	further	have	been	reported	[26,30,31,32].	The	2012	study	by	Vanhoutte
and	 colleagues	 [25]	 investigated	 whether	 clinicians	 in	 the	 neuromuscular	 field	 could	 properly
differentiate	 between	 patients	 with	 various	 neuromuscular	 disorders	 and	 degrees	 of	 muscle	 weakness












weakness	and	 sensory	deficit,	 and	hardly	any	attention	was	given	 to	being	 fatigued	 [36].	 In	 this	paper,
Merkies	and	Faber	systematically	examine	fatigue	in	113	patients	with	inflammatory	neuropathy	(n	=	83
had	GBS)	and	compare	them	to	age-	and	gender-matched	controls	[37].	‘Severe’	fatigue	was	present	in




publication,	 attempts	 were	 have	 been	 made	 to	 reduce	 fatigue	 in	 GBS,	 with	 only	 marginal	 success
[38,39,40].
From	a	clinimetric	point	of	view,	the	fatigue	severity	scale	(FSS),	another	composite	measure	with	7
Likert-type	 of	 response	 options	 per	 item,	 was	 used	 for	 the	 assessment	 of	 fatigue	 [41].	 Good	 internal
consistency,	significant	 reliability	and	validity	were	 reported.	However,	 the	composite	9-item	FSS	had




Figure	 51.1	 	 Example	 illustrating	 disordered	 threshold	 in	 item	 number	 7	 of	 the	 FSS	 in	 patients	 with	 immune-mediated
polyneuropathies	and	its	response	options	being	rescored.	FSS	=	fatigue	severity	scale.	Item	number	7	=	Fatigue	interferes	with
carrying	out	certain	duties/responsibilities.	The	top	graph	shows	the	 inability	of	patients	 to	discriminate	among	the	7	response




The	 van	Nes	 and	 colleagues’	 E-ODS	 study	 presents	 the	 development	 of	 a	 new	 scale	 based	 on	Rasch
methodology	that	challenges	the	outcome	measurement	belief	we	have	acknowledged	for	decades	[1,33].
The	paper	also	aims	to	teach	the	basic	principles	of	types	of	data	and	their	requirements,	and	highlights
the	 steps	 needed	 to	 transform	 ordinal-obtained	 data	 into	 interval	measures	 using	 the	 Rasch	 technique,
aiming	to	simplify	its	mathematical	background	to	more	digestible	pieces.	A	comprehensive	educational
paper	 on	 Rasch’s	 background,	 specifically	 for	 neurologists,	 was	 also	 recently	 published	 [44].	 The
inflammatory	RODS	(I-RODS)	is	the	first	disease-specific	interval	measure	constructed	for	patients	with













and	strove	for	consensus	on	a	specific	core	set	of	scales	 for	 future	clinical	studies	 in	various	forms	of
inflammatory	 neuropathies.	 The	 workshop	 highlighted	 themes	 like	 the	 historical	 background	 of
assessment,	 various	 trial	 design	 aspects,	 traditional	 versus	 modern	 requirements	 for	 evaluation	 and
construction	 of	 (new)	 outcome	 measures	 and	 the	 concept	 of	 minimum	 clinically	 important	 difference
(MCID).	Finally,	all	serially	obtained	comparative	data	were	presented.
Recommendations	were	ultimately	provided:	for	future	trials	in	GBS,	the	consensus	was	to	adopt	the
I-RODS	 as	 the	 primary	 outcome,	 since	 this	 outcome	 measure	 has	 demonstrated	 significantly	 higher
(heuristic	 and	 statistical	MCID	 related	 to	 varying	 standard	 errors	 (SE)	 across	 the	 metric;	MCID-SE)
responsiveness.	In	addition,	the	following	outcome	measures	were	suggested	as	part	of	the	minimum	core
set	of	scales	for	future	GBS	studies:	grip	strength	(Martin	Vigorimeter),	the	Rasch-transformed	modified






Various	educational	papers	have	been	written	on	 the	Rasch	method	some	of	which	are	 referred	 to	here
[49,50].	We	strongly	recommend	physicians	in	the	research	field	of	GBS	read	these	papers	as	well	as	the
recently	published	 “Rasch-ionale	 for	 neurologists”	 [44].	 In	 the	 latter	 paper,	 the	PeriNomS	 study	group
aimed	to	systematically	address	the	concept	of	types	of	scales	based	on	types	of	data	(nominal,	ordinal,
interval,	 ratio)	 collected,	 discussing	 differences	 between	 classical	 versus	 modern	 test	 theories,
emphasizing	the	(dis)advantages	of	both	streams,	highlighting	and	simplifying	the	various	steps	needed	in
the	 evaluation	 and	 construction	 of	 (new)	 outcome	 measures	 using	 the	 Rasch	 method,	 and	 striving	 to
increase	the	knowledge	and	utility	of	this	technique.	The	background	of	the	Rasch	modelling	is	discussed,
providing	 simple	 graphical	 examples	 to	 improve	 its	 understanding.	 In	 addition,	 various	 steps	 are
addressed	 like	 statistical	 model	 fit	 requirements,	 having	 (or	 not)	 ordered	 thresholds,	 differential	 item
functioning,	 local	 dependency,	 uni-dimensionality,	 and	 other	 requirements	 like	 items’	 weights	 and
persons’	location	reliability,	as	well	as	various	definitions	of	being	a	responder,	emphasizing	the	use	of
MCID-SE.	All	 these	 steps	 are	graphically	 explained,	highlighting	potential	 pitfalls	 and	ways	 to	handle
and	improve	the	data.	It	is	argued	that	Rasch-built	outcome	measures	should	be	used	for	future	studies	in




ongoing	 registries	 in	 GBS	 and	 other	 inflammatory	 neuropathies.	 Validation	 of	 new	 outcome	measures
using	 larger	 samples	 of	 collected	 data	 from	 independent	 cohorts,	 potential	 relation	 to	 biomarkers,
development	of	new	prognostic	models	to	predict	clinical	course,	and	examining	cross-cultural	validation
of	 selected	 outcome	 measures	 like	 the	 I-RODS	 are	 just	 some	 of	 the	 essentials	 that	 require	 further
investigation.	We	believe	that	the	lessons	learned,	particularly	from	the	PeriNomS	studies,	should	help	us



































































































Guillain-Barré	 Syndrome	 (GBS)	 or	 acute	 inflammatory	 demyelinating	 polyneuropathy	 (AIDP)	 is	 a
monophasic	immune-mediated	disorder	due	to	inflammation	of	peripheral	nerves	and	nerve	roots	[1].	It
presents	 as	 an	 evolving	 sensorimotor	 polyneuropathy	 of	 varying	 severity,	 which	 leads	 to	 rapidly
developing	motor	deficits	(symmetrical	ascending	paralysis),	autonomic	dysfunction,	sensory	deficits	and
respiratory	 failure	 [2,3,4].	 The	 annual	 incidence	 is	 estimated	 to	 be	 1–2	 per	 100,000	 worldwide	 and
affects	both	sexes	equally	[5,6].	It	can	occur	at	any	age,	but	has	a	reported	preponderance	between	ages
30	 and	 50	 (approximately	 30%	 of	 cases	 are	 under	 20	 years	 old)	 [7,8].	 GBS	 can	 be	 described	 as	 a
heterogeneous	 syndrome	 with	 several	 variants	 and	 as	 a	 collection	 of	 clinical	 syndromes,	 the	 most
common	type	being	AIDP	[4].
With	 advances	 in	 medical	 management,	 the	 incidence	 of	 GBS	 has	 been	 stable	 in	 the	 majority	 of
developing	 countries	 and	mortality	 has	 been	 reduced	 to	 2–3%	 (but	 is	 higher	 in	 the	 developing	world)
[6,9].	In	general,	mean	time	to	the	clinical	function	nadir	is	12	days,	with	98%	of	patients	reaching	a	nadir
within	4	weeks	from	onset	[8].	Overall	mortality	from	GBS	is	low;	approximately	5–10%	of	patients	may






tachycardia	 or	 bradycardia,	 fluctuating	 hypertension	 or	 hypotension,	 flushing	 of	 the	 face,	 loss	 of	 or
excessive	 sweating)	 can	occur	 in	up	 to	70%	of	patients;	 this	 can	be	associated	with	 sudden	death	 [3].
Facial	weakness	 and	 cranial	 nerve	 involvement	 occurs	 in	more	 than	 half	 of	 patients	 [2].	A	 number	 of
factors,	 including	 preceding	 diarrhoea,	 older	 age,	 rapid	 progression,	 disability	 at	 nadir	 and	 specific
neurophysiological	parameters	have	been	associated	with	poor	outcome	[12,13].
Long-Term	Disabilities	in	Persons	with	GBS












The	 World	 Health	 Organization,	 International	 Classification	 of	 Functioning,	 Disability	 and	 Health
(ICF)	[18],	provides	a	standard	framework	for	disability	and	participation	in	various	health	conditions,
including	 contextual	 factors.	 Rehabilitative	 care	 uses	 the	 terminology	 of	 this	 classification	 system	 to
describe	the	impact	of	the	disease	at	different	levels.	A	simulated	case	example	of	the	ICF	model	related
to	GBS	is	given	in	Figure	52.1.
A	 list	 of	 ICF	 categories	 (in	 all	 domains)	 relevant	 to	 the	 care	 of	 pwGBS	was	 developed	 through	 a
rigorous,	multi-method,	scientific	process,	incorporating	patient	and	multidisciplinary	perspectives	[19].
The	GBS	‘core	set’	represents	a	selection	of	ICF	categories/items	for	a	minimal	standard	of	reporting	in
clinical	 settings	 (brief	 core	 set)	 or	 comprehensive	 assessment	 (comprehensive	 core	 set)	 [19].	 It	 is
envisaged	 that	 these	 core	 sets	 describe	 specific	 biopsychosocial	 issues;	 provide	 a	 solid	 and	 stable
reference	 point;	 test	 the	 current	 and	 future	 health	 status	measures;	 and	 can	 be	 used	 for	 defining	 ‘what
should	be	measured’	[20].
An	integrated	approach	was	used,	which	included	a	comprehensive	review	of	literature	(peer	review
and	 grey	 literature)	 documenting	 rehabilitation	 interventions	 currently	 used	 in	management	 of	 a	 person
with	 GBS	 (pwGBS).	 A	 comprehensive	 search	 of	 the	 literature	 published	 up	 to	 December	 2015	 was
undertaken	 using	 the	Medline,	 Embase,	 PubMed	 and	Cochrane	 Library	 databases.	 The	 search	 strategy
included	interventional	studies	investigating	rehabilitative	management	of	pwGBS,	using	combinations	of
multiple	 search	 terms	 for	 3	 themes:	 GBS,	 rehabilitation	 interventions	 and	 patient	 outcomes.	 Medical
subject	heading	(MeSH)	search	terms	were	used	for	all	databases,	and	a	keyword	search	was	used	if	the
MeSH	 term	 was	 not	 available.	 Bibliographies	 of	 identified	 articles	 were	 scrutinised	 for	 additional
references	 and	 a	 manual	 search	 of	 relevant	 journals	 was	 undertaken.	 A	 grey	 literature	 search	 using
different	 Internet	 search	 engines	 and	 websites	 such	 as	 System	 for	 Information	 on	 Grey	 Literature	 in
Europe,	 New	 York	 Academy	 of	 Medicine	 Grey	 Literature	 Collection,	 and	 Google	 Scholar,	 was	 also
undertaken.	 Additional	 searches	 of	 the	 websites	 of	 prominent	 national	 and	 international	 organisations
associated	 with	 GBS	 management	 were	 conducted	 to	 identify	 relevant	 reports,	 health	 technology
assessments	 or	 other	 related	 materials.	 This	 review	 excluded	 pharmacological	 agents	 and	 other
alternative/conservative	interventions,	which	do	not	typically	form	part	of	the	rehabilitation	process.
Figure	52.1		ICF	model	with	case	example	for	GBS







participation	 (including	 personal	 and	 environmental	 factors).	 It	 extends	 beyond	 acute	 management,	 to
restoration	of	patient’s	previous	daily	activities	and	reintegration	into	the	home	and	community	[1,17].	It
is	estimated	that	over	one-third	of	all	GBS	patients	require	inpatient	rehabilitation,	particularly	those	who





A	 rehabilitation	 approach	 to	 GBS	 includes	 a	 wide	 spectrum	 of	 treatments	 and	 use	 of	 diverse





nursing),	 under	 medical	 supervision	 (neurologist,	 rehabilitation	 physician)”	 [23].	 It	 is	 designed	 to	 be
patient-centred,	 time-based	 and	 functionally	 oriented,	 and	 aims	 to	 maximise	 activity	 and	 participation
(social	integration)	using	a	biopsychosocial	model	[20].
Table	52.1		Summary	of	studies	evaluating	rehabilitation	intervention	in	GBS.
Khan	and	colleagues	conducted	a	 comprehensive	 systematic	 review	 to	 evaluate	 the	effectiveness	of
MD	care	in	adults	with	GBS,	especially	the	types	of	approaches	that	are	effective	(settings,	intensity)	and
the	outcomes	that	are	affected	[17].	This	review	did	not	identify	any	RCTs	or	CCTs,	and	evidence	were
summarised	 based	 on	 3	 observational	 studies,	which	 supported	 the	 effectiveness	 of	MD	 rehabilitation
programs	in	inpatient	settings	in	terms	of	improvements	in	activity	(disability)	and	participation	for	up	to
6	months	[17].	These	3	studies	[24,25,26]	included	a	total	of	128	participants	and	all	were	rated	as	‘very
low’	 quality	 using	 the	 grades	 of	 recommendation,	 assessment,	 development	 and	 evaluation	 (GRADE)
approach	[27].	All	studies	showed	a	consistent	result	with	an	improvement	in	disability	from	the	time	of
inpatient	 rehabilitation	 admission	 to	 discharge	 in	 a	 timeframe	 shorter	 than	 12	 months.	 There	 was	 no
conclusive	 evidence	 in	 regards	 to	 improvement	 in	 QoL	 during	 or	 after	 rehabilitation.	 Overall
generalisation	of	 the	 results	was	 limited,	as	 the	3	studies	 included	patients	with	severe	GBS	with	high
levels	 of	 physical	 dependency.	 This	 highlighted	 a	 need	 for	 future	 research	 using	 robust	 study	 designs,
appropriate	outcome	measures	and	optimal	intensity/modality	of	rehabilitation	therapy	[17].




oriented	 MD	 treatment	 comprising	 half-hour	 blocks	 of	 therapy	 sessions	 from	 a	 MD	 team	 (medical,
occupational,	social,	psychology,	speech	and	physiotherapist),	2	to	3	times	per	week	for	up	to	12	weeks.
The	therapeutic	model	included	physiotherapy	for	strengthening,	endurance	and	gait	training;	occupational
therapy	 to	 improve	 everyday	 function	 (domestic,	 community	 tasks),	 driving	 and	 return	 to	 work;	 and
clinical	 psychology	 for	 counselling	 and	 support,	 and	 medical	 input	 from	 rehabilitation	 consultants	 as
required.	The	findings	demonstrated	that	high-intensity	rehabilitation	programs	were	effective	in	reducing
motor	 disability	 (mobility,	 self-care,	 continence	 program)	 and	 improving	 participation	 (relationships)
[23].
Specific	Rehabilitation	Interventions
A	 variety	 of	 rehabilitative	 interventions	 have	 been	 trialled	 in	 pwGBS;	 there	 is,	 however,	 a	 dearth	 of





modalities	 may	 involve	 a	 graduated	 mobility	 program,	 which	 includes	 maintenance	 of	 posture	 and
alignment,	maintaining	joint	range	of	motion,	provision	of	orthotics,	endurance	and	muscle	strengthening,





El	Mhandi	and	colleagues	conducted	a	prospective	cohort	 study	 (N	=	 6)	 to	 evaluate	 individualized
physical	therapy	programs	based	on	muscular	reinforcement	and	active	mobilization	(average	2–3	weekly
sessions)	 for	 pwGBS	 [28].	 The	 results	 demonstrated	 significant	 muscle	 strength	 improvement	 using
dynamometric	 measures	 and	 all	 patients	 satisfied	 the	 criteria	 for	 a	 full	 recovery	 at	 18	 months.	 At	 6
months,	 manual	 muscle	 testing	 and	 functional	 independence	 motor	 total	 scores	 were	 close	 to	 normal
levels.	Compared	with	matched	healthy	controls,	isometric	and	isokinetic	strength	increased	significantly
during	the	first	6	months,	though	muscle	strength	increased	less	rapidly	between	6	and	18	months	[28].
Garssen	 and	 colleagues,	 in	 a	 prospective	 cohort	 study,	 evaluated	 the	 effectiveness	 of	 a	 12-week
bicycle	exercise	training	in	20	patients	with	polyneuropathy	(including	16	with	GBS)	and	severe	fatigue
[29].	The	findings	showed	significant	beneficial	effect	of	bicycle	training	on	physical	fitness,	functional
outcome	 and	QoL	 of	 these	 patients.	 There	was	 also	 a	 significant	 improvement	 in	 the	 post-intervention
fatigue	 scores	 (decrease	by	20%).	Further,	 all	participants	 tolerated	 intervention	well	 and	 the	majority
(80%)	were	motivated	to	continue	with	regular	training	activities	[29].
Bussmann	and	colleagues,	in	a	case	series	report,	explored	the	effects	of	physical	exercise	in	severely
fatigued	 pwGBS	 and	 chronic	 inflammatory	 demyelinating	 polyneuropathy	 patients	 [30].	 The	 authors





percutaneous	 kyphoplasty	 [33]	 and	 podiatrons	 (mechanized	 rotating	 platforms)	 [34]	 were	 explored	 in
pwGBS,	but	their	effectiveness	is	yet	to	be	determined.	Earlier	reports	suggest	that	care	should	be	taken
not	 to	overwork	muscle	groups	 [35]	 as	 this	 can	 lead	 to	paradoxical	weakening	 [36].	Patients	 also	 can
develop	tightness	of	muscles,	rather	than	joint	contractures	[1,8].	It	is	advocated	that	exercise	programs
should	 initially	 be	 non-fatiguing	 and	 strengthening	 exercises	 can	 be	 applied	 as	muscles	 regain	 greater
antigravity	strength	[37].	More	evidence	is	needed	for	the	use	of	physical	therapeutic	modalities.
Transcutaneous	Electrical	Nerve	Stimulation





A	 high	 proportion	 of	 pwGBS	 experience	 mobility	 problems,	 muscle	 weakness,	 paralysis,	 balance
impairment	and/or	fatigue,	which	can	be	alleviated	by	using	assistive	devices	[21].	To	date	there	are	no
studies	evaluating	the	effectiveness	of	these	devices	in	persons	with	GBS.	Current	guidelines	and	reports
recommend	 that	 mobility	 assistive	 devices	 such	 as	 ankle-foot	 orthoses,	 canes,	 crutches,	 walkers	 and
wheelchairs	should	be	prescribed	for	proper	positioning	and	optimising	residual	motor	function	[1,21].
Patients	 with	 prolonged	 residual	 weakness	 of	 calf	 (for	 example	 anterior	 compartment	 musculature)






activities	 in	 pwGBS	 to	 facilitate	 functional	 self-care,	 which	 may	 include	 task	 reacquisition,	 use	 of
adaptive	 equipment,	 and	 the	modification	 of	 environment	 for	 personal,	 domestic	 and	 community	 tasks
[8,21,24,41].	 The	 introduction	 of	 recreational	 therapy	 may	 also	 support	 a	 patient’s	 adjustment	 to
disability	and	improve	social	reintegration	[41].
Speech	Therapy




More	 specific	 communication	 strategy	 may	 be	 required	 for	 ventilator-dependent	 patients	 and
tracheostomies	[41].	Clinical	trials	evaluating	speech	therapy	programs	in	pwGBS	are	lacking.
Nutritional	Interventions
Malnutrition	 in	 pwGBS	 can	 be	 caused	 by	 immobility,	 decreased	 gastric	 motility,	 dysphagia	 and
psychological	symptoms	(such	as	depression)	[42].	Many	patients	tend	to	lose	weight	in	the	acute	phase;
therefore,	routine	assessment	of	nutritional	status	is	important	[43].	Those	with	malnutrition	may	require
enteric	or	parenteral	 nutrition	 and	high	protein,	 high-energy	 enteral	 diets	 [43,44].	There	 are	no	 studies
evaluating	nutritional	status	in	GBS.
Cognitive	and	Psychological	Interventions
Cognitive	 problems	 have	 been	 reported	 in	 pwGBS,	 especially	 in	 the	 acute	 phase	 and	 in	 those	 with
extended	ICU	stay	[8,17,40].	Anxiety	and	fear	are	common	due	to	the	sudden	onset	of	symptoms	and	may








as	 incomplete	 respiratory	 recovery	 including	 chronic	 obstructive	 pulmonary	 disease,	 restrictive
respiratory	disease	 (pulmonary	scarring,	pneumonia),	 tracheitis	 from	chronic	 intubation	and	 respiratory
muscle	 insufficiency	 [4,22,45].	 A	 few	 expert	 opinions	 suggest	 initiation	 of	 physical	 therapy	measures
(chest	percussion,	breathing	exercises,	resistive	inspiratory	training)	to	clear	respiratory	secretions	and,




[21,46].	Bladder	 dysfunction	may	 include	 detrusor	 acontractility,	 disturbed	 bladder	 sensation	 and	 non-
relaxing	urethral	sphincter,	causing	symptoms	such	as	voiding	difficulty,	urinary	retention,	frequency	and
urge	 incontinence	 [47,48].	 There	 is	 lack	 of	 studies	 in	 GBS	 addressing	 bowel/bladder	 dysfunction	 in
pwGBS,	 expert	 opinion	 suggests	 individualised	 management	 programs	 may	 include:	 timed	 voiding,
intermittent	 catheterization	 and	 anticholinergic	 medication	 [35].	 Pelvic	 floor	 muscle	 training	 with	 or
without	biofeedback	or	electrical	stimulation,	are	also	commonly	used	in	women	with	stress	leakage	and




This	 narrative	 review	 provides	 an	 evidence-based	 overview	 of	 the	 effectiveness	 of	 rehabilitation
intervention	 in	 pwGBS.	 A	 limited	 number	 of	 studies	 evaluate	 the	 effectiveness	 of	 rehabilitation
intervention,	and	‘best’	evidence	to	date	is	based	upon	expert	opinions	and	observational	studies.	Despite
recommendations	for	many	rehabilitation	interventions,	there	is	a	paucity	of	information	on	effectiveness
of	 these	 treatments.	 The	 ‘best’	 available	 evidence	 to	 date	 is	 for	 studies	 evaluating	MD	 rehabilitation
which	 provide	 some	 support	 in	 producing	 longer-term	 gains	 in	 the	 levels	 of	 activity	 (disability)	 and
participation	 of	 pwGBS.	 The	 evidence	 for	 most	 uni-disciplinary	 rehabilitation	 interventions	 remains
limited	 and/or	 poor	 and	 is	 based	 upon	 ‘low	 quality’	 observational	 studies	 (using	 the	 GRADE
methodology	 for	 bias)	 or	 inferred	 from	 other	 neurological	 conditions.	 Adequate	 descriptions	 of	 what
comprises	a	‘black	box	of	rehabilitation’	(therapy	intensity,	duration,	modalities)	in	GBS	are	lacking.
GBS	 is	 a	 complex	 condition	 with	 marked	 clinical	 heterogeneity	 and	 a	 varied	 level	 of	 disability,
requiring	 an	 individualised	 approach	 to	 rehabilitation.	 The	 clinical	 decision-making	 process	 can	 be
subjective	and	biased,	and	clinicians	may	not	always	agree	with	one	another	[49].	GBS	survivors	need
regular	 evaluation	 for	 persisting	 disability	 and	 psychological	 sequelae	 (especially	 over	 time),	 and
clinicians	should	incorporate	the	patient	perspective	on	functioning	and	health	[19].	The	ICF,	a	useful	tool
in	 the	rehabilitation	context,	can	describe	 the	patients’	experience	by	emphasizing	 the	complex	ways	 in
which	 the	 ‘condition’	 and	 contextual	 (environmental	 or	 personal)	 factors	 (Figure	 52.1)	 may	 modify
outcomes	 [17].	 It	 lists	 information	 for	 clinicians	 about	 domains	 that	 are	 considered	 important	 by	 the
pwGBS	and	provides	a	common	language	for	more	effective	communication	and	agreement	amongst	the
treating	MD	clinicians	[19].
Difficulties	 in	 assimilation	 of	 data	 are	 further	 compounded	 by	 a	 wide	 range	 of	 rehabilitation
interventions	 proposed	 for	 the	 pwGBS	 and	 diverse	 outcomes	 used	 [17].	 Integrated	 GBS	 services	 are
needed	 to	 address	 issues	not	 only	 in	 acute	 settings,	 but	 also	over	 the	 longer-term	care	 [17].	Further,	 a
national	 registry	 and	 or	 formal	 data	 collection	 process	 (nationally	 and	 internationally)	 are	 needed	 to
gather	information	on	variability	in	the	types	of	rehabilitation	programs	available	and	their	outcomes	in
GBS	 survivors.	 An	 analysis	 of	 the	 National	 Rehabilitation	 Dataset	 reviewed	 outcomes	 of	 inpatient







neuropsychological	 sequelae	 over	 the	 long	 term.	This	 paper	 highlights	 the	 current	 gap	 in	 evidence	 for
rehabilitation	 intervention	 in	 persons	 with	 GBS.	 However,	 a	 gap	 in	 current	 research	 should	 not	 be
interpreted	 as	 an	 ineffectiveness	 of	 rehabilitative	 intervention.	 Integrated,	 holistic,	 multidisciplinary































































































rare	 and	 there	 is	 limited	 previous	 research.	 There	 are	 currently	 no	 comprehensive,	 evidence-based










Nicholls	 and	 Cheek	 provide	 a	 commentary	 on	 the	 emergence	 of	 new	 forms	 of	 physiotherapy	 practice
against	the	social	and	political	background	of	the	late	Victorian	era	[1].	The	period	was	influenced	by	the
industrial	 revolution,	 urban	 overcrowding	 as	 the	 population	 moved	 from	 the	 country	 to	 the	 cities,
associated	public	health	developments	and	 the	greater	emancipation	of	women.	The	authors	note	 that	 it
was	 becoming	more	 acceptable	 for	 educated	women	 to	 take	 up	 professional	 roles	 not	 only	within	 the
previously	 accepted	 female	 professions	 of	 nursing	 and	 teaching	 but	 also	 in	 new	 areas.	 One	 area	 that
burgeoned	 during	 this	 period	was	 the	 use	 of	massage	 and	 the	movement	 to	 complement	 nursing.	 This




to	 the	 massage	 scandals.	 They	 sought	 to	 regulate	 the	 education,	 training,	 registration	 and	 practice	 of
massage	by	establishing	one	of	their	founding	rules	of	the	society	that	“no	massage	be	undertaken	except
under	 medical	 direction”.	Whilst	 this	 achieved	 the	 aim	 of	 distancing	 therapeutic	 massage	 from	moral
outrage,	 it	 was	 a	 rule	 that	 the	 profession	 subsequently	 fought	 long	 and	 hard	 to	 remove	 to	 establish
professional	independence.
Health	 services	 organisational	 research	 in	 the	 1980s	 [2]	 further	 documents	 the	 development	 of	 the
profession	 as	 the	 STM	 became	 chartered	 in	 1920	 and	 was	 renamed	 the	 Chartered	 Society	 of
Physiotherapy	 (CSP)	 in	 1944.	 Later,	 following	 the	 creation	 of	 the	 Council	 for	 the	 Professions
Supplementary	to	Medicine	in	1960,	where	membership	of	the	board	was	still	one-third	medical,	the	CSP
was	 awarded	 the	 right	 to	monitor	 its	 own	 standards	 and	 quality	 of	 education	 before	 finally	 achieving
autonomous	 practitioner	 status	 in	 1977.	 Since	 that	 time	 physiotherapists	 have	 furthered	 their	 clinical












of	 physiotherapy	 as	 an	 important	 therapeutic	 approach	 for	 the	management	 of	 polio	 was	 subsequently
published	in	1948	by	Dr	Frank	Cooksey	and	his	description	compares	well	with	current	recommendations
for	the	management	of	patients	with	GBS:
First	 the	 inflammatory	 phase	…	when	 treatment	 is	 directed	…	 to	 relieve	pain,	 and	 to	 prevent	 stiffness	or	 deformity	 by
prophylactic	movements.…	Treatment	involving	some	disturbance	of	the	patient	is	necessary	to	mitigate	these	secondary
effects.
Secondly	 the	stage	of	potential	 recovery	…	when	 the	purpose	of	 treatment	 is	 to	assist	 the	 recovery	of	paralysed	or
weak	muscles	within	the	limits	determined	by	the	permanent	damage	in	the	CNS.
Thirdly	 the	 stage	of	 chronic	disability	when	…	appliances,	 vocational	 training	and	 the	development	of	 compensatory
function	in	surviving	muscles	are	re-employed	…	suited	to	the	residual	capacity	of	the	individual.	[3]
Cooksey	 also	 identifies	 potential	 dangers	 of	 physiotherapy	 and	 highlights	 the	 need	 to	 evaluate
interventions	for	fidelity,	safety	and	efficacy.







Several	 previous	 reports	 identified	 persistent	 motor	 weakness	 as	 the	 primary	 cause	 of	 long-term
disability	in	people	after	GBS.	However,	Lennon	and	colleagues	demonstrated	that,	rather	than	presuming
a	 hierarchical	 relationship	 between	 impairment,	 disability	 and	 handicap,	 clinicians	 should	 undertake
objective	measurements	of	all	3	outcomes	to	evaluate	the	true	impact	of	the	condition	after	neurological




This	disconnect	between	impairment,	 function	and	societal	 impact	 is	something	that	physiotherapists
repeatedly	 encounter	 when	 working	 with	 clients,	 and	 physiotherapy	 education	 was	 a	 relatively	 early
adopter	 of	 the	 International	 Classification	 of	 Functioning	 that	 was	 published	 by	 the	 World	 Health
Organisation	 in	2001	[6].	The	ICF	superseded	 the	previous	classification	of	 impairment,	disability	and
handicap	(ICIDH)	[7]	for	use	as	the	scientific	standardization	of	data	on	health	and	disability	worldwide.














cases.	 The	 moderate	 to	 small	 effects	 of	 reduction	 in	 activity	 limitations	 of	 mobility,	 self-care	 and
continence	 as	 well	 as	 a	 similar	 improvement	 in	 participation	 for	 ‘personal	 relationships’	 suggests	 an
important	 role	 for	 MDT	 rehabilitation	 but	 highlights	 the	 challenges	 associated	 with	 interpreting	 the
findings	 for	 specific	 active	 components	of	 the	 intervention.	The	 intervention	 comprised	 individualised,
goal-oriented	 treatment	 incorporating	 therapy	 sessions	 with	 relevant	 disciplines	 based	 on	 participant
need.	The	clinical	rationale	for	this	form	of	tailored	approach	to	MDT	intervention	is	clear	but	in	RCTs
the	 impact	 of	 such	 an	 individualised	 approach	 means	 the	 role	 of	 specific	 therapeutic	 components
including	physiotherapy	is	hard	to	determine.
One	 uncontrolled	 prospective	 study	 [9]	 evaluated	 the	 feasibility	 and	 likely	 effect	 of	 unsupervised
physiotherapist-prescribed	exercise	on	disability	 for	people	 following	recovery	 from	GBS	and	chronic
inflammatory	demyelinating	polyradiculoneuropathy	 (CIDP).	 Improvements	 in	 the	majority	of	 outcomes
were	 observed	 after	 the	 intervention,	 suggesting	 that	 exercise	may	 be	 beneficial	 in	 ameliorating	 these
persistent	 problems.	 However,	 the	 study	 design	 means	 it	 is	 not	 possible	 to	 attribute	 observed
improvements	 directly	 to	 the	 intervention.	 Therefore,	 as	Khan	 recommends	 [8],	 future	 research	 should





In	 order	 to	 ensure	 that	 research	 addresses	 important	 outcomes	 for	 patients,	 evidence	 from	 qualitative
studies	 is	 essential.	 A	 recent	 qualitative	 interview	 study	 is	 one	 of	 only	 a	 few	 aimed	 at	 exploring	 the
experience	of	people	living	with	GBS	[10].	Interviews	were	conducted	with	people	at	least	2	years	after
onset	 of	GBS	 and	 reiterate	 the	 variability	 in	 recovery	 of	 impairment,	 activities	 and	 participation	 from
observational	 studies.	 The	 study’s	main	 theme	 of	 ‘Striving	 for	 balance	 in	 everyday	 life’	 highlights	 the
impact	of	symptoms	and	psychological	adaptation	on	how	patients	manage	the	recovery	process.	What	is




vulnerable	 and	had	difficulty	 accepting	 the	 consequences	of	 their	 illness.	The	 fact	 that	 all	 participants,
irrespective	of	 their	 impairments,	 including	fatigue,	described	prioritizing	 time	 to	exercise	as	a	way	of




Fatigue	 is	 a	 highly	 prevalent	 problem	 for	 people	 with	 GBS.	 Experienced	 fatigue	 is	 the	 subjective
sensation	of	persistent	feelings	of	overwhelming	tiredness	or	fatigue	unrelated	to	physical	activity.	This	is
in	contrast	to	fatigability	which	is	the	observable	change	in	physical	performance	or	muscle	fatigue	that	is
associated	with	 physical	 activity.	Whilst	 both	 are	 likely	 to	 exist	 for	 some	 people	with	GBS,	 Ingemar
Merkies	and	colleagues	demonstrated	that	experienced	fatigue	was	reported	by	80%	of	people	with	GBS
[11].	This	fatigue	was	not	associated	with	physical	symptoms	of	strength,	sensory	disturbance	or	physical
function	but	 rather	with	 social	 and	emotional	 functioning.	Severe	 fatigue,	defined	as	 a	 score	of	greater
than	5	on	the	fatigue	severity	scale,	reportedly	occurs	for	between	35%	and	80%	of	people	with	GBS	in










In	the	BMJ,	Campbell	and	colleagues	describe	 the	 important	contribution	 to	health	care	research	of	 the
MRC	guidelines	for	designing	and	evaluating	complex	interventions	[13].	Multidisciplinary	care	for	the








93	behaviour	change	 techniques	 (BCT)	by	Michie	and	colleagues	 [14].	The	BCT	 taxonomy	may	aid	 in
identifying	 components	 of	 physiotherapy	 or	 exercise	 prescription	 and	 progression	 alongside	 more
conventional	descriptions.	The	 taxonomy	includes	groupings	of	 techniques	such	as	‘goals	and	planning’
(problem	solving)	and	‘shaping	knowledge’	(behavioural	experiments).	These	could	be	used	to	explore




hold	about	exercise	(e.g.	 ‘all	exercise	will	 increase	my	fatigue’,	 ‘people	will	stare	at	me	 if	 I	go	 to	 the
gym’).	Behavioural	experiments	and	graded	activity	permit	patients	to	try	out	new	behaviours	and	use	the
results	 to	 inform	 their	 ongoing	 exercise.	 Thus	 physiotherapists	 can	 use	 BCT	 to	 ensure	 that	 they	 listen
effectively	 to	 patients’	 experiences	 and	 incorporate	 them	 in	 a	 genuinely	 client-centred	 approach	 to




The	patient-focussed	 approach	of	 physiotherapy	offers	 great	 possibilities	 in	 the	management	 of	 people
with	GBS.	I	hope	that	this	brief	history	of	physiotherapy	in	relation	to	the	condition	shows	that	in	order	to
improve	outcomes	for	patients	we	need	to	conduct	qualitative	research	in	true	collaboration	with	patients
to	 identify	 meaningful	 questions.	 This	 will	 allow	 us	 develop	 rigorous	 randomised	 controlled	 trials,














































cases	of	GBS.	We	would	 like	 to	present	2	 impressive	cases	 that	we	have	encountered	 in	 the	 last	years
showing	that	GBS	still	can	be	fatal	and	that	the	influence	of	medical	care	is	substantial.
The	first	case	was	a	child	of	4	years	old	who	was	transferred	to	our	centre	from	another	hospital	after
a	 resuscitation	and	an	emergency	 intubation.	According	 to	 the	 treating	paediatrician	of	 that	hospital	 the
patient	was	admitted	with	pain	in	the	neck,	swallowing	difficulty,	drooling	and	frequent	falling	in	the	last
days.	The	working	diagnosis	of	 the	paediatrician	was	a	 tonsillitis/tonsillar	 tumour,	and	 the	patient	was
admitted	to	the	children’s	ward	and	treated	with	antibiotics.	The	day	after	admission	he	became	abruptly
respiratory	 insufficient	and	 just	before	 intubation	 the	patient	had	an	asystole	and	required	resuscitation.
After	 transferal	 to	 our	 hospital	 we	 saw	 the	 child	 for	 the	 first	 time,	 who	 had	 a	 severe	 post-anoxic
encephalopathy	without	showing	any	sign	of	neurological	improvement	in	the	next	days.	When	we	talked
with	the	parents	about	the	grave	situation	and	the	poor	prognosis,	they	explained	to	us	that	in	the	last	week
the	patient	already	had	difficulty	walking	and	 the	day	before	admission	he	was	unable	 to	 lift	his	arms.
Considering	the	diagnosis	of	GBS,	nerve	conduction	studies	showed	a	severe	motor	polyneuropathy,	CSF
an	elevated	protein	level,	with	normal	leukocyte	count,	and	in	serum	high	titres	of	IgG	antibodies	to	the





asystole.	 In	 addition	 there	were	 severe	 decubital	wounds	 for	which	 necrotectomy	was	 necessary.	 The
patient	had	already	been	ventilated	for	more	than	3	months	without	any	signs	of	recovery	and	had	suffered
from	persistent	 and	 progressive	 pain.	 The	 treating	 neurologists	 asked	 for	 our	 advice,	 and	 although	we
indicated	 that	 even	 severe	 cases	 of	 GBS	 may	 recover,	 the	 patient,	 his	 family	 and	 the	 local	 treating
multidisciplinary	 team	made	a	decision	not	 to	perform	any	 life-prolonging	 treatments.	The	patient	died
one	week	later.
These	2	cases	of	 fatal	GBS	not	only	 illustrate	 the	 rapidity	and	severity	of	GBS,	 they	also	show	 the







studying	 the	mortality	 rate	 in	GBS.	 Table	 54.1	 gives	 a	 short	 overview	 of	 the	mortality	 rate	 of	 the	 10
articles	included	in	this	chapter.	In	1991	Ropper,	Wijdicks	and	Truax	wrote	a	monumental	book	for	the
Contemporary	Neurology	Series	[4].	In	this	book	only	a	small	section	was	dedicated	to	the	mortality	in













More	 recent	 studies	 show	 a	 somewhat	 lower	 mortality	 rate.	 Alshekhlee	 and	 colleagues	 used	 a
Nationwide	Inpatient	Sample	database	(2000–2004)	and	searched	for	patients	diagnosed	with	GBS	using





suffering	 from	high	morbidity,	have	a	good	outcome	(ability	 to	walk	 independently).	The	mortality	 rate
they	found	of	6.5%	is	probably	higher	than	in	other	recent	studies	due	to	the	selection	of	severely	affected
GBS	patients	[9].
In	our	own	 study,	 published	 in	2013,	we	 reviewed	prospectively	 collected	data	of	 a	 cohort	 of	 527
GBS	patients	 from	1986	 to	2008.	We	found	a	 low	mortality	 rate	of	2.8%	[10].	A	reason	 for	 the	 lower




was	 evident	 in	 a	 presentation	 about	 the	mortality	of	GBS	 in	Bangladesh	presented	 at	 the	 Inflammatory
Neuropathy	Consortium	meeting	of	2014	at	Dusseldorf	 [11].	 Ishaque	and	colleagues	from	the	Emerging
Diseases	and	Immunobiology	research	group	at	the	International	Centre	for	Diarrhoeal	Disease	Research
in	Bangladesh	 reported	a	high	mortality	 rate	 in	Bangladesh	of	12.4%	(61	out	of	491).	One	of	 the	most
disturbing	 results	 is	 that	 20%	 of	 the	 deceased	 GBS	 patients	 died	 because	 there	 was	 no	 mechanical
ventilator	available.






the	 causes	 of	 death	 in	 GBS	 are	 pneumonia,	 adult	 respiratory	 distress	 syndrome	 following	 aspiration,
sepsis,	 myocardial	 infarction,	 pulmonary	 embolus	 and	 profound	 dysautonomia	 [4].	 Furthermore,	 they
stated	that	dysautonomia	can	be	life	threatening	but	only	rarely	leads	directly	to	death.	Lawn	and	Wijdicks
reported	 ventilator-associated	 pneumonia	 as	 a	 leading	 cause	 of	 death,	 followed	 by	 cardiac	 arrest	 (in
absence	of	dysautonomia)	[7].	The	most	common	causes	of	death	found	by	van	den	Berg	and	colleagues




the	most	 important	 risk	 factor	 for	mortality	 from	GBS	 is	 older	 age	 [6,7,8,9,10,11].	Most	 studies	 also
found	that	GBS	fatalities	have	more	comorbidity,	more	often	need	mechanical	ventilation	and	have	more
severe	weakness	 at	 entry	 to	 the	 hospital	 [6,7,8,9,10,11].	 In	 a	 developing	 country	 like	Bangladesh,	 the
strongest	risk	factor	for	mortality	was	lack	of	ventilator	support	in	patients	with	respiratory	failure	[11].
Timing	of	Death	in	GBS
Winer	 and	 colleagues	 showed	 that	 the	majority	 of	 deceased	GBS	patients	 died	within	 an	 interval	 of	 4
weeks	 [5].	 Italian	GBS	study	group	confirmed	 this	 finding	and	stated	 that	 the	majority	of	GBS	patients
died	within	 the	 acute	 phase	 of	 the	 disease	with	 dysautonomia	 and	 cardiac	 arrest	 as	 leading	 causes	 of
death	[6].	 In	contrast,	Lawn	and	Wijdicks	described	that	only	a	minority	of	 the	fatal	GBS	patients	died
within	 the	first	28	days	[7].	 In	our	own	study	 two-thirds	of	 the	fatal	GBS	patients	died	 in	 the	recovery
phase	[10].	In	the	acute	phase	the	patient	died	of	cardiovascular	or	autonomic	complications,	in	contrast
with	 patients	 who	 died	 in	 the	 recovery	 phase.	 These	 patients	 died	 mostly	 from	 pneumonia	 or
cardiovascular	complications	[10].	 (See	Figure	54.1.)	 Important	 for	clinical	practice	 is	 the	 finding	 that
even	 in	 the	 recovery	phase	of	GBS	patients	are	at	 risk	of	dying.	This	 shift	 from	 the	majority	of	deaths
occurring	during	the	acute	phase	to	the	majority	of	deaths	occurring	in	a	later	stage	could	be	due	to	better
monitoring	 of	GBS	 patients	 in	 their	 acute	 phase	 of	 the	 disease	 at	 high	 care	 or	 intensive	 care	 units	 or
frequent	monitoring	on	a	neurology	ward.
How	to	Reduce	the	Mortality	of	GBS?
There	 is	 very	 little	 evidence	 for	measures	 that	 can	 prevent	 patients	 from	 dying	 from	GBS.	 It	 is	 clear,




Standardized	and	 routine	monitoring	of	vital,	 respiratory	 function	and	weakness,	 in	 the	 acute	phase
every	2	to	4	hours
Checking	for	autonomic	dysfunction	and	swallowing	disturbances
Use	 of	 the	 Erasmus	 GBS	 Respiratory	 Insufficiency	 Score	 to	 predict	 the	 risk	 of	 respiratory
insufficiency.	 This	 can	 help	 physicians	 decide	whether	 the	 patient	 should	 be	 admitted	 to	 a	 general
ward,	high	care	or	intensive	care	[12].





Probably	 due	 to	 improvements	 in	 general	 and	 intensive	 care	 of	 GBS	 patients	 the	 mortality	 rate	 has
decreased.	Although	dying	from	GBS	is	uncommon,	GBS	still	is	a	life-threatening	disease,	especially	in
the	elderly,	 in	ventilated	GBS	patients,	and	 in	GBS	patients	with	significant	comorbidity.	GBS	patients

































are	 traditionally	 good	 in	 diagnosing	 a	 disease,	 but	 unfortunately	 treatment	 for	 many	 neuromuscular
diseases	largely	stays	behind.	This,	however,	is	not	the	case	for	GBS!	I	can	remember	very	well	the	year




over	 the	 past	 decade.	This	 hopefully	 helps	 to	 better	 select	 drugs	 or	 any	 other	 treatment	 regimen	 to	 be
tested.	With	the	help	of	proper	outcome	measures	and	using	up-to-date	trial	design,	it	is	to	be	hoped	that






positive	effects	of	plasma	exchange	 (PE)	 in	patients	with	GBS	[3,4].	The	 first	 large	PE	 trial	had	been
conducted	 in	North	America	and	Canada	and	was	publised	 in	1985	 [1].	 I	 can	very	well	 remember	 the
publication	 of	 this	 landmark	 study.	 It	 showed	 that	 PE	 is	 the	 first	 proven	 effective	 treatment	 for	 GBS




replacement	 fluid	 for	 the	 PE	 procedure,	 because	 FFP	 is	 the	 source	 of	 IVIg,	 and	 FFP	 likely	 is	 also
effective	in	CIDP	[6].	The	PE	trials	used	some	different	exchange	regimens.	In	patients	unable	to	walk,	a
regimen	of	 five	 50-ml/kg	 exchanges	 over	 8–13	days	 seems	 appropriate.	One	other	 large	PE	 trial	 from
France	showed	that	2	PE	sessions	are	better	than	no	exchanges	in	GBS	patients	being	able	to	walk	[7].
Figure	55.1		My	personal	highlights	towards	a	better	treatment	for	GBS	patients.
IVIg	=	 intravenous	 immunoglobulin;	PE	=	 plasma	 exchange;	Methylpred	 =	methylprednisolone;	SID-GBS	=	 Second	 IVIg	 dose
randomized	 trial	 in	 GBS;	 I-SID-GBS	 =	 International	 second	 IVIg	 dose	 prospective	 study	 in	 GBS;	 ICA-GBS	 =	 inhibition	 of
complement	activation	in	GBS;	JET	=	Japanese	eculizumab	trial
*	=	North	American	PE	trial	was	followed	by	important	French	PE	trials
We	need	 to	 acknowledge	 that	PE	 is	 not	 an	 attractive	procedure	 to	be	performed	 in	many	groups	of
patients—for	 example	 young	 children—and	 that	 it	 is	 relatively	 contraindicated	 in	 individuals	 with
autonomic	failure.	Although	it	generally	is	less	expensive	than	IVIg,	it	remains	a	costly	procedure	and	it
requires	special	equipment	and	appropriately	trained	staff.	Therefore,	exchanging	multiple	small	volumes
of	 plasma	 wihout	 using	 a	 special	 apparatus	 potentially	 could	 be	 an	 attractive	 procedure	 for	 a	 large





Already	during	 the	 recruitment	phase	of	 the	North	American	PE	 trial,	 there	were	 some	pioneers	 in	 the
Netherlands	 who	 aimed	 to	 find	 another	 treatment	 for	 GBS	 and	 chronic	 inflammatory	 demyelinating
polyneuropathy	(CIDP)	[6,8].	This	was	largely	done	because	there	were	local	 logistical	problems	with
conducting	PE	as	a	regular	treatment	in	CIDP	at	that	time.	Here	in	Rotterdam,	as	far	as	I	know,	the	first
patients	 were	 treated	 with	 FFP	 instead	 of	 PE,	 and	 it	 appeared	 effective!	 Then	 a	 resident,	 I	 clearly
remember	 the	first	CIDP	patients	 receiving	 their	 regular	FFP	infusions.	This	 treatment	was	replaced	by
intravenous	immunoglobulin	(IVIg)	when	this	product	became	available	[6,9].	The	beneficial	therapeutic
effect	of	IVIg	in	CIDP	prompted	an	open	study	in	GBS.	The	first	study	included	8	GBS	patients.	It	was






The	 possible	 effect	 of	 IVIg	 in	 GBS	 was	 investigated	 in	 a	 randomized	 controlled	 trial	 (RCT)	 that
compared	IVIg	(0.4	g/kg	bodyweight	for	5	days)	with	standard	PE	treatment.	The	Dutch	GBS	study	group
led	by	Frans	van	der	Meché	started	this	RCT	in	June	1986	and	the	last	patient	entered	the	study	by	the	end
of	 1989.	After	 the	 inclusion	 of	 150	 patients	 and	 a	 follow-up	 of	 half	 a	 year,	 the	 study	was	 terminated
because	strength	had	improved	by	one	grade	or	more	on	the	GBS	diasbility	grade	after	4	weeks	in	34%	of
the	group	treated	with	PE,	compared	to	53%	in	the	group	treated	with	IVIg	(p	=	0.024).	The	IVIg	group
additionally	 had	 significantly	 fewer	 complications	 and	 less	 need	 for	 artificial	 ventilation	 [10].	 It	 was
concluded	 that	 IVIg	 is	 a	 practical,	 safe	 and	 effective	 treatment	 for	GBS.	 This	was	 a	major	 result	 and
would	finally	change	the	world’s	policy	to	treat	GBS!	However,	not	right	at	 that	moment	because	there
initially	was	a	lot	of	debate	whether	IVIg	really	would	be	as	effective	as	PE.	One	paper	indicated	that	a

















conduct	 a	 double-blind	 placebo-controlled	 RCT	 [19].	 The	 242	 patients	were	 randomized	 for	 steroids
(500	mg	methylprednisolone	for	5	days)	or	placebo	treatment.	Some	patients	additionally	received	PE.	It
was	 a	 disappointment	 that	 the	 study	 did	 not	 show	a	 beneficial	 effect	 of	 corticosteroids.	The	Cochrane
review	concluded	that	corticosteroids	given	alone	do	not	signifiantly	hasten	recovery	from	GBS	or	affect
longterm	outcome.	Additionally,	there	is	low-class	evidence	that	oral	corticosteroids	even	delay	recovery












factors	 (a	 post-hoc	 analysis)	 it	 seems	 that	 there	 is	 a	 minor	 advantage	 for	 the	 combiation	 IVIg	 and
methylprednisolone,	but	only	for	an	endpoint	at	4	weeks.	The	overall	conclusion	was	that	the	results	of
the	 trial	 were	 negative,	 but	 that	 a	 small,	 short-time	 benefit	 of	 the	 combination	 IVIg	 and







Because	 IVIg	 is	 insufficiently	 effective	 in	 a	 substantional	 portion	 of	 GBS	 patients,	 an	 international
consortium	lead	by	Professor	Hughes	conducted	an	RCT	in	383	adult	GBS	patients	who	were	randomized
for	 IVIg,	PE	and	PE	 followed	by	 IVIg	 [22].	This	 trial	unfortunately	did	not	 find	significant	differences













that	 some	 patients	 may	 require	 a	 repeated	 or	 otherwise	 higher	 IVIg	 dosage:	 (A)	 about	 10%	 of	 GBS



















the	 clinical	 knowledge	 and	 understanding	 of	GBS	 of	many	 neurologists,	 intensive	 care	 physicians	 and
others	who	take	care	of	these	patients.	Further	reports	on	good	medical	care,	like	how	to	monitor	patients
in	 the	progressive	phase	of	 the	disease	when	 admitted	on	 a	 general	 neurological	ward,	when	 to	 admit
patients	 on	 an	 intensive	 care	 unit,	 how	 to	 treat	 severe	 pain	 and	 many	 other	 aspects	 of	 giving	 better





In	 this	 amazing	 study,	 built	 upon	 the	 shouders	 of	 a	 lot	 of	 other	 studies,	 in	 particular	 from	 the	Willison
group	 in	Glasgow,	 it	was	 shown	 that	 blockade	of	 complement	 activation	by	 eculizumab,	 a	monoclonal











study	 lead	 by	 Ingemar	 Merkies.	 It	 is	 in	 large	 part	 focussed	 on	 assessment	 scales	 in	 patients	 with
inflammatory	neuropathies,	GBS	in	particular.	Rasch-based	new	assessment	scales	will	hopefully	play	an
important	role	in	new	treatment	trials	in	GBS	and	other	immune-mediated	neuropathies.	It	 is	hoped	that











currently	 is	 substantial	 interest	 in	 researching	 inflammatory	 neuropathies,	 as	 demonstrated	 by	 the	 large



































































By	 the	 1980s,	 it	 was	 generally	 accepted	 that	 GBS,	 the	 ‘acute	 inflammatory	 demyelinating
polyradiculoneuropathy’	 (AIDP),	 represented	 a	 post-infectious	 immune-mediated	 neuropathy.	 This
hypothesis	 was	 supported	 by	 preceding	 infections	 and	 by	 the	 very	 early	 pathology	 showing	 extensive
lymphocyte	 infiltrations	 in	 roots	 and	 peripheral	 nerves,	 oedema,	 deposition	 of	 complement	 on	 outer
aspects	of	myelin	sheaths	followed	by	vesicular	disruption,	and	macrophages	infiltrating	Schwann	cells
and	acting	as	scavengers	by	engulfing	the	disintegrated	myelin	and	leaving	behind	a	segmentally	denuded
axon.	 Thus,	 the	 primary	 immune	 target	 epitope	 appeared	 to	 be	 localized	 in	 the	 outer	 Schwann	 cell
membrane	or	myelin.	Simultaneously,	nodes	of	Ranvier	became	widened	as	myelin	loops	lifted	off	from
their	 ‘paranodal’	 attachments	 [1,2].	 Degeneration	 of	 axons	 was	 considered	 a	 secondary	 event.	 The
observations	suggested	a	T	cell-dependent,	complement	and	macrophage-mediated	aetiology.	While	target
antigen(s)	remained	elusive,	humoral	factors	seemed	relevant.
In	1979,	Saida	 and	 colleagues	 reported	 an	EAN	model	 in	 rabbits	 induced	by	 sensitization	with	 the
















when	 started	within	7	days	of	disease	onset,	 and	 for	patients	who	had	 required	mechanical	ventilation







1985,	 Vermeulen	 and	 colleagues	 reported	 that	 13	 out	 of	 17	 patients	 with	 chronic	 inflammatory
polyneuropathy	 (CIDP)	 had	 benefitted	 from	 infusions	 of	 fresh-frozen	 plasma	 (FFP).	 On	 average,
improvements	 lasted	 3	weeks,	 they	were	 reproducible,	 and	 functions	 stabilized	with	 repeat	 infusions.
Similar	improvements	occurred	in	8	out	of	9	CIDP	patients	after	infusions	of	polyclonal	gammaglobulin,







adult	 patients	 and	 children	 with	 severe	 GBS,	 treated	 within	 7	 days	 from	 onset	 [16].	 Outcome	 was
measured	 with	 the	 disability	 scale	 used	 in	 previous	 trials.	 Primary	 outcome	 measure	 (proportion	 of
patients	improved	by	one	or	more	functional	grades	at	4	weeks)	and	secondary	ones	(time	to	improve	one












for	 the	PE	group	(p	=	0.07).	 IVIg	 treatments	were	well	 tolerated	and	more	 likely	 to	be	completed,	and
associated	medical	complications	were	significantly	less	frequent.
The	 trial	 results	 were	 met	 with	 great	 interest,	 but	 also	 raised	 concerns	 as	 observations	 with	 PE







The	 relative	 efficacy	 of	 plasma	 exchange	 (PE),	 intravenous	 immunoglobulin	 (Sandoglobulin)	 and	 the
combined	regimen	of	PE	immediately	followed	by	IVIg	were	compared	in	383	adult	patients	with	severe
GBS,	 who	 were	 randomized	 within	 14	 days	 from	 disease	 onset	 and	 studied	 by	 an	 international,
multicentre	RCT	[17].	The	‘disability	at	4	weeks’—the	primary	endpoint—was	assessed	by	an	examiner




—‘mean	disability	 grade	 improvement	 after	 4	weeks’.	The	difference	of	 improvement	between	 the	PE
group	 and	 the	 IVIg	 group	 was	 0.1	 grade	 (95%	 CI	 –0.23	 to	 0.42),	 where	 by	 the	 pre-set	 criterion	 for
equivalence	of	the	2	treatments	was	met.	Moreover,	differences	of	improvement	between	PE+	IVIg	group
and	PE	alone	of	0.20	grade	(95%	CI	–0.14	to	0.54)	and	IVIg	alone	0.29	grade	(95%	CI	–0.04	to	0.54)
respectively,	 were	 not	 significant.	 Furthermore,	 there	 were	 no	 significant	 differences	 between	 the
treatment	groups	in	regards	to	the	secondary	outcome	measures:	time	to	recover	unaided	walking;	median
time	to	discontinue	mechanical	ventilation;	and	pattern	of	recovery	over	48	weeks.	At	48	weeks,	16%	of




severe	 GBS,	 and	 that	 the	 combined	 treatment	 did	 not	 confer	 additional	 benefit.	 A	 regression	 analysis
confirmed	 that	older	age,	 small	distally	evoked	CMAP	amplitudes,	and	prior	gastrointestinal	 infections
adversely	affected	the	prognosis,	irrespective	of	the	treatment.
Adverse	effects	attributed	to	IVIg	(malaise,	nausea/vomiting,	rigor,	fever,	flu-like	symptoms,	myalgia,











to	 sepsis	or	 autonomic	 failure	 is	 rare.	The	prognosis	 for	 children	with	GBS	 is	 excellent,	 as	nearly	 all
make	a	full	recovery.
Most	 controlled	 RCTs	 evaluating	 the	 efficacy	 of	 PE	 and	 IVIg	 had	 excluded	 children.	 Hence,
observations	 in	 severely	 affected	 adult	GBS	 patients	 have	 been	 extrapolated	 to	 children.	 This	may	 be
justified,	as	a	comparative	study	of	18	children	and	50	adults	 from	a	single	centre	 found	no	significant









regimes	 of	 IVIg	 [22].	 The	 study	 comprised	 3	 groups	 that	 were	 evenly	 matched	 in	 regards	 to	 disease
severity.	Twenty-four	children	received	IVIg	1g/kg	for	2	days,	23	children	IVIg	0.4g/kg	for	5	days,	and	28
children	 received	 supportive	 care.	 The	 primary	 outcome	 measures	 were	 ‘mean	 time	 to	 improve	 1
disability	grade’,	and	‘mean	grade	change	at	4	weeks’.	On	analysis,	the	mean	time	to	improve	1	disability
grade	was	 significantly	 shorter	with	 IVIg	 irrespective	of	dosing:	20.8	days	with	 IVIg	versus	62.4	days
with	 supportive	care	 (P	<	 0.01).	Moreover,	 at	 4	weeks	 improvement	with	 IVIg	was	 a	mean	1.0	 grade
versus	a	mean	0.35	grade	with	supportive	care	(P	<	0.01).	While	the	study	is	limited	by	its	retrospective
nature,	the	observed	large	differences	strongly	suggest	that	IVIg	benefits	childhood	GBS.	A	prospective




The	open	nature	of	 the	 trial	 left	 room	for	bias.	Results	 indicated	that	children	treated	with	PE	required
MV	for	a	median	11	days	(IQR	11.0	to	13.0)	versus	those	with	IVIg	for	a	median	13	days	(IQR	11.3	to
14.5)	P	=	0.037.	There	were	nonsignificant	differences	in	the	length	of	ICU	stay	and	in	the	outcome	at	4
weeks	 as	 20	 out	 of	 21	 children	 treated	 with	 PE	 and	 18	 out	 of	 20	 treated	 with	 IVIg	 had	 regained
independent	ambulation.	The	 trial	concluded	 that	PE	had	a	slight	but	significant	advantage	over	IVIg	 in
reducing	the	time	of	MV.	The	study	was	not	blinded,	which	could	have	introduced	bias.
A	second	prospective	randomized	multicentre	study	by	Korinthenberg	and	colleagues	sought	to	clarify
whether	 early	 treatment	with	 IVIg	mitigates	 the	 subsequent	disease	 severity	 [24].	Twenty-one	children,
who	were	able	to	walk	unaided,	were	randomized	to	IVIg	(1g/kg	over	2	days;	half	the	usual	dose)	or	no
treatment.	Concealed	randomization	resulted	in	unequal	allocation	of	14	participants	to	IVIg	and	only	7	to
no	 treatment.	 The	 2	 groups	 were	 otherwise	 matched.	 ‘Degree	 of	 disability	 at	 nadir’	 was	 the	 primary
outcome	measure.	Eleven	of	the	21	children	progressed	to	losing	the	ability	to	walk	unassisted,	7	out	of
14	 on	 IVIg	 and	 4	 out	 of	 7	 on	 no	 treatment,	 a	 nonsignificant	 difference	 (P	 =	 0.25).	 However,	 the
improvement	 in	 disability	 at	 4	 weeks	 was	 significantly	 greater	 in	 the	 group	 treated	 early	 than	 in	 the
untreated	participants	(the	mean	difference	(MD)	–1.42,	95%	CI	–2.57	to	–0.27).	The	same	investigators
assessed	 the	 effect	 of	 IVIg	 dosing	 in	 a	 second	 trial	 involving	 51	 children	 who	 were	 unable	 to	 walk
unaided:	25	participants	 randomized	 to	 IVIg	2g/kg	over	2	days,	and	26	 to	 IVIg	2g/kg	over	5	days.	The
primary	 outcome	 measure	 was	 ‘days	 to	 regain	 unaided	 walking’.	 Results	 showed	 no	 significant
differences	in	the	time	to	regain	unaided	walking	irrespective	of	IVIg	dosing:	median	19	days	for	IVIg	2
day	 group	 versus	median	 13	 days	 for	 IVIg	 5	 day	 group	 (log-rank	 test	 P	=	 0.94).	 The	median	 time	 to
improve	1	point	in	disability	score	was	5	days	in	both	groups.	Multivariate	analysis	showed	that	‘disease
severity	at	nadir’	was	the	only	prognostic	determinant	for	recovery.	Different	IVIg	dosing	regimes	did	not
influence	 recovery	 time	 or	 outcome.	 However,	 treatment-related	 fluctuations	 were	 significantly	 more
frequent	with	treatment	when	IVIg	2g/kg	was	given	over	2	days.
Despite	 efforts	 to	 arrive	 at	 objective	 guidance	 for	 the	 use	 of	 IVIg	 in	 childhood	 GBS,	 all	 studies
suffered	 from	 small	 enrolment	 and	 variable	 potential	 for	 bias.	 Nonetheless,	 observations	 point
consistently	to	a	beneficial	effect	of	IVIg	in	children.	These	underscore	the	current	guidelines	to	prescribe
immunomodulation	with	either	IVIg	or	PE	in	children	with	severe	GBS,	unable	to	walk	10	meters	without
assistance.	 There	 is	 limited	 evidence	 that	 children	 with	 milder	 disease,	 able	 to	 walk	 10	 meters
unassisted,	would	benefit	from	early	IVIg	treatment.	In	view	of	the	natural	speedy	recovery	and	excellent
outcome	in	childhood	GBS,	it	would	be	justified	to	monitor	such	children	closely	without	use	of	special








The	primary	axonal	 autoimmune	neuropathies	 constitute	 a	 spectrum	of	 clinical	disorders	with	 a	 shared
immunopathogenesis.	 The	 above	 papers	 by	 Shahrizaila,	 Susuki	 and	 Kuwabara	 and	 colleagues	 are
landmark	 publications	 in	 establishing	 this	 concept	 [26,27,28].	Most	 often,	 the	 triggering	 infections	 are







rapid	 loss	of	 function.	Depending	on	 the	degree	of	damage,	CB	may	be	 reversible	with	 resulting	early
clinical	 improvement.	 Alternatively,	 recruitment	 of	 macrophages	 and	 progression	 of	 complement-
mediated	pathology	causes	axonal	degeneration	and	consequently	protracted	recovery	[30].
The	 clinical	 manifestations	 of	 acute	 motor	 axonal	 neuropathy	 (AMAN),	 acute	 motor	 and	 sensory
axonal	neuropathy	(AMSAN),	acute	sensory	ataxic	neuropathy	(ASAN),	and	the	Fisher	syndrome	(FS)	are
each	associated	with	distinct	anti-ganglioside	autoantibody	profiles.	These	disorders	extend	the	spectrum








caused	by	C.	 jejuni	 strains	 that	 induce	 IgG	 anti-ganglioside	 antibodies	 against	GM1,	GD1a,	GalNAc-
GD1a	and	GD1b,	a	pattern	characteristic	for	AMAN.	The	clinical	course	is	marked	by	an	acute	onset	of
flaccid	 weakness	 that	 initially	 affects	 the	 lower	 limbs,	 ascending	 upwards	 but	 often	 sparing	 cranial
nerves.	In	contrast	to	AIDP,	tendon	reflexes	may	be	preserved.	Usually,	patients	will	have	reached	their
nadir	within	days,	often	at	their	first	presentation	to	a	physician.	They	may	be	able	to	ambulate	or	be	bed-
bound,	 and	 approximately	 25%	 require	 assisted	 ventilation	 [35].	At	 times,	 recovery	 from	 paralysis	 in
AMAN	can	be	remarkably	fast,	within	days	from	onset,	which	is	due	to	resolution	of	conduction	block	at
the	 nodes	 of	Ranvier.	Alternatively,	 recovery	 is	more	 protracted	because	 of	more	 severe	 complement-
mediated	 damage	 to	 motor	 axons	 with	 ensuing	 axonal	 degeneration	 [30,36].	 Preceding	 diarrhoea	 is










years	 all	 but	 1	 child	 with	 AMAN	 (93%)	 had	 regained	 independent	 ambulation.	 Hence,	 the	 authors
suggested,	that	the	long-term	prognosis	for	the	2	subtypes	of	childhood	GBS	may	be	similar.
The	 secondary	 analysis	 of	 participants	 in	 the	 original	 Dutch	 RCT	 of	 IVIg	 and	 PE	 in	 severe	 GBS
identified	27	participants	with	characteristics	of	AMAN:	16	had	 randomized	 to	 IVIg	and	11	 to	PE.	On
assessment	 at	 6	months	 14	 out	 of	 16	 participants	 treated	with	 IVIg	 had	 regained	 independent	walking




median	disability	 grades,	CMAP	 sum	 scores	 and	 frequency	of	C.	 jejuni	 infections.	 Those	 treated	with
IVIg	had	significantly	lower	disability	scores	at	1,	3	and	6	months	from	onset	of	treatment	(P	=	0.03),	and
they	 also	had	 a	higher	probability	 to	 regain	 independent	 ambulation	 at	 6	months	 (log	 rank	P	=	 0.044).
Moreover,	6	out	of	10	patients	treated	with	IVIg	had	shown	markedly	rapid	improvements	of	2	or	more
disability	 grades	 in	 the	 first	 4	weeks	 compared	 to	 only	 3	 out	 of	 14	 in	 the	 PE	 group	 (P	=	 0,03).	At	 6








GT1a	 in	 85%	 of	 cases,	 and	 observations	 of	 clinical	 overlap	 with	 GBS	 in	 ~7%	 of	 FS	 patients.	 Such
patients	 have	 a	 combined	 presentation	 of	 FS	 and	 AMAN,	 characterized	 by	 a	 descending	 pattern	 of
paralyses,	frequent	need	for	MV	and	a	less	favourable	prognosis	[40].
In	 Japan,	FS	 is	more	prevalent	 in	middle-aged	men	 (male	 to	 female	 ratio	 is	2:1).	A	 review	of	466
representative	FS	patients	indicated	that	most	patients	recalled	an	infectious	illness	within	the	preceding
week,	causing	either	only	upper	 respiratory	symptoms	 (64%),	or	only	diarrhoea	 (13%),	or	both	 (12%)
[41].	 Serologic	 and	 cultural	 evidence	 attested	 to	 a	 recent	 infection	with	H.	 influenzae	 or	C.	 jejuni	 in
some	of	the	patients,	yet	for	most	the	causative	agent	remained	undefined.	Initial	symptoms	were	abrupt
onset	 of	 diplopia	 or	 gait	 disturbance.	 All	 patients	 presented	 the	 classical	 triad	 of	 external
ophthalmoplegia,	 ataxia,	 and	 hypo-	 or	 areflexia.	 Blepharoptosis,	 mydriasis	 and	 facial	 weakness	 were
seen	in	one-third	of	patients,	while	mild	bulbar	and	limb	weakness	were	seen	in	one-quarter	of	patients.
At	 nadir,	 reached	 within	 a	 median	 4	 days	 (range	 1–20),	 nearly	 one-third	 of	 patients	 had	 complete
ophthalmoplegia	and	one-third	were	unable	to	walk	independently.
Although	half	of	 the	patients	 reported	mydriasis,	 loss	of	deep	sensation	was	rare	and	sensory	nerve
conduction	 studies	 were	 normal.	 Results	 of	 a	 body-sway	 analysis	 indicated	 dysfunction	 of	 group	 1a
sensory	neurons	 and	proprioceptive	 afferents.	Brain	MRI	 studies	were	normal	 in	 all	 but	1%	of	 the	FS
patients	in	whom	minor	abnormalities	were	found	in	the	brainstem.	CSF	albominocytological	dissociation
was	 present	 in	 76%	 of	 patients,	 and	 anti-GQ1b	 IgG	 antibodies	 and	 anti-GT1a	 IgG	 antibodies	 were
detected	in	86%	of	FS	patients	[41].	The	GQ1b	epitope	is	expressed	in	the	paranodal	regions	of	human












with	 the	exception	of	 the	frequency	of	complete	ophthalmoplegia,	which	was	significantly	higher	 in	 the
IVIg	 group	 (p	 =	 0.007).	 The	 time	 from	 onset	 of	 ataxia	 and	 ophthalmoplegia	 to	 the	 earliest	 signs	 of
improvement	was	significantly	shorter	in	the	IVIg	treated	group	compared	to	the	control	group	(ataxia	p	=
0.027;	ophthalmoplegia	p	=	0.04).	However,	 the	 times	 required	 for	 the	 full	 resolution	of	 the	symptoms
were	not	 significantly	different	between	 the	3	groups;	 this	was	also	 seen	 in	 a	 sub-analysis	of	 the	most
severely	affected	patients.	At	one	year	after	onset	of	the	neurological	symptoms	in	96%	FS	patients	had
fully	recovered.	The	study	concluded	that	IVIg	slightly	hastened	the	recovery	in	FS	patients	but	that	did
not	 affect	 the	 outcome.	 Interestingly,	 PE	 did	 not	 seem	 as	 effective	 in	 FS	 as	 had	 been	 observed	 in	 a
previous	study	[45].
In	view	of	 the	fairly	rapid	recovery	and	generally	excellent	prognosis	of	FS,	 there	is	consensus	that








Intravenous	 immunoglobulin	 (IVIg)	 preparations	 comprise	 the	 pooled	 fraction	 of	 serum	 IgG	 from
thousands	 of	 healthy	 blood	 donors,	 generated	 by	 a	multistep	 purification	 process	 of	 cryoprecipitation,
followed	by	ethanol	fractionation	and/or	chromatography.	The	large	donor	pool	ensures	a	wide	spectrum
of	 natural	 and	 induced	 antibody	 activities,	 including	 antibodies	 directed	 against	 external	 antigens,
autoantibodies	 and	 anti-idiotypes.	 This	 polyclonal	 antibody	 repertoire	 is	 likely	 important	 for	 the
therapeutic	effects	of	IVIg	[46,47,48].	Various	measures	are	taken	for	the	inactivation	of	viruses	and	other
infectious	 agents,	 and	 for	 the	 depletion	 of	 ABO	 antibodies,	 to	 reduce	 the	 risk	 of	 contamination	 and
haemolytic	 reactions,	 respectively.	Concentrations	of	 IgA	are	kept	 to	a	minimum	(<	2.5%)	 to	avoid	 the
risk	for	anaphylactic	reactions	in	patients	with	IgA	deficiency	carrying	anti-IgA	antibodies.	Care	is	taken
to	 remove	 IgG	 aggregates	 to	 avoid	 cytokine	 release	 and	 overt	 immune	 stimulation.	 Thus,	 IVIg
preparations	 contain	 ~95%	 monomeric	 IgG,	 with	 a	 distribution	 of	 IgG	 subclasses	 equalling	 those	 of
normal	 serum.	Most	 commercial	 IVIg	 preparations	 also	 include	 stabilizers,	 such	 as	 sorbitol,	 glycine,
sucrose	or	L-proline,	which	may	potentially	contribute	 to	 the	adverse	effects,	such	as	headache,	nausea
and	fever.	 In	general,	 IVIg	 infusions	are	well	 tolerated,	with	side	effects	occurring	 in	 less	 than	10%	of





via	 antigen-specific	 (mediated	 by	 the	 antigen-binding	 IgG	 Fab	 region),	 and	 non-antigen-dependent
mechanisms	(mediated	via	the	IgG	constant	Fc	region).	Both	domains	participate	in	the	anti-inflammatory
and	 immunomodulatory	 activity	 of	 IVIg.	 It	 is	 likely	 that	 several	 mutually	 nonexclusive	 mechanisms
contribute	to	the	beneficial	effects.
Commercial	 preparations	 of	 IVIg	 contain	 a	multitude	 of	 highly	 specific	 antibodies	 generated	by	 the
adaptive	 immune	 system	of	 contributing	blood	donors	 after	 exposure	 to	 infectious	microbial	organisms
and	external	foreign	antigens,	as	well	as	natural	antibodies	and	anti-idiotypic	antibodies.	The	latter	are	of
particular	 importance	 as	 they	 recognize	 the	 antigen-detecting	 domains	 of	 other	 antibodies	 and	 are	 thus
potentially	able	to	block	or	neutralize	pathogenic	autoantibodies,	thereby	preventing	the	antibody-induced
activation	of	the	complement	cascade.	Natural	self-reacting	antibodies	are	an	integral	component	of	IVIg
and	 are	 believed	 to	 contribute	 to	 immunoregulatory	 effects	 of	 IgG	 by	 establishing	 normal	 immune





membrane	 attack	 complex-mediated	 pathology.	Moreover,	 IVIg	 has	 profound	 effects	 on	 both	 T	 and	 B
lymphocytes,	 the	 key	 cellular	 components	 of	 the	 adaptive	 immune	 system,	 by	 suppressing	 pro-
inflammatory	 T	 cells,	 inhibiting	 cytotoxic	 T	 cells,	 upregulating	 T	 regulatory	 cells,	 and	 by	 inducting	 a
protective	 Th1/Th2	 shift.	 Importantly,	 IgG-induced	 upregulation	 of	 the	 inhibitory	 FcγRIIB	 receptor	 on
antigen	presenting	dendritic	cells	(DC)	modulates	T-cell	activation.	Furthermore,	upregulation	of	FcγRIIB





Despite	 solid	 evidence	 of	 the	 therapeutic	 efficacy	 of	 IVIg	 in	GBS,	 it	 remains	 unclear	which	 of	 the
above	outlined	pleiotropic	 immunomodulatory	mechanisms	are	operative	and	whether	 they	apply	 to	all






Treatment	 of	GBS	 combines	multidisciplinary	 supportive	medical	 care	 and	 immunotherapy	 [52].	 Both
IVIg	and	PE	provide	equivalent	benefit	 to	hasten	 the	 recovery	and	 shorten	 the	duration	of	disability	 in
patients	with	severe	GBS	(updated	evidence	appears	in	Cochrane	Reviews,	2014).	IVIg	is	the	generally
preferred	 treatment	 because	 it	 is	 convenient	 and	 more	 available,	 and	 is	 more	 likely	 to	 be	 completed
according	to	protocol.	Immunotherapy	is	usually	started	when	the	patient	has	lost	the	ability	to	walk	10
meters	without	assistance	(GBS	disability	grade	≥3).	It	is	currently	not	known	whether	mild	GBS	would








day	 infusion	 regime	 is	 more	 convenient	 for	 children.	 In	 adult	 patients,	 particularly	 those	 with
hemodynamic	instability,	cardiovascular	risk	factors,	and	compromised	renal	function,	and	in	the	elderly,






early	 improvement	with	 IVIg,	approximately	10%	of	patients	experience	a	secondary	deterioration,	 so-




and	 nearly	 half	 required	MV.	 In	 parallel,	 the	 investigators	 identified	 8	 (5%)	 patients	who	 represented
acute-onset	 CIDP.	 A-CIDP	 could	 be	 differentiated	 from	GBS/TRF.	 Patients	 with	 A-CIDP	 seldom	 had
cranial	 nerve	 dysfunction,	 had	 less	 weakness	 and	 disability,	 did	 not	 require	 MV,	 and	 had	 more
pronounced	signs	of	demyelination	on	electrophysiological	studies.	In	addition,	they	differed	significantly
by	 a	 later	 nadir,	 delayed	 first	worsening	 at	 ~	 4.5	weeks,	 and	 by	multiple	 exacerbations,	 all	 of	which
responded	to	IVIg.	Their	treatment	was	changed	to	a	long-term	CIDP	protocol	[58].
GBS/TRF	 patients	 likely	 have	 a	 longer-lasting	 active	 immune	 phase	 of	 their	 disease,	 and/or	 the
standard	 IVIg	 infusions	 were	 less	 effective.	 Response	 to	 immunomodulatory	 therapy	 is	 variable	 and
~20%	 GBS	 patients	 have	 a	 protracted	 disease	 course	 and	 are	 left	 severely	 disabled.	 Studying	 the
pharmacokinetics	of	IVIg	in	174	GBS	patients,	comparing	pretreatment	serum	IgG	levels	to	those	at	2	and
4	weeks,	3	months	and	6	months	after	a	standard	IVIg	dose,	it	was	found	that	the	increase	in	serum	IgG	at
2	 weeks	 varied	 markedly	 between	 patients.	 Patients	 with	 a	 low	 increase	 in	 serum	 IgG	 recovered













[62]	 have	 been	 introduced	 into	 clinical	 care,	 which	 are	 derived	 from	 readily	 available	 clinical
parameters	and	are	easily	and	quickly	applied	at	the	bedside.	As	adjustment	of	treatment	to	the	individual
patient’s	need	will	be	most	important	in	the	early	phase	of	the	illness,	the	prognostic	model	was	further
modified	 [m	EGOS]	 to	 be	 used	 at	 admission	 and	 at	 day	 7.	 It	 allows	 the	 accurate	 prediction	 of	 poor
outcome	at	4	weeks,	3	months	and	6	months	of	GBS	with	high	discriminate	value	[63].	These	approaches
are	being	used	 in	clinical	 trials	and	will	 eventually	make	 it	possible	 to	 tailor	 therapy	according	 to	 the
needs	of	individual	patients.
SID-GBS	Trial
A	placebo-controlled	RCT	compares	 the	effects	of	a	second	course	of	 IVIg	given	shortly	after	 the	 first
course	 in	GBS	patients	with	 early	 projected	poor	 outcome	 (defined	 as	 an	mEGOS	 score	 of	 6–12	 at	 1
week)	and	was	launched	by	the	Inflammatory	Neuropathy	Consortium	in	2009	and	is	ongoing.









the	 largest	 RCT	 of	 GBS	 15	 out	 of	 258	 (5.8%)	 patients	 treated	 with	 Sandoglobulin	 experienced	 side
effects,	which	led	to	early	termination	of	the	infusion	in	7	patients	=	2.8%	(PSGBST	group	1997).	In	a
small	open	trial	of	IVIg	in	young	children	with	GBS,	treatment-related	adverse	events	occurred	in	4	out	of




Assessment	 Subcommittee	 of	 the	 American	 Academy	 of	 Neurology)	 list	 the	 prevalence	 of	 common








Migraine	 headache	 and	 aseptic	 meningitis	 can	 be	 triggered	 by	 IVIg	 in	 the	 predisposed	 individual.
Symptoms	of	meningeal	irritation	usually	subside	within	48	hours,	yet	hospitalization	and	strong	analgesia
are	often	required.	The	diagnosis	is	made	clinically	and	no	further	tests	are	necessary.	Pretreatment	with
steroids	or	nonsteroidal	anti-inflammatory	drugs	may	 lessen	 the	recurrence	with	repeat	 IVIg	 treatments.
Immobilized	 individuals	 or	 those	 prone	 to	 thrombophlebitis	 are	 at	 higher	 risk	 to	 develop	 a	 deep-vein
thrombosis.	Thromboembolic	events,	such	as	strokes,	pulmonary	embolism	or	myocardial	infarction	are
reported	but	are	rare.	The	main	causative	factor	is	an	increase	in	serum	viscosity	by	IVIg.	Skin	reactions
such	as	urticarial,	 lichenoid	 lesions,	eczema,	pruritus	of	 the	palms	and	petechiae	of	 the	extremities	can
develop	2–5	days	after	the	infusion	and	last	for	up	to	a	month.
Most	 serious	 anaphylactic	 reactions	 occur	 in	 patients	 with	 IgA	 deficiency	 (prevalence	 1:1000
population),	of	whom	~30%	have	anti-IgA	antibodies	that	can	cross-react	with	infused	IgA	contaminates
in	 the	 IVIg	 preparation,	 and	 can	 lead	 to	 the	 formation	 of	 macromolecular	 complexes.	 Fortunately	 the
complication	 is	 rare.	The	potential	 risk	 should	be	considered	at	 the	 start	of	each	 first	 infusion.	Rarely,
haemolytic	anaemia	may	be	provoked	by	haemolytic	antibody	contaminates	 in	 IVIg	preparations.	Acute







































































































































Aristotle	 (384–322	 BC),	 reflecting	 the	 poetry	 of	 the	 physician	 Empedoches	 (500–430	 BC),	 linked
respiration	 to	 inward	 and	 outward	 movement	 of	 air	 through	 small	 pores	 in	 the	 skin.	 The	 concept	 of
alternating	 repulsion	and	attraction	between	elements	was	dominant	 in	Plato’s	 (427–327	BC)	dialogue,
the	Timaeus.	In	his	system	the	diaphragm	separated	the	uppermost,	‘better	soul’	(responsible	for	courage
and	spirit)	from	the	lower,	base	soul	responsible	for	our	animal	appetites	for	food,	drink	and	other	wants.






to	 the	 Alexandrian	 physicians	 Herophilus	 and	 Erasistramus	 (approx.	 300	 BC)	 who	 based	 their
observations	on	 the	 first	 animal	experiments;	 indeed,	 they	even	 taught	 that	 the	diaphragm	was	 the	main
muscle	 of	 respiration.	 Their	 work	 was	 later	 described	 in	 the	 writings	 of	 Galen	 (AD	 130–200)	 in
Pergamum	and	Rome	but	it	is	to	Galen	himself	that	we	owe	the	first	clear	description	of	the	workings	of








the	 original	 eponymous	 description	 by	 Landry	 in	 1859	 in	 which	 he	 described	 involvement	 of	 the
respiratory	 muscles	 and	 the	 eventual	 danger	 of	 asphyxia	 when	 the	 paralysis	 reached	 its	 maximum
intensity.	 Richard	 Hughes	 [3]	 draws	 attention	 to	 Landry’s	 prescient	 recognition	 of	 the	 presence	 of
diaphragmatic	weakness	by	observing	paradoxical	movement	of	the	abdomen.	Landry	observed:	“On	the
day	before	dying	of	 asphyxia	 the	patient	was	 lying	quietly	on	his	back	and	 there	was	hollowing	of	 the
abdomen	during	 inspiration	and	outward	movement	during	expiration.	This	paradoxical	movement	was
much	less	evident	when	the	patient	was	sitting	up”.




progressive	 motor	 and	 sensory	 impairments	 were	 characteristic	 of	 Guillain-Barré	 syndrome	 and	 he
recognised	 that	 “in	 two	 cases	which	died	 from	pulmonary	 complications	 the	paresis	 of	 the	 respiratory
movements	was	probably	a	contributory	factor	to	the	fatal	termination”.
Pinckney	 (1936)	 describes	 3	 similar	 cases	 in	 which	 diaphragm	 weakness	 or	 paralysis	 occurred,
although	only	one	of	the	patients	died	[6].	By	1943	the	diagnosis	was	more	clearly	understood	and	a	case





incipient	 respiratory	 muscle	 insufficiency:	 “the	 fact	 that,	 in	 this	 case,	 the	 shoulders	 were	 severely
involved	 almost	 from	 the	 start	 made	 me	 a	 little	 cautious	 about	 the	 prognosis	 because	 the	 lesion	 was
getting	 closer	 to	 the	 fourth	 cervical	 segment,	 where	 the	 phrenic	 nerve	 comes	 off”.	 This	 remains	 an
important	 observation	 in	 routine	 clinical	 practice	 because	 shoulder	weakness	 indicates	 involvement	 of
C3/4	innervation	of	the	trapezius,	which	often	precedes	phrenic	nerve	impairment.
The	major	 stimulus	 to	 the	 development	 of	 intensive	 care	 came	 from	 the	 poliomyelitis	 epidemic	 in
Copenhagen	in	1952	and	a	later	one	in	London.	Lassen	reviewed	his	experience	in	Denmark	noting	that
“during	 the	11	years,	1934–44	respirator	 treatment	was	used	 in	76	cases	with	a	mean	mortality	 rate	of
80%.	Only	cuirass	respirators	were	used”	[9].	When	the	epidemic	occurred	available	ventilatory	support
was	 completely	 inadequate.	 In	 consultation	 with	 Dr	 Bjorn	 Ibsen,	 a	 Copenhagen	 anaesthetist,	 Lassen
undertook	 tracheostomy	 in	 those	 patients	 who	 could	 not	 maintain	 their	 airway	 because	 of	 excessive
secretions,	generally	due	to	acute	bulbar	poliomyelitis.	Positive	pressure	ventilation	was	then	delivered
manually	with	 a	 rubber	 bag.	At	 the	 height	 of	 the	 epidemic	 over	 300	 such	 patients	were	 admitted	 and
treated	 each	week	with	 continuous	manual	 ventilation	 being	 provided	 by	 teams	 of	medical	 and	 dental
students.	The	mortality	 fell	 from	over	80%	to	40%.	This	experience	 led	not	only	 to	 the	 introduction	of
intermittent	positive	pressure	ventilation	 (IPPV)	but	also	 to	 the	 idea	of	caring	 for	all	 sick	patients	 in	a
dedicated	ward	in	which	each	patient	could	have	their	own	nurse.	Thus,	 it	might	be	considered,	 that	 in
December	1953	the	specialty	of	intensive	care	medicine	was	born	[10].
The	 polio	 epidemic	 was	 also	 severe	 in	 London	 in	 1952.	 This	 led	 to	 the	 development	 of	 several
respiratory	isolation	units	across	the	city.	In	October	1953	an	intensive	care	unit	was	established	at	Queen
Square	 by	 Dr	Michael	 Kremer,	 and	 this	 continued	 to	 function	 after	 the	 polio	 epidemic.	 The	 unit	 was
subsequently	 led	by	Professor	 John	Marshall	 and	Dr	Atwood	 ‘Bobby’	Beaver.	Marshall	 described	 the
development	 of	 neurological	 intensive	 care	 to	 encompass	 the	management	 of	 temporary	 neuromuscular
paralysis	 [11].	 He	 described	 the	 ICU	 management	 of	 229	 patients	 over	 6	 years,	 including	 39	 with
polyneuritis.	 He	 notes	 “polyneuritis	 is	 in	 many	 ways	 a	 more	 gratifying	 condition	 to	 treat	 [than
poliomyelitis],	because	in	the	vast	majority	of	cases	there	is	no	residual	disability”.	This	important	paper
is	 remarkable	 in	 recognising	 many	 issues	 concerning	 the	 introduction	 of	 ventilatory	 care	 which	 have
become	 increasingly	 apparent	 over	 the	 intervening	 years.	 In	 particular	Marshall	 draws	 attention	 to	 the
rapid	 introduction	 of	 intermittent	 positive	 pressure	 respiration	 (IPPR),	 the	 importance	 of	 early
tracheostomy	 undertaken	 by	 a	 skilled	 operator,	 early	 recognition	 of	 CO2	 retention	 and	 incipient
ventilatory	failure,	the	importance	of	early	intervention	with	ventilatory	support	and	of	good	supportive
management	 including	 fluid	 and	 nutritional	 intake,	 metabolic,	 bowel	 and	 bladder	 care,	 the	 risk	 of
atelectasis	and	infection	and	the	importance	of	regular	nursing	and	physiotherapy	support.	This	important
paper	 also	describes	 the	difficulties	 in	providing	 respiratory	 support	 in	 patients	with	bulbar	weakness




[12].	Marshall	 described	 the	Queen	 Square	 experience	 in	Brain,	 noting	 4	 of	 35	 patients	 died,	 3	 from
respiratory	 failure	 and	 one	 from	 cardiac	 arrest,	 but	 there	 is	 no	 description	 of	 those	 who	 received
respiratory	support	[13].	The	rapid	development	of	intensive	care	through	the	1960s	and	1970s	is	been
described	 in	 a	 number	 of	 papers,	 including	 those	 by	 Pontoppodou,	 Hilberman,	 McCleave	 and,	 more
recently,	Widjicks	[8,14,15,16].
The	intensive	care	management	of	acute	Guillain-Barré	syndrome	has	evolved	with	the	introduction	of
new	 modes	 of	 ventilation,	 better	 techniques	 of	 supportive	 care	 and	 the	 widespread	 availability	 of
intravenous	 immunoglobulin	 as	 a	 more	 convenient	 form	 of	 immunomodulatory	 treatment	 than	 plasma
exchange	 [17].	 In	 the	 UK,	 highly	 specialised	 neurological	 ICU	 has	 become	 easier	 to	 access	 with	 the
development	 of	 neuroscience	 units,	 although	 there	 is	 considerable	 variation	 in	 the	 provision	 of
neurological	 support	 for	 patients	 admitted	 to	 general	 ICUs.	 It	 remains	 uncertain	whether	 these	 changes





12.2%	 but	 there	 are	 significant	 differences	 in	 the	 severity	 and	 clinical	 pattern	 of	 the	 cases	 seen	 and
treated	 [19,20].	 Most	 patients	 died	 from	 complications	 of	 intensive	 care	 and	 prolonged	 immobility,




showed	 that	 patients	 referred	 over	 the	 last	 15	 years,	 when	 compared	 to	 the	 earlier	 cohort,	 were	 of	 a
similar	age	and	sex,	had	a	similar	incidence	and	range	of	ICU	complications	and	a	comparable	range	of
immunomodulation	treatment.	However,	patients	admitted	more	recently	were	transferred	to	the	ICU	later,
required	mechanical	 ventilation	 for	 longer	 periods	 and	 required	 longer	 ICU	 and	 hospital	 stays.	 In	 the
more	 recent	 group	 there	 was	 a	 much	 higher	 incidence	 of	 axonal	 neuropathy	 (51%	 >	 24%)	 but	 the
increased	 duration	 of	 ventilation	 and	 length	 of	 stay	 applied	 whether	 the	 primary	 neuropathy	 was




The	 results	 suggest	a	change	 in	 the	pattern	of	 referral,	 at	 least	 to	 this	 specialised	neurological	 ICU,
indicating	 that	 patients	 with	 acute	 GBS	 are	 now	 referred	 later	 and	 with	 more	 prolonged	 and	 severe
disease,	reflected	in	a	higher	proportion	of	severe	axonal	neuropathy	requiring	longer	ICU	and	hospital








seem	 to	 be	 associated	with	 delayed	weaning	 and	 long-term	ventilatory	 impairment.	Weaning	 and	 step-
down	 care	 are	 critically	 important	 in	 determining	 long-term	 outcome	 after	 severe	 GBS.	 Prolonged
weaning	 requires	 specialist	 techniques	 of	 care	 and	 general	 medical	 ICUs	 do	 not	 always	 possess	 the







days.	 19	 patients	 were	 successfully	 weaned	 from	 invasive	 ventilatory	 support,	 5	 required	 nocturnal
noninvasive	ventilatory	(NIV)	support	for	10	to	225	days,	1	continues	to	use	nocturnal	NIV	and	1	patient
died.	 Nineteen	 patients	 were	 successfully	 discharged.	 This	 study	 emphasises	 that,	 with	 appropriate
management,	 many	 patients	 with	 severe	 and	 prolonged	 residual	 disability	 due	 to	 GBS	 can	 make	 an
excellent	or	good	recovery	of	respiratory	function	with	meticulous	ongoing	care	and	rehabilitation,	often




obvious	 relevance	 to	 the	 future	care	of	GBS	 throughout	a	world	 in	which	 facilities	and	 resources	vary
enormously.	 It	 is	 uncertain	 if	 their	 primary	 role	 should	 lie	 in	 managing	 patients	 with	 common
presentations	 of	 acute	 neurological	 disorders	 or	 if	 the	 scarce	 resources	 should	 be	 focused	 on	 the
specialised	care	of	tertiary	referrals	of	the	most	complex	and	difficult	management	problems,	which	often



























































autonomic	 nerves	 or	 even	 systematic	 effects;	 at	 least,	 when	 reading	 their	 seminal	 paper	 or	 later
publications	on	variants	it	does	not	jump	off	the	page.	Why	would	they?	Professor	Guillain	strongly	felt
the	syndrome	he	described	with	Barré	(and	with	some	assistance	from	André	Strohl)	was	utterly	unique








pneumonia	 and	 sepsis	 [1].	 Perhaps	 it	 started	 with	 Mitchell	 and	 Meilman,	 who	 concluded	 there	 was






nephropathy)	 or	 that	 manifestations	 are	 nonspecific	 and	 a	 result	 of	 failure	 to	 recognize	 and	 treat
dysautonomia	 (e.g.	 posterior	 reversible	 encephalopathy	 syndrome	 in	 dysautonomia	 -associated
hypertension).	 There	 is	 a	 good	 argument	 to	 be	 made	 that	 in	 the	 more	 severe	 cases	 of	 GBS	 there	 is
probably	another	‘hidden’	syndrome	(Figure	58.1).
Here,	I	will	interpret	a	collection	of	articles	published	over	the	years,	but	others	have	summarized	the






28	patients	died	“during	or	 immediately	after	episodes	of	 severe	autonomic	dysfunction”	as	a	 result	of
“cardiac	arrest	following	several	hours	of	rapidly	fluctuating	autonomic	status”	or	were	“found	dead	after
extremely	high	blood	pressure	recordings	although	paralysis	was	not	severe”	or	“died	suddenly	after	the
development	of	 a	 cardiac	arrhythmia	preceded	by	electrographic	 abnormalities”	 [3].	His	 sound	advice
included	that	“patients	with	inadequate	sympathetic	responsiveness	must	be	positioned	carefully,	straining
at	 bowel	 movements	 must	 be	 avoided,	 respiratory	 pressures	 deliberately	 set	 and	 at	 the	 first	 sign	 of
autonomic	dysfunction	a	cardiac	monitor	employed”.
Dysautonomia	in	GBS	is	recognized	by	blood	pressure	fluctuations	and	exaggerated	drug	responses,
cardiac	 arrhythmias,	 hypersecretions,	 gastrointestinal	 dysfunction	 and	 bladder	 dysfunction.	 Curiously
profound	flushing	and	sweating	had	some	clinicians	considering	a	coexisting	pheochromocytoma,	and	of
course,	in	many	patients	urinary	catecholamines	were	increased.	Paroxysmal	or	sustained	hypertension	is
seen	 in	 nearly	 1	 in	 4	 patients	 with	 GBS	 but	 not	 always	 the	 more	 severely	 affected.	 Systolic	 blood
pressures	can	become	substantially	elevated	and	reach	values	that	may	not	only	cause	the	left	ventricle	to
acutely	 strain,	 but	 can	 even	 predispose	 the	 patient	 to	 develop	 posterior	 reversible	 encephalopathy
syndrome.	 Encephalopathy	 with	 new	 onset	 seizures	 or	 visual	 disturbances	 is	 totally	 unexpected	 in	 a
patient	with	GBS	 and	 therefore	 an	MRI	of	 the	 brain	 is	 essential	 to	 find	 its	 characteristic	white	matter
vasogenic	oedema.
Why	these	blood	pressure	fluctuations	occur	 is	not	entirely	known,	but	a	baroreflex	abnormality	has






nicardipine	 have	 been	 used	 to	 treat	 severe	 hypertension,	 but	 simply	 controlling	 these	 responses	 with
multiple	doses	of	IV	morphine	is	just	as	effective	and	perhaps	safer.
The	whole	gamut	of	cardiac	arrhythmias	can	be	seen	in	GBS,	including	complete	heart	block	[11,12].
Sinus	 tachycardia	 and	 so-called	 vagal	 bradycardia	 spells	 are	 most	 frequent	 in	 patients	 with	 GBS.
Persistent	sinus	tachycardia	may	appear	at	any	time	during	the	illness	and	generally	is	not	associated	with
hypotension	or	chest	pain	but	slowing	of	rate	is	indicated	with	signs	of	myocardial	ischemia	on	EKG.	In




pacemaker	may	 be	 considered	 if	 these	 episodes	 are	 symptomatic	 and	 recurrent	 [14].	 In	 some	patients,
atrioventricular	block	or	other	more	benign	arrhythmias	(e.g.	bigeminy)	become	apparent.
Bronchial	 function	 is	 also	 likely	 impaired	 in	Guillain-Barré	 syndrome,	because	bronchoconstriction
and	bronchodilatation	are	under	the	control	of	vagal	and	sympathetic	innervation.	There	is	some	evidence
that	 impaired	bronchoconstriction	and	dilation	due	 to	abnormal	 innervation	of	bronchial	smooth	muscle
can	 lead	 to	 profound	 impairment	 of	 clearing	 of	 already	 increased	 secretions	 and,	 in	 turn,	 lead	 to
atelectasis	of	large	lung	segments.
As	part	of	the	screening	for	dysautonomia,	patients	should	also	be	carefully	examined	for	development
of	adynamic	 ileus.	This	occurs	 in	about	1	 in	10	patients	with	severe	GBS	and	is	recognized	by	loss	of
abdominal	 sounds,	 expansion	 of	 the	 abdominal	 girth,	 and	 enlarged	 colonic	 loops	 on	 abdominal	 x-ray.
Perforation	 of	 the	 colon	 is	 a	 major	 complication	 which	 can	 substantially	 change	 the	 outcome	 of	 a
recoverable	neurologic	 illness.	The	 treatment	of	patients	with	 severe	adynamic	 ileus	 is	 rectal	 and	oral
suction	 tubes,	 and	 a	 therapeutic	 decompressive	 colonoscopy.	 Opiates	 should	 be	 stopped.	 Peripherally
acting	mu-opioid	 receptor	 antagonists	 in	 the	 future	may	offer	 the	 reversal	of	 ileus	without	 loss	of	pain
relief.	 The	 use	 of	 erythromycin,	metoclopramide	 or	 neostigmine	might	 be	 considered,	 but	 side	 effects
(cardiac	arrhythmias)	may	make	 it	a	much	 less	 favourable	choice.	 In	our	series	of	patients	with	severe
GBS,	adynamic	ileus	developed	in	15%,	but	only	a	few	instances	seemed	correlated	with	dysautonomia.
Pre-existing	 conditions,	 such	 as	 prior	 abdominal	 surgery,	 and	 incremental	 doses	 of	 opioids	 for	 pain
management,	were	dominant	causes	[15].
Fatality	 from	 dysautonomia	 is	 difficult	 to	 prove.	 We,	 and	 particularly	 the	 Massachusetts	 General
Hospital	 retrospective	 and	 prospective	 series	 [16],	 found	 none	 including	 among	 the	 more	 severely
affected	 patients	 who	 were	 ICU	 admissions.	 The	 Queen	 Square	 series	 mentioned	 in	 this	 book	 (see
Howard	and	Hirsh	chapter)	did	not	mention	a	single	fatal	case.	Still,	a	report	from	the	Dutch	GBS	group
with	a	large	number	of	patients	retrospectively	reviewed	between	1986	and	2008	noted	2	of	527	patients









could	 be	 explained	 by	 sympathetic	 overdrive	 resulting	 in	 marked	 reduction	 in	 ejection	 fraction	 from
sudden	 ventricular	 strain	 with	 hypertension.	 Morphologic	 EKG	 abnormalities	 are	 uncommon	 and
nonspecific	 in	GBS,	 but	when	 they	 are	 present,	 ST-segment	 abnormalities	 are	 frequent.	 It	 is	 uncertain
whether	they	represent	myocardial	damage.	Myocarditis	has	been	found	in	fatal	cases	that	went	to	autopsy
but	 this	 entity	 remains	 poorly	 understood.	 It	 might	 be	 difficult	 to	 sort	 it	 out	 from	 a	 co-existing	 viral
infection	 affecting	 the	 heart.	When	 I	 read	 through	many	 of	 these	 cases	 the	 full	 ICU	 course	 is	 not	 fully
known	and	little	has	been	published	lately.
Most	 fascinating	 is	 a	membranous	nephropathy	causing	 in	 some	patients	 a	mild	nephrotic	 syndrome
and	pitting	oedema.	The	cases	are	detected	if	attentive	physicians	note	the	urinalysis	results	with	marked
proteinuria	 and	 microscopic	 heamaturia	 [5].	 Reported	 renal	 biopsies	 (including	 one	 case	 of	 subacute
GBS	I	remember	clearly)	have	been	unquestionably	confirmative,	but	not	all	cases	in	the	literature	may	be
GBS	and	an	underlying	systemic	disorder	such	as	lymphoma	or	vasculitis	should	be	considered.
Transient	 abnormalities	 of	 transaminases	 (rarely	 double	 from	 baseline)	 have	 been	 found	 with	 no
evidence	of	viral	or	 toxic	hepatitis	other	 than	an	association	with	IVIg	[18].	Sucrose	containing	IVIg	is
more	likely	to	cause	these	largely	clinically	 insignificant	changes,	and	liver	function	abnormalities	may
coincide	 with	 worsening	 renal	 function	 but	 resolution	 is	 seen	 in	 2	 weeks.	 Immunoglobulins	 acting	 as
immune	 complexes	 is	 a	 speculative	 explanation	 for	 increased	 transaminases.	 In	 most	 practices	 liver
function	abnormalities	are	not	a	concern	with	IVIg.





manifestations	 and	 mostly	 spontaneous	 wild	 blood	 pressure	 swings—one	moment	 in	 frank	 shock	 then
markedly	hypertensive	after	being	placed	in	 the	Trendelenburg	position.	Although	I	have	personally	not
encountered	 fatality	 or	 cardiac	 arrest	 associated	with	 dysautonomia	 and	 I	 have	not	 seen	 a	 patient	who
needed	a	pacemaker,	I	still	feel	very	uncomfortable	with	keeping	patients	with	GBS	and	dysautonomia	on
the	ward.	 The	 last	 patient	 I	 have	 seen	 at	 the	 time	 of	 this	writing	was	 improving	 from	GBS	 but	 had	 a
sustained	sinus	tachycardia	for	several	weeks	(Figure	58.2)	and	no	other	explanation.	 In	severe	GBS	a
neurointensivist	 will	 have	 to	 differentiate	 a	 veritable	 dysautonomia	 from	 early	 sepsis,	 pulmonary
embolus,	aspiration	pneumonia,	opioid	overuse	and	other	guises,	 including	urethra	obstruction.	Another
practical	 problem	 is	 that	 drugs	 to	 treat	 dysautonomia	 may	 worsen	 dysautonomia	 (glycopyrrolate	 for
increased	secretions,	neostigmine	for	ileus,	beta	blockers	for	tachycardia)	and	there	is	no	good	solution.
Acute	 autonomic	 failure	 in	 GBS	 usually	 resolves	 before	 full	 improvement	 in	 motor	 function.	Marked
orthostatic	hypotension	may	persist	during	the	recovery	phase.	Whether	this	is	due	to	persistent	autonomic
failure	or	a	result	of	long-standing	bed	rest	is	undetermined.	Dysautonomia	and	organ	dysfunction	plays











































(DTRs)	 and	 abnormally	 elevated	 spinal	 fluid	 protein	with	 a	 normal	white	 blood	 cell	 count	 [2].	Other
variants,	such	as	the	Miller	Fisher	syndrome	of	external	ophthalmoplegia,	sluggish	pupil	reflex	and	DTR
loss	[3],	as	well	as	pure	sensory,	pure	motor,	autonomic	and	multiple	cranial	nerve	presentations,	were
subsequent	 identified.	Most	 research	 suggests	 that	 the	 aetiology	 of	 this	 syndrome	 is	 complement-fixing
antibody	 (Ab)	with	 specificity	 for	 elements	 of	 peripheral	 nerve	myelin	 or	 axolemma	 [4–6].	 Treatment
with	plasma	exchange	or	intravenous	immunoglobulin	shortens	the	clinical	course	and	reduces	the	time	on
the	ventilator,	 the	 time	 in	 the	 ICU	and	 the	 time	 to	 independent	walking	 [7].	This	 is	 particularly	 true	 in
patients	with	high-risk	factors	including	older	age	(>	60	years),	ventilator	dependence	within	a	week	of
onset,	 and	 preceding	 diarrheal	 illness	 [8,9].	 The	 patient’s	 perspective,	 although	 appreciative	 of	 these
advances,	 includes	 issues	 of	 communication;	 isolation;	 availability	 of	 accurate	 information;	 quality	 of





















5	 near-death	 situations.	 The	 ventilator	was	 noisy.	 I	was	manually	 bagged	 during	 turning	 and	 bed	 linen	 changes.	 I	was
frightened,	 reliant	on	human	expertise	and	nasogastric	 tube	 feeding,	 could	not	 communicate	despite	an	alphabet	 chart
(only	 movement	 was	 to	 blink	 my	 eyes),	 and	 had	 concurrent	 hallucinations.	 No	 audio	 books,	 radio	 or	 television	 were
available.	I	was	unable	to	see	my	two	young	sons	because	of	ICU	policy.	Insertion	of	a	speaking	trachea	tube	resulted	in















I	was	given	a	 tetanus	 immunization	and	developed	swollen	 lymph	nodes	after	4	weeks.	While	 in	 ICU	I	was	visited	by	a









linked	 to	 abnormalities	 in	 REM	 sleep,	 autonomic	 dysfunction	 and	 decreased	 levels	 of	 hypothalamic
hypocretin-1	[10],	suggesting	involvement	of	the	central	nervous	system.
Josua	Baer
In	1996,	 I,	Josua	Baer,	11	years	old,	USA,	following	a	flu-like	 illness,	developed	paraesthesia	and	mild	weakness	 in	my
legs.	The	family	doctor,	anticipating	recovery,	approved	a	family	vacation	to	Israel.	On	the	first	day,	I	was	unable	to	drink
from	a	straw,	developed	an	inability	to	whistle	and	fully	to	open	or	close	my	eyelids.	I	progressed	to	generalized	weakness
and	 unsteady	 gait,	 prompting	 hospitalization	 and	 diagnostic	 studies	 in	 Jerusalem	 that	 supported	 a	 diagnosis	 of	 Miller
Fisher	syndrome	with	GBS	overlap	reflecting	diffuse	motor	weakness.	Following	a	course	of	IVIg,	I	was	flown	home	to	the
United	 States	 unable	 to	 walk,	 with	 persistent	 double	 vision	 and	 loss	 of	 deep	 tendon	 reflexes,	 the	 last	 of	 which	 never
returned.	 I	 lost	20%	of	my	body	weight	and	was	 in	physical	 therapy	 for	10	months.	 I	 very	gradually	 regained	strength,
















with	difficulty	standing.	Nerve	conduction	studies	showed	prolonged	distal	 latencies	and	spinal	 fluid	 findings	supported	a




weight.	 I	was	discharged	5	months	 into	my	course,	 largely	confined	 to	a	wheelchair.	Gradually,	over	several	months	of
outpatient	rehab,	3	days	per	week,	I	discontinued	my	wheelchair,	progressed	to	a	walker,	a	cane	and	finally	no	support.	I




Trevor	Sammut,	Republic	of	Malta.	 In	November	of	2011,	as	a	30-year-old	man,	 I	was	struck	down	with	 food	poisoning
associated	with	 vomiting,	 abdominal	 pain	and	 runny	diarrhoea	 that	was	 treated	with	 two	different	 courses	of	 antibiotics.
Midway	through	the	second	week	I	was	unable	to	form	a	scoop	with	the	fingers	of	my	left	hand.	I	had	fatigue,	cramping	and
‘laziness’	 in	 my	 legs.	 I	 could	 not	 write	 despite	 resolution	 of	 the	 gastroenteritis.	 Difficulty	 standing	 up	 from	 a	 sofa	 and
climbing	up	and	down	one	 flight	of	stairs	prompted	an	emergency	 room	visit.	 I	entered	 the	hospital	 limping	at	9	pm	on
Sunday	20th	November	2011	and	was	wheelchair-dependent	within	 6	 hours.	 I	 had	good	 sensation	but	 prominent	 distal
weakness	in	both	upper	and	lower	extremities.	A	diagnosis	of	GBS	was	verified	with	a	 lumbar	puncture	and	NCSs.	IVIg
initially	stabilized	the	downward	course	and	after	10	days	allowed	me	to	begin	to	walk	a	few	steps	independently.	After	a	20-
day	hospitalization,	 I	 had	distal	 atrophy	and	shortened	ankle	 tendons.	 I	 underwent	physical	and	occupational	 therapy.	 I
psychologically	 fought	 real	 hard	 not	 to	 let	 GBS	 win	 over	 my	morale	 and	mind.	 At	 times	 GBS	 did	 win,	 as	 I	 definitely
imagined	myself	 permanently	 crippled	at	moments	of	weakness.	 I	 imagined	myself	 secretly	wheeling	myself	 to	a	high





years	 of	 age	 to	 1.7/100,000	 to	 3.3/100,000	 a	 year	 [11].	 In	 this	 study,	 up	 to	 70%	 of	 cases	 reported	 a
preceding	 infection,	 either	 a	 URI	 or	 diarrheal	 illness,	 as	 was	 the	 case	 in	 all	 of	 the	 above	 series	 of
patients.	Only	1	of	this	series	was	in	their	sixth	decade	of	age,	most	were	in	the	fourth	decade	and	2	were






after	3	decades.	Nonetheless,	 the	overall	 response	was	good	and	2	currently	participate	 in	competitive
sports	requiring	good	balance,	strength	and	coordination.
Many	cited	the	importance	of	the	support	by	their	family.	I	feel	that	the	physician’s	role	is	not	only	to
diagnose	 and	 provide	 appropriate	 treatment	 but	 also	 to	 follow	 the	 patient	 during	 rehabilitation.
Documentation	of	 the	patient’s	 improvement	provides	a	different	 type	of	 support	 and	encouragement.	 It
also	identifies	any	relapse	that	might	require	additional	retreatment.	Knowing	and	working	with	more	than






























We	 are	 a	 group	 of	 medical	 students	 from	 Singapore	 in	 our	 third	 to	 final	 years	 of	 medical	 school
researching	Guillain-Barré	syndrome	(GBS)	under	the	supervision	of	Dr	Umapathi.	We	maintain	a	GBS




Our	 first	 encounter	 with	 GBS	 was	 in	 a	 textbook,	 in	 a	 short	 paragraph	 buried	 amongst	 other	 medical
conditions.	Descriptors	like	‘uncommon’	and	‘autoimmune’	prompted	us	to	subconsciously	relegate	GBS
to	‘a	good-to-know,	but	not	a	must-know’	condition	for	the	examinations.	During	tutorials	on	the	approach
to	 patients	 with	 flaccid	 weakness,	 GBS	 would	 be	 briefly	 mentioned	 as	 a	 differential	 diagnosis	 with
minimal	elaboration,	 some	even	using	 the	 terms	 ‘acute	 inflammatory	demyelinating	neuropathy’	 (AIDP)
and	 ‘GBS’	 interchangeably.	 As	 we	 first	 embarked	 on	 our	 research	 journey,	 we	 learnt	 the	 global
importance	 of	 this	 most	 common	 cause	 of	 acute	 flaccid	 paralysis.	 However,	 it	 was	 only	 after	 our
encounter	with	Mr	T	that	we	appreciated	the	tremendous	impact	GBS	had	on	patients.
A	GBS	Patient’s	Experience
“It	 began	when	 I	 suddenly	 lost	my	 appetite,	 felt	 bloated	 and	 unwell,	 but	 couldn’t	 figure	 out	what	was
happening.”	Such	was	Mr	T’s	first	encounter	with	something	that	would	soon	change	his	life	forever.
At	60	years	old,	Mr	T	 led	an	active	 life,	worked	as	a	construction	company’s	 technical	officer	and
was	 happily	married	with	 children	 and	grandchildren.	When	his	 vague	 symptoms	 failed	 to	 resolve,	 he
consulted	a	general	practitioner	and	was	treated	for	indigestion.	He	did	not	get	better	and	instead	started
finding	 it	difficult	 to	walk	steadily	and	perform	simple	 tasks	 like	picking	up	a	cup.	His	hands	and	 feet




him,	 but	 much	 remained	 incomprehensible.	 Elderly	 people	 were	 supposed	 to,	 at	 some	 point	 in	 time,
develop	 heart	 failure,	 strokes	 or	 cancer,	 but	GBS?	None	 of	 his	 friends	 had	 the	 disease.	He	 had	 never
heard	of	GBS	before,	nor	of	the	nerve	conductions	studies	(NCS)	nor	intravenous	immunoglobulins	(IVIg)




weakness	 and	 unsteadiness	made	 it	 too	 dangerous	 for	 him	 to	 continue	 his	 physically	 demanding	work



















years	 ago,	Mdm	 T	 quit	 her	 job	 to	 be	 her	 full-time	 caregiver	 as	 well	 as	 to	 raise	 her	 young	 children.
Although	it	was	a	trying	time,	she	attributes	her	ability	to	tide	through	Mr	T’s	illness	to	the	‘training’	she
got	when	caring	for	her	mother-in-law	and	young	children	simultaneously.	This	time,	she	had	to	care	for
both	Mr	T	 and	her	 2	 grandchildren	 as	 she	 shuttled	 between	 the	 kindergarten,	 hospital	 and	home	 every
single	day.
The	ordeal	continued	even	after	Mr	T	was	sent	home	from	the	rehabilitation	hospital.	Petite	Mdm	T
struggled	 to	 support	 him	 as	 he	walked	 and	 to	 deal	with	 her	 husband’s	 frustration	 over	 his	 inability	 to
perform	simple	tasks	such	as	bathing	independently,	something	they	took	for	granted	prior	to	his	illness.
Reflecting	on	the	entire	experience,	Mdm	T	explained,	“There	will	always	be	difficult	times	in	life	but





smiled	 fondly	 when	 she	 recounted	 how	 the	 medical	 team	 supported	 her	 during	 those	 difficult	 weeks,
thanking	them	for	their	care,	comfort	and	concern	which	made	the	experience	more	bearable.
How	Do	Clinicians	Diagnose	GBS?
When	we	 first	 started	 learning	 to	 diagnose	 patients	with	GBS,	 it	 felt	 as	 if	we	were	 running	 through	 a
checklist.	 Reflexes	 decreased?	 Check.	 Ascending	 pattern	 of	 sensory	 loss?	 Check.	 Power	 decreased
distally	more	than	proximally?	Check.	Recent	onset	of	symptoms	and	a	flu	a	few	weeks	prior?	Splendid,





mimics	 such	 as	 thyrotoxic	 hypokalaemic	 periodic	 paralysis,	 acute	 myelopathy	 and	 acute	 beriberi
neuropathy	as	GBS.
We	 also	 began	 to	 appreciate	 the	 value	 of	 the	 various	 investigations	 involved.	 These	 include










Through	 our	 database,	 we	 also	 encountered	 patients	 with	 central	 nervous	 system	 involvement	 namely
Bickerstaff	brainstem	encephalitis	(BBE).










AIDP,	 are	 clinically	 indistinct.	 Serial	 NCS	 is	 the	 current	 gold	 standard	 [2,3,4].	 GBS,	 being	 an
autoimmune	 disease,	 also	 has	 a	 serological	 footprint.	Research	 in	 this	 area	 has	 shed	 light	 on	 both	 the
identification	of	subtypes	and	on	underlying	pathogenesis	at	a	molecular	 level.	For	instance,	anti-GQ1b
anti-ganglioside	 antibodies	 are	 present	 in	majority	 of	 patients	 afflicted	with	MFS;	 these	 patients	 often
have	ophthalmoplegia,	and	it	has	been	found	that	GQ1b	gangliosides	are	concentrated	in	the	oculomotor,
trochlear	and	abducens	nerves.	Likewise,	antibodies	to	GM1,	GM1b,	GD1a	and	GalNac-GD1a	are	raised
in	AMAN,	 and	 these	 have	 been	 implicated	 in	 paranodal	 injury.	Mr	 T’s	 serial	 nerve	 conduction	 study












remains	 the	same,	with	 the	 focus	on	supportive	care	and	either	 IVIg	or	plasmapheresis	 to	minimise	 the
extent	 of	 autoimmune-mediated	 damage	 to	 peripheral	 nerve.	 Beyond	 the	 utility	 in	 prognosticating	 the
individual	patient’s	 expected	clinical	 course,	 the	distinction	does	not	generally	 affect	 clinical	practice.
This	question	kept	recurring	during	the	many	late	nights	we	spent	trying	to	make	sense	of	our	research	data
and	 derive	 better	ways	 of	 subtyping	GBS.	We	 learnt	 that	 our	 current	methods,	 while	 being	 constantly
improved,	 are	 still	 unable	 to	 consistently	 distinguish	 between	 subtypes.	 We	 encountered	 patients,
undifferentiated	 at	 presentation,	 who	 were	 later	 reclassified	 as	 our	 research	 entailed	 serial	 NCS	 and
long-term	follow-ups.	However,	repeat	NCS	and	serologies	are	not	feasible	for	patients	in	underserved
parts	of	the	world.
Nevertheless,	 questioning	 the	 purpose	 of	 our	 research	 is	 just	 as	 important,	 if	 not	more	 so,	 than	 the

















We	 hold	 the	 same	 hope	 as	 Mr	 T	 to	 find	 a	 cure	 for	 GBS	 and	 read	 with	 excitement	 some	 of	 the
developments	 in	GBS.	We	 now	know	 that	 neuronal	 injury	 is	 a	 complement-mediated	 process	 [5]	with
immunologic	targets	differing	amongst	subtypes,	such	as	Schwann	cells	in	AIDP	and	nodal	and	paranodal





The	conundrum	 that	 is	GBS	 is	 a	 lesson	 in	humility	and	patience	 for	us.	 It	has	 taught	us	 respect	 for	 the
scientific	 method.	 Our	 initial	 lofty	 aspirations	 of	 making	 the	 next	 breakthrough	 in	 GBS	 by	 the	 end	 of
medical	school	evolved	into	smaller,	more	deliberate	steps	at	improving	understanding	of	this	disease	by
working	with	the	global	community	of	GBS	researchers.	The	immediate	benefits	of	our	work	may	not	yet




current	 evidence-based	 therapeutic	 and	 supportive	 protocols,	 deepening	 our	 understanding	 of	 the
immunopathology	 of	 GBS	 and	 designing	 new,	 inexpensive,	 accessible	 and	 more	 effective	 therapeutic
approaches.	What	we	know	of	GBS	in	the	future	will	likely	be	different	from	what	we	believe	we	now
know;	the	last	100	years	is	proof	of	that.	With	so	much	still	a	work	in	progress,	we	realise	it	is	important
to	 keep	 an	 open	 mind	 to	 new	 solutions,	 yet	 not	 forget	 the	 art	 of	 applying	 our	 currently	 imperfect
knowledge	in	clinical	practice.
Finally,	 it	 has	 been	 our	 greatest	 privilege	 to	 have	 been	mentored	 and	 taught	 by	 experts	 in	 the	 field





































was	 that	 of	McKhann	 and	 colleagues’	 clinical	 and	 electrophysiological	 description	 of	 axonal	 GBS	 in
children	[1].	Until	 their	ground-breaking	work,	GBS	was	thought	of	as	demyelinating,	synonymous	with
what	 is	 now	 referred	 to	 as	 acute	 inflammatory	 demyelinating	 polyneuropathy	 (AIDP).	 This	 paper
described	a	paralytic	 syndrome	which	occurred	 in	 rural	China,	 similar	 to	GBS	 in	all	 features	with	 the
exception	of	the	electrophysiological	tests	[1].	These	tests	indicated	not	a	demyelinating	disease,	but	one
which	appeared	to	affect	motor	neuron	axons.	This	syndrome	was	also	seasonal,	a	feature	not	believed	to





targeting	 peripheral	 nerves.	 Of	 course	 this	 only	 begins	 to	 scratch	 the	 surface	 of	 GBS	 pathogenesis.









whether	 the	 antibodies	 were	 pathogenic	 or	 simply	 biomarkers	 of	 disease.	 Evidence	 in	 support	 of	 the
former	 came	with	 the	 development	 of	 the	 first	 animal	model	 of	AMAN.	When	 Japanese	white	 rabbits







The	generation	of	mice	 lacking	 the	enzymes	 responsible	 for	 synthesizing	ganglioside	plays	an	essential
role	in	our	story.	GalNAcT-/-	mice	generated	by	Takamiya	and	colleagues	lack	all	complex	gangliosides,
a	subset	of	gangliosides	whose	production	is	dependent	on	the	GalNAcT	enzyme	[4].	The	generation	of
these	mice,	who	develop	 an	 age-dependent	 degenerative	phenotype,	 led	 to	 further	 understanding	of	 the
roles	of	gangliosides	in	nervous	system	maintenance.	On	a	personal	level	they	have	served	me	faithfully
as	 negative	 controls	 in	 many	 of	 my	 studies	 which	 require	 an	 interaction	 between	 antibody	 and








lab,	 this	has	 led	 to	 the	use	of	 these	mice	as	hosts	 for	generating	many	of	our	 in-house	anti-ganglioside
antibodies.	 The	 incorporation	 of	 liposomes	 into	 our	 immunisations,	 as	 described	 by	 Bowes	 and
colleagues,	have	proved	to	be	an	effective	way	of	introducing	gangliosides	into	the	mice	in	a	way	which
at	 least	 in	part	mimics	the	way	gangliosides	are	presented	in	the	membrane,	especially	when	some	ova






of	 a	 very	 complex	 (no	 pun	 intended)	 story.	 It	 has	 become	 increasingly	 clear	 that	 the	 organisation	 of
gangliosides	in	the	plasma	membrane	is	incredibly	important	in	GBS.	Kaida	and	colleagues	demonstrated
that	 a	 proportion	 of	 GBS	 patients	 had	 antibodies	 against	 neoepitopes	 formed	 by	 a	 combination	 (or
complex)	of	ganglioside	antigens,	an	observation	Alan	Pestronk	previously	made	about	GM1	and	other








A	development	which	 greatly	 served	my	 PhD	was	 the	 generation	 of	 new	 transgenic	mice,	which	 only
expressed	the	usually	ubiquitous	gangliosides	on	neuronal	or	glial	membranes	[10].	These	mice	are	not
only	useful	for	the	study	of	ganglioside	function,	they	are	great	tools	for	the	study	of	GBS.	For	unknown




















directly	 influenced	 the	background	or	was	 essential	 to	 the	methods	 employed	during	my	PhD.	My	next
choice	 heavily	 influenced	 the	 direction	which	my	 PhD	 studies	 took.	 This	 paper	was	 the	 first	 to	 show
explicitly	 that	 antibodies	 against	 gangliosides	 can	 bind	 the	 axonal	 component	 of	 the	 neuromuscular
junction	and	become	 internalised	at	 this	 site	 [12].	This	observation	 is	one	which	has	a	 lot	of	potential
implications.	 First	 of	 all,	 it	 provides	 an	 explanation	 as	 to	 why	 the	motor	 nerve	 terminal	 is	 relatively









at	antibodies	against	nonspecific	 synaptic	membrane	components	 indicated	 that	 this	uptake	at	 the	nerve
terminal	is	not	the	end	of	the	road	for	these	antibodies.	In	fact,	immunoglobulins	which	are	taken	up	at	the





From	starting	out	my	project,	 completely	overwhelmed	by	 the	 expanse	of	new	 information	 I	 needed	 to
retain,	eventually	finding	my	niche	within	the	field,	and	coming	out	the	other	end	with	a	PhD,	it	has	been	a
long	 journey.	That	 journey	 is	 reflected	 in	my	 top	10	papers	which	helped	me	build	my	knowledge	and
shape	 the	 direction	 of	 my	 studies.	 You	 may	 have	 noticed	 that	 4/10	 of	 my	 papers	 have	 a	 distinct
Glaswegian	quality	about	them.	From	this	you	may	have	guessed	that	my	PhD	was	carried	out	in	Glasgow
in	the	lab	of	Professor	Hugh	Willison.	It	is	not	that	I	am	biased	(well	maybe	a	little),	just	simply	that	these
papers	 are	 very	 personal	 to	my	 journey,	 often	 describing	methods	 or	 resources	 critical	 to	my	PhD,	 or
work	which	I	took	forward	in	my	own	research.











































Citation	 analysis	 is	 not	 an	 exact	 science	 and	 what	 is	 presented	 here	 is	 one	 interpretation	 of	 the	 top
research	and	researchers	 in	Guillain-Barré	syndrome.	There	will	be	other	 interpretations	depending	on
the	tool	or	the	methodology	used	to	derive	the	citation	analysis.	There	are	a	number	of	different	tools	that
can	 be	 used;	 the	 tools	which	 are	 commonly	 available	 in	 higher	 education	 are	Web	 of	 Science	 (WoS),
Scopus	and	Google	Scholar.	These	databases	each	give	different	citation	counts	for	the	same	article	(WoS



















based	 on	 tests	 using	 a	 number	 of	 different	 variations–for	 example,	 searches	 for	Guillain-Barré	missed
those	articles	where	Barré	 is	spelt	as	Barr	or	Barri.	 ‘Guillain’	 is	a	broad	search	 term	and	some	of	 the
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increasingly	 interested	 in	wider	 impacts	 such	 as	 the	 impact	 of	 research	 on	 the	 economy,	 or	 on	 society
more	generally,	or	on	the	culture.	There	are	a	new	group	of	metrics	which	are	designed	to	try	to	measure
this	 wider	 impact;	 these	 are	 referred	 to	 as	 altmetrics	 or	 alternative	 metrics.	 Altmetrics	 are	 seen	 as
complementary	 to	 traditional	 citation	 analysis	 and	 include	 article	 views,	 downloads,	 and	 mentions	 in
social	 media,	 news	 media	 and	 policy	 documents.	 Altmetrics	 can	 provide	 real-time	 and	 immediate
feedback	on	 the	attention	being	paid	 to	 scholarly	content	and	can	be	very	useful	 in	particular	 for	early
career	 researchers	 whose	 research	may	 not	 yet	 be	 cited.	 One	 example	 of	 the	 use	 of	 altmetrics	 is	 the
University	 of	 Glasgow’s	 institutional	 repository,	 Enlighten.	 The	 altmetrics.com	 API	 tool	 has	 been
embedded	 into	 the	 repository	 and	 uses	 a	 journal	 article’s	 DOI	 or	 PubMed	 ID	 to	 provide	 a	 ‘donut’















It	 is	 notoriously	 difficult	 to	 make	 predictions,	 especially	 about	 the	 future,	 as	 Niels	 Bohr	 (may	 have)
previously	noted.	Nevertheless,	this	final	chapter	speculates	on	the	directions	GBS	research	and	treatment






It	 may	 seem	 curious	 to	 start	 this	 chapter	 with	 a	 paper	 that	 reports	 on	 nothing	more	 cutting	 edge	 than
epidemiological	 incidence	 data,	 yet	 this	 2012	 publication	 by	 Baker	 and	 colleagues	 [1]	 in	Wellington,
New	Zealand,	highlights	the	way	in	which	existing	knowledge	might	be	used	with	substantial	effect	in	the
future.	It	has	long	been	appreciated	that	Campylobacter	jejuni	is	the	most	commonly	identified	prodromal
infection	 in	 GBS.	 This	 study	 simply	 showed	 that	 population-level	 efforts	 to	 reduce	 Campylobacter
contamination	of	poultry	meat	have	a	significant	effect	on	preventing	GBS,	reducing	its	incidence	by	13%.
Likewise,	 influenza	 immunisation	 programmes	 have	 been	 shown	 to	 have	 a	 longer-term	 benefit	 in
preventing	GBS,	which	outweighs	the	smaller,	short-term	risk	of	disease	induction	[2].	Moving	forward,
the	 combination	 of	 an	 increased	 understanding	 of	 environmental	 risk	 factors,	 greater	 international









It	 is	 clear	 (at	 least	 to	 me!)	 that	 in	 addition	 to	 environmental	 factors,	 genetic	 influences	 must	 also	 be
involved	 in	GBS	 susceptibility.	This	 is	 supported	 by	 the	 observations	 that	 the	 disease	 recurs	 at	 a	 rate
much	 higher	 than	 expected	 by	 chance,	 but	 often	with	 different	 serological	 findings,	 and	 that	 even	with




genetic	 (and	 bio-informatics)	 techniques,	 boosted	 significantly	 during	 the	 completion	 of	 the	 Human
Genome	Project	[5],	even	now	facilitate	much	more	extensive	studies.	It	 is	already	possible	to	perform
genome-wide	 association	 studies	 looking	 for	 single	 nucleotide	 polymorphisms	 (SNPs)	 across	 many
thousands	of	genes,	and	 indeed,	 this	 is	one	of	 the	proposed	facets	of	 the	current	 IGOS	project.	Similar
studies	 have	 already	 benefited	 from	 the	 SNP	 datasets	 made	 freely	 available	 via	 the	 internationally
collaborative	HapMap	Project.	The	observation	 that	 large	proportions	of	SNP	hits	 occur	 in	noncoding
regions	 surely	 foreshadows	 an	 increasing	 awareness	 and	understanding	of	 their	 importance	 in	 disease.
With	 the	 decreasing	 cost,	 and	 increasing	 speed,	 of	whole	 exome	 and	 even	whole	 genome	 sequencing,
future	studies	will	be	able	to	draw	upon	ever	more	extensive	genetic	data,	offering	new	and	unexpected
insights	into	disease	pathogenesis,	and	implicating	critical	processes	both	within	and	outside	the	immune
system	amenable	 to	 therapeutic	 intervention.	 Indeed,	others	have	already	predicted	a	next	generation	of





power	 to	 manipulate	 genes.	 Cre-recombinase	 systems,	 allowing	 triggered	 activation	 or	 inhibition	 of
defined	 genes	 in	 specific	 cells,	 are	 already	 in	 widespread	 use	 in	 biomedical	 research.	 The	 current
pinnacle	of	genetic	manipulation	is,	however,	currently	best	demonstrated	by	the	application	of	CRISPR
technology	first	outlined	by	Jinek	and	colleagues	[6]	in	2012.	In	essence,	the	use	of	guide	RNAs	allows
an	 endonuclease	 to	 cut	 DNA	 at	 defined	 points,	 facilitating	 the	 relatively	 simple,	 and	 cost-effective,
removal,	addition	or	replacement	of	particular	nucleotide	sequences.	The	implications	for	many	diseases,
including	GBS,	are	potentially	enormous.	Cell-	and	animal-based	disease	models	could	have	individual
genes	 modified	 to	 assess	 their	 influence	 on	 key	 aspects	 of	 the	 disease	 process.	 Ultimately,	 similar
technology	could	be	applied	 to	patients,	with	 the	enticing	possibility	of	genetically	engineered	cellular
robots	being	designed	 to	manipulate	 specific	aspects	of	 the	 immune	 response,	enhance	nerve	 repair,	or
interfere	with	other	pathologically	relevant	processes.
In	 many	 ways,	 however,	 obtaining	 and	 analysing	 the	 genetic	 data	 itself	 is	 likely	 to	 be	 one	 of	 the
simpler	 tasks	 undertaken	 by	 GBS	 researchers	 of	 the	 future.	 It	 is	 now	 appreciated	 that	 much	 of	 the
















long	 ago	 as	 1992.	 Lloyd	 and	 colleagues,	 studying	 melanoma	 cells,	 realised	 that	 the	 ability	 of	 a
ganglioside	 antibody	 to	 interact	 with	 its	 membrane	 target	 was	 markedly	 influenced	 by	 the	 overall
ganglioside	 composition	 of	 the	 cell	membrane	 [9].	Over	 a	 decade	 later,	 researchers	working	 in	Hugh
Willison’s	 lab,	 including	 myself,	 demonstrated	 a	 similar	 phenomenon	 with	 anti-GM1	 antibodies	 [10],
known	 to	 be	 associated	with	 the	 acute	motor	 axonal	 neuropathy	 (AMAN)	 subtype	 of	 GBS.	While	 all
GM1-antibodies	studied,	including	those	derived	from	patients,	were	able	to	bind	purified	GM1	in	solid
phase	 assays	 (typically	 ELISA),	 a	 proportion	 were	 unable	 to	 bind	 when	 GM1	was	mixed	 with	 other
gangliosides,	 notably	 GD1a,	 a	 pattern	 we	 termed	 ‘complex	 attenuated’.	 It	 became	 apparent	 that	 these
observations	 had	 direct	 relevance	 to	 the	 pathogenic	 potential	 of	 the	 antibodies.	 Using	 ex	 vivo
preparations	 of	 neuromuscular	 tissue,	 we	 demonstrated	 that	 the	 complex	 attenuated	 antibodies	 were
pathologically	inert,	whereas	complex	independent	clones—able	to	bind	GM1	regardless	of	the	presence
or	 absence	 of	 other	 glycolipids—caused	 complement	 dependent	 structural	 and	 functional	 injury	 at	 the
neuromuscular	junction.	The	implication	is	that	the	precise	density,	orientation	and	interactions	of	target
antigens	 within	 the	 cell	 membrane	 have	 a	 critical	 role	 in	 modulating	 antibody	 interactions.	 These
observations	built	upon	the	then-recent	discovery	by	Kaida	and	Kusunoki	of	GBS-associated	antibodies






providing	 a	 potential	 explanation	 for	 the	 topographically	 focussed	 pathophysiological	 effects	 of
antibodies	directed	against	widely	expressed	membrane	glycolipids.	It	is	now	evident	that	internalisation
can	 significantly	 influence	 circulating	 levels	 of	 antibody,	 as	 discussed	 below,	 and	 this	 too	 is	 likely	 to
prove	an	important	area	of	future	study.
Binnig	G,	et	al.	Atomic	force	microscope.	Physical	Review	Letters,	1986
Given	 the	 obvious	 importance	 of	 the	 membrane	 microenvironment	 in	 GBS	 pathology,	 how	 will	 the
scientists	 of	 the	 future	 study	 this	 important	 area?	 Antibodies	 cannot	 be	 relied	 upon	 to	 unambiguously
indicate	the	presence	or	absence	of	an	antigen	within	the	cell	membrane,	and	the	cis	interactions	between
neighbouring	 molecules	 in	 the	 lipid	 bilayer	 cannot	 be	 visualised	 by	 the	 light	 or	 even	 by	 electron
microscope.	Technologies	already	exist	to	address	this	but	have	so	far	been	little	utilised	in	this	field.
One	 particular	 technique	which	 shows	 promise	 in	 this	 area	 is	 that	 of	 atomic	 force	microscopy.	By
measuring	the	atomic-level	physical,	electrical	and	magnetic	interactions	at	the	probe	tip,	the	atomic	force











likely	 to	 continue	 well	 into	 the	 second	 century	 of	 GBS.	 In	 the	 original	 methodology,	 pluripotency-
associated	genes	are	introduced	into	adult	cells	using	viral	vectors.	By	this	process,	patient-	and	disease-
specific	 induced	 pluripotent	 stem	 cells	 (iPSCs)	 are	 produced.	 These	 cells	 should	 be	 immunologically
inert	if	transplanted	back	into	the	individual	they	are	derived	from,	and	thus	have	great	potential	for	use	as
disease-modifying	 and	 repair-promoting	 agents.	 Although	 therapeutic	 uses	 are	 currently	 limited	 by










previously	 been	 used	 to	 study	 antigen-antibody	 interactions	 and	 pathological	 events,	 but	 even	 this
platform	 has	 important	 differences	 compared	 to	 its	 human	 equivalent,	 with	 rodents	 notably	 entirely
lacking	some	types	of	glycolipid.	Human	nerve	biopsy	tissue	is	available	in	only	limited	quantities,	and
cannot	 be	 easily	 studied	 in	 a	 live	 state.	 Unfortunately,	 fixation	 procedures	 are	 known	 to	 disrupt	 the
membrane	 antigen	 profile.	 By	 utilising	 Yamanaka	 and	 Studer’s	 methodologies,	 we	 have	 been	 able	 to
generate	myelinating	 sensory	nerve	 co-cultures	with	neurons	derived	 from	human	 iPSCs	 (Figure	 63.1).
Nodes	of	Ranvier,	recently	identified	as	targets	for	neuropathy-associated	antibodies,	form	spontaneously
in	 this	 system.	The	methodology	 is	 now	being	 optimised	 for	 iPSC-derived	 human	Schwann	 cells,	 thus
generating	 a	 human-specific	 membrane	 antigen	 environment	 for	 use	 in	 forthcoming	 studies.	 Future




The	 potential	 ability	 to	 recreate	multiple	 examples	 of	 human	GBS	 across	 tissue	 culture	 plates	will
soon	 be	 exploited.	 The	 increasing	 availability	 of	 iPSCs	 generated	 from	 GBS	 patients	 and	 multiple
controls	will	 facilitate	 assessment	of	 the	 importance	of	 the	polygenetic	background	on	GBS	pathology.
Very	high	 throughput	 studies	 driven	by	 robotic	management	 of	 culture	 conditions	will	 enable	 the	 rapid
evaluation	of	strategies	aimed	at	ameliorating	the	disease	process	and/or	facilitating	improved	recovery,







the	 immune	 response	 [17].	The	 discovery	 of	 a	whole	 new	 class	 of	T	 cells	was	 in	 itself	 a	 remarkable
development.	 The	 observation	 that	 the	 precursors	 of	 these	 Th17-type	 pro-inflammatory	 cells	 could	 in
certain	circumstances	 instead	produce	 regulatory	anti-inflammatory	cells	 is	perhaps	even	more	exciting
[17].	 It	 is	 now	 apparent	 that	 transdifferentiation	 occurs	 between	 the	 multiple	 types	 of	 mature	 cells,
opening	up	the	possibility	that	neuroimmunologists	of	the	future	will	be	able	to	specifically	switch	off	the
disease-causing	 components	 of	 an	 autoimmune	 response,	 while	 simultaneously	 enhancing	 the	 anti-
inflammatory	aspects	of	the	immune	system	itself.
Figure	63.1		Human-induced	pluripotent	stem	cell	myelinating	culture	methodology
(A)	 Schematic	 of	 hiPSC-myelinating	 co-culture	 methodology.	 (B)	 hiPSCs	 differentiated	 to	 sensory	 neurons	 form	 ganglia-like





The	work	 of	 Corti	 and	 colleagues	 has	 already	 shown	 that	 it	 is	 possible	 to	 isolate	 and	 interrogate	 the
function	 of	 individual	 antibody-producing	 cells	 [18].	A	 future	 ability	 to	 target	 specific	 subsets	 in	 vivo
would	clearly	have	therapeutic	value,	but	even	the	current	technology	offers	the	ability	to	dissect	out	and
study	 pathogenically	 relevant	 clones	 from	 within	 the	 polyclonal	 background.	 The	 implication,	 from
studies	of	antibody	internalisation	on	an	organism-wide	scale,	is	that	the	circulating	levels	of	pathogenic









The	 engineered	 antibodies	 of	 the	 future	 could	 affect	 blocking	 rather	 than	 destructive	 processes,	 be
conjugated	to	drugs	to	deliver	directed	therapies,	or	have	their	binding	sites	alone	incorporated	into	other




our	 ability	 to	 precisely	 modulate	 these	 for	 therapeutic	 effect.	 New	 research	 techniques	 will	 generate




















































Nous	attirons	 l’attention,	dans	 la	présente	note,	 sur	un	syndrome	clinique	que	nous	avons	observé	chez
deux	malades,	 syndrome	 caractérisé	 par	 des	 troubles	moteurs,	 l’abolition	 des	 réflexes	 tendineux	 avec
conservation	des	reflexes	cutanés,	des	paresthésies	avec	troubles	légers	de	la	sensibilité	objective,	des
douleurs	 à	 la	 pression	 des	 masses	 musculaires,	 des	 modifications	 peu	 accentuées	 des	 réactions
électriques	 des	 nerfs	 et	 des	muscles,	 de	 l’hyper	 albuminose	 très	 notable	 du	 liquide	 céphalo-rachidien
avec	 absence	 de	 réaction	 cytologique	 (dissociation	 albumino-cytologique).	 Ce	 syndrome	 nous	 a	 paru




de	 la	 participation,	 dans	 ce	 syndrome,	 de	 tout	 l’appareil	 moteur	 neuromusculaire	 périphérique.	 Nous










Ces	différents	 troubles	 se	 sont	 développés	 sans	 cause	 apparente:	 le	malade	n’avait	 eu	 aucune	maladie
infectieuse	 récente,	 aucune	 angine	même	 légère,	 Il	 n’avait	 présenté	 aucun	 symptôme	 d’une	 intoxication
alimentaire,	 il	 n’avait	 pas	 eu	 de	 grandes	 fatigues.	 Nous	 ajouterons	 que,	 dans	 ses	 antécédents









La	marche	est	possible	durant	quelques	pas,	on	 remarque	alors	une	certaine	 instabilité	 et	 la	 station
debout	sur	un	pied	ne	peut	être	maintenue.
Il	n’existe	aucun	trouble	de	la	musculature	faciale.
L’examen	 électrique	 montre	 qu’aux	 membres	 supérieurs	 l’excitabilité	 faradique	 est	 normale	 et
l’excitabilité	 galvanique	 bonne	 pour	 tous	 les	 muscles	 avec	 secousses	 vives;	 il	 n’y	 a	 pas	 d’inversion
polaire;	ou	constate	seulement	une	légère	hypoexcitabilité	de	l’extenseur	des	doigts;	parfois	la	secousse
est	 légèrement	 ralentie;	 on	 constate	 de	 l’inversion	polaire	 pour	 le	 jumeau	 externe,	mais	 la	 réaction	de
dégénérescence	est	très	incomplète.
Les	 réflexes	 rotuliens,	achilléens,	medio-plantaires	 recherchés	par	 le	marteau	percuteur	sont	abolis,
de	même	que	les	réflexes	antibrachiaux,	radio-et	cubito-pronateurs,	olécraniens.
Le	réflexe	cutané	plantaire	amène	la	flexion	franche	des	orteils	avec	contraction	à	distance	du	tenseur




dans	 les	 deux	mains	 jusqu’au-dessus	du	poignet.	 Il	 n’y	 a	 pas	 de	 troubles	 nettement	 appréciables	 de	 la














Le	2	 septembre,	 on	 constate	 une	 certaine	 amélioration	 de	 la	 force	 musculaire,	 et	 il	 n’y	 a	 plus	 de
fourmillements	dans	les	pieds;	ceux-ci	persistent	aux	mains;	 les	réflexes	tendineux	sont	toujours	abolis.
Une	 nouvelle	 ponction	 lombaire	montre,	 comme	 au	 précèdent	 examen,	 une	 très	 forte	 hyperalbuminose
sans	réaction	leucocytaire	appréciable.
Le	19	septembre,	 les	 troubles	moteurs	sont	 très	améliorés;	 le	malade	est	capable	de	marcher	durant
une	 heure,	 il	 peut	 se	 tenir	 sur	 un	 seul	 pied;	 les	 paresthésies	 ont	 complètement	 disparu	 aux	 membres
inferieurs,	 elles	 persistent	 encore,	 quoique	 atténuées,	 au	 niveau	 des	 mains;	 les	 réflexes	 tendineux







Le	28	 aout,	 Après	 une	marche	 de	 15	 kilomètres,	 il	 ressent	 une	 fatigue	 anormale,	 de	 la	 céphalée,	 des
douleurs	erratiques	dans	les	membres	supérieurs	et	 inferieurs,	 il	se	couche,	ne	peut	dormir	et	frissonne
une	partie	de	la	nuit.	Le	lendemain	matin	il	marche	avec	de	grandes	difficultés	pour	se	rendre	à	la	visite,
il	 est	 exempté	 de	 service	 durant	 quatre	 jours	 consécutifs.	 L’état	 parétique	 a	 débuté	 par	 les	 membres









membres	 supérieurs	ou	 les	 troubles	prédominent	nettement	 à	 la	périphérie.	La	 tête	est	généralement	en
rotation	à	gauche	et	le	malade	éprouve	de	la	difficulté	pour	la	tourner	à	droite;	il	peut	ouvrir	et	fermer	la
bouche,	mais	lentement	et	incomplètement.
L’examen	des	 réactions	 électriques	montre	 une	 légère	 hyperexcitabilité	 des	 nerfs	 et	 des	muscles	 au
courant	 faradique.	Au	courant	galvanique	 l’excitabilité	est	 légèrement	accrue,	 surtout	pour	 les	nerfs	du
membre	supérieur;	il	n’y	a	pas	de	réaction	de	dégénérescence.
Les	reflexes	rotuliens	sont	très	difficiles	à	rechercher	à	cause	de	l’hypertonie	musculaire,	ils	semblent
exister.	 Les	 reflexes	 achilléens	 et	 medio-plantaires	 sont	 abolis.	 L’état	 des	 reflexes	 des	 membres
supérieurs	 ne	 peut	 être	 déterminé	 à	 cause	 de	 l’hypertonie	 et	 de	 l’impossibilité	 d’une	 résolution
musculaire	complète.	Les	réflexes	cutanés	plantaires	amènent	la	flexion	franche	des	orteils;	les	reflexes
crémastériens	 et	 cutanés	 abdominaux	 sont	 normaux.	On	 ne	 constate	 aucun	 reflexe	 de	 défense,	 soit	 par
pincement	 du	 dos	 du	 pied,	 soit	 par	 hyperflexion	 des	 orteils,	 mais	 le	 malade	 perçoit	 les	 sensations
provoquées	par	ces	excitations.
L’excitabilité	neuromusculaire	au	marteau	percuteur	est	conservée.
Le	 malade	 se	 plaint	 de	 fourmillements	 aux	 extrémités,	 il	 n’existe	 pas	 de	 trouble	 de	 la	 sensibilité
objective	sinon	une	légère	hypoesthésie	tactile,	douloureuse	et	thermique	aux	pieds	et	aux	mains.
Les	masses	musculaires	 du	mollet	 et	 de	 l’avant-bras	 sont	 douloureuses	 à	 la	 pression.	 Les	 pupilles
égales	 réagissent	 à	 la	 lumière	 et	 à	 l’accommodation.	 Le	malade	 urine	 seul,	 il	 sent	 le	 besoin	mais	 ne
perçoit	pas	l’écoulement	des	urines.
Il	n’a	pas	de	fièvre,	pas	de	signe	de	Kernig,	pas	de	nausées,	pas	de	vomissements.
Les	 urines	 examinées	 au	 Laboratoire	 de	 Bactériologie	 et	 de	 Chimie	 de	 l’Armée	 ne	 contiennent	 ni
sucre,	ni	albumine,	ni	indoxyle;	les	éléments	chimiques	sont	dans	leur	proportion	normale.






albumineux	(plus	de	0	gr.	85	d’albumine	au	 rachi	albuminimètre	de	Sicard),	 sans	 réaction	 leucocytaire
notable	(3	à	4	lymphocytes	par	champ).
Les	 symptômes	 constatés	 au	 premier	 examen	 ont	 eu	 une	 légère	 tendance	 à	 l’amélioration.	 Au	 20
septembre,	 on	 constatait	 encore	 cependant	 la	 faiblesse	 des	 muscles	 de	 la	 périphérie	 des	 membres,
l’abolition	de	tous	les	reflexes	tendineux	à	l’exception	du	reflexe	antibrachial	gauche,	la	conversation	des
reflexes	cutanés,	 la	douleur	des	masses	musculaires	à	 la	pression,	 les	paresthésies	des	extrémités	avec
hypoesthésie	légère.	On	observait	aussi	par	intermittences	dans	les	muscles	du	mollet	et	de	la	cuisse	de
petites	 secousses	 myocloniques.	 Une	 nouvelle	 ponction	 lombaire	 a	 permis	 de	 noter	 les	 mêmes





au	 début,	 par	 des	 troubles	 moteurs	 atteignant	 l’ensemble	 des	 muscles	 des	 membres	 supérieurs	 et
inferieurs	et	prédominant	aux	extrémités	de	ceux-ci,	l’abolition	des	reflexes	tendineux	avec	conservation




L’hyper	 albuminose	 accentuée	 du	 liquide	 céphalo-rachidien	 sans	 réaction	 cellulaire	 est	 une
particularité	 qui	 nous	parait	 importante	 à	 signaler.	Cette	 dissociation	 albumino	 cytologique	 (Sicard	 et-
Foix)	 est	 observée	 le	 plus	 souvent	 dans	 certaines	 compressions	médullaire,	 dans	 le	mal	 de	Pott,	 dans
certains	 cas	 de	 syphilis	 du	 névraxe,	mais	 on	 ne	 l’a	 pas	 décrite,	 nous	 semble-t-il,	 dans	 les	 radiculites
pures	et	les	polynévrites.
Chez	 le	 second	 de	 nos	 malades	 se	 surajoutait	 à	 l’élément	 paralytique	 une	 certaine	 hypertonie	 des
muscles	qui	mérite	d’être	mise	en	relief.	Le	malade	étant	au	repos,	la	consistance	de	tous	les	muscles	est
nettement	 supérieure	 à	 celle	 des	muscles	 d’un	 individu	 sain	 dans	 la	même	 situation.	 Les	mouvements







Le	 signe	 de	 Kernig	 n’existe	 par	 conséquent	 pas	 chez	 notre	 malade.	 Cet	 état	 d’hypertonie	 n’est	 donc




de	 certaines	 paralysies	 faciales	 ne	 sont	 pas	 une	 exception	 dans	 les	 lésions	 périphériques	 des	 nerfs,
comme	on	le	croyait	classiquement.
L’ensemble	 des	 troubles	 observés	 chez	 ces	 deux	malades	 appartient	 à	 la	 pathologie	 simultanée	des
racines	rachidiennes,	des	nerfs	périphériques	et	des	muscles.	L’hyper	albuminose	considérable	du	liquide
céphalo-rachidien	 témoigne	 de	 la	 participation	 méningée;	 les	 caractères	 des	 troubles	 paralytiques
prédominant	aux	extrémités	et	les	douleurs	des	masses	musculaires	à	la	pression	montrent	la	participation
névritique	et	musculaire.	D’ailleurs,	 il	nous	 semble	que	c’est	 avec	une	 schématisation	 trop	grande	que
l’on	 isole	 en	 neurologie	 les	 polynévrites	 et	 les	 polymyosites	 ;	 dans	 un	 très	 grand	 nombre	 de	 cas	 de
polynévrites	infectieuses	ou	toxiques,	les	terminaisons	nerveuses	intramusculaires,	les	fibres	musculaires
elles-mêmes	 peuvent	 être	 atteintes	 et	 en	 réalité	 il	 peut	 s’agir	 très	 souvent	 beaucoup	 plus	 de	 poly-
neuromyosites	que	de	polynévrites	pures.
Chez	notre	premier	malade	des	recherches	expérimentales	par	la	méthode	graphique	nous	ont	permis
d’apporter	 certains	 caractères	 nouveaux	 dans	 l’étude	 des	 reflexes	 et	 de	 la	 contractilité	musculaire.	 La
méthode	 graphique	 peut	 donner	 des	 éléments	 importants	 pour	 l’interprétation	 des	 symptômes	 et	 des
lésions.
Chez	ce	malade,	alors	que	les	reflexes	tendineux	ont	paru,	à	l’examen	clinique,	abolis	durant	tout	le
cours	de	 la	maladie,	 l’inscription	graphique	du	gonflement	des	muscles	quadriceps	 fémoral	et	 jumeaux
sous	l’influence	d’une	percussion	portant	sur	les	tendons	de	ces	muscles	ou	leurs	masses	musculaires	ont
montré	 des	 particularités	 intéressantes.	 C’est	 ainsi	 que,	 dès	 le	 début	 de	 la	 maladie,	 la	 recherche	 du
réflexe	 rotulien	 amène	 une	 contraction	 que	 l’on	 voit	 nettement	 sur	 la	 figure	 1	 après	 la	 secousse
mécanique.	Cette	 contraction,	 notablement	 plus	 faible	 que	 celle	 obtenue	 chez	 un	 sujet	 sain,	 se	 produit
après	un	temps	perdu	de	0’’056	environ	et	n’est	pas	suivie	d’une	deuxième	contraction	plus	ample	et	plus
longue	 qui	 caractérise	 dans	 la	 courbe	 du	 reflexe	 normal	 la	 partie	 de	 la	 réponse	musculaire	 d’origine
véritablement	“reflexe“	C’est	a	peine	si	0’’152	après	le	début	de	l’excitation	on	remarque	un	très	léger
soulèvement	de	la	courbe	indiquant	le	vestige	de	la	contraction	reflexe.	Le	réflexe	rotulien	est	ainsi	resté
presque	entièrement	 réduit	à	une	contraction	 idio-musculaire	 jusqu’a	 la	guérison	de	 la	maladie.	Durant
cette	 période	 la	 percussion	 de	 la	masse	 du	quadriceps	 provoquait	 une	 belle	 contraction	musculaire	 se
produisant	 avec	 un	 retard	 de	 0’051,	 suivie	 elle-même	 d’une	 deuxième	 contraction	 ayant	 tous	 les
caractères	d’une	secousse	d’origine	reflexe	(fig.1)	et	se	produisant	0’’150	après	le	début	de	l’excitation.
Le	 muscle,	 qui	 ne	 répond	 que	 faiblement	 et	 partiellement	 à	 une	 excitation	 mécanique	 portée	 sur	 son
tendon	 et	 transmise	 par	 propagation	 aux	 fibres	musculaires,	 présente,	 lorsqu’il	 est	 percuté	 directement
une	double	contraction	a	peu	près	normale.	Il	semble	être	le	siège	d’une	hypoexcitabilité	mécanique	qui
ne	le	rend	excitable	que	pour	des	déformations	brusques	portées	sur	le	corps	même	du	muscle.







secousse	 mécanique.	 Celle-ci	 (fig.2)	 d’amplitude	 très	 faible,	 se	 produit	 après	 un	 temps	 perdu
extrêmement	 long,	 soit	 environ	 0’’110,	 et	 n’est	 suivie	 d’aucune	 contraction	 d’origine	 reflexe.	Mais,	 à
l’encontre	de	ce	qui	s’est	passé	pour	le	reflexe	rotulien,	ces	altérations	ont	rétrocédé	en	partie,	et,	déjà	le



















portent	 les	 altérations,	 nous	 conduit	 à	une	 série	de	 remarques	dignes	d’intérêt.	D’abord,	 la	 disparition
complète	 de	 la	 partie	 reflexe	 de	 la	 courbe	 myographique,	 ou,	 lorsqu’elle	 subsiste,	 ses	 caractères
morphologiques	 d’amplitude	 extrêmement	 réduite	 et	 de	 grande	 lenteur,	 enfin	 son	 temps	 perdu
considérable,	 presque	 double	 de	 la	 normale,	 nous	montrent	 l’altération	 profonde	 et	 prédominante	 des
conducteurs	 nerveux	 ou	 de	 la	 partie	 central	 du	 reflexe.	Mais,	 de	 plus,	 la	 secousse	musculaire	 parait
également	modifiée,	diminuée	de	hauteur,	 ralentie,	et	 retardée	dans	son	apparition,	elle	nous	permet	de




quoique	 paraissant	 aboli	 cliniquement,	 a	 pu	 être	 enregistré	 avec	 des	 caractères	 se	 rapprochant
progressivement	de	la	normale.	Nous	insistons	sur	ce	fait	important	que	la	méthode	graphique	permet
beaucoup	mieux	que	 l’examen	avec	 le	marteau	percuteur	d’avoir	des	notions	précises	sur	 l’état	des
reflexes	tendineux.
La	pathogénie	du	syndrome	de	radiculo-névrite	observé	chez	nos	malades	n’a	pu	être	précisée.	Une
infection	 on	 une	 intoxication	 doivent	 sans	 doute	 être	 invoquées,	mais	 nous	 n’avons	 pu	 les	 déceler.	 Le
pronostic	ne	parait	pas	être	 très	grave,	 si	nous	en	 jugeons	par	 l’évolution	de	 l’affection	chez	nos	deux
malades,	le	premier	était	presque	guéri	et	le	second	en	voie	d’amélioration	quand	ils	furent	évacués	de
l’Armée.
-----------------------------
(1)	Cette	observation	a	été	succinctement	analysé	par	l’un	de	nous	à	une	réunion	médicale	de	la	VI	Armée
a	Villers-Cotterets	au	mois	d’aout	1915










